



# Effective Health Care Program

---

Comparative Effectiveness Review  
Number 30

## **Pain Management Interventions for Hip Fracture**



Agency for Healthcare Research and Quality  
Advancing Excellence in Health Care • [www.ahrq.gov](http://www.ahrq.gov)

# *Comparative Effectiveness Review*

---

Number 30

## **Pain Management Interventions for Hip Fracture**

**Prepared for:**

Agency for Healthcare Research and Quality  
U.S. Department of Health and Human Services  
540 Gaither Road  
Rockville, MD 20850  
www.ahrq.gov

**Contract No. 290-02-0023**

**Prepared by:**

University of Alberta Evidence-based Practice Center  
Edmonton, Alberta, Canada

**Research Team:**

Ahmed M. Abou-Setta, M.D., Ph.D.  
Lauren A. Beupre, P.T., Ph.D.  
C. Allyson Jones, P.T., Ph.D.  
Saifee Rashiq, MB, MSc, FRCPC  
Michele P. Hamm, M.Sc.  
Cheryl A. Sadowski, B.Sc.(Pharm), Pharm.D.  
Matthew R.G. Menon, MD, F.R.C.S.C., M.H.Sc.  
Sumit R. Majumdar, M.D., M.P.H.  
Donna M. Wilson, R.N., Ph.D.  
Mohammad Karkhaneh, M.D., Ph.D. (Candidate)  
Kai Wong, M.Sc.  
Shima S. Mousavi, M.D.  
Lisa Tjosvold, M.L.I.S.  
Donna M. Dryden, Ph.D.

**AHRQ Publication No. 11-EHC022-EF**  
**May 2011**

This report is based on research conducted by the University of Alberta Evidence-based Practice Center (UAEPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-02-0023). The findings and conclusions in this document are those of the authors, who are responsible for its content, and do not necessarily represent the views of AHRQ. No statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services.

The information in this report is intended to help clinicians, employers, policymakers, and others make informed decisions about the provision of health care services. This report is intended as a reference and not as a substitute for clinical judgment.

This report may be used, in whole or in part, as the basis for the development of clinical practice guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products or actions may not be stated or implied.

This document is in the public domain and may be used and reprinted without permission except those copyrighted materials noted for which further reproduction is prohibited without the specific permission of copyright holders.

The investigators have no relevant financial interests in the report. The investigators have no employment, consultancies, honoraria, or stock ownership or options, or royalties from any organization or entity with a financial interest or financial conflict with the subject matter discussed in the report.

**Suggested citation:** Abou-Setta AM, Beaupre LA, Jones CA, Rashid S, Hamm MP, Sadowski CA, Menon MR, Majumdar SR, Wilson MD, Karkhaneh M, Wong K, Mousavi SS, Tjosvold L, Dryden DM. Pain Management Interventions for Hip Fracture. Comparative Effectiveness Review No. 30. (Prepared by the University of Alberta Evidence-based Practice Center under Contract No. 290-02-0023.) AHRQ Publication No. 11-EHC022-EF. Rockville, MD: Agency for Healthcare Research and Quality. May 2011. Available at: [www.effectivehealthcare.ahrq.gov/reports/final.cfm](http://www.effectivehealthcare.ahrq.gov/reports/final.cfm).

## Preface

The Agency for Healthcare Research and Quality (AHRQ) conducts the Effective Health Care Program as part of its mission to organize knowledge and make it available to inform decisions about health care. As part of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, Congress directed AHRQ to conduct and support research on the comparative outcomes, clinical effectiveness, and appropriateness of pharmaceuticals, devices, and health care services to meet the needs of Medicare, Medicaid, and the Children's Health Insurance Program (CHIP).

AHRQ has an established network of Evidence-based Practice Centers (EPCs) that produce Evidence Reports/Technology Assessments to assist public- and private-sector organizations in their efforts to improve the quality of health care. The EPCs now lend their expertise to the Effective Health Care Program by conducting Comparative Effectiveness Reviews (CERs) of medications, devices, and other relevant interventions, including strategies for how these items and services can best be organized, managed, and delivered.

Systematic reviews are the building blocks underlying evidence-based practice; they focus attention on the strength and limits of evidence from research studies about the effectiveness and safety of a clinical intervention. In the context of developing recommendations for practice, systematic reviews are useful because they define the strengths and limits of the evidence, clarifying whether assertions about the value of the intervention are based on strong evidence from clinical studies. For more information about systematic reviews, see <http://effectivehealthcare.ahrq.gov/reference/purpose.cfm>.

AHRQ expects that CERs will be helpful to health plans, providers, purchasers, government programs, and the health care system as a whole. In addition, AHRQ is committed to presenting information in different formats so that consumers who make decisions about their own and their family's health can benefit from the evidence.

Transparency and stakeholder input are essential to the Effective Health Care Program. Please visit the Web site ([www.effectivehealthcare.ahrq.gov](http://www.effectivehealthcare.ahrq.gov)) to see draft research questions and reports or to join an e-mail list to learn about new program products and opportunities for input. Comparative Effectiveness Reviews will be updated regularly.

We welcome comments on this CER. They may be sent by mail to the Task Order Officer named below at: Agency for Healthcare Research and Quality, 540 Gaither Road, Rockville, MD 20850, or by e-mail to [epc@ahrq.hhs.gov](mailto:epc@ahrq.hhs.gov).

Carolyn M. Clancy, M.D.  
Director  
Agency for Healthcare Research and Quality

Jean Slutsky, P.A., M.S.P.H.  
Director, Center for Outcomes and Evidence  
Agency for Healthcare Research and Quality

Stephanie Chang, M.D., M.P.H.  
Director  
Evidence-based Practice Program  
Center for Outcomes and Evidence  
Agency for Healthcare Research and Quality

CAPT Karen Lohmann Siegel, P.T., M.A.  
Task Order Officer  
Center for Outcomes and Evidence  
Agency for Healthcare Research and Quality

## **Acknowledgments**

We are grateful to members of the technical expert panel, Dr. Paul Arnstein (Massachusetts General Hospital, MA), Dr. Mohit Bhandari (McMaster University, ON), Dr. Cary Brown (University of Alberta and Glenrose Hospital, AB), Dr. Jeffrey Fudin (Albany College of Pharmacy & Health Sciences, NY), Dr. Jay Magaziner (University of Maryland Medical Center, MD), Dr. Kathleen Mangione (Arcadia University, PA), Dr. R. Sean Morrison (Mount Sinai School of Medicine, NY), and Dr. Richard Rosenquist (Anesthesia Pain Clinic, IA) who provided direction for the scope and content of the review.

The authors gratefully acknowledge the following individuals for their contributions to this project: Ms. Annabritt Chisholm (article retrieval), Ms. Teodora Radisic (article retrieval), Mr. Ben Vandermeer (data analysis), Ms. Andrea Milne (literature searching), Ms. Amy Beath (literature searching), Ms. Carol Spooner (data verification), Dr. Lisa Hartling (French translation), Ms. Jennifer Seida (German translation), Dr. Susan Armijo-Olivo (Spanish translation), and Dr. Liliane Zorzela (Portuguese, Spanish translation).

# Pain Management Interventions for Hip Fracture

## Structured Abstract

**Objectives.** To review and synthesize the evidence on pain management interventions in nonpathological hip fracture patients following low-energy trauma. Outcomes include pain management (short and long term), mortality, functional status, pain medication use, mental status, health-related quality of life, quality of sleep, ability to participate in rehabilitation, return to pre-fracture living arrangements, health services utilization, and adverse effects.

**Data Sources.** Comprehensive literature searches were conducted in 25 electronic databases from 1990 to present. Searches of the grey literature, trial registries, and reference lists of previous systematic reviews and included studies were conducted to identify additional studies.

**Methods.** Study selection, quality assessment, data extraction, and grading of the evidence were conducted independently and in duplicate. Discrepancies were resolved by consensus or third-party adjudication. Meta-analyses were conducted where data were available and deemed appropriate.

**Results.** In total, 83 studies were included (69 trials, 14 cohort studies). Most participants were females older than 75 with no cognitive impairment. The methodological quality of cohort studies was generally moderate; most trials were at high or unclear risk of bias. Included studies were grouped into eight intervention categories: systemic analgesia, anesthesia, complementary and alternative medicine, multimodal pain management, nerve blocks, neurostimulation, rehabilitation, and traction.

Most studies examined peri- and postoperative pain management, albeit from few perspectives such as reported pain, mortality, and adverse effects. Long-term pain was not reported, and other outcomes were reported infrequently. Nerve blockade was effective for relief of acute pain; however, most studies were limited to either assessing acute pain or use of additional analgesia and did not report on how nerve blockades may affect rehabilitation such as ambulation or mobility if the blockade has both sensory and motor effects. Acupressure, relaxation therapy, and transcutaneous electrical neurostimulation may be associated with potentially clinically meaningful reductions in pain, but further evidence is warranted before any firm conclusions are reached. While the strength of evidence is insufficient to make firm conclusions, postoperative physical therapy may improve pain control, and intravenous parecoxib, a systemic analgesic not available in North America, may be a possible alternative to traditional intramuscular injections of opiates and older nonsteroidal anti-inflammatory drugs (NSAIDs). Preoperative traction and spinal anesthesia (with or without additional agents) did not consistently reduce pain or complications in any demonstrable way compared with standard care. Although most studies reported on adverse effects, they were short term and not adequately powered to identify significant differences.

None of the included studies exclusively examined participants from institutional settings or with cognitive impairment, which reduces the generalizability of results to the overall hip fracture patient population.

**Conclusion.** For most interventions in this review there were sparse data available, which precludes firm conclusions for any single approach or for the optimal overall pain management following hip fracture.

# Contents

Executive Summary .....	ES-1
Introduction.....	1
Background .....	1
Interventions .....	1
Outcomes .....	3
Scope and Key Questions .....	4
Methods.....	8
Topic Development.....	8
Search Strategy .....	8
Study Selection .....	9
Assessment of Methodological Quality of Individual Studies .....	10
Data Extraction .....	11
Data Analysis .....	12
Applicability .....	13
Rating the Body of Evidence .....	13
Peer Review .....	13
Results.....	15
Search Results.....	15
Description of Included Studies.....	16
Methodological Quality of Included Studies .....	16
Randomized and Nonrandomized Controlled Trials .....	17
Cohort Studies.....	17
Results of Included Studies.....	17
Systemic Analgesia.....	17
Anesthesia.....	20
Complementary and Alternative Medicine (CAM) .....	35
Multimodal Pain Management.....	37
Nerve Blocks.....	39
Neurostimulation.....	58
Rehabilitation.....	60
Traction.....	61
Discussion.....	65
Overview.....	65
Summary of Findings.....	65
Applicability .....	67
Limitations of Existing Evidence.....	68
Recommendations for Future Research .....	68
Conclusions.....	69
References and Included Studies .....	74
Acronyms and Abbreviations .....	82

## Tables

Table A. Summary of Evidence for Key Outcomes for Pain Management Following Hip Fracture.....	ES-13
Table 1. Inclusion and Exclusion Criteria.....	10



Table 2. Characteristics of Included Studies.....	16
Table 3. Evidence Addressing Key Questions: Systemic Analgesia.....	18
Table 4. Evidence Summary Table (Randomized Controlled Trials): Systemic Analgesia.....	20
Table 5. Evidence Addressing Key Questions: Anesthesia.....	21
Table 6. Evidence Summary Table (Randomized and Nonrandomized Controlled Trials): Anesthesia.....	29
Table 7. Evidence Summary Table (Cohort Studies): Anesthesia.....	34
Table 8. Evidence Addressing Key Questions: Complementary and Alternative Medicine.....	36
Table 9. Evidence Summary Table (Randomized Controlled Trials): Complementary and Alternative Medicine.....	37
Table 10. Evidence Addressing Key Questions: Multimodal Pain Management.....	38
Table 11. Evidence Summary Table (Cohort Studies): Multimodal Pain Management.....	39
Table 12. Evidence Addressing Key Questions: Nerve Blocks.....	40
Table 13. Evidence Summary Table (Randomized Controlled Trials): Nerve Blocks.....	52
Table 14. Evidence Summary Table (Cohort Studies): Nerve Blocks.....	57
Table 15. Evidence Addressing Key Questions: Neurostimulation.....	58
Table 16. Evidence Summary Table (Randomized Controlled Trials): Neurostimulation.....	60
Table 17. Evidence Addressing Key Questions: Rehabilitation.....	60
Table 18. Evidence Summary Table (Randomized Controlled Trials): Rehabilitation.....	61
Table 19. Evidence Addressing Key Questions: Traction.....	62
Table 20. Evidence Summary Table (RCT/nRCT): Traction.....	64
Table 21. Evidence Summary Table (Cohort Studies): Traction.....	64
Table 22. Summary of Evidence for Key Outcomes for Pain Management Following Hip Fracture.....	70

## Figures

Figure 1. Analytic Framework for Pain Management Interventions.....	7
Figure 2. Flow Diagram for Study Retrieval and Selection.....	15
Figure 3. Neuraxial Anesthesia: Addition of Fentanyl—Acute Pain (Day 1).....	24
Figure 4. Neuraxial Anesthesia: Addition of Fentanyl—Hypotension.....	27
Figure 5. Neuraxial Anesthesia: Addition of Fentanyl—Nausea/Vomiting.....	27
Figure 6. Nerve Blocks Versus No Block—Acute Pain (Post-Treatment).....	43
Figure 7. Nerve Blocks Versus No Block—Pain on Movement (Post-Treatment).....	44
Figure 8. Nerve Blocks Versus No Block—Pain on Rest (Post-Treatment).....	45
Figure 9. Nerve Blocks Versus No Block—Participants Requiring Additional Pain Medication.....	46
Figure 10. Nerve Blocks Versus No Block—Nausea/Vomiting.....	48
Figure 11. Nerve Blocks Versus No Block—Respiratory Infection.....	50
Figure 12. Neurostimulation Acute Pain (Post-Treatment).....	59
Figure 13. Traction—Acute Pain (Post-Treatment Means).....	63

## Appendixes

Appendix A. Technical Expert Panel and Peer Reviewers
Appendix B. Exact Search Strings
Appendix C. Sample Data Extraction and Quality Assessment Form
Appendix D. Excluded Studies
Appendix E. Description of Included Studies

Appendix F. Characteristics of Interventions

Appendix G. Risk of Bias Assessment for Randomized Controlled Trials and Nonrandomized  
Controlled Trials

Appendix H. Summary Risk of Bias Assessments

Appendix I. Newcastle-Ottawa Scale Assessment of Cohort Studies

Appendix J. GRADE Tables: Assessing the Strength of Evidence

# Executive Summary

## Introduction

Hip fractures are a source of significant morbidity and mortality. Incidence increases substantially with age, rising for men and women, respectively, from 22.5 and 23.9 per 100,000 populations at age 50, to 630.2 and 1,289.3 per 100,000 populations by age 80. Short-term mortality rates are high and range from 25 percent for women to 37 percent for men in the first year following a hip fracture. Furthermore, a large proportion of those patients who survive never recover to their prefracture level of function, and approximately 25 to 50 percent of elderly patients with hip fractures have not returned home by 1 year postfracture. Up to 25 percent of hip fractures occur in continuing care facilities (i.e., long-term residential care for dependent people).

Pain following hip fracture has been associated with delirium, depression, sleep disturbance, and decreased response to interventions for other disease states. Therefore, it is important to treat and manage complaints of pain adequately during acute treatment for hip fracture. Furthermore, poorly managed postoperative pain is associated with delayed ambulation, pulmonary complications, and delayed transition to lower levels of care. The patient's self-report of pain is the gold standard for evaluating its character and intensity. However, those with dementia or acute delirium may have difficulty reporting pain levels. The potential for underreporting of pain has direct ramifications for the hip fracture population, as many patients are frail older people with postoperative confusion and an impaired ability to communicate.

## Key Questions

**Key Question (KQ) 1.** In older adults ( $\geq 50$  years) admitted to the hospital following acute hip fracture, what is the effectiveness of pharmacologic and/or nonpharmacologic pain management interventions for controlling acute (up to 30 days postfracture) and chronic pain (up to 1 year postfracture) compared with usual care or other interventions in all settings?

**KQ 2.** In older adults ( $\geq 50$  years) admitted to the hospital following acute hip fracture, what is the effectiveness of pharmacologic and/or nonpharmacologic pain management interventions on other outcomes up to 1 year postfracture compared with usual care or other interventions in all settings? Other outcomes include:

- a. Mortality (30-day and up to 1 year postfracture)
- b. Functional status
- c. Pain medication use; change in type and quantity
- d. Mental status
- e. Health-related quality of life
- f. Quality of sleep in the hospital
- g. Ability to participate in rehabilitation
- h. Return to prefracture living arrangements
- i. Health services utilization

**KQ 3.** In older adults ( $\geq 50$  years) admitted to the hospital following acute hip fracture, what is the nature and frequency of adverse effects that are directly or indirectly associated with

pharmacologic and nonpharmacologic pain management interventions up to 1 year postfracture compared with usual care or other interventions in all settings?

**KQ 4.** In older adults ( $\geq 50$  years) admitted to the hospital following acute hip fracture, how do the effectiveness and safety of pharmacologic and nonpharmacologic pain management interventions vary in differing subpopulations following acute hip fracture up to 1 year after fracture compared with usual care or other interventions in all settings?

## **Methods**

### **Literature Search**

The following bibliographic databases were searched systematically for studies published from 1990 to 2010: AMED (Allied and Complementary Medicine); Global Health; International Pharmaceutical Abstracts; BIOSIS Previews; CINAHL (Cumulative Index to Nursing & Allied Health Literature); Academic Search Elite; Health Source: Nursing and Academic Edition; Cochrane Complementary and Alternative Medicine and Pain Database; Cochrane Database of Systematic Reviews; Database of Abstracts of Reviews of Effects; EBM Reviews – Cochrane Central Register of Controlled Trials; Embase; Global Health Library; MEDLINE; Pascal; PeDRO (The Physical Therapy Evidence Database); ProQuest Dissertations and Theses–Full Text; Scopus; Web of Science; and TOXLINE. Hand searches were conducted to identify literature from proceedings from the following scientific meetings: American Geriatric Society, American Physical Therapy Association, American Society of Regional Anesthesia and Pain Medicine, European Society of Regional Anesthesia, European Society of Anesthesiology, and International Anesthesia Research Society. Ongoing studies were identified by searching clinical trials registers in addition to contacting experts in the field. Reference lists of relevant reviews were searched to identify additional studies. No language restrictions were applied.

### **Study Selection**

Two reviewers independently screened titles and abstracts using general inclusion criteria. The full-text publication of all articles identified as “include” or “unclear” were retrieved for formal review. Each full-text article was independently assessed by two reviewers using detailed a priori inclusion criteria and a standardized form. Disagreements were resolved by consensus or by third-party adjudication. Randomized controlled trials (RCTs), nonrandomized controlled trials (nRCTs), cohort studies (prospective or retrospective), and case-control studies were included if they were published in 1990 or later, focused on older adults ( $\geq 50$  years) who were admitted to the hospital with acute hip fracture due to low-energy trauma, and examined any pharmacological or nonpharmacological pain management therapy, regardless of mode of administration or time point during the care pathway.

### **Quality Assessment and Rating the Body of Evidence**

Two reviewers independently assessed the methodological quality of included studies, with disagreements resolved through discussion or third-party adjudication, as needed. The Cochrane Collaboration’s Risk of Bias tool was used to assess RCTs and nRCTs. Observational analytic studies were assessed using the cohort and case-control Newcastle Ottawa Scales. In addition, the source of funding was recorded for all studies.

The body of evidence was rated by two reviewers using the Agency for Healthcare Research and Quality GRADE approach (Grading of Recommendations, Assessment, Development, and Evaluation). The strength of evidence was assessed for outcomes identified by the clinical investigators to be most clinically important: acute pain (up to 30 days), chronic pain (up to 1 year), mortality (30-day), and the incidence of serious adverse effects (e.g., delirium, myocardial infarction, renal failure, stroke). The following four major domains were assessed: risk of bias (low, medium, high), consistency (no inconsistency, inconsistency present, unknown, or not applicable), directness (direct, indirect), and precision (precise, imprecise).

## **Data Extraction**

Data were independently double-extracted by two reviewers using a standardized form; discrepancies were resolved by consensus or third-party adjudication. Extracted data included study characteristics, inclusion/exclusion criteria, participant characteristics, interventions, and outcomes.

## **Data Analysis**

Evidence tables and qualitative description of results were presented for all included studies. Comparative studies were considered appropriate to combine in a meta-analysis if the study design, study population, interventions being compared, and outcomes were deemed sufficiently similar. Dichotomous outcomes were combined using the DerSimonian and Laird random-effects model, except in instances where the percentage of participants with an event was less than 1 percent, in which case Peto's odds ratio (OR) was calculated using a fixed-effect model. Continuous outcomes were combined using the mean difference (MD), or standardized mean difference (SMD), where appropriate. Statistical heterogeneity was quantified using the I-squared ( $I^2$ ) statistic.

## **Results**

### **Description of Included Studies**

The search strategy identified 9,357 citations; 83 unique studies met the eligibility criteria and were included in the review. The studies included 64 RCTs, 5 nRCTs, and 14 cohort studies. The number of participants in the studies ranged from 14 to 1,333 (median = 60 [interquartile range (IQR): 40 to 90]). The mean age of study participants ranged from 59.2 to 86.3 years. Based on the interventions reported in each study, the studies were divided into eight groups: systemic analgesia (n = 3), anesthesia (n = 30), complementary and alternative medicine (CAM) (n = 2), multimodal pain management (n = 2), nerve blocks (n = 32), neurostimulation (n = 2), rehabilitation (n = 1), and traction (n = 11).

### **Methodological Quality of Included Studies**

All but two of the RCTs were considered to have a high or unclear risk of bias. The most common sources of potential bias were inadequate description of the randomization procedure, allocation concealment, and external sources of funding. The methodological quality of the cohort studies was moderate, with a median score of 7 stars on a possible score of 9 (IQR: 6 to 8). Common weaknesses in the design of the studies included lack of independent blind outcome assessment and failure to adequately control for potential confounding factors.

## Results of Included Studies

The results of the studies are presented by the type of intervention and by the key questions. A table with the summary of findings for outcomes for each intervention is presented at the end of the executive summary.

### Systemic Analgesia

Three RCTs (n = 214) evaluated different types of systemic analgesia. The mean age ranged from 77.2 to 78.5 years; most patients were female.

**KQ1: Acute pain management.** All three trials reported acute pain. Acute pain was measured using the 10cm Visual Analogue Scale (VAS); the mean baseline measure was 6.5cm. One trial (n = 90) comparing parecoxib intravenous (IV) versus diclofenac intramuscular (IM) ± meperidine IM found a significant difference in favor of parecoxib IV (MD -0.70; 95% confidence interval [CI] -1.04, -0.36; p <0.0001). The second trial (n = 30) comparing intrathecal isotonic clonidine versus intrathecal hypertonic clonidine reported a significant difference in favor of isotonic clonidine (MD -1.69; 95% CI -2.01, -1.37; p <0.00001). The third trial (n = 94) comparing lysine clonixinate versus metamizole found no significant difference (MD -0.43; 95% CI -1.30, 0.44; p = 0.33). The strength of the evidence was rated as insufficient.

**KQ2: Other outcomes.** Additional pain medication use was reported in one trial comparing lysine clonixinate versus metamizole and reported no significant difference between groups (OR 3.00; 95% CI 0.30, 29.94; p = 0.35). Delirium was reported in one trial comparing lysine clonixinate versus metamizole and found no significant difference (OR 0.96; 95% CI 0.06, 15.77; p = 0.98). The strength of the evidence was rated as insufficient.

**KQ3: Adverse effects.** One trial comparing lysine clonixinate versus metamizole reported the number of participants with any adverse event and found a significant difference in favor of metamizole (OR 3.50; 95% CI 1.04, 11.81; p = 0.04). Similarly, fewer patients in the metamizole group reported any gastrointestinal disturbance (OR 11.84; 95% CI 1.45, 96.75; p = 0.02). The remaining reported adverse effects were from single studies and did not demonstrate any significant statistical differences between the pain management interventions.

**KQ 4: Efficacy, effectiveness, and safety in subpopulations.** No data were reported.

### Anesthesia

Twenty-one RCTs and one nRCT (n = 1,062) evaluated anesthesia including neuraxial (i.e., continuous vs. single administration) or neuraxial versus general anesthesia, or another form of anesthesia (i.e., spinal or regional); sample sizes ranged from 20 to 90. Additionally, eight cohort studies (n = 3,086) provided additional data. The mean age of participants ranged from 70 to 86 years; most were female. Acute pain was measured using different scales (numeric rating score (1–5) and 10cm VAS). The studies were grouped as follows: spinal versus epidural or general anesthesia (n = 10); neuraxial anesthesia: addition of clonidine, fentanyl, meperidine, morphine, or sufentanil (n = 14); neuraxial anesthesia: different doses or modes of administration (continuous vs. single administration) (n = 13).

KQ1: Acute pain management. The average baseline VAS pain score was 4.7.

Spinal versus general anesthesia. One RCT (n = 30) reported a statistically significant difference of additional pain relief in favor of spinal anesthesia (MD = -0.86; 95% CI -1.30, -0.42; p = 0.0001). The strength of the evidence was rated as insufficient.

Neuraxial anesthesia: addition of clonidine, fentanyl, meperidine, morphine, or sufentanil. Three RCTs compared additional fentanyl (n = 40), morphine (n = 40), and sufentanil (n = 50) versus standard spinal anesthesia. In the studies comparing the addition of fentanyl or sufentanil, no patients reported feeling pain following the procedure. In the study comparing the addition of morphine, there was no significant difference between groups (MD = -0.36; 95% CI -1.11, 0.39; p = 0.35). One RCT and one nRCT (n = 80) comparing additional fentanyl reported acute pain on day 1 and found no significant difference between groups (OR 1.24; 95% CI 0.34, 4.48; p = 0.75). The strength of the evidence was rated as insufficient.

KQ2: Other outcomes. Spinal versus general anesthesia or spinal versus epidural anesthesia. Two RCTs reported 30-day mortality (n = 99) and found no statistically significant difference in mortality rates (OR 1.73; 95% CI 0.53, 5.68; p = 0.36). In two cohort studies (n = 650), pooling was not performed due to marked statistical heterogeneity and conflicting results between the studies. The strength of the evidence was rated as insufficient.

In one RCT (n = 30) that reported delirium there was no significant difference between groups (OR 0.76; 95% CI 0.18, 3.24; p = 0.71). The strength of the evidence was rated as insufficient.

Length of stay (LOS) for acute hospitalization was reported in two RCTs (n = 99). LOS was significantly less in the general anesthesia group (MD 1.69; 95% CI 0.38, 3.01; p = 0.01).

Neuraxial anesthesia: addition of clonidine, fentanyl, meperidine, morphine, or sufentanil. Additional pain medication use was reported in six RCTs. In one RCT (n = 40) comparing the addition of clonidine versus standard spinal anesthesia, all participants required additional pain medication. The pooled estimate from three trials examining the addition of fentanyl (n = 102) showed no significant difference between groups (OR 5.51; 95% CI 0.25, 122.08; p = 0.28). There was no significant difference in additional pain medication use in one RCT (n = 40) that compared the addition of morphine (OR 0.27; 95% CI 0.07, 1.04; p = 0.06). Similarly, three RCTs (n = 132) that compared the addition of sufentanil found no difference between groups (Peto's OR 7.39; 95% CI 0.15, 372.38; p = 0.32).

Delirium was reported in one RCT (n = 40) comparing the addition of morphine and found no significant difference between groups (OR 3.15; 95% CI 0.12, 82.16; p = 0.49). The strength of the evidence was rated as insufficient.

Neuraxial anesthesia: different doses and modes of administration (continuous vs. single administration). Three RCTs (n = 163) reported 30-day mortality. In two, there were no deaths. In the third, there was no significant difference between groups (OR 0.46; 95% CI 0.07, 3.02; p = 0.42). Additionally, 30-day mortality was reported in one cohort study (n = 291) that found no

significant difference between groups (OR 0.96; 95% CI 0.30, 3.00;  $p = 0.94$ ). The strength of the evidence was rated as low.

Additional pain medication use was reported in two RCTs ( $n = 134$ ); there were no events in either group. LOS for acute hospitalization was reported in two RCTs ( $n = 89$ ). There was no significant difference between groups (MD = -0.98; 95% CI -2.06, 0.10;  $p = 0.07$ ). In two RCTs ( $n = 134$ ) that reported delirium, there was no significant difference between groups (OR 1.27; 95% CI 0.32, 4.99;  $p = 0.73$ ). The strength of the evidence was rated as low.

Spinal anesthesia (different doses). One cohort study ( $n = 182$ ) reported that there was no significant difference in 30-day mortality rates between groups (OR 0.49; 95% CI 0.12, 2.02;  $p = 0.32$ ). The strength of the evidence was rated as insufficient. Another cohort study ( $n = 60$ ) reported no significant difference in the incidence of delirium (OR 0.46; 95% CI 0.08, 2.75).

In one RCT ( $n = 60$ ) that reported on additional pain medication use, there was no significant difference between groups at different doses (4 vs. 5mg, 4 vs. 6mg, or 5 vs. 6mg).

KQ 3: Adverse effects. Spinal versus general anesthesia or spinal versus epidural anesthesia. Two RCTs ( $n = 73$ ) and one cohort study ( $n = 335$ ) reported adverse effects. Overall, the RCTs reported no significant differences in the occurrence of hypotension, myocardial infarction, or ST segment depression. The cohort study found no difference in the incidence of headaches and hypotension.

*Neuraxial anesthesia:* addition of clonidine, fentanyl, meperidine, morphine, or sufentanil. Eleven RCTs and one nRCT ( $n = 490$ ) provided data on adverse effects.

- (a) Addition of clonidine. One trial ( $n = 40$ ) reported no damage to surrounding structures, headaches, or infections.
- (b) Addition of fentanyl. There was no significant difference in the number of participants reporting an allergic reaction in four RCTs ( $n = 164$ ). There was no significant difference in the number of participants reporting bradycardia in one RCT ( $n = 42$ ). Seven trials ( $n = 284$ ) reported the frequency of hypotension. Results were inconsistent across studies and the pooled results are not reported due to high heterogeneity. Five trials ( $n = 204$ ) reported nausea or vomiting and found no significant difference between groups (OR 1.10; 95% CI 0.06, 20.73;  $p = 0.95$ ). There were no reports of neurological complications in one RCT ( $n = 40$ ); no reports of respiratory distress in three RCTs ( $n = 124$ ); no reports of gastrointestinal symptoms in three RCTs ( $n = 140$ ); and no reports of headaches in one trial ( $n = 40$ ).
- (c) Addition of meperidine. There were no reports of headaches in one RCT ( $n = 34$ ).
- (d) Addition of morphine. One RCT ( $n = 40$ ) reported no significant difference in the number of participants reporting allergic reactions, gastrointestinal symptoms, or nausea or vomiting.
- (e) Addition of sufentanil. There was no significant difference in the incidence of bradycardia in one trial. Three trials ( $n = 132$ ) reported a significantly lower incidence of hypotension in participants receiving sufentanil (OR = 0.05; 95% CI 0.01, 0.34). In one RCT ( $n = 42$ ) there were no reports of allergic reaction, nausea or vomiting, or respiratory distress.



Neuraxial anesthesia: different modes of administration. In one cohort study (n = 291), there were no reports of adverse effects. In one RCT (n = 60) there was no significant difference in the occurrence of gastrointestinal symptoms. In two trials (n = 103) that reported on hypotension there was a significant difference between groups in favor of continuous spinal anesthesia (OR 0.12; 95% CI 0.03, 0.51; p = 0.004). Similarly, in one cohort study (n = 291) there was a statistically significant difference in favor of continuous spinal anesthesia (OR 0.08; 95% CI 0.04, 0.14; p < 0.00001). There was no significant difference in myocardial infarction in one trial (n = 29). There was no significant difference in the occurrence ST depression in one trial (n = 29). In one RCT (n = 74) there were no reports of bradycardia, myocardial ischemia, or stroke, and no reports of headache in one trial (n = 60) or one cohort study (n = 291).

Neuraxial anesthesia: different doses. In one cohort study (n = 182), there were no reports of adverse effects. In one RCT (n = 60) there was no significant difference in the occurrence of allergic reaction for the different doses of bupivacaine. Bradycardia was reported in two trials (n = 120); there was no significant difference among the different doses of bupivacaine or levobupivacaine. Hypotension was reported in four RCTs (n = 190). There was a significant difference following 4mg versus 6mg of bupivacaine (OR 0.03; 95% CI 0.00, 0.58; p = 0.02), but not 5 versus 6mg of bupivacaine (OR 0.31; 95% CI 0.08, 1.13; p = 0.08). Three cohort studies reported hypotension (n = 267) and found a significant difference following 2.5mg versus 5mg of bupivacaine (OR 0.08; 95% CI 0.03, 0.23; p < 0.00001), 4 versus 12mg of bupivacaine (OR 0.03; 95% CI 0.01, 0.15; p < 0.00001), and 0.125 versus 0.5 percent of bupivacaine (OR 0.15; 95% CI 0.03, 0.87; p = 0.03). One cohort study reported a significant difference in the incidence of hypotension following 4mg versus 12mg (OR 0.03; 95% CI 0.01, 0.15; p < 0.00001), but no difference in the incidence of *delirium*. There were no reports of nausea or vomiting in two trials (n = 100); no reports of residual sensory deficits or motor weakness, respiratory distress, sedation, or urinary retention in one RCT (n = 60); no reports of gastrointestinal symptoms in two trials (n = 100); and no reports of headache in one cohort study (n = 182).

**KQ 4: Efficacy, effectiveness, and safety in subpopulations.** No data were reported.

## Complementary and Alternative Medicine

Two RCTs (n = 98) evaluated the administration of CAM interventions versus no or sham intervention. The mean age ranged from 76.8 to 86.3 years; most were female. One trial (n = 38) compared acupressure versus sham control delivered preoperatively. Acute pain was measured using the 10cm VAS; the baseline measure was 6.5cm. The second trial (n = 60) compared the Jacobson relaxation technique (a two-step process of contracting and relaxing specific muscles) versus no intervention. Pain was measured using a 10-point verbal scale; the baseline measure was not reported.

KQ1: Acute pain. Acupressure reduced pain versus a sham intervention (MD -3.01; 95% CI -4.53, -1.49; p < 0.0001). Relaxation also showed a reduction in pain versus no relaxation (MD -1.10; 95% CI -1.43, -0.77; p < 0.00001). The strength of the evidence was rated as insufficient.

KQ2: Other outcomes. In the RCT that examined relaxation, fewer patients in the relaxation group required additional pain medication (e.g., meperidine or morphine) versus the control group (MD -8.43; 95% CI -15.11, -1.75;  $p = 0.01$ ).

KQ3: Adverse effects. No data were reported.

KQ 4: Efficacy, effectiveness, and safety in subpopulations. No data were reported.

## **Multimodal Pain Management**

Two cohort studies ( $n = 226$ ) evaluated multimodal pain management versus standard care. These studies described the use of multiple pain management strategies (sequential or in parallel) as part of the clinical pathway for patients with hip fractures. The mean age was not reported; most participants were female. One study compared a formal postoperative protocol of IV-administered and oral tramadol plus acetaminophen versus standard care. The second compared a formal preoperative protocol of skin traction, morphine, and acetaminophen versus standard care.

KQ1: Acute pain. No data were reported.

KQ2: Other outcomes. Mortality was reported in one study ( $n = 106$ ). There was no significant difference between groups after 30 days (OR 0.54; 95% CI 0.16, 1.77;  $p = 0.31$ ), or at 1 year (OR 0.60; 95% CI 0.25, 1.47;  $p = 0.26$ ). Both studies reported delirium and found no significant difference between groups. The strength of the evidence for both outcomes was rated as insufficient.

KQ 3: Adverse effects. Data were reported in one study ( $n = 106$ ). There were no significant differences between groups.

KQ 4: Efficacy, effectiveness, and safety in subpopulations. No data were reported.

## **Nerve Blocks**

Twenty-nine RCTs ( $n = 1,757$ ) evaluated nerve blocks, including 3-in-1 (neurostimulation [NS]/ultrasound-guided [US]), combined lumbar/sacral plexus, fascia iliaca compartment, femoral, lumbar plexus plus sciatic nerve, posterior lumbar plexus, psoas compartment, oburator, and epidural nerve blocks. These were compared with placebo/standard care, or a different method of nerve blocks. Additionally, three cohort studies ( $n = 696$ ) evaluated 3-in-1, femoral, and lumbar plexus plus sciatic nerve blocks versus analgesia, or comparing different analgesic medications in femoral lumbar plexus plus sciatic blocks. The mean age of participants ranged from 59.2 to 85.9 years; most were female. Acute pain was measured using different scales (i.e., numeric rating scales and 10cm VAS). Eight studies using the VAS reported mean baseline scores from 1.4cm to 7.3cm. The studies were grouped as follows: nerve blocks versus standard care/placebo; nerve blocks versus neuraxial anesthesia; nerve blocks–ropivacaine versus bupivacaine; nerve blocks–addition of clonidine; and nerve blocks–ultrasound versus neurostimulation.

KQ1: Acute pain management. Nerve blocks versus no block. Acute pain was reported in 13 RCTs (n = 942). There was significant heterogeneity between the study results ( $I^2 = 92$  percent) and so pooled results are not reported. Even so, subgroup analyses showed significant results in favor of individual nerve blocks, except 3-in-1 block. Also preoperative nerve blocks seemed to be more effective than postoperative administration. One trial (n = 50) reported a significant difference in postoperative pain on day 1 favoring nerve blocks (OR 0.10; 95% CI 0.03, 0.36; p = 0.0005). The strength of the evidence was rated as moderate.

Nerve blocks versus neuraxial anesthesia. Acute pain was reported in three RCTs (n = 109). There was no significant difference between groups (MD -0.35; 95% CI -1.10, 0.39; p = 0.35). The strength of the evidence was rated as low.

KQ 2: Other outcomes. Nerve blocks versus no block. Four RCTs (n = 228) evaluated 30-day mortality; there was no significant difference between groups (OR 0.28; 95% CI 0.07, 1.12; p = 0.07). The strength of the evidence was rated as low. There was no significant difference in 1-year mortality in two RCTs (n = 112) (OR 0.82; 95% CI 0.25, 2.72; p = 0.74), or in one cohort study (n = 535) (OR 0.73; 95% CI 0.48, 1.10; p = 0.14). Seven RCTs (n = 378) evaluated additional pain medication use and found a significant difference favoring nerve blocks (OR 0.32; 95% CI 0.14, 0.72; p = 0.006). Similarly, one cohort study (n = 99) reported a significant difference favoring nerve blocks (OR 0.03; 95% CI 0.00, 0.44; p = 0.01). Pooled results for four RCTs (n = 461) and two cohort studies (n = 634) that provided data on delirium showed a significant difference favoring nerve blocks (OR 0.33; 95% CI 0.16, 0.66; p = 0.002 [RCTs]; OR 0.24; 95% CI 0.08, 0.72; p = 0.01 [cohort studies]). The strength of the evidence was rated as moderate. LOS for acute hospitalization (days) was reported in two cohort studies (n = 634), but the pooled results are not reported due to marked heterogeneity between the original study results. Quality of sleep was reported in one RCT (n = 77) that found no significant difference (MD 0.30; 95% CI -0.46, 1.06; p = 0.44).

Nerve blocks versus neuraxial anesthesia. Additional pain medication use was reported in one RCT (n=30); there was no significant difference between groups (OR 2.00; 95% CI 0.38, 10.51; p = 0.41). Delirium was reported in one RCT (n = 29); there was no significant difference between groups (OR 1.20; 95% CI 0.27, 5.40; p = 0.81). The strength of the evidence was rated as insufficient.

Ropivacaine versus bupivacaine. Additional pain medication use and delirium were reported in one cohort study (n=62). There was no significant difference between groups for either outcome (OR 1.25; 95% CI 0.42, 3.76; p=0.69; OR 1.93; 95% CI 0.17, 22.50; p=0.60, respectively). The strength of the evidence for delirium was rated as insufficient.

KQ3: Adverse effects. *Nerve blocks versus no block. Respiratory infection* was reported in five RCTs (n=268) and found no significant difference (OR 0.43; 95% CI 0.18, 1.04; p=0.06). There were no significant differences between groups for the following adverse effects: *cardiac complications* (2 RCTs, n=128; 1 cohort study, n=99); *damage to surrounding structures* (3 RCTs, n=224); *deep venous thrombosis* (2 RCTs, n=100); *myocardial infarction* (2 RCTs, n=145; 1 cohort study, n=535); *nausea/vomiting* (6 RCTs, n=421); *pulmonary embolism* (2 RCTs, n = 128); *surgical wound infection* (2 RCTs, n = 110); *urinary retention* (2 RCTs, n = 62);

1 cohort study, n = 535). There were no reports of infection in two RCTs (n = 184). The remaining reported adverse effects were from single studies and did not demonstrate any significant statistical differences between the pain management interventions.

Nerve blocks versus neuraxial anesthesia, ropivacaine versus bupivacaine and addition of clonidine. The reported adverse effects were from single studies and did not demonstrate any significant statistical differences between the pain management interventions.

US versus NS. Two RCTs (n = 100) reported no significant difference in damage to surrounding structures (OR 0.16; 95% CI 0.02, 1.30; p = 0.09). The remaining reported adverse effects were from single studies and did not demonstrate any significant statistical differences between the pain management interventions.

KQ 4: Efficacy, effectiveness, and safety in subpopulations. One RCT recruited patients with pre-existing heart disease. There was a significant reduction in pain favoring nerve blocks (MD -0.55; -0.81, -0.29; p <0.0001). There was no significant difference in 30-day mortality (OR 0.10; 95% CI 0.01, 1.90; p = 0.12) or adverse effects. One RCT recruited participants that were independent prior to their hip fracture. There was no significant difference between nerve blocks versus standard care for 30-day mortality (OR 1.00; 95% CI 0.06, 16.76; p = 1.00).

## Neurostimulation

Two RCTs (n = 123) evaluated transcutaneous electrical neurostimulation (TENS) versus sham control. One trial administered the TENS preoperatively, and the other postoperatively. The mean age of participants ranged from 71.2 to 80.5 years; most were female. Pain was measured using the VAS; the mean baseline measure was 8.4 to 8.8.

KQ1: Acute pain. Two RCTs (n = 123) found a significant difference in additional pain relief in favor of TENS (MD -2.79; 95% CI -4.95, -0.64; p = 0.01). Pain on movement was reported in one trial (n = 60) and found a significant difference in favor of TENS (MD -3.90; 95% CI -6.22, -1.58; p = 0.001). The strength of the evidence was rated as insufficient.

KQ2: Other outcomes. One RCT (n = 60) provided data on *health-related quality of life* (HRQOL) and quality of sleep. TENS provided significant improvement in HRQOL (MD -4.30; 95% CI -6.86, -1.74; p = 0.001) and quality of sleep (MD -3.60; 95% CI -5.75, -1.45; p = 0.001).

KQ3: Adverse effects. No data were reported.

KQ 4: Efficacy, effectiveness, and safety in subpopulations. No data were reported.

## Rehabilitation

One RCT (n = 37) evaluated physical therapy (stretching and strengthening of spinal and psoas muscles) versus standard care. The mean age was 67.1; all participants were female. Pain was measured using the 10cm VAS; the mean baseline measure was 7.9cm.

KQ1: Acute pain. There was a significant difference in additional pain relief following physical therapy (MD -1.39; 95% CI -2.27, -0.51;  $p = 0.002$ ). The strength of the evidence was rated as insufficient.

KQ2: Other outcomes. No other outcomes were reported.

KQ3: Adverse effects. No data were reported.

KQ 4: Efficacy, effectiveness, and safety in subpopulations. All participants were female.

## **Traction**

Nine RCTs, four nRCTs, and one cohort study evaluated skin or skeletal traction versus no intervention or other interventions. Sample sizes ranged from 60 to 311. The mean age ranged from 74.0 to 81.0; most participants were female.

KQ1: Acute pain management. Acute pain was measured using the 10cm VAS; the mean baseline measure ranged from 0.3 to 6.9cm. Eight trials compared skin traction ( $n = 498$ ) versus no traction ( $n = 594$ ) and found no significant difference between groups. The strength of the evidence was rated as low. One trial ( $n = 78$ ) compared skin traction versus skeletal traction and found no difference between groups. The strength of the evidence was rated as insufficient.

KQ2: Other outcomes. LOS for acute hospitalization was reported in two trials ( $n = 326$ ) comparing skin traction versus no traction and no significant difference was found. Thirty-day mortality was reported in one RCT ( $n = 80$ ) that found no difference between skin and skeletal traction versus no traction. Additional pain medication use was reported in one RCT and one nRCT ( $n = 352$ ). There was no significant difference between groups.

KQ3: Adverse effects. Seven RCTs ( $n = 1,043$ ) and one cohort study ( $n = 134$ ) provided data on adverse effects. The reported adverse effects were from one to two studies, and did not demonstrate any significant statistical differences between the pain management interventions.

KQ 4: Efficacy, effectiveness, and safety in subpopulations. No data were reported.

## **Rating the Body of Evidence**

Most of the evidence for the key outcomes (acute pain, chronic pain, mortality [30-day]), and the incidence of serious adverse effects (i.e., delirium, myocardial infarction, renal failure, stroke) came from single trials and cohort studies precluding any conclusions. The strength of evidence was low to moderate to support the use of some interventions for alleviating acute pain, preventing delirium, and decreasing the 30-day mortality rate (see Table A). The strength of evidence for the remaining outcomes was classified as insufficient due to lack of an adequate number of studies and study power.

## **Future Research**

Multicenter research studies. Adequately powered multicenter research studies are needed to provide a comprehensive assessment of safe, effective, and appropriate pain management

following a hip fracture. Studies need to be large enough to allow subgroup analyses by age, sex, comorbidities, or functional groups (e.g., independent vs. dependent in ambulation). In addition, researchers need to consider inclusion of common subpopulations of hip fracture patients. In particular, those with altered cognition who make up a substantial proportion of the overall hip fracture patient population should be included in future studies of pain management following hip fracture.

**Outcomes.** Standardization of outcomes and outcome measures will allow easier and meaningful comparisons across different interventions and among studies. The types of outcomes reported do not reflect the multidimensional nature of pain. Relevant outcomes should include validated pain scores, prescription of opiates and other agents, and adverse effects or complications attributable or related to the intervention. Associated outcomes of pain such as function, quality of life, and time to recovery should also be evaluated. The evaluation of pain should include long-term followup of outcomes beyond the acute hospital setting to determine the pattern of pain recovery and whether early effective pain management techniques affect ultimate recovery levels.

**Methods.** Future research should seek to minimize bias by blinding outcome assessors, use of validated and standardized outcome assessment instruments, adequate allocation concealment (where applicable), and appropriate handling and reporting of missing data.

## **Conclusions**

For the majority of interventions, sparse data are available, which precludes firm conclusions for any single approach or for the optimal overall pain management following nonpathological hip fracture due to low energy trauma. The dearth of evidence related to long-term outcomes and the fact that the majority of the data is derived from studies of low methodological quality or from study designs associated with higher risk of bias (i.e., cohort studies) further weaken any conclusions. Overall, the evidence shows that most interventions result in improvements in short-term pain scores; however, few differences of long-term clinical importance are noticeable when comparisons between interventions are available. The rates of complication were generally low, and the majority of complications were not significantly different among the interventions. Well-designed and -powered, long-term trials are needed in order to determine the relative effectiveness of pain interventions for hip fracture patients. Until then, pain management in this population will rely heavily on availability of the interventions, staff skills, and training and pre-existing patient comorbidities.

**Table A. Summary of evidence for key outcomes for pain management following hip fracture**

Outcome	Comparison (# studies)	Strength of Evidence	Summary
<b><i>Systemic analgesia</i></b>			
Acute pain	Parecoxib IV vs. diclofenac ± meperidine IM (1 RCT)	Insufficient	Significant effect in favor of parecoxib IV (MD = -0.70; 95% CI -1.04, -0.36)
	Intrathecal isotonic clonidine vs. intrathecal hypertonic clonidine (1 RCT)		Significant effect in favor of intrathecal isotonic clonidine (MD = -1.69; 95% CI -2.01, -1.37)
	Lysine clonixinate vs. metamizole (1 RCT)		No significant difference
Acute pain at rest	Lysine clonixinate vs. metamizole (1 RCT)	Insufficient	No significant difference
Chronic pain	None	Insufficient	No data
30-day mortality	None	Insufficient	No data
Delirium	Lysine clonixinate vs. metamizole (1 RCT)	Insufficient	No significant difference
Myocardial infarction	None	Insufficient	No data
Renal failure	None	Insufficient	No data
Stroke	None	Insufficient	No data
<b><i>Anesthesia: spinal vs. general anesthesia</i></b>			
Acute pain	Spinal vs. general anesthesia (1 RCT)	Insufficient	Significant effect in favor of spinal anesthesia (MD = -0.86; 95% CI -1.30, -0.42)
Chronic pain	None	Insufficient	No data
30-day mortality	Spinal vs. general anesthesia (2 RCTs, 2 cohort studies)	Low	No significant difference
Delirium	Spinal vs. general anesthesia (1 RCT)	Insufficient	No significant difference
Myocardial infarction	Spinal vs. general anesthesia (2 RCT)	Insufficient	No significant difference
Renal failure	None	Insufficient	No data
Stroke	None	Insufficient	No data
<b><i>Anesthesia: spinal – continuous vs. single administration</i></b>			
Acute pain	None	Insufficient	No data
Chronic pain	None	Insufficient	No data
30-day mortality	Continuous vs. single administration (3 RCTs, 1 cohort study)	Low	No significant difference
Delirium	Continuous vs. single administration (2 RCTs)	Low	No significant difference
Myocardial infarction	Continuous vs. single administration (1 RCT)	Insufficient	No significant difference
Renal failure	None	Insufficient	No data
Stroke	Continuous vs. single administration (1 RCT)	Insufficient	No significant difference

**Table A. Summary of evidence for key outcomes for pain management following hip fracture (continued)**

Outcome	Comparison (# studies)	Strength of Evidence	Summary
<b><i>Anesthesia: spinal – addition of other medications</i></b>			
Acute pain	Addition of fentanyl vs. standard spinal anesthesia (1 RCT)	Insufficient	No significant difference
	Addition of morphine vs. standard spinal anesthesia (1 RCT)	Insufficient	No significant difference
	Addition of sufentanil vs. standard spinal anesthesia (1 RCT)	Insufficient	No significant difference
Chronic pain	None	Insufficient	No data
30-day mortality	None	Insufficient	No data
Delirium	Addition of morphine vs. standard spinal anesthesia (1 RCT)	Insufficient	No significant difference
Myocardial infarction	None	Insufficient	No data
Renal failure	None	Insufficient	No data
Stroke	None	Insufficient	No data
<b><i>Anesthesia: spinal – different doses</i></b>			
Acute pain	Bupivacaine 2.5mg vs. 5mg (1 cohort study)	Insufficient	No significant difference
Chronic pain	None	Insufficient	No data
30-day mortality	None	Insufficient	No data
Delirium	Bupivacaine 4mg vs. 12mg (1 cohort study)	Insufficient	No significant difference
Myocardial infarction	None	Insufficient	No data
Renal failure	None	Insufficient	No data
Stroke	None	Insufficient	No data
<b><i>Complementary and alternative medicine</i></b>			
Acute pain	Acupressure vs. standard care (1 RCT)	Insufficient	No significant difference
	Relaxation vs. standard care (1 RCT)	Insufficient	No significant difference
Chronic pain	None	Insufficient	No data
30-day mortality	None	Insufficient	No data
Delirium	None	Insufficient	No data
Myocardial infarction	None	Insufficient	No data
Renal failure	None	Insufficient	No data
Stroke	None	Insufficient	No data



**Table A. Summary of evidence for key outcomes for pain management following hip fracture (continued)**

Outcome	Comparison (# studies)	Strength of Evidence	Summary
<b>Multimodal pain management</b>			
Acute pain	None	Insufficient	No data
Chronic pain	None	Insufficient	No data
30-day mortality	Multimodal pain management vs. standard care (1 cohort study)	Insufficient	No significant difference
Delirium	Multimodal pain management vs. standard care (1 cohort study)	Insufficient	No significant difference
Myocardial infarction	Multimodal pain management vs. standard care (1 cohort study)	Insufficient	No significant difference
Renal failure	None	Insufficient	No data
Stroke	Multimodal pain management vs. standard care (1 cohort study)	Insufficient	No significant difference
<b>Nerve blockade</b>			
Acute pain	Nerve block vs. no nerve block (11 RCTs)	Moderate	Significant effect in favor of nerve block in subgroup analyses
Pain on movement	Nerve block vs. no nerve block (4 RCTs)	Low	Significant effect in favor of nerve block in subgroup analyses
Pain at rest	Nerve block vs. no nerve block (3 RCTs)	Low	Data inconsistent for conclusions to be made
Day 1 pain	Nerve block vs. no nerve block (1 RCTs)	Insufficient	No significant difference
Chronic pain	None	Insufficient	No data
30-day mortality	Nerve block vs. no nerve block (4 RCTs)	Low	No significant difference
Delirium	Nerve block vs. no nerve block (3 RCTs, 2 cohort studies)	Moderate	Significant effect in favor of nerve block (OR <sub>RCT</sub> = 0.36; 95% CI 0.17, 0.74) (OR <sub>Cohort</sub> = 0.24; 95% CI 0.08, 0.72)
Myocardial infarction	Nerve block vs. no nerve block (2 RCTs, 1 cohort study)	Insufficient	No significant difference
Stroke	Nerve block vs. no nerve block (1 RCT, 1 cohort study)	Insufficient	No significant difference
Renal failure	None	Insufficient	No data
<b>Nerve blockade vs. regional anesthesia</b>			
Acute pain	Nerve block vs. regional anesthesia (3 RCTs)	Low	No significant difference
Chronic pain	None	Insufficient	No data
30-day mortality	None	Insufficient	No data
Delirium	Nerve block vs. regional anesthesia (1 RCT)	Insufficient	No significant difference
Myocardial infarction	None	Insufficient	No data
Renal failure	None	Insufficient	No data
Stroke	None	Insufficient	No data

**Table A. Summary of evidence for key outcomes for pain management following hip fracture (continued)**

Outcome	Comparison (# studies)	Strength of Evidence	Summary
<b><i>Nerve Blocks: ropivacaine vs. bupivacaine</i></b>			
Acute pain	None	Insufficient	No data
Chronic pain	None	Insufficient	No data
30-day mortality	None	Insufficient	No data
Delirium	Ropivacaine vs. bupivacaine (1 cohort study)	Insufficient	No significant difference
Myocardial infarction	None	Insufficient	No data
Renal failure	None	Insufficient	No data
Stroke	None	Insufficient	No data
<b><i>Neurostimulation</i></b>			
Acute pain	Neurostimulation vs. standard care (2 RCTs)	Insufficient	Significant effect in favor of neurostimulation (MD = -2.79; 95% CI -4.95, -0.64)
Pain on movement	Neurostimulation vs. standard care (1 RCT)	Insufficient	Significant effect in favor of neurostimulation (MD = -3.90; 95% CI -6.22, -1.58)
Chronic pain	None	Insufficient	No data
30-day mortality	None	Insufficient	No data
Delirium	None	Insufficient	No data
Myocardial infarction	None	Insufficient	No data
Renal failure	None	Insufficient	No data
Stroke	None	Insufficient	No data
<b><i>Rehabilitation</i></b>			
Acute pain	Physical therapy vs. standard care (1 RCT)	Insufficient	Significant effect in favor of physical therapy (MD = -1.39; 95% CI -2.27, -0.51)
Chronic pain	None	Insufficient	No data
30-day mortality	None	Insufficient	No data
Delirium	None	Insufficient	No data
Myocardial infarction	None	Insufficient	No data
Renal failure	None	Insufficient	No data
Stroke	None	Insufficient	No data
<b><i>Traction</i></b>			
Acute pain	Skin traction vs. no traction (7 RCTs)	Low	No significant difference
	Skin traction vs. skeletal traction (1 RCT)	Insufficient	No significant difference
Chronic pain	None	Insufficient	No data
30-day mortality	Skin traction vs. no traction (1 RCT)	Insufficient	No significant difference
	Skeletal traction vs. no traction (1 RCT)	Insufficient	No significant difference
Delirium	None	Insufficient	No data
Myocardial infarction	None	Insufficient	No data
Renal failure	None	Insufficient	No data
Stroke	None	Insufficient	No data

CI = confidence interval; IM = intramuscular; IV = intravenous; MD = mean difference; OR = odds ratio; RCT = randomized controlled trial

# Introduction

## Background

Hip fractures are a source of significant morbidity and mortality. Incidence increases substantially with age, rising for men and women, respectively, from 22.5 and 23.9 per 100,000 population at age 50, to 630.2 and 1,289.3 per 100,000 population by age 80.<sup>1-4</sup> The impact of hip fractures is far reaching. Short-term mortality rates are high and range from 25 percent for women to 37 percent for men in the first year following a hip fracture.<sup>5</sup> Furthermore, a large proportion of those patients who survive never recover to their prefracture level of function,<sup>6-8</sup> and approximately 25 to 50 percent of elderly patients with hip fractures have not returned home by 1 year postfracture.<sup>9</sup> Up to 25 percent of hip fractures occur in continuing care facilities (long-term residential care for dependent people).<sup>10,11</sup> Because of poor functional recovery, health service utilization associated with recovery is substantially increased for at least 1 year, with much of the health care cost attributable to subsequent long-term care.<sup>1,12-14</sup>

Pain following hip fracture has been associated with delirium, depression, sleep disturbance, and decreased response to interventions for other disease states.<sup>15-17</sup> Therefore, it is important to treat and manage complaints of pain adequately during acute treatment for hip fracture. Furthermore, poorly managed postoperative pain is associated with delayed ambulation, pulmonary complications, and delayed transition to lower levels of care.<sup>18</sup>

Hip fracture patients require a continuum of pain management from the time of prehospital admission through the completion of final rehabilitation. Therefore the interventions administered to relieve pain in this population can be divided according to both the timing of the intervention (e.g., pre-, peri-, and postoperative) and according to their classification (e.g., systemic analgesia, nerve blocks, etc.).

According to the timing of the intervention, preoperative pain management has traditionally been achieved using systemic analgesia and in some cases, lower limb traction. Recently, nerve blocks, which block the nerve impulses from reaching the sensory cortex, have been introduced.

Intra-operative pain management has also traditionally been achieved with systemic analgesia in association with general anesthesia. Even so, neuraxial anesthesia is gaining momentum as a replacement for general anesthesia.

Postoperative pain management is usually accomplished by a more diverse array of interventions including systemic analgesia, nerve blocks, physical therapy, and transcutaneous electrical nerve stimulation (TENS).

## Interventions

Pain management interventions can be divided into pharmacological and nonpharmacological interventions. Pharmacological interventions include systemic analgesia and medications used in nerve blocks and neuraxial anesthesia (e.g., bupivacaine). Nonpharmacological interventions include TENS, acupuncture, or stabilization of the fracture using traction. The following broad categories represent the interventions covered by this report.

## **Systemic Analgesia**

This classification of intervention is broad and encompasses both narcotic and non-narcotic medications. The general goal is to provide pharmacologic analgesia although some also have anti-inflammatory properties.

Opiates (e.g., morphine) can be used at all stages of pain management to treat mild to severe pain.<sup>19</sup> Fentanyl, primarily targets the *mu* receptors in the brain and spinal cord and, is used in the treatment of severe pain. Sufentanil is 5–10 times more potent than fentanyl and, due to its immediate onset of action and its limited accumulation, it is ideal for short, quick action.

Nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g., diclofenac) are used for their analgesic properties and act by inhibiting both cyclooxygenase (COX) isoenzymes (COX-1 and COX-2).<sup>20</sup> Acetaminophen, a commonly used analgesic, has minimal inhibition of COX-1 and COX-2, with appreciable inhibition of central COX-3, but its precise mechanism for analgesia has not been confirmed. The use of COX-II selective inhibitors (coxibs) has fluctuated since their introduction on the U.S. market in the 1990s with the current use of coxibs in decline.

## **Anesthesia**

Anesthesia can generally be divided into general and neuraxial, with the latter constituting spinal and epidural anesthesia. Pain management during general anesthesia is usually accomplished by the use of pharmacological systemic analgesia (e.g., opioids). During neuraxial anesthesia, injection of a local anesthetic into the epidural or subarachnoid space (e.g., spinal anesthesia) causes pain relief and often does not require additional pain medications.

## **Complementary and Alternative Medicine (CAM)**

Complementary and alternative medicine (CAM) has been defined as a group of diverse medical and health care systems, practices, and products that are not generally considered part of conventional medicine (i.e., medicine as practiced by holders of M.D. (medical doctor) and D.O. (doctor of osteopathy) degrees and by allied health professionals, such as physical therapists, psychologists, and registered nurses).<sup>21</sup> CAM practices are often grouped into broad categories, such as natural products, mind-body medicine, and manipulative and body-based practices. In this report, two CAM practices were identified as having been used with hip fracture patients: acupressure and the Jacobson relaxation technique.

According to traditional Chinese acupuncture, auricular acupressure involves the placing of tiny beads onto the outer ear at acupuncture points, thereby stimulating the corresponding acupuncture points. Bilateral auricular acupressure can be performed at sites known to decrease pain and anxiety (e.g., shenmen, hip, valium point).<sup>22</sup> Using these body points, areas can be stimulated to direct energy flow.

Another CAM procedure used for hip fracture patients is the Jacobson relaxation technique. This involves a two-step process of contracting and relaxing specific muscles. With practice the patient learns which muscles are related to pain and relaxes them.

## **Multimodal Pain Management**

Multimodal pain management is the use of multiple pain management strategies (consecutively or in parallel) as part of the clinical pathway for patients with hip fractures. The goal is to decrease pain to a greater extent than with one intervention alone.

## **Nerve Blocks**

Nerve blocks include the lateral cutaneous nerve of the thigh, femoral nerve, sciatic nerve, 3-in-1 nerve block (femoral, obturator, and sciatic nerves), psoas (lumbar plexus), or continuous epidural block.<sup>23</sup> Local anesthetics (e.g., bupivacaine) are used in regional nerve blocks to prevent the generation and conduction of nerve impulses to the spinal column and brain.<sup>24</sup> Additional medications used with nerve blocks include clonidine, morphine, fentanyl, and sulfetanil.

## **Rehabilitation**

Rehabilitation is a standard part of postoperative care in patients with hip fractures to increase mobility and reduce pain. The goal is to increase muscle strength and range of motion as soon as possible following hip fracture. One of the major factors that can limit patient participation in rehabilitation is the degree of delirium and pain that the patient may be experiencing.

## **Traction**

Preoperative skin or skeletal traction was traditionally standard care in this patient population. The theory is that by maintaining the lower limb stretched, using 5 to 10 pounds, intracapsular pressure and pain is decreased, and fracture reduction is made easier. However, a recent Cochrane systematic review of 10 randomized controlled trials (1,546 participants) reported no benefits for traction use.<sup>25</sup>

Skin traction is used to stabilize a fractured leg and to decrease pain and the risk of surgical complications prior to any operation. Skin traction is applied by using adhesive tape, bandaging the limb, and placing it on a traction sled with an appropriate weight hung from it.<sup>20,26</sup> Foam boot traction, a form of skin traction, uses a foam boot strapped around the leg and placed on a traction sled with an appropriate weight attached.<sup>26</sup> Skeletal traction involves passing a metal pin through the proximal tibia or distal femur, under local anesthesia. Traction is applied using ropes and weights attached to the end of the pin.<sup>20</sup>

## **Transcutaneous Electrical Nerve Stimulation (TENS)**

TENS uses electrodes to apply electrical energy to peripheral nerves to treat acute and chronic musculoskeletal pain. Electrical stimulation can be administered at varying amplitudes and frequencies, depending on the indication.<sup>27</sup>

## **Outcomes**

The patient's self-report of pain is the gold standard for evaluating its character and intensity.<sup>15</sup> However, those with dementia or acute delirium may have difficulty reporting pain levels. Acute delirium, or confusion, following hip fracture may be a complication of the fracture, the resulting pain due to tissue trauma and/or the pain management interventions used. The potential for underreporting of pain has direct ramifications for the hip fracture population, as many patients are frail older people with postoperative confusion and an impaired ability to communicate.<sup>28-31</sup>

The most commonly used measure of pain in clinical settings is the visual analogue scale (VAS).<sup>32</sup> It consists of a 100mm unmarked line printed where the patients are instructed to point to the position on the line to indicate how much pain they are currently feeling. The far left end

of the line indicates “No pain” and the far right end of the line indicates “Worst pain ever.” Its ease of use, especially with older patients, reproducible results and extensive use in clinical practice makes it one of the first choices among pain measurement scales.<sup>33</sup> Additionally, it has been shown not to be biased by the severity of pain.<sup>34</sup>

Other commonly used scales include numerical, verbal, and facial pain scales. The numerical scales usually consist of a number between zero and 10, and the patients are instructed to give a number relating to how much pain they are currently feeling, with the higher numbers indicating greater pain intensity. Many variations of this scale exist including a numerical scale of zero to three, one to five, etc. Numerical scales have been shown to have a linear correlation with the VAS and don't require the use of any printed material.<sup>35,36</sup>

With regard to clinically important effect size differences for pain measurements, no exact cutoff has been defined in the medical literature; however, it has been widely accepted as ranging from 20 to 30 percent absolute pain reduction. This would reflect an additional 30mm of absolute difference on the VAS.

Most research to date has focused on the management of acute pain, the expected sensory and emotional response to injury, which lasts for the duration of the injury and healing (i.e., up to 30 days post hip fracture). It is possible that pain following a hip fracture has longer-term effects on recovery as has been seen in recovery from hip replacement surgery.

The need to improve recovery after hip fracture, particularly among frail elderly patients, is a pressing worldwide problem that will only increase in the future as the population ages.<sup>37</sup> Synthesized data are lacking regarding pain management after hip fracture; therefore, our review will be of interest to patients and families, the medical community and health care decisionmakers. The review will also elucidate evidence on important subgroups of patients and interventions for which further research is needed.

## Scope and Key Questions

We have focused the key questions using the PICOTS framework (population, intervention, comparison, outcome, timing, and setting) as follows:

### Key Question 1

In older adults ( $\geq 50$  years) admitted to the hospital following acute hip fracture, what is the effectiveness of pharmacologic and/or nonpharmacologic pain management interventions for controlling acute (up to 30 days postfracture) and chronic pain (up to 1 year postfracture) compared with usual care or other interventions in all settings?

### Key Question 2

In older adults ( $\geq 50$  years) admitted to the hospital following acute hip fracture, what is the effectiveness of pharmacologic and/or nonpharmacologic pain management interventions on other outcomes up to 1 year postfracture compared with usual care or other interventions in all settings? Other outcomes include:

- a. Mortality (30-day and up to 1 year postfracture)
- b. Functional status
- c. Pain medication use; change in type and quantity
- d. Mental status
- e. Health-related quality of life
- f. Quality of sleep in the hospital

- g. Ability to participate in rehabilitation
- h. Return to prefracture living arrangements
- i. Health services utilization

### Key Question 3

In older adults ( $\geq 50$  years) admitted to the hospital following acute hip fracture, what is the nature and frequency of adverse effects that are directly or indirectly associated with pharmacologic and nonpharmacologic pain management interventions up to 1 year postfracture compared with usual care or other interventions in all settings?

### Key Question 4

In older adults ( $\geq 50$  years) admitted to the hospital following acute hip fracture, how do the effectiveness and safety of pharmacologic and nonpharmacologic pain management interventions vary in differing subpopulations following acute hip fracture up to 1 year after fracture compared with usual care or other interventions in all settings?

Important refinement points regarding the key questions:

- **Population(s):**

Older adults of either sex who were diagnosed as having an acute hip fracture resulting from low-energy trauma (e.g., slip and fall) were included. This includes patients with intracapsular (e.g., subcapital and femoral neck) and extracapsular (e.g., basal, trochanteric, intertrochanteric, and subtrochanteric) fractures regardless of whether surgical repair was performed. There were no restrictions on comorbidities or baseline functionality.

Patients with hip fracture due to the following etiologies were not considered: pathologic hip fractures (e.g., metastatic fractures, Paget's disease); femoral head fractures; periprosthetic fractures (i.e., post-hip replacement fractures/arthroplasty population); fractures resulting from high energy trauma (e.g., motor vehicle crashes, falls from heights, etc.).

- **Interventions:**

We considered all interventions, alone or in combination, with various methods of administration and modes of delivery, and at various time points during the care pathway (e.g., preoperative, intra-operative, postoperative, rehabilitation, and following discharge from acute care). The same intervention may be administered at different time points (e.g., epidural block for preoperative analgesia and intra-operatively for anesthesia). Interventions included traditional and nontraditional medications/interventions (e.g., natural health products). Interventions that were directly related to surgical/nonsurgical treatment of the hip fracture (e.g., reduction, fixation, hemiarthroplasty, total hip replacement) were not considered.

- **Comparators:**

Comparators of interest were defined in the primary studies. This included, but was not limited to, opioid, nonopioid, or NSAIDs, and nonpharmacological comparators.

- **Outcomes for each question:**

For KQ1, pain had to be assessed using a validated pain measurement tool—either patient defined or proxy reported.

For KQ2, all reported outcomes that were directly or indirectly related to the intervention for pain management were investigated.

For KQ3, all reported adverse effects that were directly or indirectly associated to the intervention for pain management (e.g., medication complications such as constipation or gastrointestinal bleeding; pain interventions (e.g., femoral blocks) that may delay ambulation) were investigated. Adverse effects of interventions directly related to surgical/nonsurgical/medical treatment of the hip fracture (e.g., wound infection, etc.) were not investigated.

For KQ4: Subgroups to be investigated included sex, age, race, marital status, comorbidities, body mass index, prefracture functional status, and family distress.

- **Timing:**

We included all followup time points from the time of the trauma leading to the hip fracture and thereafter.


- **Settings:**

Settings included, but were not limited to, emergency department, hospital, rehabilitation facilities, skilled nursing facility, subacute care facility, and place of residence.

Figure 1 provides an analytic framework to illustrate the population, interventions, and outcomes that guided the literature search and synthesis. The figure depicts the key questions within the context of the PICOTS described in the previous section. In general, the figure illustrates how pharmacologic and nonpharmacologic pain management interventions, alone or in combination, may result in (1) intermediate outcomes such as control of acute pain, pain medication use, the ability to participate in rehabilitation, the quality of sleep in hospital, and length of stay, and (2) long-term outcomes such as chronic pain, changes in the mental status, the functional status (e.g., activities of daily living), the ability to return to prefracture place of residence, health-related quality of life, health service utilization, and mortality. Also, adverse effects may occur at any point after the treatment is received (e.g., medication adverse effects such as constipation, gastrointestinal irritation, rash).



**Figure 1. Analytic framework for pain management interventions**



## Methods

This chapter describes the prospectively designed protocol that the University of Alberta Evidence-based Practice Center (UAEPC) used to synthesize the evidence on pain management interventions following hip fracture. The topic refinement process for developing the key questions is described. We outline the literature search strategy, the selection process for identifying relevant articles, the process for extracting data from eligible studies, the methods for assessing the methodological quality of individual studies and for rating the overall body of evidence, and our approach to data analysis and synthesis.

### Topic Development

The UAEPC was commissioned to conduct a preliminary literature review to gauge the availability of evidence and to draft the key research questions for a full comparative effectiveness review (CER). In consultation with the Agency for Healthcare Research and Quality (AHRQ) and the Scientific Resource Center, a Technical Expert Panel (TEP) was invited to provide input in the development of the key questions and scope of the report. Initial questions were posted on the AHRQ Web site, and the public was invited to comment on these questions. After reviewing the public comments, the key questions were finalized and submitted to AHRQ for approval.

The TEP was subsequently invited to provide high-level content and methodological expertise throughout the development of the CER. The names of technical experts are available in Appendix A.

### Search Strategy

The research librarian, in collaboration with the research team, developed and implemented search strategies designed to identify evidence relevant to the key questions (Appendix B).

For the questions on efficacy and effectiveness, we conducted comprehensive searches in the following electronic databases: AMED (Allied and Complementary Medicine); Global Health; International Pharmaceutical Abstracts; BIOSIS Previews; CINAHL (Cumulative Index to Nursing & Allied Health Literature); Academic Search Elite and Health Source: Nursing and Academic Edition; Cochrane Complementary Alternative Medicine and Pain Database; Cochrane Database of Systematic Reviews; Database of Abstracts of Reviews of Effects; EBM Reviews – Cochrane Central Register of Controlled Trials; Embase; Global Health Library; MEDLINE; Pascal; PeDRO (The Physical Therapy Evidence Database); ProQuest Dissertations and Theses–Full Text; Scopus; Web of Science. For the questions on adverse effects, in addition to the above databases, we also searched TOXLINE (Appendix B-1 to B-15).

In order to identify literature from symposia proceedings, we searched Conference Papers Index (1982 to 2010), OCLC PapersFirst (1993 to 2010), and ScienceDirect Tables of Contents for select journals (Appendix B). We also hand searched proceedings for the following associations: American Geriatric Society, American Physical Therapy Association, American Society of Regional Anesthesia and Pain Medicine, European Society of Regional Anesthesia, European Society of Anesthesiology, and International Anesthesia Research Society (Appendix B-16 to B-19).

Unpublished studies and studies in progress were identified by searches of clinical trials registers (ClinicalStudyResults.org; ClinicalTrials.gov; Current Controlled Trials; ICTRP Search

Portal; IFPMA Clinical Trials Portal; UMIN-CTR Clinical Trials) (Appendix B-20 to B-25), by contacting experts in the field, and by contacting authors of relevant studies.

The reference lists of reviews and guidelines were reviewed to help identify potential studies for inclusion. Original studies that met the inclusion criteria for this review were searched for citing studies using Scopus Citation Tracker.

Search terms were selected by scanning search strategies of systematic reviews on similar topics and by examining index terms of potentially relevant studies. A combination of subject headings and text words were adapted for each electronic resource. This included terms for hip fracture (fracture\* and (hip or intertrochanter\* or petrochanter\* or subtrochanter\* or intracapsular or extracapsular or petrochant\* or trochant\* or hip or "femoral neck")) and pain terms (pain\* or heal or healing or therap\* or recover\* or "quality of life" or rehabilitat\* or "drug therapy" or pharmacological or acupunct\* or acupress\* or traction or "electrical stimulation" or "passive motion" or morphine or acetaminophen or paracetamol or tylenol or anesth\* or analges\*). All searches were restricted to studies published from 1990. No language or study design restrictions were applied. The detailed search strategies for each database are presented in Appendix B. The original searches were conducted between July 9 and July 27, 2009. On May 6, 2010 and December 16, 2010, the searches were updated using the original search strategies in Ovid MEDLINE, Embase, Cochrane Central Register of Controlled Trials, PASCAL, CINAHL, Scopus, DARE and ClinicalTrials.gov.

Results from the literature searches were entered into Reference Manager 11.0.1 (Thomson Reuters, Carlsbad, CA).

## Study Selection

The results of the electronic literature searches, hand searches, and expert nominated records were screened using a two-step process. We included studies published as full-text manuscripts, conference abstracts, or other grey literature with no language restrictions. Research published prior to 1990 was not considered based on the rationale that surgical procedures and medical care in North America (particularly as related to aggressive postsurgery mobilization) for this patient population has changed and the earlier research may not be applicable to current care.

Study selection was based on an a priori set of criteria for inclusion and exclusion of studies including study design, patient population, interventions, and outcome measures (Table 1). First, two reviewers independently screened the titles and abstracts (level I screening) to determine if an article met the broad inclusion/exclusion criteria for study design, population, and intervention. Each article was rated independently as: include, exclude or unclear. Records rated as "include" or "unclear" by at least one reviewer were advanced to level II screening. The full-text versions of all potentially relevant articles were retrieved for independent formal review by two reviewers, applying a priori eligibility criteria and using a standardized screening form that was developed and piloted by the review team. Discrepancies regarding inclusion/exclusion of a study were resolved through discussion and consensus or by third-party adjudication if consensus could not be reached. Reviewers were not masked to the study authors, institution, or journal.<sup>38</sup>

**Table 1. Inclusion and exclusion criteria****(A) Inclusion criteria**

<b>Study design</b>	Randomized controlled trials , nonrandomized controlled trials (e.g. quasi-randomized trials), cohort studies (prospective or retrospective), case-control studies
<b>Participants</b>	Older adults ( $\geq 50$ years old) of either sex admitted to hospital with acute hip fracture due to low energy trauma
<b>Interventions</b>	Pharmacological and/or nonpharmacological pain management monotherapy or combination therapy, regardless of mode of administration or time point during the care pathway
<b>Comparator</b>	Usual care (as defined by study authors) or another intervention(s) for pain management, administered as monotherapy or combination therapy
<b>Outcomes</b>	Primary outcomes: <ul style="list-style-type: none"> <li>• Acute pain</li> <li>• Chronic pain</li> </ul> Secondary outcomes: <ul style="list-style-type: none"> <li>• Mortality</li> <li>• Functional status</li> <li>• Pain medication use; change in type and quantity</li> </ul> Adverse effects: <ul style="list-style-type: none"> <li>• Adverse effects related to the pain management intervention</li> <li>• Mental status</li> <li>• Health-related quality of life</li> <li>• Quality of sleep in hospital</li> <li>• Ability to participate in rehabilitation</li> <li>• Return to prefracture place of residence</li> <li>• Length of stay for acute hospitalization, skilled nursing facility, subacute care facility</li> <li>• Health service utilization</li> </ul>
<b>Timing</b>	From time of trauma leading to acute hip fracture and thereafter
<b>Setting</b>	All settings

**(B) Exclusion criteria**

<b>Study design</b>	Observational study designs with no comparison group (case reports, case series, cross-sectional studies)
<b>Participants</b>	Majority (>80%) of participants <50 years, as stated by the study investigators or evident from the study characteristics (e.g., mean/SD of patient population); participants with underlying pathological conditions that may directly lead to fracture; acute hip fractures due to high energy trauma
<b>Interventions</b>	Interventions directly related to surgical/nonsurgical treatment of the hip fracture and not a pain management intervention
<b>Comparator</b>	Initial care for patients is substantially different than the current practices in North America (e.g., based on time to discharge from acute care to subacute care)
<b>Outcomes</b>	None of the aforementioned outcomes were available from the trial report or through communication with the study's corresponding author

**Assessment of Methodological Quality of Individual Studies**

The risk of bias of the included trials was assessed using the Cochrane Collaboration's Risk of Bias (RoB) tool<sup>39</sup> for randomized controlled trials (RCTs) and nonrandomized controlled trials (nRCTs). The methodological quality of cohort and case-control studies was assessed using the Newcastle-Ottawa Scale (NOS)<sup>40</sup> for cohort and case-control studies, respectively. Decision rules regarding application of the tools were developed a priori by the research team. For RCTs and nRCTs, we performed a domain-based risk of bias assessment according to the principles of the RoB tool. The domains were: (1) sequence generation (e.g., was the allocation sequence adequately generated?); (2) allocation concealment (e.g., was allocation adequately concealed?); (3) blinding of participants, personnel and outcome, assessors (e.g., was knowledge of the

allocated intervention adequately prevented during the study?); (4) incomplete outcome data (e.g., were incomplete outcome data adequately addressed?); (5) selective outcome reporting (e.g., were reports of the study free of suggestion of selective outcome reporting?); and (6) other sources of bias (e.g., was the study apparently free of other problems that could put it at a high risk of bias?). Other sources of bias included baseline imbalances, source of funding, early stopping for benefit, appropriateness of crossover design. For cohort and case-control studies, the NOS uses a “star system” in which a study is judged on three broad perspectives: (1) the selection of the study groups; (2) the comparability of the groups; and (3) the ascertainment of either the exposure or outcome of interest for case-control or cohort studies, respectively.

Two reviewers in a four-person team (AMAS, MH, MK, KW) independently performed quality assessment of the included studies with disagreements resolved through discussion or third-party adjudication, as needed.

## Data Extraction

Published data were independently double-extracted by members of the research team (AMAS, MH, MK, KW, SM). Standardized data extraction forms were developed in Microsoft Word (Microsoft Corporation, Redmond, WA; Appendix C). Data extraction forms were piloted with three studies<sup>41-43</sup> and identified issues were resolved. We extracted data on the following: general study characteristics (e.g., study design); population characteristics (e.g., age, sex); interventions and dosing regimens; numbers of patients allocated into relevant treatment groups; outcomes measured, method of ascertainment, and the results of each outcome, including measures of variability, by relevant intervention arm. Funding source, if reported, was also recorded.

When there were multiple reports of the same study we referenced the primary or most relevant study, and extracted only additional data from companion reports. Corresponding authors were contacted for data clarification and missing data. All data were imported into Microsoft Excel (Microsoft Corporation, Redmond, WA) for data management.

Dichotomous data were extracted as the number (n) of participants with events and the total number of participants (N). Continuous outcomes were extracted as the mean with the accompanying measure of variance for each treatment group, or as a mean difference (MD) between treatments based on the method of outcome measurement (e.g., scale, score system). Continuous data were analyzed as post-treatment score or absolute difference (or change score) from baseline.<sup>44</sup> Multiple scales and scoring systems were used to measure the outcomes (e.g., pain scores). Therefore, in addition to summary data and measure of variance, the scale and the type of analysis used in the study were extracted (Appendix C). For all outcomes (e.g., delirium, hypotension) we used the definitions as reported by the authors of individual studies.

When data were available only in a graphical format, data were extracted from the available graphs using the distance measurement tool in Adobe Acrobat 8 Professional (Adobe Systems Inc., San Jose, CA). When data were not available for the measure of variability for continuous outcomes, the variability was calculated from the computed p-value or, if not available, it was imputed from other studies in the same analysis. When relevant data for multiple followup/observation periods were reported, only the followup data for the reported period that demonstrated the greatest improvement for the intervention arm was extracted. When studies incorporated multiple relevant treatment arms, data from all were extracted. We noted the specific intervention, dosage and intervals of each intervention to determine if arms were

clinically appropriate for pooling. For the purpose of this review, acute outcomes (mortality, acute pain, and delirium) occurred up to 30 days postfracture.

## Data Analysis

Evidence tables and qualitative description of results are presented for all included studies. Where appropriate, we conducted meta-analyses to answer the key questions. Meta-analyses were performed in Review Manager 5.0 (The Cochrane Collaboration, Copenhagen, Denmark). For dichotomous outcomes, the Review Manager software allows pooling with one of the following statistical methods: Mantel-Haenszel (MH), inverse variance (IV) or the Peto's modified Mantel-Haenszel (Peto). For continuous outcomes, pooling is performed using IV. Additionally, for the aforementioned methods both fixed-effects or random-effects models are available, except for Peto, which uses only a fixed-effect model. For the purpose of this review, we pooled binary data using the MH and a random-effects model (DerSimonian and Laird),<sup>45</sup> except in instances where the percentage of participants with an event was less than one percent, in which case Peto's odds ratio was calculated using a fixed-effects model.<sup>46</sup> For continuous outcomes, we used the IV and a random-effects model (DerSimonian and Laird).<sup>45</sup> Chi-square tests were used to test for significant heterogeneity reduction in partitioned subgroups. A chi-square test of  $p < 0.1$  was considered to be significant. Forest plots were generated and presented for the primary outcomes as long as at least two trials contributed to the synthesis. For secondary outcomes, forest plots were presented only if there were at least five included studies.

In the meta-analyses, RCTs and nRCTs were combined. Cohort studies were synthesized separately, as meta-analysis including both trials and cohort studies is controversial.<sup>47</sup> For continuous summary estimates where the same measure of analysis was used the MD was calculated with 95 percent confidence intervals (CI). When different measures of analysis (e.g., different scales) were used, the standardized mean difference was used. Dichotomous summary estimates were reported as odds ratios with accompanying 95 percent CI.

Heterogeneity was tested using an  $I^2$  statistic,<sup>48</sup> with an  $I^2$  value 75 percent or greater considered to be substantial, thereby precluding pooling of studies. In the case of substantial statistical heterogeneity, if there were at least 10 studies in the analysis, we proposed to explore heterogeneity through meta-regression, subgroup analyses, and sensitivity analyses. If the number of included studies was less than 10, we explored heterogeneity qualitatively through subgroup and sensitivity analyses. Effect modifiers that were considered important to explain heterogeneity included specific intervention details (e.g., type and quantity), study design, and risk of bias. In addition, we conducted sensitivity analyses on studies with imputed data to determine if the imputations had any effect on the effect estimate or heterogeneity. A priori subgroup analyses included sex, age, race, body mass index, marital status, comorbidities, prefracture functional ability, and family distress.

Almost one-fourth (22.1 percent) of the trials had multiple intervention arms comparing different doses or concentrations of the same intervention, or drugs of the same class. When appropriate, data from the available arms were pooled before being included in the meta-analysis. Dichotomous arms were pooled by simple addition, while pooling of continuous arms was performed using generic inverse variance.

Dichotomous data with zero values (i.e., no participant experienced an event) were not included in meta-analyses because summary trial results were not estimable, but the results from these studies were reported in the narrative synthesis for the relevant intervention.

Potential publication bias was explored graphically through funnel plots for comparisons for which meta-analyses were conducted and when there were at least 10 studies in the analysis. Additionally, if bias was suspected, publication bias was quantitatively assessed using the Begg adjusted rank correlation test and Egger regression asymmetry test.<sup>49</sup>

## **Applicability**

Applicability of evidence distinguishes between effectiveness studies conducted in primary care or office-based settings that use less stringent eligibility criteria, assess health outcomes, and have longer followup periods than most efficacy studies.<sup>50</sup> The results of effectiveness studies are more applicable to the spectrum of patients in the community, than efficacy studies, which usually involve highly selected populations. The applicability of the body of evidence was assessed following the PICOTS (population, intervention, comparator, outcomes, timing of outcome measurement, setting) format used to assess study characteristics. Clinically important outcomes and participant characteristics are reported in the results.

## **Rating the Body of Evidence**

We evaluated the overall strength of the evidence for key outcomes. We used the AHRQ GRADE<sup>51</sup> approach, which is based on the standard GRADE approach developed by the Grading of Recommendation Assessment, Development and Evaluation (GRADE) Working Group.<sup>52</sup> The strength of evidence was assessed for outcomes identified by the clinical investigators to be most clinically important: acute pain, chronic pain, mortality (30-day), and the incidence of serious adverse effects (e.g., stroke, myocardial infarction, delirium, renal failure). The following four major domains were examined: risk of bias (low, medium, high), consistency (inconsistency not present, inconsistency present, unknown or not applicable), directness (direct, indirect), and precision (precise, imprecise).

Each key outcome on each comparison of interest was given an overall evidence grade based on the ratings for the individual domains. The overall strength of evidence was graded as “high” (indicating high confidence that the evidence reflects the true effect and further research is very unlikely to change our confidence in the estimate of effect); “moderate” (indicating moderate confidence that the evidence reflects the true effect and further research may change our confidence in the estimate of effect and may change the estimate); “low” (indicating low confidence that the evidence reflects the true effect and further research is likely to change our confidence in the estimate of effect and is likely to change the estimate); and “insufficient” (indicating that evidence is either unavailable or does not permit estimation of an effect). When no studies were available for an outcome or comparison of interest, the evidence was graded as insufficient. A detailed explanation of the parameters used to grade the evidence and their operationalization are summarized in Appendix J. The GRADEprofiler (GRADEpro), software (GRADE Working Group) was used and the results modified in accordance with the AHRQ GRADE model. The body of evidence was graded independently by two reviewers (AMAS, DD); disagreements were resolved through discussion.

## **Peer Review**

Ten experts in the field (Appendix A) agreed to peer review the draft report and provide comments. Reviewer comments were considered by the UAEPC in preparation of the final

report. All peer reviewer comments and the UAEPC disposition of comments were submitted to AHRQ for assessment and approval.




# Results

## Search Results

All citations generated from electronic or hand searching and expert nominated studies were pooled into a single database (Figure 2).<sup>53</sup> Of these 9,357 citations retrieved, 2,241 were duplicates and 7,116 were considered to be unique study reports. Following level I screening, 6,496 were excluded and 620 were further evaluated for inclusion. Of these, 83 primary publications<sup>26,41-43,54-132</sup> passed level II screening and were included in this Comparative Effectiveness Review. An additional 15 companion publications<sup>133-146</sup> were identified and also included. The characteristics of the publications excluded at level II screening are presented in Appendix D. The main exclusion criteria were publication type (e.g., case-report, observational study, review), population characteristics (e.g., average age below 50, fractures other than hip fractures), no details of pain management intervention, and no extractable data related to outcomes of importance to the review (e.g., ongoing studies).

**Figure 2. Flow diagram for study retrieval and selection**



## Description of Included Studies

Based on the interventions reported in each study, the primary publications were divided into eight groups: systemic analgesia (n = 3),<sup>41,42,55</sup> anesthesia (n = 30),<sup>56-73,75-85,145</sup> complementary and alternative medicine (CAM) (n = 2),<sup>43,54</sup> multimodal pain management (n = 2),<sup>86,87</sup> nerve blocks (n = 32),<sup>88-119</sup> neurostimulation (n = 2),<sup>120,121</sup> rehabilitation (n = 1),<sup>122</sup> and traction (n = 11).<sup>26,123-132</sup> The studies were published between 1990 and 2010 (median = 2003 [interquartile range (IQR): 1998 to 2007]). The majority of the studies were RCTs performed in single university settings in Europe, investigated pre- or intra-operative pain management interventions for hip fracture patients, and were published in peer-reviewed journals (Table 2).

**Table 2. Characteristics of included studies**

<b>Publication type</b>	Published manuscript	75
	Conference proceedings	7
	Dissertation	1
<b>Study design</b>	RCT	64
	nRCT	5
	Retrospective cohort study	8
	Prospective cohort study	6
<b>Setting</b>	General hospital	28
	Orthopedic hospital	1
	University hospital	54
<b>Country</b>	Asia/Australia	9
	Europe	56
	Middle East/North Africa	11
	North America	5
	South America	2
<b>Number of centers</b>	Single center	78
	Two centers	4
	Multicenter	1
<b>Timing of intervention</b>	Preoperative	32
	Intra-operative	36
	Postoperative	15

nRCT = nonrandomized controlled trial; RCT = randomized controlled trial

## Methodological Quality of Included Studies

The risk of bias (RoB) of each included randomized and nonrandomized trial was assessed using the RoB tool by two independent reviewers and the consensus ratings are presented in Appendices G and H. The methodological quality of each included cohort study was assessed using the Newcastle Ottawa Scale (NOS) by two independent reviewers and the consensus ratings are presented in Appendix I. A summary of the overall quality trends by study design is presented below.

## Randomized and Nonrandomized Controlled Trials

Of the 69 randomized controlled trials (RCTs) and nonrandomized controlled trials (nRCTs), 30 trials<sup>26,54,56,60,64,68,77,88,90,92-94,98,106,110,112,114,116,120-131</sup> were rated as having high risk of bias (RCTs = 24; nRCTs = 5), 37 RCTs<sup>41-43,55,57-59,61-63,65-67,69-73,75,76,89,91,97,99-105,107-109,111,113,115,145</sup> were rated as having an unclear risk of bias, and 2 RCTs<sup>95,96</sup> were considered to have a low risk of bias.

## Cohort Studies

Data were prospectively collected in six cohort studies<sup>78,79,85-87,132</sup> and retrospectively in eight.<sup>80-84,117-119</sup> Overall, the methodological quality of the cohort studies was moderate (median score =7 stars; IQR: 6 to 8).

## Results of Included Studies

This section is organized by intervention category (i.e., systemic analgesia, anesthesia, etc.). Within each intervention category, the results are presented for the four key questions addressed in this report: KQ1: Acute and chronic pain management; KQ2: Other outcomes; KQ3: Adverse effects; and, KQ4: Effectiveness and safety in differing subpopulations. For each category, we provide a description of the characteristics and findings of the individual trials and cohort studies and a summary of key findings. Appendixes E and F present detailed evidence tables on each of the included studies.

## Systemic Analgesia

### Overview of Included Studies

Three RCTs<sup>41,42,55</sup> evaluated the efficacy and/or harms of different types of systemic analgesia, in a total of 214 participants; sample sizes ranged from 30 to 94. See Table E-1 (Appendix E) for details of the study characteristics. Two RCTs<sup>41,42</sup> compared different parenteral analgesics (parecoxib IV vs. diclofenac ± meperidine IM, and intrathecal isotonic clonidine vs. intrathecal hypertonic clonidine, respectively). The third RCT<sup>55</sup> compared different oral analgesics (lysine clonixinate vs. metamizole). See Table F-1 (Appendix F) for details of the interventions. The mean age of participants in the trials ranged from 77.3 to 78.5 years. Most were female (74.5 percent). Acute pain was measured using the 10cm Visual Analogue Scale (VAS) and the mean baseline pain measure was 6.5cm. All three trials had an unclear risk of bias (Appendix G). Summary of the evidence from these trials is provided in Table 3.

**Table 3. Evidence addressing key questions: Systemic analgesia**

Key Question	Outcome	Evidence availability	Summary of Evidence
KQ1	Acute pain*	Yes	2 RCTs reported statistically significant effects in favor of parecoxib IV and intrathecal isotonic clonidine vs. diclofenac ± meperidine IM and intrathecal hypertonic clonidine, respectively.  1 RCT reported no statistically significant difference between lysine clonixinate vs. metamizole.  The strength of the evidence was rated as insufficient to make any firm conclusions regarding these interventions.
	Chronic pain*	No	
KQ2	Mortality (30-day* and up to 1-year postfracture)	No	
	Functional status	No	
	Pain medication use; change in type and quantity	Yes	1 RCT comparing lysine clonixinate vs. metamizole reported no statistically significant difference.
	Mental status* (e.g., delirium, confusion)	Yes	1 RCT comparing lysine clonixinate vs. metamizole reported no statistically significant difference. The strength of the evidence was rated as insufficient.
	Health-related quality of life	No	
	Quality of sleep in the hospital	No	
	Ability to participate in rehabilitation	No	
	Return to prefracture living arrangements	No	
KQ3	Health services utilization	No	
	Frequency of adverse effects (e.g. stroke*, myocardial infarction*, renal failure*)	Yes	1 RCT comparing intrathecal isotonic vs. hypertonic clonidine reported no events of damage to surrounding structures, headaches, or infections.  1 RCT comparing lysine clonixinate vs. metamizole reported a statistically significant higher incidence of adverse effects and gastrointestinal disturbances in the lysine clonixinate group; other adverse effects were not significant.
KQ4	Effectiveness and safety in differing subpopulations	No	

KQ = key question; RCT = randomized controlled trial; \* = body of evidence rated using the AHRQ GRADE approach (Grading of Recommendation Assessment, Development and Evaluation)

## Key Question 1. Acute and chronic pain management

Acute pain (post-treatment means) was reported in all three RCTs<sup>41,42,55</sup> (Table 4). One RCT<sup>41</sup> compared parecoxib intravenous (IV) (n = 35) vs. diclofenac intramuscular (IM) ± meperidine IM (n = 55). There was a statistically significant effect difference in additional pain relief in favor of parecoxib IV (mean difference [MD] -0.70; 95% confidence interval [CI] -1.04, -0.36; p <0.0001). This was not considered clinically significant.

The second RCT<sup>42</sup> compared intrathecal isotonic clonidine (n = 15) versus intrathecal hypertonic clonidine (n = 15). There was a statistically significant effect difference in additional

acute pain relief (post-treatment means) in favor of isotonic clonidine (MD -1.69; 95% CI -2.01, -1.37;  $p < 0.00001$ ). This was not considered clinically significant.

The third RCT<sup>55</sup> compared lysine clonixinate (n = 48) versus metamizole (n = 46), but no evidence of a significant effect difference (post-treatment means and at rest) was noted (MD -0.43; 95% CI -1.30, 0.44;  $p = 0.33$ ).

The strength of the evidence was rated as insufficient to make any firm conclusions regarding these interventions.

## Key Question 2. Other outcomes

**Pain medication use.** Additional pain medication use was reported in one RCT<sup>55</sup> comparing lysine clonixinate (n = 48) versus metamizole (n = 46). There was no statistically significant difference in the number of participants requiring additional pain medication (odds ratio [OR] 3.00; 95% CI 0.30, 29.94;  $p = 0.35$ ) (Table 4).

**Mental status.** The incidence of delirium was reported in one RCT<sup>55</sup> comparing lysine clonixinate (n = 48) versus metamizole (n = 46). There was no statistically significant difference in the number of participants developing delirium (OR 0.96; 95% CI 0.06, 15.77;  $p = 0.98$ ) (Table 4). The strength of the evidence was rated as insufficient to make any firm conclusions regarding this intervention.

## Key Question 3. Adverse effects

Data on adverse effects associated with the administration of different types of systemic analgesia were available from two RCTs.<sup>42,55</sup> One RCT<sup>55</sup> comparing lysine clonixinate (n = 48) versus metamizole (n = 46) reported the number of participants with any adverse event and found a statistically significant difference in the number of patients experiencing any adverse event, in favor of metamizole (OR 3.50; 95% CI 1.04, 11.81;  $p = 0.04$ ) (Table 4). Similarly, fewer patients in the metamizole group reported any gastrointestinal disturbance (OR 11.84; 95% CI 1.45, 96.75;  $p = 0.02$ ) (Table 4). The remaining reported adverse effects were from single studies and did not demonstrate any significant statistical differences between the pain management interventions.

## Key Question 4: Efficacy, effectiveness, and safety in subpopulations

No data were reported on subpopulations.

**Table 4. Evidence summary table (randomized controlled trials): Systemic analgesia**

	Outcome or subgroup	Studies (N)	Participants (N)	Statistical method	Effect estimate	I <sup>2</sup>
<b>KQ1</b>	<b>Acute pain (post-treatment means)</b>					
	Parecoxib IV vs. diclofenac ± meperidine IM <sup>41</sup>	1	90	MD (95% CI)	<b>-0.70 (-1.04, -0.36)*</b>	NA
	Intrathecal isotonic clonidine vs. intrathecal hypertonic clonidine <sup>42</sup>	1	30	MD (95% CI)	<b>-1.69 (-2.01, -1.37)*</b>	NA
	Lysine clonixinate vs. metamizole <sup>55</sup>	1	94	MD (95% CI)	-0.43 (-1.30, 0.44)	NA
	<b>Acute pain (at rest)</b>					
	Lysine clonixinate vs. metamizole <sup>55</sup>	1	94	MD (95% CI)	-0.43 (-1.30, 0.44)	NA
<b>KQ2</b>	<b>Additional pain medication use</b>					
	Lysine clonixinate vs. metamizole <sup>55</sup>	1	94	OR (95% CI)	3.00 (0.30, 29.94)	NA
	<b>Mental status (e.g., delirium, confusion)</b>					
	Lysine clonixinate vs. metamizole <sup>55</sup>	1	94	OR (95% CI)	0.96 (0.06, 15.77)	NA
<b>KQ3</b>	<b>Any adverse event</b>					
	Lysine clonixinate vs. metamizole <sup>55</sup>	1	94	OR (95% CI)	<b>3.50 (1.04, 11.81)*</b>	NA
	<b>Damage to surrounding structures</b>					
	Intrathecal isotonic clonidine vs. intrathecal hypertonic clonidine <sup>42</sup>	1	30		NE	
	<b>Gastrointestinal disturbances</b>					
	Lysine clonixinate vs. metamizole <sup>55</sup>	1	94	OR (95% CI)	<b>11.84 (1.45, 96.75)*</b>	NA
	<b>Headache</b>					
	Intrathecal isotonic clonidine vs. intrathecal hypertonic clonidine <sup>42</sup>	1	30		NE	
	<b>Infection</b>					
	Intrathecal isotonic clonidine vs. intrathecal hypertonic clonidine <sup>42</sup>	1	30		NE	
	<b>Respiratory distress</b>					
Lysine clonixinate vs. metamizole <sup>55</sup>	1	94	OR (95% CI)	0.96 (0.06, 15.77)	NA	

CI = confidence interval; IM = intramuscular; KQ = key question; MD = mean difference; NA = not applicable; NE = not estimable; OR = odds ratio; \* = statistically significant difference

## Anesthesia

### Overview of Included Studies

Twenty-one RCTs<sup>56-73,75,76,145</sup> and one nRCT<sup>77</sup> evaluated the efficacy and/or harms of anesthesia including neuraxial (i.e., continuous or single administration spinal or epidural anesthesia) or neuraxial anesthesia versus general anesthesia in a total of 1,062 participants; study sample sizes ranged from 20 to 90. Additionally, eight cohort studies<sup>78-85</sup> provided data on spinal anesthesia versus general anesthesia or other modes of administration of spinal anesthesia in 3,086 participants; study sample sizes ranged from 25 to 1,333. The mean age of participants ranged from 69.8 to 86.0 years. Most were female (range = 38.9 to 100 percent). Acute pain was measured using different scales (numeric rating score [NRS] [1-5] and 10cm VAS). The average

baseline VAS pain score was 4.7. See Tables E-2 and F-2 (Appendices E and F) for details of the study characteristics and the interventions.

Four RCTs<sup>56,60,64,68</sup> and one nRCT<sup>77</sup> had a high risk of bias, while the other 17 RCTs<sup>57-59,61-63,65-67,69-76</sup> had an unclear risk of bias (Appendix G). The cohort studies were of moderate quality (median = 8) (Appendix I). Summary of the evidence from these trials is provided in Table 5.

Based on the primary interventions and comparison groups, the studies were grouped as follows:

1. Spinal anesthesia versus epidural or general anesthesia (n = 10);<sup>56,59,60,64,65,78,81,82,84,85</sup>
2. Neuraxial anesthesia: addition of clonidine, fentanyl, meperidine, morphine, or sufentanil (n = 14);<sup>57,58,63,65-70,73,74,76,77,80</sup>
3. Neuraxial anesthesia: different doses or modes of administration (n = 13)
  - a. Spinal anesthesia (mode of administration: [e.g., continuous vs. single administration])<sup>62,64,65,71,82,83</sup>
  - b. Spinal anesthesia (different doses)<sup>61,63,72,74,75,79,80,82</sup>

**Table 5. Evidence addressing key questions: Anesthesia**

Key Question	Outcome	Evidence availability	Summary of evidence
KQ 1	Acute pain*	Yes	1 RCT reported a statistically significant effect difference in favor of spinal anesthesia vs. general anesthesia. The strength of the evidence was rated as insufficient.  3 RCTs and 1 nRCT reported no significant difference comparing the addition of fentanyl, morphine or sufentanil vs. standard spinal anesthesia. The strength of the evidence was rated as insufficient.
	Chronic pain*	No	
KQ2	Mortality (30-day* and up to 1-year postfracture)	Yes	2 RCTs and 2 cohort studies comparing continuous vs. single spinal anesthesia reported no statistically significant difference except for the incidence of 30-day mortality following continuous spinal anesthesia compared with general anesthesia. The strength of the evidence was rated as low.

**Table 5. Evidence addressing key questions: Anesthesia (continued)**

Key Question	Outcome	Evidence availability	Summary of Evidence
KQ2	Mortality (30-day* and up to 1-year postfracture)		3 RCTs and 1 cohort study comparing continuous vs. single spinal anesthesia reported no statistically significant difference. The strength of the evidence was rated as insufficient.
	Functional status	No	
	Pain medication use; change in type and quantity	Yes	6 RCTs comparing the addition of clonidine, fentanyl, morphine or sufentanil with standard spinal anesthesia were indeterminate.  2 RCTs comparing continuous vs. single spinal anesthesia were indeterminate.  1 RCT comparing different doses of spinal anesthesia found no statistically significant difference.
	Mental status* (e.g., delirium, confusion)	Yes	1 RCT comparing the use of spinal anesthesia vs. general anesthesia found no statistically significant difference. The strength of the evidence was rated as insufficient.  1 RCT comparing the addition of morphine with standard spinal anesthesia found no statistically significant difference. The strength of the evidence was rated as low.  2 RCTs comparing continuous vs. single spinal anesthesia found no statistically significant difference. The strength of the evidence was rated as low.  1 cohort study comparing 4 vs. 12mg bupivacaine found no statistically significant difference. The strength of the evidence was rated as insufficient.
	Health-related quality of life	No	
	Quality of sleep in the hospital	No	
	Ability to participate in rehabilitation	No	
	Return to prefracture living arrangements	No	
Health services utilization	Yes		2 RCTs comparing spinal vs. general anesthesia found LOS for acute hospitalization was significantly less in the general anesthesia group.  2 RCTs comparing continuous vs. single spinal anesthesia found no statistically significant difference.



**Table 5. Evidence addressing key questions: Anesthesia (continued)**

Key Question	Outcome	Evidence availability	Summary of Evidence
KQ3	Frequency of adverse effects (e.g. stroke*, myocardial infarction*, renal failure*)	Yes	<p>2 cohort studies comparing single dose spinal vs. general anesthesia, and 4mg vs. 12mg bupivacaine reported a statistically significant effect difference in hypotension in favor of spinal anesthesia and less bupivacaine. Evidence for the other outcomes was indeterminate.</p> <p>1 RCT comparing the addition of sufentanil vs. standard spinal anesthesia reported a significantly higher incidence of hypotension with standard spinal anesthesia. Evidence for the other outcomes in 10 RCTs comparing the addition of clonidine, fentanyl, meperidine, morphine or sufentanil vs. standard spinal anesthesia was indeterminate.</p> <p>1 RCT and 1 cohort study comparing different doses of spinal anesthesia reported the incidence of participants having hypotension was significantly greater with higher doses and higher concentrations of spinal anesthesia.</p> <p>Other adverse events were examined in single trials and the strength of the evidence for the probability of stroke, myocardial infarction, delirium or renal failure was rated as insufficient.</p>
KQ4	Effectiveness and safety in differing subpopulations	No	

KQ = key question; nRCT = nonrandomized controlled trial; RCT = randomized controlled trial; \* = body of evidence rated using the AHRQ GRADE approach (Grading of Recommendation Assessment, Development and Evaluation)

## Key Question 1. Acute and chronic pain management

### Spinal vs. General Anesthesia

One RCT<sup>60</sup> comparing spinal anesthesia (n = 15) vs. general anesthesia (n = 15) reported a statistically significant difference of additional pain relief in favor of spinal anesthesia (MD = -0.86; 95% CI -1.30, -0.42; p = 0.0001) (Table 6-B). This was not considered clinically significant. The strength of the evidence was rated as insufficient to make any firm conclusions regarding these interventions.


### Neuraxial Anesthesia: Addition of Clonidine, Fentanyl, Meperidine, Morphine, or Sufentanil

Acute pain (post-treatment means) was reported in three RCTs<sup>66,69,73</sup> comparing additional fentanyl (n = 20) vs. standard spinal anesthesia (n = 20),<sup>69</sup> additional morphine (n = 20) versus standard spinal anesthesia (n = 20),<sup>66</sup> and additional sufentanil (n = 25) versus standard spinal anesthesia (n = 25).<sup>73</sup> In the studies comparing the addition of fentanyl or sufentanil, no patients reported feeling pain following the procedure. In the study comparing the addition of morphine, there was no significant difference in pain relief versus standard spinal anesthesia (MD = -0.36; 95% CI -1.11, 0.39; p = 0.35) (Table 6-G).

Acute pain on day 1 was reported in one RCT<sup>69</sup> and one nRCT<sup>77</sup> comparing additional fentanyl (n = 40) versus standard spinal anesthesia (n = 40). There was no significant difference

in pain on day 1 following the addition of fentanyl (OR 1.24; 95% CI 0.34, 4.48;  $p = 0.75$ ) (Table 6-E and Figure 3). The strength of the evidence was rated as insufficient to make any firm conclusions regarding these interventions.

**Figure 3. Neuraxial anesthesia: Addition of fentanyl—acute pain (day 1)**



## Key Question 2. Other outcomes

### Spinal vs. General Anesthesia or Spinal vs. Epidural Anesthesia

**Mortality (30-day).** Thirty-day mortality was reported in two RCTs<sup>56,64</sup> ( $n = 99$  participants). There was no significant difference in mortality rates following spinal anesthesia versus general anesthesia (10/53 vs. 5/46; OR 1.73; 95% CI 0.53, 5.68;  $p = 0.36$ ) (Table 6-B).

Additionally, 30-day mortality was reported in five cohort studies<sup>78,81,82,84,85</sup> ( $n = 2960$  participants) (Table 7-A). There was no significant difference in mortality rates following spinal anesthesia vs. general anesthesia (78/1259 vs. 117/1701; OR 0.87; 95% CI 0.45, 1.67;  $p = 0.68$ ). Subgroup analyses according to the mode of administration of spinal anesthesia revealed a statistically significant difference in the incidence of 30-day mortality for participants receiving continuous spinal anesthesia compared with general anesthesia (8/182 vs. 4/28; OR 0.28; 95% CI 0.08, 0.99;  $P = 0.05$ ) favoring spinal anesthesia. There was no significant difference in mortality rates following single dose spinal versus general anesthesia (70/1077 vs. 113/1673; OR 1.08; 95% CI 0.58, 2.01;  $p = 0.80$ ). The strength of the evidence was rated as insufficient to make any firm conclusions regarding these interventions.

**Mental status.** Delirium measured with the Mini Mental State Examination (MMSE) was reported in one RCT<sup>60</sup> comparing spinal anesthesia ( $n = 15$ ) vs. general anesthesia ( $n = 15$ ) (Table 6-B). There was no significant difference between the two groups (8/15 vs. 9/15; OR 0.76; 95% CI 0.18, 3.24;  $p = 0.71$ ). Additionally, delirium was reported in two cohort studies<sup>78,84</sup>. There was no significant difference in the incidence of delirium comparing spinal versus general anesthesia (12/448 vs. 11/529; OR 0.79; 95% CI 0.04, 14.13;  $p = 0.87$ ). The strength of the evidence was rated as insufficient to make any firm conclusions regarding these interventions.

**Health services utilization.** Length of stay (LOS) for acute hospitalization was reported in two RCTs<sup>56,64</sup> comparing spinal anesthesia ( $n = 53$ ) vs. general anesthesia ( $n = 46$ ) (Table 6-B). The LOS was significantly less in the general anesthesia group (MD 1.69; 95% CI 0.38, 3.01;  $p = 0.01$ ). The variance for one trial<sup>64</sup> was imputed from the reported  $p$ -value, while the variance for the second trial<sup>56</sup> was imputed from the first trial,<sup>64</sup> as no measure of variance was reported. LOS for acute hospitalization was also reported in one cohort study<sup>85</sup> comparing single spinal anesthesia ( $n = 383$ ) to general anesthesia ( $n = 950$ ) but the difference could not be estimated as no measure of variance was reported.

## Neuraxial Anesthesia: Addition of Clonidine, Fentanyl, Meperidine, Morphine, or Sufentanil

**Additional pain medication use.** Additional pain medication use was reported in six RCTs<sup>58,65-67,73,76</sup> (Table 6D to 6-H). Differences in effect estimates from one RCT<sup>65</sup> (n = 40 participants) comparing the addition of clonidine vs. standard spinal anesthesia was not estimable because all participants required additional pain medication. The pooled estimate from three trials<sup>58,67,76</sup> comparing the addition of fentanyl vs. standard spinal anesthesia (n = 102 participants) showed no statistically significant difference between groups (2/51 vs. 0/51; OR 5.51; 95% CI 0.25, 122.08; p = 0.28).

There was no significant difference in additional pain medication use in the RCT<sup>66</sup> (n = 40) that compared the addition of morphine to spinal anesthesia vs. standard spinal anesthesia (9/20 vs. 15/20; OR 0.27; 95% CI 0.07, 1.04; p = 0.06). Similarly, there was no difference in reported additional pain medication use between three RCTs<sup>67,73,76</sup> that compared the addition of sufentanil to spinal anesthesia with standard spinal anesthesia (1/66 vs. 0/66; Peto OR 7.39; 95% CI 0.15, 372.38; p = 0.32).

**Mental status.** Confusion was reported in one RCT<sup>66</sup> (n = 40) comparing the addition of morphine versus standard spinal anesthesia (Table 6-G). There was no significant difference in the incidence of postoperative confusion (1/20 vs. 0/20; OR 3.15; 95% CI 0.12, 82.16; p = 0.49). The strength of the evidence was rated as insufficient to make any firm conclusions regarding these interventions.

## Neuraxial Anesthesia: Different Doses and Modes of Administration

### Spinal Anesthesia (Continuous vs. Single Administration)

**Mortality (30-day).** Three RCTs<sup>62,64,71</sup> (n = 163) reported 30-day mortality (Table 6-C). Two of the RCTs<sup>62,71</sup> did not record any events in either group. In the third RCT,<sup>64</sup> there was no significant difference between continuous vs. single administration spinal anesthesia (2/14 vs. 4/15; OR 0.46; 95% CI 0.07, 3.02; p = 0.42). Additionally, it should be noted that 30-day mortality was reported in one other cohort study<sup>82</sup> (n = 291) (Table 7-B). There was no significant difference between continuous vs. single administration of spinal anesthesia (8/182 vs. 5/109; OR 0.96; 95% CI 0.30, 3.00; p = 0.94). The strength of the evidence was rated as low to make any firm conclusions regarding these interventions.

**Additional pain medication.** Additional pain medication use was reported in two RCTs<sup>62,71</sup> (n = 134) (Table 6-C). The OR in additional pain medication use was not estimable as there were no events in either group.

**Health services utilization.** LOS for acute hospitalization was reported in two RCTs<sup>62,64</sup> (n = 89). There was no significant difference between groups (MD = -0.98; 95% CI -2.06, 0.10; p = 0.07; Table 6-C). The variance for one trial<sup>64</sup> was imputed from the reported p-value.

**Mental status.** Confusion was reported in two RCTs<sup>62,71</sup> (n = 134) (Table 6-C). There was no significant difference between groups in the occurrence of confusion (5/67 vs. 4/67; OR 1.27; 95% CI 0.32, 4.99; p = 0.73). The strength of the evidence was rated as low to make any firm conclusions regarding these interventions.

### **Spinal Anesthesia (Different Doses)**

**Delirium.** One cohort study<sup>80</sup> (n = 60) reported that there was no significant difference in the incidence of delirium between the two groups (2/30 vs. 4/30; OR 0.46; 95% CI 0.08, 2.75; p = 0.40) (Table 7-D). The strength of the evidence was rated as insufficient to make any firm conclusions regarding these interventions.

**Mortality (30-day).** One cohort study<sup>82</sup> (n = 182) reported that there was no significant difference in 30-day mortality rates between the two groups (4/121 vs. 4/61; OR 0.49; 95% CI 0.12, 2.02; p = 0.32) (Table 7-D). The strength of the evidence was rated as insufficient to make any firm conclusions regarding these interventions.

**Pain medication use.** Additional pain medication use was reported in one RCT<sup>63</sup> (n = 60) (Table 6-I). There was no significant difference between groups following spinal anesthesia at different doses (4 vs. 5mg, 4 vs. 6mg, or 5 vs. 6mg).

### **Key Question 3. Adverse effects**

#### **Spinal vs. General Anesthesia or Spinal vs. Epidural Anesthesia**

Two RCTs<sup>60,64</sup> (n = 73) and one cohort study<sup>82</sup> (n = 333) evaluated the nature and frequency of adverse effects associated with the administration of spinal anesthesia versus general anesthesia (Table 6-B, 7-A). There were no significant differences in the occurrence of hypotension in the RCTs<sup>60,64</sup> (21/44 vs. 21/29; OR 0.36; 95% CI 0.04, 2.92; p = 0.34). The pooled incidence of hypotension from the different arms of the cohort study<sup>82</sup> is not reported because of marked heterogeneity among the included cohorts. There was no significant difference in the incidence of hypotension in the continuous spinal anesthesia groups compared with general anesthesia (OR 0.35; 95% CI 0.10, 1.28; p = 0.11). There was a significantly lower incidence of hypotension with single dose spinal anesthesia compared with general anesthesia (OR 0.04; 95% CI 0.01, 0.13; p < 0.00001). The remaining reported adverse effects were from single studies and did not demonstrate any significant statistical differences between the pain management interventions.

#### **Neuraxial Anesthesia: Addition of Clonidine, Fentanyl, Meperidine, Morphine, or Sufentanil**

A total of 11 RCTs<sup>57,58,65-70,73,74,76</sup> and one nRCT<sup>77</sup> (n = 490) evaluated the harms of the administration of clonidine, fentanyl, meperidine, morphine, or sufentanil during neuraxial anesthesia (Table 6-D to 6-H).

##### **Addition of Clonidine**

The reported adverse effects were from a single RCT<sup>65</sup> and did not demonstrate any significant statistical differences (Table 6-D).


##### **Addition of Fentanyl**

**Allergic reaction.** There was no statistically significant difference in the number of participants reporting an allergic reaction in four trials<sup>67-69,77</sup> (14/81 vs. 5/83; OR 2.68; 95% CI 0.83, 9.80; p = 0.10) (Table 6-E).

**Gastrointestinal (GI) symptoms.** There were no reports of GI symptoms in three trials<sup>69,74,77</sup> (n = 140) (Table 6-E).


**Hypotension.** Seven trials<sup>57,58,67-69,76,77</sup> (n = 284) reported the frequency of hypotension (Figure 4). The pooled results are not reported due to high heterogeneity ( $I^2 = 83$  percent) between the included studies, which was not explained by study design (i.e., removal of the nRCT<sup>77</sup>), risk of bias (i.e., removal of the trials<sup>68,77</sup> with a high risk of bias), or specific intervention details (i.e., type and quantity). No firm conclusion can be made regarding the impact of fentanyl on this outcome.

**Figure 4. Neuraxial anesthesia: Addition of fentanyl—hypotension**



**Nausea/vomiting.** In the five RCTs<sup>58,67-69,74</sup> (n = 204) that reported the frequency of nausea or vomiting there was no statistically significant difference between the groups (6/111 vs. 3/93; OR 1.10; 95% CI 0.06, 20.73; p = 0.95) (Figure 5).

**Figure 5. Neuraxial anesthesia: Addition of fentanyl—nausea/vomiting**



**Respiratory distress.** There were no reports of respiratory distress in three trials<sup>67,68,77</sup> (n = 124).

**Other adverse effects.** The remaining reported adverse effects were from single trials and did not demonstrate any statistically significant differences.

### Addition of Meperidine

**Adverse effects.** The reported adverse effects were from a single trial and did not demonstrate any significant statistical differences.

## **Addition of Morphine**

**Adverse effects.** The reported adverse effects were from a single trial and did not demonstrate any significant statistical differences.

## **Addition of Sufentanil**

**Hypotension.** Three RCTs<sup>67,73,76</sup> (n = 132) reported a significantly lower incidence of hypotension in participants receiving sufentanil (8/66 in the group with sufentanil vs. 45/66 in the group with no sufentanil; OR 0.05; 95% CI 0.01, 0.34; p = 0.002).

**Other adverse effects.** The remaining reported adverse effects were from single studies and did not demonstrate any significant statistical differences.

## **Neuraxial Anesthesia: Different Doses and Modes of Administration (i.e., Continuous vs. Single Administration)**

### **Spinal Anesthesia (Continuous vs. Single Administration)**

**Hypotension.** Hypotension was reported for two RCTs<sup>64,71</sup> (n = 103). There was a statistically significant difference between the groups (13/51 vs. 37/52; OR 0.12; 95% CI 0.03, 0.51; p = 0.004). Similarly, one cohort study<sup>82</sup> (n = 291) reported a statistically significant difference between groups (26/182 vs. 74/109; OR 0.08; 95% CI 0.04, 0.14; p < 0.00001).

**Other adverse effects.** The remaining reported adverse effects were from single trials and studies and did not demonstrate any significant statistical differences between the pain management interventions.

### **Spinal Anesthesia (Different Doses)**

**Bradycardia.** Bradycardia was reported in two RCTs<sup>61,63</sup> (n = 180). There was no significant difference for different doses of spinal anesthesia (bupivacaine: 4 vs. 5mg: 0/30 vs. 0/30; 4 vs. 6mg: 0/30 vs. 0/30; 5 vs. 6 mg: 3/29 vs. 3/31; levobupivacaine: 3/29 vs. 3/31).

**Hypotension.** Hypotension was reported in four RCTs<sup>61,63,72,75</sup> (n = 210). There were statistically significant differences in hypotension following spinal anesthesia with 4mg versus 6mg of bupivacaine (0/30 vs. 10/30; OR 0.03; 95% CI 0.00, 0.58; p = 0.02). The remaining comparisons were not statistically significant.

Three cohort studies<sup>79,80,82</sup> reported hypotension in 267 participants. There was a statistically significant reduction in hypotension following spinal anesthesia with 2.5mg versus 5mg of bupivacaine (5/121 vs. 21/61; OR 0.08; 95% CI 0.03, 0.23; p < 0.00001), 4mg versus 12mg of bupivacaine (3/30 vs. 23/30; OR 0.03; 95% CI 0.01, 0.15) and 0.125% vs. 0.5% of bupivacaine (4/12 vs. 10/13; OR 0.15; 95% CI 0.03, 0.87; p = 0.03).

**Nausea/vomiting.** There were no reports of nausea or vomiting in two RCTs<sup>63,74</sup> (n = 100).

**Other adverse effects.** The remaining reported adverse effects were from single RCTs and cohort studies and did not demonstrate any significant statistical differences between the pain management interventions.

## Key Question 4. Efficacy, effectiveness, and safety in subpopulations

No data were reported on subpopulations.

**Table 6. Evidence summary table (randomized and nonrandomized controlled trials): Anesthesia**

**Table 6-A. Epidural (continuous) versus spinal anesthesia (continuous): (RCT/nRCT)**

	Outcome or Subgroup	Studies (N)	Participants (N)	Statistical Method	Effect Estimate	I <sup>2</sup>
KQ3	Damage to surrounding structures <sup>65</sup>	1	40		NE	NA

KQ = key question; NA = not applicable; NE = not estimable; RCT/nRCT = randomized and nonrandomized controlled trials

**Table 6-B. Spinal versus general anesthesia: (RCT/nRCT)**

	Outcome or Subgroup	Studies (N)	Participants (N)	Statistical Method	Effect Estimate	I <sup>2</sup>
KQ1	<b>Acute pain (post-treatment means)</b>					
	Spinal anesthesia (single) <sup>60</sup>	1	30	MD (95% CI)	<b>-0.86 (-1.30, -0.42)*</b>	NA
KQ2	<b>Mental status (e.g., delirium, confusion)</b>					
	Spinal anesthesia (single) <sup>60</sup>	1	30	OR (95% CI)	0.76 (0.18, 3.24)	NA
	<b>LOS</b> <sup>56,64</sup>	2	99	MD (95% CI)	<b>1.69 (0.38, 3.01)*</b>	0%
	Spinal anesthesia (incremental) <sup>64</sup>	1	21	MD (95% CI)	2.00 (-0.16, 4.16)	NA
KQ2	Spinal anesthesia (single) <sup>56,64</sup>	2	78	MD (95% CI)	1.55 (-0.20, 3.31)	7%
	<b>Mortality 30-day</b> <sup>56,64</sup>	2	99	OR (95% CI)	1.73 (0.53, 5.68)	0%
	Spinal anesthesia (incremental) <sup>64</sup>	1	21	OR (95% CI)	1.00 (0.07, 13.37)	NA
KQ3	Spinal anesthesia (single) <sup>56,64</sup>	2	78	OR (95% CI)	2.01 (0.53, 7.61)	0%
	<b>Hypotension</b>	2	73	OR (95% CI)	0.36 (0.04, 2.92)	72%
	Spinal anesthesia (incremental) <sup>64</sup>	1	21	OR (95% CI)	<b>0.07 (0.01, 0.61)*</b>	0%
	Spinal anesthesia (single) <sup>60,64</sup>	2	52	OR (95% CI)	0.76 (0.06, 9.90)	75%
	<b>Myocardial infarction</b>	1	43	OR (95% CI)	1.55 (0.06, 42.91)	NA
	Spinal anesthesia (incremental) <sup>64</sup>	1	21		NE	
	Spinal anesthesia (single) <sup>64</sup>	1	22	OR (95% CI)	1.55 (0.06, 42.91)	NA
	<b>ST depression</b>	1	43	OR (95% CI)	0.56 (0.11, 2.81)	27%
Spinal anesthesia (incremental) <sup>64</sup>	1	21	OR (95% CI)	0.22 (0.03, 1.85)	NA	
Spinal anesthesia (single) <sup>64</sup>	1	22	OR (95% CI)	1.17 (0.19, 7.12)	NA	

CI = confidence intervals; KQ = key question; LOS = length of stay; MD = mean difference; NA = not applicable; NE = not estimable; OR = odds ratio; RCT/nRCT = randomized and nonrandomized controlled trials; \* = statistically significant

**Table 6-C. Spinal anesthesia (continuous vs. single administration): (RCT/nRCT)**

	Outcome or Subgroup	Studies (N)	Participants (N)	Statistical Method	Effect Estimate	I <sup>2</sup>
KQ2	Additional pain medication use <sup>62,71</sup>	2	134		NE	
	Mental status (e.g., delirium or confusion) <sup>62,71</sup>	2	134	OR (95% CI)	1.27 (0.32, 4.99)	0%
	LOS <sup>62,64</sup>	2	89	MD (95% CI)	-0.98 (-2.06, 0.10)	0%
	Mortality 30-day <sup>62,64,71</sup>	3	163	OR (95% CI)	0.46 (0.07, 3.02)	NA
KQ3	Bradycardia <sup>71</sup>	1	74		NE	
	GI symptoms <sup>62</sup>	1	60	OR (95% CI)	1.00 (0.06, 16.76)	NA
	Headache <sup>62</sup>	1	60		NE	
	Hypotension <sup>64,71</sup>	2	103	OR (95% CI)	<b>0.12 (0.03, 0.51)*</b>	50%
	MI <sup>64</sup>	1	29	OR (95% CI)	0.33 (0.01, 8.88)	NA
	Myocardial ischemia <sup>71</sup>	1	74		NE	
	ST depression <sup>64</sup>	1	29	OR (95% CI)	0.19 (0.03, 1.16)	NA
	Stroke <sup>71</sup>	1	74		NE	

CI = confidence intervals; KQ = key question; LOS = length of stay; MD = mean difference; MI = myocardial infarction; NE = not estimable; OR = odds ratio; \* = statistically significant; RCT/nRCT = randomized and nonrandomized controlled trials

**Table 6-D. Neuraxial anesthesia (addition of clonidine): RCT/nRCT**

	Outcome or Subgroup	Studies (N)	Participants (N)	Statistical Method	Effect Estimate	I <sup>2</sup>
KQ2	Additional pain medication use <sup>65</sup>	1	40		NE	
	Epidural anesthesia (continuous) <sup>65</sup>	1	20		NE	
	Spinal anesthesia (continuous) <sup>65</sup>	1	20		NE	
KQ3	Damage to surrounding structures <sup>65</sup>	1	40		NE	
	Epidural anesthesia (continuous) <sup>65</sup>	1	20		NE	
	Spinal anesthesia (continuous) <sup>65</sup>	1	20		NE	
	Headache <sup>65</sup>	1	40		NE	
	Epidural anesthesia (continuous) <sup>65</sup>	1	20		NE	
	Spinal anesthesia (continuous) <sup>65</sup>	1	20		NE	
	Infection <sup>65</sup>	1	40		NE	
	Epidural anesthesia (continuous) <sup>65</sup>	1	20		NE	
Spinal anesthesia (continuous) <sup>65</sup>	1	20		NE		

KQ = key question; NE = not estimable; RCT/nRCT = randomized and nonrandomized controlled trials



**Table 6-E. Spinal (single) anesthesia (addition of fentanyl): RCT/nRCT**

	Outcome or Subgroup	Studies (N)	Participants (N)	Statistical Method	Effect Estimate	I <sup>2</sup>
KQ1	Acute pain (post-treatment means) <sup>69</sup>	1	40		NE	
	Day 1 pain <sup>69,77</sup>	2	80	OR (95% CI)	1.24 (0.34, 4.48)	0%
KQ2	Additional pain medication use <sup>58,67,76</sup>	3	102	OR (95% CI)	5.51 (0.25, 122.08)	
KQ3	Allergic reaction <sup>67, 69,77</sup>	4	164	OR (95% CI)	2.86 (0.83, 9.80)	16%
	Bradycardia <sup>67</sup>	1	42	OR (95% CI)	8.14 (0.39, 167.98)	NA
	GI symptoms <sup>69,74,77</sup>	3	140		NE	
	Headache <sup>77</sup>	1	40		NE	
	Hypotension <sup>57,58,67, 69,74,77</sup>	7	284		NR	83%
	Nausea/vomiting <sup>58,67-69,74</sup>	5	204	OR (95% CI)	1.10 (0.06, 20.73)	63%
	Neurological complications <sup>77</sup>	1	40		NE	
Respiratory distress <sup>67,68,77</sup>	3	124		NE		

CI = confidence intervals; KQ = key question; NA = not applicable; NR = not reported; NE = not estimable OR = odds ratio; RCT/nRCT = randomized and nonrandomized controlled trials

**Table 6-F. Spinal (continuous) anesthesia (addition of meperidine): RCT/nRCT**

	Outcome or Subgroup	Studies (N)	Participants (N)	Statistical Method	Effect Estimate	I <sup>2</sup>
KQ3	Headache <sup>70</sup>	1	34		NE	

KQ = key question; NE = not estimable; RCT/nRCT = randomized and nonrandomized controlled trials

**Table 6-G. Spinal (single) anesthesia (addition of morphine): RCT/nRCT**

	Outcome or Subgroup	Studies (N)	Participants (N)	Statistical Method	Effect Estimate	I <sup>2</sup>
KQ1	Acute pain (post-treatment means) <sup>66</sup>	1	40	MD (95% CI)	-0.36 (-1.11, 0.39)	NA
KQ2	Additional pain medication use <sup>66</sup>	1	40	OR (95% CI)	0.27 (0.07, 1.04)	NA
	Mental status (e.g., delirium, confusion) <sup>66</sup>	1	40	OR (95% CI)	3.15 (0.12, 82.16)	NA
KQ3	Allergic reaction <sup>66</sup>	1	40	OR (95% CI)	1.00 (0.06, 17.18)	NA
	Any adverse event <sup>66</sup>	1	40	OR (95% CI)	4.75 (0.48, 46.91)	NA
	GI symptoms <sup>66</sup>	1	40	OR (95% CI)	11.18 (0.56, 222.98)	NA
	Headache <sup>66</sup>	1	40		NE	
	Hypopnoea <sup>66</sup>	1	40		NE	
	Hypotension <sup>66</sup>	1	40		NE	
	Nausea/vomiting <sup>66</sup>	1	40	OR (95% CI)	11.18 (0.56, 222.98)	NA
Respiratory distress <sup>66</sup>	1	40		NE		

CI = confidence intervals; KQ = key question; MD = mean difference; NA = not applicable; NE = not estimable; OR = odds ratio; RCT/nRCT = randomized and nonrandomized controlled trials

**Table 6-H. Spinal (single) anesthesia (addition of sufentanil): RCT/nRCT**

	Outcome or Subgroup	Studies (N)	Participants (N)	Statistical Method	Effect Estimate	I <sup>2</sup>
KQ1	Acute pain (post-treatment means) <sup>73</sup>	1	50		NE	
KQ2	Additional pain medication use) <sup>67,73,76</sup>	3	132	OR (95% CI)	7.39 (0.15, 372.38)	0%
KQ3	Allergic reaction <sup>67</sup>	1	42		NE	
	Bradycardia <sup>67</sup>	1	42	OR (95% CI)	11.06 (0.56, 219.68)	NA
	Hypotension <sup>67,73,76</sup>	3	132	OR (95% CI)	<b>0.05 (0.01, 0.34)*</b>	71%
	Nausea/vomiting <sup>67</sup>	1	42		NE	
	Respiratory distress <sup>67</sup>	1	42		NE	

CI = confidence intervals; KQ = key question; NA = not applicable; NE = not estimable; OR = odds ratio; \* = statistically significant; RCT/nRCT = randomized and nonrandomized controlled trials

**Table 6-I. Spinal anesthesia (Different doses): RCT/nRCT**

	Outcome or Subgroup	Studies (N)	Participants (N)	Statistical Method	Effect Estimate	I <sup>2</sup>
KQ2	<b>Additional pain medication use</b>					
	Bupivacaine: 4 vs. 5mg <sup>63</sup>	1	60	OR (95% CI)	2.36 (0.63, 8.92)	NA
	Bupivacaine: 4 vs. 6mg <sup>63</sup>	1	60	OR (95% CI)	3.27 (0.77, 13.83)	NA
	Bupivacaine: 5 vs. 6mg <sup>63</sup>	1	60	OR (95% CI)	1.38 (0.28, 6.80)	NA
KQ3	<b>Allergic reaction</b>					
	Bupivacaine: 4 vs. 5mg <sup>63</sup>	1	60	OR (95% CI)	0.62 (0.15, 2.45)	NA
	Bupivacaine: 4 vs. 6mg <sup>63</sup>	1	60	OR (95% CI)	0.62 (0.15, 2.45)	NA
	Bupivacaine: 5 vs. 6mg <sup>63</sup>	1	60	OR (95% CI)	1.00 (0.28, 3.54)	NA

**Table 6-I. Spinal anesthesia (Different doses): RCT/nRCT (continued)**

	<b>Outcome or Subgroup</b>	<b>Studies (N)</b>	<b>Participants (N)</b>	<b>Statistical Method</b>	<b>Effect Estimate</b>	<b>I<sup>2</sup></b>
<b>KQ3</b>	<b>Bradycardia</b>					
	Bupivacaine: 4 vs. 5mg <sup>63</sup>	1	60		NE	
	Bupivacaine: 4 vs. 6mg <sup>63</sup>	1	60		NE	
	Bupivacaine: 5 vs. 6mg <sup>63</sup>	1	60		NE	
	Levobupivacaine: 0.5% vs. 0.75% <sup>61</sup>	1	60	OR (95% CI)	1.08 (0.20, 5.82)	NA
	<b>GI symptoms</b>					
	Bupivacaine: 6 vs. 8mg <sup>74</sup>	1	40		NE	
	Bupivacaine: 6 vs. 10mg <sup>74</sup>	1	40		NE	
	Bupivacaine: 8 vs. 10mg <sup>74</sup>	1	40		NE	
	<b>Hypotension</b>					
	Bupivacaine: 2.5 vs. 5mg <sup>75</sup>	1	40	OR (95% CI)	0.81 (0.22, 2.91)	NA
	Bupivacaine: 4 vs. 5mg <sup>63</sup>	1	60	OR (95% CI)	0.10 (0.00, 1.88)	NA
	Bupivacaine: 4 vs. 6mg <sup>63</sup>	1	60	OR (95% CI)	<b>0.03 (0.00, 0.58)*</b>	NA
	Bupivacaine: 5 vs. 6mg <sup>63</sup>	1	60	OR (95% CI)	0.31 (0.08, 1.13)	NA
	Bupivacaine: 0.15 – 0.25% vs. 0.5% <sup>72</sup>	1	30	OR (95% CI)	0.22 (0.04, 1.11)	NA
	Levobupivacaine: 0.5% vs. 0.75% <sup>61</sup>	1	60	OR (95% CI)	1.71 (0.60, 4.88)	NA
	<b>Nausea/vomiting</b>					
	Bupivacaine: 4 vs. 5mg <sup>63</sup>	1	60		NE	
	Bupivacaine: 4 vs. 6mg <sup>63</sup>	1	60		NE	
	Bupivacaine: 5 vs. 6mg <sup>63</sup>	1	60		NE	
	Bupivacaine: 6 vs. 8mg <sup>74</sup>	1	40		NE	
	Bupivacaine: 6 vs. 10mg <sup>74</sup>	1	40		NE	
	Bupivacaine: 8 vs. 10mg <sup>74</sup>	1	40		NE	
	<b>Residual sensory deficits/motor weakness</b>					
	Levobupivacaine: 0.5% vs. 0.75% <sup>61</sup>	1	60		NE	
	<b>Respiratory distress</b>					
	Bupivacaine: 4 vs. 5mg <sup>63</sup>	1	60		NE	
	Bupivacaine: 4 vs. 6mg <sup>63</sup>	1	60		NE	
	Bupivacaine: 5 vs. 6mg <sup>63</sup>	1	60		NE	

**Table 6-I. Spinal anesthesia (Different doses): RCT/nRCT (continued)**

	Outcome or Subgroup	Studies (N)	Participants (N)	Statistical Method	Effect Estimate	I <sup>2</sup>
KQ3	<b>Sedation</b>					
	Bupivacaine: 4 vs. 5mg <sup>63</sup>	1	60		NE	
	Bupivacaine: 4 vs. 6mg <sup>63</sup>	1	60		NE	
	Bupivacaine: 5 vs. 6mg <sup>63</sup>	1	60		NE	
	<b>Urinary retention</b>					
	Bupivacaine: 4 vs. 5mg <sup>63</sup>	1	60		NE	
	Bupivacaine: 4 vs. 6mg <sup>63</sup>	1	60		NE	
Bupivacaine: 5 vs. 6mg <sup>63</sup>	1	60		NE		

CI = confidence intervals; KQ = key question; NA = not applicable; NE = not estimable; OR = odds ratio; RCT/nRCT = randomized and nonrandomized controlled trials

**Table 7. Evidence summary table (cohort studies): Anesthesia****Table 7-A. Spinal versus general anesthesia: Cohort studies**

	Outcome or Subgroup	Studies (N)	Participants (N)	Statistical Method	Effect Estimate	I <sup>2</sup>
KQ2	<b>Mortality 30-day</b> <sup>78,81,82,84,85</sup>	5	2960	OR (95% CI)	0.87 (0.45, 1.67)	61%
	Spinal anesthesia (continuous) <sup>82</sup>	1	210	OR (95% CI)	<b>0.28 (0.08, 0.99)*</b>	NA
	Spinal anesthesia (single) <sup>78,81,82,84,85</sup>	5	2750	OR (95% CI)	1.08(0.58, 2.01)	53%
KQ3	<b>Headache</b> <sup>82</sup>	1	333		NE	
	Spinal anesthesia (continuous) <sup>82</sup>	1	203		NE	
	Spinal anesthesia (single) <sup>82</sup>	1	130		NE	
	<b>Hypotension</b> <sup>82</sup>	1	333		NR	84%
	Spinal anesthesia (incremental) <sup>82</sup>	1	130	OR (95% CI)	0.35 (0.10, 1.28)	NA
	Spinal anesthesia (single) <sup>82</sup>	1	203	OR (95% CI)	<b>0.04 (0.01, 0.13)*</b>	NA

CI = confidence intervals; KQ = key question; NA = not applicable; NE = not estimable; NR = not reported; OR = odds ratio; \* = statistically significant

**Table 7-B. Spinal anesthesia (continuous vs. single administration): Cohort studies**

	Outcome or Subgroup	Studies (N)	Participants (N)	Statistical Method	Effect Estimate	I <sup>2</sup>
KQ2	<b>Mortality 30-day</b> <sup>82</sup>	1	291	OR (95% CI)	0.96 (0.30, 3.00)	NA
KQ3	<b>Any adverse event</b> <sup>82</sup>	1	291		NE	
	<b>Headache</b> <sup>82</sup>	1	291		NE	
	<b>Hypotension</b> <sup>82</sup>	1	291	OR (95% CI)	<b>0.08 (0.04, 0.14)*</b>	NA

CI = confidence intervals; KQ = key question; NA = not applicable; NE = not estimable; OR = odds ratio; \* = statistically significant

**Table 7-C. Spinal (single) anesthesia (lateral vs. supine position): Cohort studies**

	Outcome or Subgroup	Studies (N)	Participants (N)	Statistical Method	Effect Estimate	I <sup>2</sup>
KQ3	Bradycardia <sup>83</sup>	1	41	OR (95% CI)	0.55 (0.15, 1.98)	NA
	Hypotension <sup>83</sup>	1	41	OR (95% CI)	<b>0.22 (0.06, 0.86)*</b>	NA

CI = confidence intervals; KQ = key question; NA = not applicable; NE = not estimable; OR = odds ratio; \* = statistically significant

**Table 7-D. Spinal anesthesia (Different doses): Cohort studies**

	Outcome or Subgroup	Studies (N)	Participants (N)	Statistical Method	Effect Estimate	I <sup>2</sup>
KQ2	Delirium					
	Bupivacaine 4 vs. 12mg <sup>80</sup>	1	60	OR (95% CI)	0.46 (0.08, 2.75)	NA
	<b>Mortality 30-day</b>					
	Bupivacaine 2.5 vs.5mg <sup>82</sup>	1	182	OR (95% CI)	0.49 (0.12, 2.02)	NA
KQ3	<b>Any adverse event</b>					
	Bupivacaine 2.5 vs.5mg <sup>82</sup>	1	182		NE	
	<b>Headache</b>					
	Bupivacaine 2.5 vs.5mg <sup>82</sup>	1	182		NE	
	<b>Hypotension</b>					
	Bupivacaine: 2.5 vs.5mg <sup>82</sup>	1	182	OR (95% CI)	<b>0.08 (0.03, 0.23)*</b>	NA
	Bupivacaine: 4 vs. 12mg <sup>80</sup>	1	60	OR (95% CI)	<b>0.03 (0.01, 0.15)*</b>	NA
Bupivacaine: 0.125% vs. 0.5% <sup>79</sup>	1	25	OR (95% CI)	<b>0.15 (0.03, 0.87)*</b>	NA	

CI = confidence intervals; KQ = key question; NA: not applicable; NE = not estimable; OR = odds ratio; \* = statistically significant

## Complementary and Alternative Medicine (CAM)

### Overview of Included Studies

Two RCTs<sup>43,54</sup> evaluated the efficacy and/or harms of the administration of complementary and alternative medicine (CAM) interventions vs. no intervention or sham intervention (n = 98 participants); sample sizes ranged from 38 to 60. The mean age ranged from 76.8 to 86.3 years. Most were female (81.7 to 86.7 percent). One RCT<sup>43</sup> compared acupuncture (n = 18 participants) to sham control (n = 20) delivered preoperatively. Acute pain was measured using the VAS and the baseline pain measure was 6.5cm. The second RCT<sup>54</sup> compared the Jacobson relaxation technique (n = 30 participants) with no intervention (n = 30). Acute pain was measured using the 10-point verbal “Sensation of Pain and Distress Scale.” Baseline pain measure was not reported for this trial. See Tables E-3 and F-3 (Appendices E and F) for details of the study characteristics and interventions.

One RCT<sup>43</sup> had an unclear risk of bias, while the other<sup>54</sup> had a high risk of bias (Appendix G). Summary of the evidence from these trials is provided in Table 8.

**Table 8. Evidence addressing key questions: Complementary and alternative medicine**

Key Question	Outcome	Evidence availability	Summary of Evidence
KQ 1	Acute pain*	Yes	2 RCTs reported a statistically significant effect in favor of the CAM interventions. The strength of the evidence was rated as insufficient.
	Chronic pain*	No	
KQ2	Mortality (30-day* and up to 1-year postfracture)	No	1 RCT reported a statistically significant effect in favor of relaxation.
	Functional status	No	
	Pain medication use; change in type and quantity	Yes	
	Mental status* (e.g., delirium, confusion)	No	
	Health-related quality of life	No	
	Quality of sleep in the hospital	No	
	Ability to participate in rehabilitation	No	
	Return to prefracture living arrangements	No	
	Health services utilization	No	
	KQ3	Frequency of adverse effects (e.g. stroke*, myocardial infarction*, renal failure*)	
KQ4	Effectiveness and safety in differing subpopulations	No	

KQ = key question; RCT = randomized controlled trial; \* = body of evidence rated using the AHRQ GRADE approach (Grading of Recommendation Assessment, Development and Evaluation); CAM = complementary and alternative medicine

## Key Question 1. Acute and chronic pain management

### Acute Pain (Post-Treatment Means)

Acupressure reduced pain compared with a sham intervention<sup>43</sup> (MD -3.01; 95% CI -4.53, -1.49;  $p < 0.0001$ ; Table 9). It should be noted that the variance was imputed from the reported  $p$  value presented in this study. Relaxation also showed a reduction in pain compared with no relaxation (Sensation of Pain Scale (0-10): MD -1.10; 95% CI -1.43, -0.77;  $p < 0.00001$ ) (Table 9). This was not considered clinically significant. The strength of the evidence was rated as insufficient to make any firm conclusions regarding these interventions.

## Key Question 2. Other outcomes

In the RCT<sup>54</sup> that compared relaxation versus no intervention, patients in the relaxation group required less additional pain medication (e.g., meperidine (mg) or morphine (mg)) compared with the control group (MD -8.43; 95% CI -15.11, -1.75;  $p = 0.01$ ; Table 9).

## Key Question 3. Adverse effects

No data were reported on adverse effects.

## Key Question 4. Efficacy, effectiveness and safety in subpopulations

No data were reported on subpopulations.

**Table 9. Evidence summary table (randomized controlled trials): Complementary and alternative medicine**

	Outcome or Subgroup	Studies	Participants	Statistical Method	Effect Estimate	I <sup>2</sup>
KQ1	<b>Acute pain (post-treatment means)</b>					
	Acupressure <sup>43</sup>	1	38	MD (95% CI)	<b>-3.01 (-4.53, -1.49)*</b>	NA
	Relaxation <sup>54</sup>	1	60	MD (95% CI)	<b>-1.10 (-1.43, -0.77)*</b>	NA
KQ2	<b>Additional pain medication</b>					
	Relaxation <sup>54</sup>	1	60	MD (95% CI)	<b>-8.43 (-15.11, -1.75)*</b>	NA

KQ = key question; CI = confidence intervals; MD = mean difference; NA = not applicable; \* = statistically significant

## Multimodal Pain Management

### Overview of Included Studies

Two prospective cohort studies<sup>86,87</sup> evaluated the effectiveness and/or harms of the administration of multimodal pain management versus standard care in 226 participants; sample size ranged from 106 to 120. The mean age was not reported for either study. Most were female (80.8 percent). One study<sup>86</sup> compared a formal postoperative protocol of IV and oral tramadol plus acetaminophen versus standard care. The second study<sup>87</sup> compared a formal preoperative protocol of skin traction, morphine and acetaminophen versus standard care. See Tables E-4 and F-4 (Appendixes E and F) for details of the study characteristics and interventions.

Based on the NOS, the study quality for both studies was moderate (5 to 7 stars) (Appendix I). Summary of the evidence from these studies is provided in Table 10.

**Table 10. Evidence addressing key questions: Multimodal pain management**

Key Question	Outcome	Evidence availability	Summary of evidence
KQ 1	Acute pain*	No	
	Chronic pain*	No	
KQ2	Mortality (30-day* and up to 1-year postfracture)	Yes	1 prospective cohort study comparing multimodal pain management with standard care reported no statistically significant difference. The strength of the evidence was rated as insufficient.
	Functional status	No	
	Pain medication use; change in type and quantity	No	
	Mental status* (e.g., delirium, confusion)	Yes	2 prospective cohort studies comparing multimodal pain management with standard care reported no statistically significant difference. The strength of the evidence was rated as insufficient.
	Health-related quality of life	No	
	Quality of sleep in the hospital	No	
	Ability to participate in rehabilitation	No	
	Return to prefracture living arrangements	No	
	Health services utilization	No	
KQ3	Frequency of adverse effects (e.g. stroke*, myocardial infarction*, renal failure*)	Yes	1 prospective cohort study comparing multimodal pain management with standard care reported no statistically significant difference. The strength of the evidence for the probability of stroke, myocardial infarction, delirium or renal failure was rated as insufficient.
KQ4	Effectiveness and safety in differing subpopulations	No	

KQ = key question; \* = body of evidence rated using the AHRQ GRADE approach (Grading of Recommendation Assessment, Development and Evaluation)

## Key Question 1. Acute and chronic pain management.

There were no data on pain management.

## Key Question 2. Other outcomes

**Mortality (30-day and one year).** Mortality was reported in one prospective cohort study<sup>87</sup> (n = 106) (Table 11). There was no significant difference between groups after 30 days (5/55 vs. 8/51; OR 0.54; 95% CI 0.16, 1.77; p = 0.31), or at 1 year (11/55 vs. 15/51; OR 0.60; 95% CI 0.25, 1.47; p = 0.26). The strength of the evidence was rated as insufficient to make any firm conclusions regarding these interventions.

**Mental status.** Delirium was reported in two prospective cohort studies<sup>86,87</sup> (n = 226) (Table 11). There was no significant difference between groups in the number of patients with delirium (12/60 vs. 14/60; OR 0.82; 95% CI 0.34, 1.96; p = 0.66);<sup>86</sup> (1/55 vs. 2/51; OR 0.45; 95% CI 0.04, 5.16; p = 0.52).<sup>87</sup> The strength of the evidence was rated as insufficient to make any firm conclusions regarding these interventions.



### Key Question 3. Adverse effects

Data on adverse effects were reported in one prospective cohort study<sup>87</sup> and were not statistically significant (Table 11).

### Key Question 4. Efficacy, effectiveness and safety in subpopulations

No data were reported on subpopulations.

**Table 11. Evidence summary table (cohort studies): Multimodal pain management**

	Outcome or Subgroup	Studies	Participants	Statistical Method	Effect Estimate	I <sup>2</sup>
<b>KQ2</b>	<b>Mental status (e.g., delirium or confusion)</b>					
	Postoperative protocol <sup>86</sup>	1	120	OR (95% CI)	0.82 (0.34, 1.96)	NA
	Preoperative protocol <sup>87</sup>	1	106	OR (95% CI)	0.45 (0.04, 5.16)	NA
	<b>Mortality 30-day</b>					
	Preoperative protocol <sup>87</sup>	1	106	OR (95% CI)	0.54 (0.16, 1.77)	NA
<b>KQ3</b>	<b>Mortality 1 year</b>					
	Preoperative protocol <sup>87</sup>	1	106	OR (95% CI)	0.60 (0.25, 1.47)	NA
	<b>Angina</b>					
	Preoperative protocol <sup>87</sup>	1	106	OR (95% CI)	0.13 (0.00, 6.32)	NA
	<b>Deep venous thrombosis</b>					
	Preoperative protocol <sup>87</sup>	1	106	OR (95% CI)	6.87 (0.14, 347.23)	NA
	<b>Dehydration</b>					
	Preoperative protocol <sup>87</sup>	1	106	OR (95% CI)	0.93 (0.06, 15.20)	NA
	<b>GI bleeding</b>					
	Preoperative protocol <sup>87</sup>	1	106	OR (95% CI)	6.87 (0.14, 347.23)	NA
	<b>Hyponatremia</b>					
	Preoperative protocol <sup>87</sup>	1	106	OR (95% CI)	6.87 (0.14, 347.23)	NA
	<b>Myocardial infarction</b>					
	Preoperative protocol <sup>87</sup>	1	106	OR (95% CI)	0.45 (0.04, 5.16)	NA
	<b>Postoperative ileus</b>					
	Preoperative protocol <sup>87</sup>	1	106	OR (95% CI)	0.13 (0.00, 6.32)	NA
	<b>Pulmonary edema</b>					
	Preoperative protocol <sup>87</sup>	1	106	OR (95% CI)	6.87 (0.14, 347.23)	NA
	<b>Pulmonary embolism</b>					
	Preoperative protocol <sup>87</sup>	1	106	OR (95% CI)	0.45 (0.04, 5.16)	NA
<b>Respiratory infection</b>						
Preoperative protocol <sup>87</sup>	1	106	OR (95% CI)	0.13 (0.00, 6.32)	NA	
<b>Sepsis</b>						
Preoperative protocol <sup>87</sup>	1	106	OR (95% CI)	6.87 (0.14, 347.23)	NA	
<b>Stroke</b>						
Preoperative protocol <sup>87</sup>	1	106	OR (95% CI)	0.13 (0.00, 6.32)	NA	
<b>Urinary retention</b>						
Preoperative protocol <sup>87</sup>	1	106	OR (95% CI)	0.10 (0.00, 1.81)	NA	
<b>Urinary tract infection</b>						
Preoperative protocol <sup>87</sup>	1	106	OR (95% CI)	0.45 (0.04, 5.16)	NA	

CI = confidence intervals; KQ = key question; NA = not applicable; OR = odds ratio

## Nerve Blocks

### Overview of Included Studies

Twenty-nine RCTs<sup>88-116</sup> (n = 1,757) evaluated the efficacy and/or harms of the administration of nerve blocks, including 3-in-1 (neurostimulation [NS]/ultrasound-guided [US]), combined lumbar/sacral plexus, fascia iliaca compartment, femoral, lumbar plexus ± sciatic nerve, posterior lumbar plexus, psoas compartment, obutatorator and epidural nerve blocks. These were

compared with standard care ± placebo, or a different method of nerve blocks. Sample sizes ranged from 14 to 207 participants. Additionally, three retrospective cohort studies<sup>117-119</sup> (n = 696) evaluated 3-in-1, femoral, lumbar plexus plus sciatic nerve blocks versus systemic analgesia, or comparing different analgesic medications in femoral, lumbar plexus plus sciatic blocks. Sample sizes ranged from 62 to 535 participants. The mean age ranged from 59.2 to 85.9 years. Most were female (43.3 to 90.0 percent). Acute pain was measured using different scales (i.e., NRS (0-3, 1-5 and 1-10) and 10cm VAS). Eight studies using the 10cm VAS reported mean baseline pain scores ranging from 1.4cm to 7.3cm. See Tables E-5 and F-5 (Appendices E and F) for details of the study characteristics and interventions.

Two RCTs<sup>95,96</sup> had a low risk of bias, 16 RCTs<sup>89,91,97,99-105,107-109,111,113,115</sup> had an unclear risk of bias, while the remaining 11<sup>88,90,92-94,98,106,110,112,114,116</sup> had a high risk of bias (Appendix G). Summary of the evidence from these trials is provided in Table 12.

Based on the primary interventions and comparison groups, the studies were grouped as follows:

1. Nerve blocks versus standard care ± placebo
2. Nerve blocks versus neuraxial anesthesia
3. Nerve blocks: ropivacaine versus bupivacaine
4. Nerve blocks: addition of clonidine
5. Nerve blocks: US versus NS

**Table 12. Evidence addressing key questions: Nerve blocks**

Key Question	Outcome	Evidence availability	Summary of evidence
KQ 1	Acute pain*	Yes	<p>11 RCTs reported on acute pain following nerve blocks compared with standard care. There was marked heterogeneity between the studies and subgroup analyses revealed that the type and timing of the intervention affected the homogeneity of the results. Additionally removal of the outlying study also generated more homogenous results. In general, there was a statistically significant effect in favor of nerve blocks over standard care. Additional analyses of pain at rest and on movement were also not reported due to marked statistical heterogeneity. One RCT reported a statistically significant reduction in number of participants with pain on day 1. The strength of the evidence was rated as moderate.</p> <p>3 RCTs reported no significant difference between the use of nerve blocks vs. neuraxial anesthesia on acute pain reduction. The strength of the evidence was rated as low.</p>
	Chronic pain*	No	

**Table 12. Evidence addressing key questions: Nerve blocks (continued)**

<b>Key Question</b>	<b>Outcome</b>	<b>Evidence availability</b>	<b>Summary of evidence</b>
<b>KQ2</b>	<b>Mortality (30-day* and up to 1-year postfracture)</b>	Yes	4 RCTs reported no statistically significant difference between nerve blocks and standard care regarding 30-day mortality. The strength of the evidence was rated as low.  2 RCTs and 1 retrospective cohort study reported no statistically significant difference between nerve blocks and standard care regarding 1-year mortality.
	<b>Functional status</b>	No	
	<b>Pain medication use; change in type and quantity</b>	Yes	7 RCTs and 1 retrospective cohort study reported statistically significantly fewer participants requiring additional pain medications when nerve blocks were administered compared with standard care.  1 RCT comparing nerve blocks with neuraxial anesthesia found no significant difference in the number of participants requiring additional pain medications.  1 Retrospective cohort study comparing ropivacaine with bupivacaine for nerve block found no significant difference in the number of participants requiring additional pain medications.
	<b>Mental status* (e.g., delirium, confusion)</b>	Yes	3 RCTs and 2 retrospective cohort studies reported a statistically significant difference in participants developing delirium in favor of the nerve blocks compared with standard care. The strength of the evidence was rated as moderate.  1 RCT comparing nerve blocks with neuraxial anesthesia found no significant difference in the number of participants experiencing delirium.  1 Retrospective cohort study comparing ropivacaine with bupivacaine for nerve block found no significant difference in the number of participants experiencing delirium.
	<b>Health-related quality of life</b>	No	
	<b>Quality of sleep in the hospital</b>	Yes	1 RCT reported no statistically significant difference between nerve blocks and standard care.
	<b>Ability to participate in rehabilitation</b>	No	
	<b>Return to prefracture living arrangements</b>	No	
	<b>Health services utilization</b>	Yes	2 retrospective cohort studies reported conflicting results between nerve blocks and standard care with one demonstrating a statistically significant decrease in hospital LOS while the other showed no difference.

**Table 12. Evidence addressing key questions: Nerve blocks (continued)**

Key Question	Outcome	Evidence availability	Summary of Evidence
KQ3	Frequency of adverse effects (e.g. stroke*, myocardial infarction*, renal failure*)	Yes	20 RCTs and 2 retrospective cohort studies reported on different adverse effects between nerve blocks and other modes of care with no statistically significant differences except between nerve blocks and standard care except for urinary tract and respiratory infections, drowsiness and dizziness which occurred less frequently in the nerve block groups.  The strength of the evidence for the probability of stroke, myocardial infarction, or renal failure was rated as insufficient.
KQ4	Effectiveness and safety in differing subpopulations	Yes	Comparing nerve blocks and standard care, 1 RCT included only participants with heart disease and 1 RCT included only participants who were independent prior to the hip fracture.


KQ = key question; LOS = length of stay; RCT = randomized controlled trial; \* = body of evidence rated using the AHRQ GRADE approach (Grading of Recommendation Assessment, Development and Evaluation)

## Key Question 1. Acute and chronic pain management

### Nerve Blocks vs. No Block

Acute pain (post-treatment) was reported in 13 RCTs<sup>89,91,94,99,100,106-112,114</sup> (Figure 6 and Table 13-A). The pooled results are not reported due to high heterogeneity ( $I^2 = 92$  percent) between the included studies, which was not explained by study design (i.e. all were RCTs) or risk of bias (i.e., removal of the trials with a high risk of bias). Specific intervention details (i.e., type and quantity) could partially explain the heterogeneity with removal of combined nerve blocks groups (e.g. 3-in-1 nerve block group) substantially decreasing the quantified heterogeneity ( $I^2 = 41$ %). Additionally, another source of identified heterogeneity is the timing of the intervention with postoperative administration of nerve blocks in three RCTs<sup>91,111,114</sup> showing marked heterogenous results ( $I^2 = 95$ %), while preoperative administration showed more homogenous results ( $I^2 = 53$ %) in eight RCTs.<sup>89,94,99,100,106,108-110</sup> Removal of one of the included RCTs<sup>111</sup> decreased the heterogeneity for both the overall results ( $I^2 = 64$ %) and the subgroup analysis ( $I^2 = 0$ %) of only postoperative administration of nerve blocks.

**Figure 6. Nerve blocks versus no block—acute pain (post-treatment)**




**Day 1 pain.** One trial<sup>101</sup> (n = 50) reported a statistically significant difference in the frequency of patients who reported postoperative pain on day 1 favoring nerve blocks (7/25 vs. 20/25; OR 0.10; 95% CI 0.03, 0.36; p = 0.0005) (Table 13-A).

**Pain on movement.** Pain on movement (post-treatment means) was reported in four trials<sup>94,97,106,114</sup> (n = 258) (Table 13-A). The pooled results were not reported due to significant heterogeneity (I<sup>2</sup> = 95 percent) between the studies (Figure 7). Meta-analysis restricted to two RCTs<sup>94,114</sup> using 3-in-1 nerve block vs. no block showed a significant reduction in pain on movement favoring nerve blocks (SMD -1.02; 95% CI -1.83, -0.21; p = 0.01). One RCT<sup>94</sup> investigated preoperative pain relief (numeric rating scale [0-3]) while the other RCT<sup>114</sup> investigated postoperative pain (10cm VAS) relief. Both trials had a high risk of bias.

The third RCT<sup>106</sup> examined preoperative epidural analgesia versus no block and showed a significant increase in pain relief (10cm VAS) on movement favoring nerve blocks (MD -2.30; 95% CI -2.92, -1.68; p < 0.00001). The trial had a high risk of bias.

The last RCT<sup>97</sup> examined preoperative femoral nerve block versus no block and showed no significant difference in pain relief (5-point Verbal Rating Scale) on movement (MD 0.36; 95% CI -0.04, 0.75; p = 0.08).


**Figure 7. Nerve blocks versus no block—pain on movement (post-treatment)**



**Pain on rest.** Pain on rest (posttreatment) was reported in three trials<sup>97,106,114</sup> (n = 208) (Table 13-A). The pooled results were not reported due to significant heterogeneity (I<sup>2</sup> = 91 percent) between the studies (Figure 8). One RCT<sup>114</sup> examined postoperative 3-in-1 nerve block versus standard care and found no significant difference in pain relief (10cm VAS) (MD -0.07; 95% CI -0.41, 0.27; p = 0.69). This study had a high risk of bias. The second RCT<sup>106</sup> examined preoperative epidural analgesia versus standard care and found a statistically difference in pain relief in favor of the nerve blocks (10cm VAS) (MD -0.55; 95% CI -0.81, -0.29; p < 0.0001). This study had a high risk of bias. The last RCT<sup>97</sup> examined preoperative femoral nerve block versus standard care and reported a statistically significant difference in pain relief in favor of standard care (5-point Verbal Rating Scale) (MD 0.18; 95% CI 0.03, 0.33; p = 0.02). This study had an unclear risk of bias.

The strength of the evidence was rated as moderate regarding these interventions.

Figure 8. Nerve blocks versus no block – pain on rest (posttreatment)



## Nerve Blocks vs. Neuraxial Anesthesia

Acute pain (posttreatment) was reported in three RCTs<sup>92,93,115</sup> (n = 109) (Table 13-B). There was no statistically significant difference in pain between the two groups (MD -0.35; 95% CI -1.10, 0.39; p = 0.35).

## Key Question 2. Other outcomes

### Nerve Blocks vs. No Block


**30-day mortality.** A total of four RCTs<sup>95,99,105,106</sup> evaluated 30-day mortality in a total of 228 participants (Table 13-A). Meta-analysis did not provide evidence of a significant difference in 30-day mortality (2/114 vs. 10/114; OR 0.28; 95% CI 0.07, 1.12; p = 0.07). The strength of the evidence was rated as low to make any firm conclusions regarding these interventions.

**1-year mortality.** Two RCTs<sup>91,94</sup> evaluated 1-year mortality in a total of 112 participants (Table 13-A). Additionally, one retrospective cohort study<sup>119</sup> reported data for 535 participants (Table 14). There was no evidence of a significant difference in mortality in the RCTs (5/45 vs. 9/67; OR 0.82; 95% CI 0.25, 2.72; p = 0.74), or in the cohort study (41/178 vs. 104/357; OR 0.73; 95% CI 0.48, 1.10; p = 0.14).

**Additional pain medication use.** Seven RCTs<sup>89,90,94,96,97,101,114</sup> evaluated additional pain medication use in a total of 378 participants (Table 13-A). Additionally, one retrospective cohort study<sup>117</sup> compared femoral nerve block vs. no block, reporting data for 99 participants (Table 14). Meta-analysis of the seven trials<sup>89,90,94,96,97,101,114</sup> resulted in a significant difference in additional pain medication use, favoring nerve blocks (49/197 vs. 68/181; OR 0.32; 95% CI 0.14, 0.72; p = 0.006) (Figure 9). The retrospective cohort study<sup>117</sup> reported a statistically

significant effect difference favoring nerve blocks (0/49 vs. 14/50; OR 0.03; 95% CI 0.00, 0.44;  $p = 0.01$ ).

**Figure 9. Nerve blocks versus no block – participants requiring additional pain medication**



**Mental status.** Four RCTs<sup>95,98,107,108</sup> ( $n = 461$ ) and two cohort studies<sup>117,119</sup> ( $n = 634$ ) reported the occurrence of delirium (Table 13-A, 14-A). Meta-analysis of the trials<sup>95,98,107,108</sup> showed a significant difference favoring nerve blocks (11/242 vs. 33/219; OR 0.33; 95% CI 0.16, 0.66;  $p = 0.002$ ). The pooled results of the cohort studies<sup>117,119</sup> also showed a significant difference in favor



of nerve blocks (11/227 vs. 55/407; OR 0.24; 95% CI 0.08, 0.72;  $p = 0.01$ ). The strength of the evidence was rated as moderate.

**Length of stay for acute hospitalization.** LOS for acute hospitalization (days) was reported in two retrospective cohort studies<sup>117,119</sup> ( $n = 634$ ) (Table 14-A). There was significant heterogeneity between the studies and pooled results are not reported. The first study<sup>117</sup> was performed using a 3-in-1 nerve block while the second study<sup>119</sup> used a femoral nerve block. Both studies showed lower LOS for the nerve blocks with the magnitude larger for the 3-in-1 block.

**Quality of sleep.** Quality of sleep (10cm VAS) (post-treatment means) was reported in one RCT<sup>110</sup> ( $n = 77$ ) (Table 13-A). There was no significant difference between groups (MD 0.30; 95% CI -0.46, 1.06;  $p = 0.44$ ).

### **Nerve Blocks vs. Neuraxial Anesthesia**

**Additional pain medication use.** Additional pain medication use was reported in one RCT<sup>115</sup> ( $n = 30$ ) (Table 13-B). There was no significant difference between the two groups (5/15 vs. 3/15; OR 2.00; 95% CI 0.38, 10.51;  $p = 0.41$ ).

**Mental status.** Delirium (MMSE) was reported in one RCT<sup>92</sup> ( $n = 29$ ) (Table 13-B). There was no significant difference between the two groups (6/15 vs. 5/14; OR 1.20; 95% CI 0.27, 5.40;  $p = 0.81$ ). The strength of the evidence was rated as insufficient to make any firm conclusions.

### **Nerve Blocks: Ropivacaine vs. Bupivacaine**

**Additional pain medication use.** Additional pain medication use was reported in one cohort study<sup>118</sup> ( $n = 62$ ) (Table 14-B). There was no significant difference between the two groups (10/32 vs. 8/30; OR 1.25; 95% CI 0.42, 3.76;  $p = 0.69$ ).

**Mental status.** Delirium (user defined) was reported in one cohort study<sup>118</sup> ( $n = 62$ ) (Table 14-B). There was no significant difference between the two groups (2/32 vs. 1/30; OR 1.93; 95% CI 0.17, 22.50;  $p = 0.60$ ). The strength of the evidence was rated as insufficient to make any firm conclusions.

## **Key Question 3. Adverse effects**

### **Nerve Blocks vs. No Block**

**Any adverse event.** Any adverse effects were reported in five RCTs<sup>88,97,98,100,107</sup> ( $n = 392$ ) and there was significant heterogeneity ( $I^2 = 94\%$ ) (Table 13-A). Two retrospective cohort studies<sup>117,119</sup> ( $n = 634$ ) found no significant effect difference between the two groups (62/227 vs. 76/407; OR 1.64; 95% CI 0.79, 3.42;  $p = 0.18$ ) (Table 14-A).

**Cardiac complications.** Cardiac complications were reported in two RCTs<sup>95,106</sup> ( $n = 128$ ). There was no significant difference between the two groups (3/64 vs. 8/64; OR 0.35; 95% CI 0.08, 1.44;  $p = 0.15$ ) (Table 13-A). One retrospective cohort study<sup>117</sup> ( $n = 99$ ) found no significant difference between the two groups (0/49 vs. 1/50; OR 0.33; 95% CI 0.01, 8.38;  $p = 0.50$ ) (Table 14-A).

**Damage to surrounding structures.** Damage to surrounding structures was reported in three RCTs<sup>88,97,116</sup> (n = 224) and found no significant difference between the two groups (3/119 vs. 0/105; OR = 7.44; 95% CI 0.37, 147.92; p = 0.19) (Table 13-A).


**Deep venous thrombosis.** Deep venous thrombosis was reported in two RCTs<sup>94,99</sup> (n = 100). There was no significant difference between the two groups (4/49 vs. 3/51; OR 1.40; 95% CI 0.29, 6.72; p = 0.67) (Table 13-A).

**Infection.** There were no reports of infection in two RCTs<sup>88,97</sup> (n = 184) (Table 13-A).

**Myocardial infarction.** Myocardial infarction was reported in two RCTs<sup>106,110</sup> (n = 145). There was no significant difference between the two groups (1/72 vs. 1/73; OR 1.00; 95% CI 0.06, 16.67; p = 1.00) (Table 13-A). One retrospective cohort study<sup>119</sup> (n = 535) found no significant difference between the two groups (1/178 vs. 3/357; Peto OR 0.69; 95% CI 0.09, 5.53; p = 0.72) (Table 14-A).

**Nausea/vomiting.** Nausea/vomiting was reported in six RCTs<sup>91,96,97,107,113,114</sup> (n = 421) and found no evidence of a significant difference between the two groups (18/217 vs. 31/204; OR 0.65; 95% CI 0.27, 1.55; p = 0.33) (Table 13-A and Figure 10).

**Figure 10. Nerve blocks versus no block—nausea/vomiting**




**Pulmonary embolism.** Pulmonary embolism was reported in two RCTs<sup>95,106</sup> (n = 128) and found no significant difference between the two groups (2/64 vs. 1/64; OR 1.63; 95% CI 0.19, 13.61; p = 0.65) (Table 13-A).

**Respiratory infection.** Respiratory infection was reported in five RCTs<sup>94,95,99,106,116</sup> (n = 268) and found no significant difference between the two groups (9/133 vs. 22/135; OR 0.43; 95% CI 0.18, 1.04; p = 0.06) (Table 13-A and Figure 11). One retrospective cohort study<sup>119</sup> (n = 535) found a statistically significant difference favoring nerve blocks (9/178 vs. 39/357; OR 0.43; 95% CI 0.21, 0.92; p = 0.03) (Table 14-A).

**Stroke.** Stroke was reported in one RCT<sup>99</sup> (n = 50) and found no significant effect between the two groups (1/25 vs. 0/25; OR 3.12; 95% CI 0.12, 80.39; p = 0.49) (Table 13-A). Stroke was also reported in one retrospective cohort study<sup>119</sup> (n = 535) and found no significant difference between the two groups (1/178 vs. 8/357; OR 0.25; 95% CI 0.03, 1.99; p = 0.19) (Table 14-A).

**Surgical wound infection.** Surgical wound infection was reported in two RCTs<sup>95,99</sup> (n = 110) and found no significant difference between the two groups (3/55 vs. 4/55; OR 0.77; 95% CI 0.11, 5.63; p = 0.80) (Table 13-A).

**Figure 11. Nerve blocks versus no block—respiratory infection**



**Urinary retention.** Urinary retention was reported in two RCTs<sup>91,113</sup> (n = 62) and found no significant difference between the two groups (3/31 vs. 1/31; OR 2.23; 95% CI 0.27, 18.71; p = 0.46) (Table 13-A). One retrospective cohort study<sup>119</sup> (n = 535) and found no significant difference between the two groups (4/178 vs. 17/357; OR 0.46; 95% CI 0.15, 1.39; p = 0.17) (Table 14-A).

**Urinary tract infection.** Urinary tract infection was reported in one RCT<sup>99</sup> (n = 50) and found no significant difference between the two groups (4/25 vs. 6/25; OR 0.60; 95% CI 0.15, 2.47; p = 0.48) (Table 13-A). One retrospective cohort study<sup>119</sup> (n = 535) found a statistically significant difference favoring nerve blocks (12/178 vs. 63/357; OR 0.34; 95% CI 0.18, 0.64; p = 0.001) (Table 14-A).

**Other adverse effects.** The remaining reported adverse effects were from single RCTs and cohort studies and did not demonstrate any significant statistical differences between the pain management interventions (Tables 13-A and 14-A).

### Nerve Blocks vs. Neuraxial Anesthesia

**Adverse effects.** The reported adverse effects were from single RCTs and did not demonstrate any significant statistical differences between the pain management interventions (Table 13-B).

### **Nerve Blocks: Ropivacaine vs. Bupivacaine**

**Adverse effects.** The reported adverse effects were from single RCTs and cohort studies and did not demonstrate any significant statistical differences between the pain management interventions (Tables 13-C, 14-B).

### **Nerve Blocks: Addition of Clonidine**

**Adverse effects.** The reported adverse effects were from single RCTs and did not demonstrate any significant statistical differences between the pain management interventions (Table 13-D).

### **Nerve Blocks: US vs. NS**

**Damage to surrounding structures.** Damage to surrounding structures was reported in two RCTs<sup>103,104</sup> (n = 100) (Table 13-E). There was no statistically significant difference between the two groups (0/40 vs. 7/60; OR 0.16; 95% CI 0.02, 1.30; p = 0.09).

**Other adverse effects.** The remaining reported adverse effects were from a single RCT<sup>103</sup> and did not demonstrate any significant statistical differences between the pain management interventions.

### **Key Question 4. Efficacy, effectiveness and safety in subpopulations**

One RCT<sup>106</sup> only recruited patients with pre-existing heart disease. There was a significant reduction in acute pain (MD -0.98; 95% CI -1.49, -0.48; p <0.0001) favoring nerve blocks. There was no significant difference in 30-day mortality (0/34 vs. 4/34; OR 0.10; 95% CI 0.01, 1.90; p = 0.12) or adverse effects: participants with any cardiac complications (2/34 vs. 7/34; OR 0.24; 95% CI 0.05, 1.26; p = 0.09); congestive heart failure (1/34 vs. 2/34; OR 0.48; 95% CI 0.04, 5.61; p = 0.56); myocardial infarction (1/34 vs. 1/34; OR 1.00; 95% CI 0.06, 16.67; p = 1.00); respiratory infection (2/34 vs. 2/34; OR 1.00; 95% CI 0.13, 7.54; p = 1.00); or pulmonary embolism (1/34 vs. 1/34; OR 1.00; 95% CI 0.06, 16.67; p = 1.00).

One RCT<sup>95</sup> only recruited participants that were independent prior to their hip fracture. There was no significant difference between nerve blocks versus standard care for 30-day mortality (1/30 vs. 1/30; OR 1.00; 95% CI 0.06, 16.76; p = 1.00).

Table 13. Evidence summary table (randomized controlled trials): Nerve blocks

Table 13-A. Nerve blocks versus no block: RCT/nRCT

	Outcome or Subgroup	Studies	Participants	Statistical Method	Effect Estimate	I <sup>2</sup>	
KQ1	<b>Acute pain (post-treatment means)</b> <sup>89,91,94,99,100,106-112,114</sup>	13	1002		NR	92%	
	3-in-1 NB <sup>91,94,114</sup>	3	152		NR	85%	
	Epidural analgesia <sup>106,110</sup>	2	145	SMD (95% CI)	<b>-0.83 (-1.17, -0.49)*</b>	0%	
	Fascia iliaca NB <sup>107,108,112</sup>	3	421	MD (95% CI)	NR	97%	
	Femoral NB <sup>99,100,109</sup>	3	109	SMD (95% CI)	<b>-1.01 (-1.46, -0.57)*</b>	12%	
	Psoas compartment NB <sup>89</sup>	1	40	MD (95% CI)	<b>-0.70 (-1.10, -0.30)*</b>	NA	
	Combined NB <sup>111,112</sup>	2	135	MD (95% CI)	<b>-3.08 (-3.44, -2.73)*</b>	19%	
	<b>Day 1 pain</b>						
	3-in-1 NB <sup>101</sup>	1	50	OR (95% CI)	<b>0.10 (0.03, 0.36)*</b>	NA	
	<b>Pain on movement (post-treatment)</b> <sup>94,97,106,114</sup>	4	258		NR	95%	
	3-in-1 NB <sup>94,114</sup>	2	90	SMD (95% CI)	<b>-1.02 (-1.83, -0.21)*</b>	69%	
	Epidural analgesia <sup>106</sup>	1	68	MD (95% CI)	<b>-2.30 (-2.92, -1.68)</b>	NA	
	Femoral NB <sup>97</sup>	1	100	MD (95% CI)	0.36 (-0.04, 0.75)	NA	
	<b>Pain on rest (post-treatment)</b> <sup>97,106,114</sup>	3	208		NR	91%	
	3-in-1 NB <sup>114</sup>	1	40	MD (95% CI)	-0.07 (-0.41, 0.27)	NA	
	Epidural analgesia <sup>106</sup>	1	68	MD (95% CI)	<b>-0.55 (-0.81, -0.29)*</b>	NA	
	Femoral NB <sup>97</sup>	1	100	MD (95% CI)	<b>0.18 (0.03, 0.33)*</b>	NA	
	KQ2	<b>Additional pain medication use</b> <sup>89,90,94,96,97,101,114</sup>	7	378	OR (95% CI)	<b>0.32 (0.14, 0.72)*</b>	31%
		3-in-1 NB <sup>90,94,101,114</sup>	4	165	OR (95% CI)	<b>0.14 (0.05, 0.37)*</b>	0%
Fascia iliaca NB <sup>96</sup>		1	48	OR (95% CI)	1.00 (0.18, 5.53)	NA	
Femoral NB <sup>97</sup>		1	100	OR (95% CI)	0.35 (0.11, 1.09)	NA	
Lateral cutaneous NB <sup>90</sup>		1	25	OR (95% CI)	0.24 (0.01, 5.31)	NA	
Psoas compartment NB <sup>89</sup>		1	40	OR (95% CI)	1.59 (0.24, 10.70)	NA	
<b>Mental status (e.g., delirium, confusion)</b> <sup>95,98,107,108</sup>		4	461	OR (95% CI)	<b>0.33 (0.16, 0.66)*</b>	0%	
3-in-1 NB <sup>98</sup>		1	40	OR (95% CI)	0.22 (0.01, 4.92)	NA	
Epidural analgesia <sup>95</sup>		1	60	OR (95% CI)	0.19 (0.01, 4.06)	NA	
Fascia iliaca NB <sup>107,108</sup>		2	361	OR (95% CI)	<b>0.30(0.09, 1.00)</b>	19%	
<b>Mortality 30-day</b> <sup>95,99,101,106</sup>		4	228	OR (95% CI)	0.28 (0.07, 1.12)	0%	
3-in-1 NB <sup>101</sup>		1	50	OR (95% CI)	0.32 (0.01, 8.25)	NA	
Epidural analgesia <sup>95,106</sup>		2	128	OR (95% CI)	0.33 (0.03, 3.34)	23%	
Femoral NB <sup>99</sup>		1	50	OR (95% CI)	0.22 (0.02, 2.11)	NA	
<b>Mortality 1 year</b>							
3-in-1 NB <sup>91,94</sup>		2	112	OR (95% CI)	0.82 (0.25, 2.72)	0%	
<b>Quality of sleep</b>							
Epidural analgesia <sup>110</sup>		1	77	MD (95% CI)	0.30 (-0.46, 1.06)	NA	
KQ3		<b>Allergic reaction</b>					
	3-in-1 NB <sup>114</sup>	1	40	OR (95% CI)	0.07 (0.00, 1.34)	NA	

**Table 13-A. Nerve blocks versus no block: RCT/nRCT (continued)**

	Outcome or Subgroup	Studies	Participants	Statistical Method	Effect Estimate	I <sup>2</sup>	
KQ3	<b>Any adverse event</b> <sup>88,97,98,100,107</sup>	5	392	OR (95% CI)	NE	94%	
	3-in-1 NB <sup>98</sup>	1	40		NE		
	Femoral NB <sup>88,97,100</sup>	3	198	OR (95% CI)	4.49 (1.61, 12.55)*	NA	
	<b>Cardiac complications</b>						
	Epidural analgesia <sup>95,106</sup>	2	128	OR (95% CI)	0.35 (0.08, 1.44)	0%	
	<b>Cardiovascular complications</b>						
	Femoral NB <sup>99</sup>	1	50	OR (95% CI)	1.00 (0.13, 7.72)	NA	
	<b>Cardiovascular or neurological toxicity</b>						
	Femoral NB <sup>88</sup>	1	84		NE		
	<b>Congestive heart failure</b>						
	Epidural analgesia <sup>106</sup>	1	68	OR (95% CI)	0.48 (0.04, 5.61)	NA	
	<b>Constipation</b>						
	3-in-1 NB <sup>91</sup>	1	42	OR (95% CI)	3.86 (0.97, 15.44)	NA	
	<b>Damage to surrounding structures</b> <sup>88,97,116</sup>						
	Fascia iliaca compartment NB <sup>116</sup>	1	40		NE		
	Femoral NB <sup>88,97</sup>	2	184	OR (95% CI)	7.44 (0.37, 147.92)	0%	
	<b>Deep venous thrombosis</b> <sup>94,99</sup>						
	3-in-1 NB <sup>94</sup>	1	50	OR (95% CI)	1.09 (0.06, 18.40)	NA	
	Femoral NB <sup>99</sup>	1	50	OR (95% CI)	1.57 (0.24, 10.30)	NA	
	<b>Direct skin damage</b>						
	Femoral NB <sup>99</sup>	1	50	OR (95% CI)	0.17 (0.02, 1.55)	NA	
	<b>Dizziness</b>						
	Fascia iliaca compartment NB <sup>116</sup>	1	40	OR (95% CI)	<b>0.00 (0.00, 0.03)*</b>	NA	
	<b>Drowsiness</b>						
	Fascia iliaca compartment NB <sup>116</sup>	1	40	OR (95% CI)	<b>0.02 (0.00, 0.31)*</b>	NA	
	<b>Hematoma</b>						
	Lumbar plexus block <sup>113</sup>	1	20		NE		
	<b>Hypotension</b>						
	3-in-1 NB <sup>101</sup>	1	50	OR (95% CI)	0.52 (0.17, 1.61)	NA	
<b>Infection</b>							
Femoral NB <sup>88,97</sup>	2	184		NE			
<b>Major medical complications</b>							
Epidural analgesia <sup>95</sup>	1	60	OR (95% CI)	0.69 (0.21, 2.30)	NA		
<b>Myocardial infarction</b>							
Epidural analgesia <sup>106,110</sup>	2	145	OR (95% CI)	1.00 (0.06, 16.67)	0%		
<b>Myocardial ischemia</b>							
Epidural analgesia <sup>110</sup>	1	77	OR (95% CI)	0.92 (0.36, 2.40)	NA		
<b>Nausea/vomiting</b> <sup>91,96,97,113,114</sup>							
3-in-1 NB <sup>91,114</sup>	2	102	OR (95% CI)	1.05 (0.25, 4.45)	61%		
Lumbar plexus block <sup>113</sup>	1	20	OR (95% CI)	1.00 (0.11, 8.95)	NA		
Femoral NB <sup>97</sup>	1	100	OR (95% CI)	0.10 (0.01, 1.95)	NA		
Fascia iliaca NB <sup>96,107</sup>	2	199	OR (95% CI)	0.35 (0.09, 1.42)	0%		
<b>Paresthesia</b> <sup>97,116</sup>							
Femoral NB <sup>97</sup>	1	100	OR (95% CI)	5.21 (0.24, 111.24)	NA		
Fascia iliaca compartment NB <sup>116</sup>	1	40		NE			

**Table 13-A. Nerve blocks versus no block: RCT/nRCT (continued)**

	Outcome or Subgroup	Studies	Participants	Statistical Method	Effect Estimate	I <sup>2</sup>
<b>KQ3</b>	<b>Pulmonary embolism</b>					
	Epidural analgesia <sup>95,106</sup>	2	128	OR (95% CI)	1.63 (0.19, 13.61)	0%
	<b>Respiratory infection</b> <sup>94,95,99,106,116</sup>	5	268	OR (95% CI)	0.43 (0.18, 1.04)	6%
	3-in-1 NB <sup>94</sup>	1	50	OR (95% CI)	0.50 (0.08, 3.02)	NA
	Epidural analgesia <sup>95,106</sup>	2	128	OR (95% CI)	1.00 (0.27, 3.65)	0%
	Femoral NB <sup>99</sup>	1	50	OR (95% CI)	<b>0.15 (0.03, 0.81)*</b>	NA
	Fascia iliaca compartment NB <sup>116</sup>	1	40	OR (95% CI)	0.09 (0.00, 1.78)	NA
	<b>Stroke</b>					
	Femoral NB <sup>99</sup>	1	50	OR (95% CI)	3.12 (0.12, 80.39)	NA
	<b>Surgical wound infection</b> <sup>95,99</sup>	2	110	OR (95% CI)	0.77 (0.11, 5.63)	0%
	Epidural analgesia <sup>95</sup>	1	60	OR (95% CI)	0.19 (0.01, 4.06)	NA
	Femoral NB <sup>99</sup>	1	50	OR (95% CI)	1.57 (0.24, 10.30)	NA
	<b>Urinary retention</b> <sup>91,113</sup>	2	62	OR (95% CI)	2.23 (0.27, 18.71)	0%
	Lumbar plexus block <sup>113</sup>	1	20	OR (95% CI)	1.00 (0.05, 18.57)	NA
	3-in-1 NB <sup>91</sup>	1	42	OR (95% CI)	5.51 (0.25, 122.08)	NA
	<b>Urinary tract infection</b>					
Femoral NB <sup>99</sup>	1	50	OR (95% CI)	0.60 (0.15, 2.47)	NA	

KQ: key question; CI = confidence intervals; MD = mean difference; NA = not applicable; NB = nerve block; NR = not reported; OR = odds ratio; RCT/nRCT = randomized and nonrandomized controlled trials; SMD = standardized mean difference; \* = statistically significant



**Table 13-B. Nerve blocks versus neuraxial anesthesia: RCT/nRCT**

	Outcome or Subgroup	Studies	Participants	Statistical Method	Effect Estimate	I <sup>2</sup>
<b>KQ1</b>	<b>Acute pain (posttreatment means)</b> <sup>92,93,115</sup>	3	109	MD (95% CI)	-0.35 (-1.10, 0.39)	0%
	Psoas compartment NB vs. epidural anesthesia (single) <sup>115</sup>	1	30	MD (95% CI)	0.34 (-1.22, 1.90)	NA
	Posterior lumbar plexus NB vs. spinal anesthesia (single) <sup>93</sup>	1	50	MD (95% CI)	-0.60 (-1.73, 0.53)	NA
	Combined lumbar + sacral plexus NB vs. spinal anesthesia (single) <sup>92</sup>	1	29	MD (95% CI)	-0.50 (-1.78, 0.78)	NA
<b>KQ2</b>	<b>Additional pain medication use</b>					
	Psoas compartment NB vs. epidural anesthesia (single) <sup>115</sup>	1	30	OR (95% CI)	2.00 (0.38, 10.51)	NA
	<b>Mental status (e.g, delirium, confusion)</b>					
	Combined lumbar + sacral plexus NB vs. spinal anesthesia (single) <sup>92</sup>	1	29	OR (95% CI)	1.20 (0.27, 5.40)	NA
<b>KQ3</b>	<b>Allergic reaction</b>					
	Psoas compartment NB vs. epidural anesthesia (single) <sup>115</sup>	1	30	OR (95% CI)	0.23 (0.04, 1.41)	NA
	<b>Cardiac arrest</b>					
	Psoas compartment NB vs. epidural anesthesia (single) <sup>115</sup>	1	30		NE	
	<b>Damage to surrounding structures</b>					
	Psoas compartment NB vs. epidural anesthesia (single) <sup>115</sup>	1	30		NE	
	<b>Deep venous thrombosis</b>					
Psoas compartment NB vs. epidural anesthesia (single) <sup>115</sup>	1	30		NE		
<b>GI symptoms</b>						
Psoas compartment NB vs. epidural anesthesia (single) <sup>115</sup>	1	30	OR (95% CI)	<b>0.06 (0.00, 1.24)*</b>	NA	
<b>KQ3</b>	<b>Hematoma</b>					
	Psoas compartment NB vs. epidural anesthesia (single) <sup>115</sup>	1	30		NE	
	<b>Hypotension</b>					
	Psoas compartment NB vs. epidural anesthesia (single) <sup>115</sup>	1	30	OR (95% CI)	0.11 (0.01, 1.04)	NA
	<b>Infection</b>					
Psoas compartment NB vs. epidural anesthesia (single) <sup>115</sup>	1	30		NE		
<b>Urinary retention</b>						
Psoas compartment NB vs. epidural anesthesia (single) <sup>115</sup>	1	30	OR (95% CI)	0.04 (0.00, 0.72)*	NA	

KQ: key question; CI = confidence intervals; MD = mean difference; NB = nerve block; NA = not applicable; NE = not estimable; OR = odds ratio; RCT/nRCT = randomized and nonrandomized controlled trials; \* = statistically significant

**Table 13-C. Nerve blocks (Ropivacaine versus bupivacaine): RCT/nRCT**

	Outcome or Subgroup	Studies	Participants	Statistical Method	Effect Estimate	I <sup>2</sup>
<b>KQ3</b>	<b>Infection</b>					
	3-in-1 NB <sup>105</sup>	1	50		NE	

KQ: key question; CI = confidence intervals; NB = nerve block; NE = not estimable; RCT/nRCT = randomized and nonrandomized controlled trials

**Table 13-D. Nerve block (addition of clonidine): RCT/nRCT**

	Outcome or Subgroup	Studies	Participants	Statistical Method	Effect Estimate	I <sup>2</sup>
<b>KQ3</b>	<b>Bradycardia</b>					
	Psoas compartment NB: clonidine IV vs. no clonidine <sup>102</sup>	1	24	OR (95% CI)	1.40 (0.28, 7.02)	NA
	Psoas compartment NB: clonidine intra-catheter vs. no clonidine <sup>102</sup>	1	24	OR (95% CI)	1.40 (0.28, 7.02)	NA
	Psoas compartment NB: clonidine IV vs. clonidine intra-catheter <sup>102</sup>	1	24	OR (95% CI)	1.00 (0.20, 4.95)	NA
	<b>Hypotension</b>					
	Psoas compartment NB: clonidine IV vs. no clonidine <sup>102</sup>	1	24	OR (95% CI)	1.00 (0.12, 8.56)	NA
	Psoas compartment NB: clonidine intra-catheter vs. no clonidine <sup>102</sup>	1	24	OR (95% CI)	1.00 (0.12, 8.56)	NA
	Psoas compartment NB: clonidine IV vs. clonidine intra-catheter <sup>102</sup>	1	24	OR (95% CI)	1.00 (0.12, 8.56)	NA
	<b>Nausea/vomiting</b>					
	Psoas compartment NB: clonidine IV vs. no clonidine <sup>102</sup>	1	24	OR (95% CI)	1.50 (0.25, 8.84)	NA
	Psoas compartment NB: clonidine intra-catheter vs. no clonidine <sup>102</sup>	1	24	OR (95% CI)	0.27 (0.02, 3.09)	NA
	Psoas compartment NB: clonidine IV vs. clonidine intra-catheter <sup>102</sup>	1	24	OR (95% CI)	5.50 (0.51, 59.01)	NA

KQ: key question; CI = confidence intervals; NA = not applicable; NB = nerve block; OR = odds ratio; RCT/nRCT = randomized and nonrandomized controlled trials

**Table 13-E. Nerve blocks (US vs. NS): RCT/nRCT**

	Outcome or Subgroup	Studies	Participants	Statistical Method	Effect Estimate	I <sup>2</sup>
<b>KQ3</b>	<b>Damage to surrounding structures</b> <sup>103,104</sup>	2	100	OR (95% CI)	0.16 (0.02, 1.30)	NA
	<b>Infection</b> <sup>103</sup>	1	40		NE	

KQ = key question; CI = confidence intervals; NA = not applicable; NE = not estimable; OR = odds ratio; RCT/nRCT = randomized and nonrandomized controlled trials

**Table 14. Evidence summary table (cohort studies): Nerve blocks**

**Table 14-A. Nerve blocks versus no block: Cohort studies**

	Outcome or Subgroup	Studies	Participants	Statistical Method	Effect Estimate	I <sup>2</sup>
<b>KQ2</b>	<b>Additional pain medication use</b>					
	Femoral NB <sup>117</sup>	1	99	OR (95% CI)	<b>0.03 (0.00, 0.44)*</b>	NA
	<b>Mental status (e.g, delirium, confusion)</b> <sup>117,119</sup>	2	634	OR (95% CI)	<b>0.24 (0.08, 0.72)*</b>	60%
	3-in-1 NB <sup>119</sup>	1	535	OR (95% CI)	<b>0.39 (0.17, 0.90)*</b>	NA
	Femoral NB <sup>117</sup>	1	99	OR (95% CI)	<b>0.12 (0.04, 0.39)*</b>	NA
	<b>LOS</b> <sup>117,119</sup>	2	634		NR	93%
	3-in-1 NB <sup>119</sup>	1	535	MD (95% CI)	<b>-6.10 (-8.40, -3.80)*</b>	NA
	Femoral NB <sup>117</sup>	1	99	MD (95% CI)	-0.90 (-2.18, 0.38)	NA
	<b>Mortality 1 year</b>					
	3-in-1 NB <sup>119</sup>	1	535	OR (95% CI)	0.73 (0.48, 1.10)	NA
<b>KQ3</b>	<b>Acute heart failure</b>					
	3-in-1 NB <sup>119</sup>	1	535	OR (95% CI)	0.70 (0.33, 1.47)	NA
	<b>Any adverse event</b>	2	634	OR (95% CI)	1.64 (0.79, 3.42)	28%
	3-in-1 NB <sup>119</sup>	1	535	OR (95% CI)	<b>1.96 (1.31, 2.94)*</b>	NA
	Femoral NB <sup>117</sup>	1	99	OR (95% CI)	0.75 (0.16, 3.54)	NA
	<b>Cardiac complications</b>					
	Femoral NB <sup>117</sup>	1	99	OR (95% CI)	0.33 (0.01, 8.38)	NA
	<b>GI bleeding</b>					
	3-in-1 NB <sup>119</sup>	1	535	OR (95% CI)	1.00 (0.18, 5.53)	NA
	<b>Myocardial Infarction</b>					
	3-in-1 NB <sup>119</sup>	1	535	OR (95% CI)	0.69 (0.09, 5.53)	NA
	<b>Renal disease</b>					
	Femoral NB <sup>117</sup>	1	99	OR (95% CI)	2.09 (0.18, 23.77)	NA
	<b>Respiratory distress</b>					
	Femoral NB <sup>117</sup>	1	99	OR (95% CI)	0.50 (0.04, 5.70)	NA
	<b>Respiratory infection</b>					
	3-in-1 NB <sup>119</sup>	1	535	OR (95% CI)	<b>0.43 (0.21, 0.92)*</b>	NA
	<b>Stroke</b>					
	3-in-1 NB <sup>119</sup>	1	535	OR (95% CI)	0.25 (0.03, 1.99)	NA
	<b>Urinary retention</b>					
3-in-1 NB <sup>119</sup>	1	535	OR (95% CI)	0.46 (0.15, 1.39)	NA	
<b>Urinary tract infection</b>						
3-in-1 NB <sup>119</sup>	1	535	OR (95% CI)	<b>0.34 (0.18, 0.64)*</b>	NA	

CI = confidence intervals; KQ = key question; LOS: length of stay; MD = mean difference; NA = not applicable; NB: nerve block; NR = not reported; OR = odds ratio

**Table 14-B. Nerve blocks (Ropivacaine vs. bupivacaine): Cohort studies**

	Outcome or Subgroup	Studies	Participants	Statistical Method	Effect Estimate	I <sup>2</sup>
<b>KQ2</b>	<b>Additional pain medication use</b>					
	Lumbar/sacral plexus NB <sup>118</sup>	1	62	OR (95% CI)	1.25 (0.42, 3.76)	NA
<b>KQ3</b>	<b>Deleirium</b>					
	Lumbar/sacral plexus NB <sup>118</sup>	1	62	OR (95% CI)	1.93 (0.17, 22.50)	NA
<b>KQ3</b>	<b>Any adverse event</b>					
	Lumbar/sacral plexus NB <sup>118</sup>	1	62		NE	

CI = confidence intervals; KQ = key question; NA = not applicable; NB: nerve block; NE = not estimable; OR = odds ratio

## Neurostimulation

### Overview of Included Studies

Two RCTs<sup>120,121</sup> evaluated the efficacy and/or harms of the administration of transcutaneous electrical neurostimulation (TENS) versus sham control in 123 participants; sample sizes ranged from 60 to 63. One trial administered the TENS preoperatively,<sup>121</sup> and the other post-operatively.<sup>120</sup> The mean age ranged from 71.2 to 80.5 years. Most were female (66.7 to 92.1 percent). Acute pain was measured using the VAS and the average baseline pain measure 8.8 to 8.9. See Tables E-6 and F-6 (Appendices E and F) for details of the study characteristics and interventions.

Both RCTs had a high risk of bias (Appendix G). Summary of the evidence from these trials is provided in Table 15.

**Table 15. Evidence addressing key questions: Neurostimulation**

Key Question	Outcome	Evidence availability	Summary of Evidence
<b>KQ 1</b>	<b>Acute pain*</b>	Yes	2 RCTs reported a statistically significant effect in favor of neurostimulation compared with sham control. The strength of the evidence was rated as insufficient.
	<b>Chronic pain*</b>	No	
<b>KQ2</b>	<b>Mortality (30-day* and up to 1-year postfracture)</b>	No	
	<b>Functional status</b>	No	
	<b>Pain medication use; change in type and quantity</b>	No	
	<b>Mental status* (e.g., delirium, confusion)</b>	No	
	<b>Health-related quality of life</b>	Yes	1 RCT reported a statistically significant difference in favor of neurostimulation.
	<b>Quality of sleep in the hospital</b>	Yes	1 RCT reported a statistically significant difference in favor of neurostimulation.
	<b>Ability to participate in rehabilitation</b>	No	
	<b>Return to prefracture living arrangements</b>	No	
	<b>Health services utilization</b>	No	

**Table 15. Evidence addressing key questions: Neurostimulation (continued)**


Key Question	Outcome	Evidence availability	Summary of Evidence
KQ3	Frequency of adverse effects (e.g. stroke*, myocardial infarction*, renal failure*)	No	
KQ4	Effectiveness and safety in differing subpopulations	No	

KQ = key question; RCT = randomized controlled trial; \* = body of evidence rated using the AHRQ GRADE approach (Grading of Recommendation Assessment, Development and Evaluation)

## Key Question 1. Acute and chronic pain management

Acute pain (post-treatment) was reported in both RCTs<sup>120,121</sup> (n = 123) (Table 16). It should be noted that the variance was imputed from the reported p value presented in one of the trials.<sup>120</sup> The pooled results showed a significant difference in additional pain relief in favor of TENS (MD -2.79; 95% CI -4.95, -0.64; p = 0.01) (Figure 12). This was not considered clinically significant.

**Figure 12. Neurostimulation acute pain (post-treatment)**



**Pain on movement.** Pain on movement (post-treatment means) was reported in one trial<sup>120</sup> (n = 60) (Table 16). Neurostimulation provided significantly more pain relief versus sham control (MD -3.90; 95% CI -6.22, -1.58; p = 0.001). The variance was imputed from the reported p value presented in the trial.<sup>120</sup>

## Key Question 2. Other outcomes

One RCT<sup>120</sup> comparing TENS (n = 30) versus sham control (n = 30) provided data on health-related quality of life (HRQOL) (10cm VAS) and quality of sleep (10cm VAS) (Table 16). Neurostimulation provided significant improvement in HRQOL versus sham control (MD -4.30; 95% CI -6.86, -1.74; p = 0.001). Similarly neurostimulation provided significant improvement in quality of sleep (MD -3.60; 95% CI -5.75, -1.45; p = 0.001). The variance was imputed from the reported p value in the trial for both outcomes.<sup>120</sup>

## Key Question 3: Adverse effects

No data were reported on adverse effects.

## Key Question 4. Efficacy, effectiveness, and safety in subpopulations

No data were reported on subpopulations.

**Table 16. Evidence summary table (randomized controlled trials): Neurostimulation**

	Outcome or Subgroup	Studies	Participants	Statistical Method	Effect Estimate	I <sup>2</sup>
KQ1	Acute pain (post-treatment) <sup>120,121</sup>	2	123	MD (95% CI)	<b>-2.79 (-4.95, -0.64)*</b>	67%
	Pain on movement (post-treatment) <sup>120</sup>	1	60	MD (95% CI)	<b>-3.90 (-6.22, -1.58)*</b>	NA
KQ2	HRQOL <sup>120</sup>	1	60	MD (95% CI)	<b>-4.30 (-6.86, -1.74)*</b>	NA
	Quality of sleep <sup>120</sup>	1	60	MD (95% CI)	<b>-3.60 (-5.75, -1.45)*</b>	NA

KQ = key question; CI = confidence intervals; MD = mean difference; NA = not applicable; \* = statistically significant

## Rehabilitation

### Overview of Included Studies

One RCT<sup>122</sup> evaluated the efficacy and/or harms of the administration of physical therapy (stretching and strengthening of spinal and psoas muscles (n = 18) vs. standard care (n = 19)). The mean age was 67.1 years and all participants were female. Acute pain was measured using the 10cm VAS and the mean baseline pain measure was 7.9cm. See Tables E-7 and F-7 (Appendices E and F) for details of the study characteristics and interventions.

The trial had a high risk of bias (Appendix G). Summary of the evidence from this trial is provided in Table 17.

**Table 17. Evidence addressing key questions: Rehabilitation**

Key Question	Outcome	Evidence availability	Summary of Evidence
KQ 1	Acute pain*	Yes	1 RCT reported a statistically significant effect in favor of physical therapy vs. standard care. The strength of the evidence was rated as insufficient.
	Chronic pain*	No	
KQ2	Mortality (30-day* and up to 1-year postfracture)	No	
	Functional status	No	
	Pain medication use; change in type and quantity	No	
	Mental status (e.g., delirium, confusion)	No	
	Health-related quality of life	No	
	Quality of sleep in the hospital	No	
	Ability to participate in rehabilitation	No	
	Return to prefracture living arrangements	No	
	Health services utilization	No	
KQ3	Frequency of adverse effects (e.g. stroke*, myocardial infarction*, renal failure*)	No	
KQ4	Effectiveness and safety in differing subpopulations	No	

KQ = key question; RCT = randomized controlled trial; \* = body of evidence rated using the AHRQ GRADE approach (Grading of Recommendation Assessment, Development and Evaluation)

## Key Question 1. Acute and chronic pain management

### Acute Pain (Post-Treatment Means)

There was a statistically significant difference in additional pain relief following stretching-strengthening of spinal and psoas muscles vs. standard care (MD -1.39; 95% CI -2.27, -0.51;  $p = 0.002$ ) (Table 18). This was not considered clinically significant.

## Key Question 2. Other outcomes

No other outcomes were reported.

## Key Question 3. Adverse effects

No data were reported for adverse effects.

## Key Question 4. Efficacy, effectiveness and safety in subpopulations

All participants in this trial were female.

**Table 18. Evidence summary table (randomized controlled trials): Rehabilitation**

	Outcome or Subgroup	Studies	Participants	Statistical Method	Effect Estimate	$I^2$
KQ1	Acute pain (post-treatment means) <sup>122</sup>	1	37	MD (95% CI)	-1.39 (-2.27, -0.51)*	NA

CI = confidence intervals; KQ = key question; MD = mean difference; NA = not applicable; \* statistically significant

## Traction

### Overview of Included Studies

Six RCTs<sup>26,123-127</sup> and four nRCTs<sup>128-131</sup> ( $n = 1,310$ ) evaluated the efficacy and/or harms of the administration of traction vs. no intervention or other interventions; sample sizes ranged from 64 to 311 participants. Additionally, one prospective cohort study<sup>132</sup> ( $n = 134$ ) provided data. The mean age ranged from 74.0 to 81.0 years. Most were female (66.2 to 84.7 percent). Acute pain was measured using the VAS and the mean baseline pain measure ranged from 0.3 to 6.9. See Tables E-8 and F-8 (Appendices E and F) for details of the study characteristics and interventions.

All the RCTs and nRCTs had a high risk of bias; the cohort study had a moderate score ( $n = 6$  stars) on the NOS (Appendices G, I). Summary of the evidence from these trials is provided in Table 19.

**Table 19. Evidence addressing key questions: Traction**

Key Question	Outcome	Evidence availability	Summary of Evidence
KQ 1	Acute pain*	Yes	9 trials reported no statistically significant difference between skin, skeletal, and no traction. The strength of the evidence was rated as low.  1 trial reported no statistically significant difference between skin and skeletal traction. The strength of the evidence was rated as insufficient.
	Chronic pain*	No	
KQ2	Mortality (30-day* and up to 1-year postfracture)	Yes	1 trial reported no statistically significant difference between skin, skeletal, and no traction. The strength of the evidence was rated as insufficient.
	Functional status	No	
	Pain medication use; change in type and quantity	Yes	2 trials reported no statistically significant difference between skin traction and no traction.
	Mental status* (e.g., delirium, confusion)	No	
	Health-related quality of life	No	
	Quality of sleep in the hospital	No	
	Ability to participate in rehabilitation	No	
	Return to prefracture living arrangements	No	
	Health services utilization	Yes	2 trials reported no statistically significant difference between skin traction and no traction.
KQ3	Frequency of adverse effects (e.g. stroke*, myocardial infarction*, renal failure*)	Yes	7 trials and 1 cohort study demonstrated no statistically significant difference in any adverse event, peroneal palsy, damage to surrounding structures, difficult reduction, pressure sores, direct skin damage, deep venous thrombosis, or failure to heal.
KQ4	Effectiveness and safety in differing subpopulations	No	

KQ = key question; \* = body of evidence rated using the AHRQ GRADE approach (Grading of Recommendation Assessment, Development and Evaluation)

## Key Question 1. Acute and chronic pain management

### Acute Pain (Post-Treatment Means)


Eight trials<sup>26,124,125,127-131</sup> compared skin traction (n = 498) versus no traction (n = 594) (Table 20). There was no significant difference in pain relief between the groups (MD 0.20; 95% CI -0.24, 0.65; p = 0.36) (Figure 13). The variance was imputed for one of the trials<sup>127</sup> using the reported p value in the original publication and from the other included trials for four trials.<sup>125,128,129,131</sup> The strength of the evidence was rated as insufficient to make any firm conclusions.

In the trial<sup>126</sup> that compared skin traction (n = 40) vs. skeletal traction (n = 38), there was no significant difference between the two groups (MD 0.10; 95% CI -0.60, 0.80; p = 0.78).

The strength of the evidence was rated as insufficient to make any firm conclusions.



**Figure 13. Traction—acute pain (post-treatment means)**



## Key Question 2. Other outcomes

**Health services utilization.** LOS for acute hospitalization was reported in two trials<sup>128,129</sup> comparing skin traction (n = 137) vs. no traction (n = 189) (Table 20). In one trial<sup>128</sup> there was no significant difference between the groups (MD 1.20; 95% CI -0.93, 3.33; p = 0.27). The MD was not estimable in the other study<sup>129</sup> as no measure of variance was reported; however, the authors reported that the difference was not statistically significant. In order to allow pooling of the two trials, the variance was imputed from the available study variance.<sup>128</sup> There was no significant difference in LOS between the two groups (MD 1.08; 95% CI -0.78, 2.95; p = 0.26).

**Mortality (30-day).** Thirty-day mortality was reported in one trial<sup>123</sup> (n = 80) (Table 20). There was no difference in mortality between skin or skeletal traction vs. no traction (0/55 vs. 2/25; OR 0.14; 95% CI 0.01, 1.44; p = 0.10). There were no reports of mortality when comparing skin vs. skeletal traction.

**Pain medication use.** Additional pain medication use was reported in two trials<sup>127,128</sup> (n = 352) (Table 20). There was no significant difference in pain medication use following skin traction vs. no traction (99/151 vs. 111/201; OR 1.47; 95% CI 0.83, 2.61; p = 0.18).

## Key Question 3. Adverse effects

Seven trials<sup>124,126-131</sup> (n = 1,043) evaluated the nature and frequency of adverse effects associated with the administration of skin or skeletal traction vs. no traction (Table 20). Additionally, one cohort study<sup>132</sup> (n = 134) compared skeletal traction vs. pillow (Table 21). In two trials<sup>126,131</sup> (n = 389) no adverse effects were reported in either the intervention or control groups. For the following specific adverse effects, there were no significant differences between the study groups: damage to surrounding structures,<sup>127</sup> deep venous thrombosis,<sup>124</sup> difficult reduction,<sup>128,129</sup> direct skin damage,<sup>129,130</sup> failure to heal,<sup>124</sup> peroneal palsy,<sup>127,130</sup> and pressure sores.<sup>124</sup>

## Key Question 4. Efficacy, effectiveness and safety in subpopulations

One trial<sup>131</sup> was conducted in Asian participants comparing skin traction (n = 166) versus no traction (n = 145). Acute pain reduction was not significantly different between the two groups (MD -0.04; 95% CI -0.61, 0.53; p = 0.89). No adverse effects were recorded (0/166 vs. 0/145).

**Table 20. Evidence summary table (RCT/nRCT): Traction**

	Outcome or Subgroup	Studies	Participants	Statistical Method	Effect Estimate	I <sup>2</sup>
<b>KQ1</b>	<b>Acute pain (post-treatment means)</b>					
	Skin traction vs. no traction <sup>26,124,125,127,129,131</sup>	8	1092	MD (95% CI)	0.20 (-0.24, 0.65)	63%
	Skin traction vs. skeletal traction <sup>26</sup>	1	78	MD (95% CI)	0.10 (-0.60, 0.80)	NA
<b>KQ2</b>	<b>Additional pain medication use</b>					
	Skin traction vs. no traction <sup>127,128</sup>	2	352	OR (95% CI)	1.47 (0.83, 2.61)	17%
	<b>Length of stay for acute hospitalization</b>					
	Skin traction vs. no traction <sup>128,129</sup>	2	326	MD (95% CI)	1.08 (-0.78, 2.95)	0%
	<b>Mortality 30-day</b>					
	Traction vs. no traction <sup>123</sup>	1	80	OR (95% CI)	0.14 (0.01, 1.44)	NA
	Skin traction vs. no traction <sup>123</sup>	1	51	OR (95% CI)	0.18 (0.01, 3.89)	NA
	Skeletal traction vs. no traction <sup>123</sup>	1	54	OR (95% CI)	0.07 (0.00, 3.48)	NA
	Skin traction vs. skeletal traction <sup>123</sup>	1	55		NE	
	<b>KQ3</b>	<b>Any adverse event</b>				
Skin traction vs. no traction <sup>131</sup>		1	311		NE	
Skin traction vs. skeletal traction <sup>126</sup>		1	78		NE	
<b>Damage to surrounding structures</b>						
Skin traction vs. no traction <sup>127</sup>		1	100	OR (95% CI)	5.21 (0.24, 111.24)	NA
<b>Deep venous thrombosis</b>						
Skin traction vs. no traction <sup>124</sup>		1	120		NE	
<b>Difficult reduction</b>						
Skin traction vs. no traction <sup>128,129</sup>		2	326	OR (95% CI)	0.90 (0.43, 1.98)	0%
<b>Direct skin damage</b>						
Skin traction vs. no traction <sup>129,130</sup>		2	182	OR (95% CI)	10.51 (0.49, 224.84)	0%
<b>Failure to heal</b>						
Skin traction vs. no traction <sup>124</sup>		1	120	OR (95% CI)	1.72 (0.68, 4.36)	NA
<b>Peroneal palsy</b>						
Skin traction vs. no traction <sup>127,130</sup>		2	208	OR (95% CI)	4.33 (0.44, 42.35)	0%
<b>Pressure sores</b>						
Skin traction vs. no traction <sup>124</sup>	1	120	OR (95% CI)	11.99 (0.65, 221.86)	NA	
<b>Peroneal palsy</b>						
Skeletal traction vs. no traction <sup>132</sup>	1	134	OR (95% CI)	0.09 (0.00, 1.60)	NA	

CI = confidence intervals; KQ = key question; NA = not applicable; NE = not estimable; OR = odds ratio; RCT/nRCT = randomized and nonrandomized controlled trials

**Table 21. Evidence summary table (cohort studies): Traction**

	Outcome or Subgroup	Studies	Participants	Statistical Method	Effect Estimate	I <sup>2</sup>
<b>KQ3</b>	<b>Peroneal palsy</b>					
	Skeletal traction vs. no traction <sup>123</sup>	1	134	OR (95% CI)	0.09 (0.00, 1.60)	NA

CI = confidence intervals; KQ = key question; NA = not applicable; OR = odds ratio

# Discussion

## Overview

Hip fracture due to low-energy trauma (e.g., slip and fall) is a common condition in the geriatric population. Today, nearly all hip fractures in the developed world are surgically treated and represent one of the most common emergency orthopedic procedures. Even so, the associated morbidity and mortality of hip fracture are significant. One year mortality for hip fracture is estimated to be up to 37 percent, and a large proportion of those patients who do survive will never recover to their prefracture level of function.<sup>5</sup>

Hip fractures are frequently characterized by acute pre-, peri- and postoperative pain; with pain manifesting on a number of fronts. Preoperative pain arises from injury to the muscles and joint capsule from the serrated edges of broken bone and the associated release of local inflammatory factors. Immediate postoperative pain is attributed to the procedures required for the surgical fixation of the femur (e.g., skin incision, femur stabilization). Patients with greater postoperative pain are slower to mobilize and have longer hospital stays.<sup>147</sup> Additionally, pain at all stages is aggravated by psychological stress and anxiety.

Pain that is not properly managed in geriatric patients can have deleterious effects in terms of increased risk of cardiovascular adverse effects and postoperative delirium. While little is known about the impact of postoperative pain in older adults, physicians are hesitant to prescribe opioid analgesics for fear of adverse effects such as delirium, nausea, respiratory depression, drowsiness, hypotension, and constipation as these events have been demonstrated to occur more frequently in the geriatric population.<sup>147,148</sup> Others have reported that postoperative pain management in older adults is more commonly undertreated and untreated than in younger patients.<sup>149</sup> This may reflect a belief among patients and health professionals that pain in the elderly is a natural phenomenon that is self-limiting and should be left to take its course without any intervention.<sup>19</sup>

This comparative effectiveness review (CER) identified, summarized, critically appraised, and compared the evidence on pain management interventions following hip fracture. We conducted a comprehensive search of over 25 electronic databases for published studies and ongoing trials. In addition, we hand searched major conference proceedings in order to identify additional relevant studies. Finally, we did not exclude studies on the basis of their published language. All these safeguards were implemented to help identify the evidence and limit the possibility of publication bias. To reduce the possibility of selection bias, we performed duplicate, independent study selection, and all data were independently extracted by two reviewers.

## Summary of Findings

Table 22 summarizes the findings for key outcomes for each intervention. Many studies within this review included small numbers of participants and reported only a small number of outcome measures. Several studies had a poor level of methodological rigor, in particular regarding their inherent risk of bias. Of the 65 included trials, the majority were assessed with an unclear risk for bias. Twenty-eight trials were considered to be at high risk of bias while only two were considered to be of low risk of bias. The strength of the evidence for most outcomes was considered insufficient or low. This is a reflection of the general poor methodological

quality, lack of study power, and number of studies investigating each intervention in this population.

The majority of studies included in this review fell into the categories of nerve blocks (n = 30),<sup>88-106,108-111,113-119</sup> and anesthesia (n = 26),<sup>56-58,60-73,75-777,79-83,145</sup> while fewer studies dealt with traction (n = 11),<sup>26,123-132</sup> systemic analgesia (n = 3),<sup>41,42,55</sup> complementary and alternative medicine (n = 2),<sup>43,54</sup> multimodal pain management (n = 2),<sup>86,87</sup> neurostimulation (n = 2),<sup>120,121</sup> and rehabilitation (n = 1).<sup>122</sup> Although we restricted the publication of studies from 1990, there appears to be a trend for more recent studies to examine pain management following hip fracture (median publication date = 2003; IQR: 1998 to 2007). Most studies included in this review were RCTs conducted in single university settings in Europe with few studies included from North American sites.

Most studies examined the pharmaceutical management of peri- and postoperative pain in this patient population. Short-term (in hospital) postoperative pain was the most frequent pain examined. None of the studies examined the longer-term pain associated with hip fracture; that is pain extending beyond the initial 30 days of hip fracture. Management of pain was often evaluated from few perspectives such as reported pain, mortality and adverse effects. The ramifications of pain were infrequently examined in terms of functional recovery, HRQOL, and health services utilization.

Although the majority of hip fracture patients are elderly women, this patient population consists of subgroups that warrant further investigation. For instance, almost half of the studies (n = 31) reported excluding patients with any cognitive impairment, or inability to cooperate. Researchers have reported that approximately 35 percent of the elderly hip fracture population includes patients with some degree of cognitive impairment, be it, dementia, delirium, or acute confusion.<sup>150</sup> None of the included studies in this CER exclusively examined participants from institutional settings or with cognitive impairment, which reduces the external validity or generalizability of our findings to the overall hip fracture patient population.

Regardless of these limitations, some general consensus can be made from this review.

**Key Questions 1 and 2: Pain management and other outcomes.** The available evidence suggests that, in general, the **nerve blockade** is effective for the relief of the acute pain of hip fracture compared with standard care alone. Nerve blockade also reduces the need for supplemental systemic analgesia and may reduce the risk of delirium, a common and dangerous complication of hip fracture. However, most studies were limited to either assessing acute pain or examining use of additional analgesia and did not report on how nerve blockades may affect rehabilitation such as ambulation or mobility if the blockade has both sensory and motor effects. Furthermore, our decision to extract followup data demonstrating the greatest improvement for the intervention arm may have introduced a bias favoring the intervention. However, we do not expect this to have had a major impact because most studies presented data for only one time point. Nerve blockade of the types described in this CER are within the repertoire of most practicing anesthesiologists, but many institutions are deterred from providing them due to the additional time, effort, and supervision they require if they are to work well.

This review also calls into question some commonly held beliefs about the care of those with hip fracture. **Preoperative traction**, for instance, does not appear to reduce pain or complications in any demonstrable way compared with no traction. These results are consistent with those of the previously published Cochrane review on this topic.<sup>25</sup> While the strength of evidence is insufficient to make firm conclusions, spinal **anesthesia** used during the operation to

fix the fracture, while effective and safe, does not demonstrably differ in rates of mortality, delirium, or other medical complications of the fracture as compared with general anesthesia. Adding other agents to plain local anesthetic for spinal anesthesia does not seem to make any difference to outcomes outside the operating room. Furthermore, bigger doses of spinal anesthetic may cause more hypotension issues without improving pain control or outcome.<sup>151</sup>

The evidence guiding the selection of **systemic drugs** for hip fracture analgesia is very scant and warrants further study.

This review also finds that **acupressure, relaxation therapy, and transcutaneous electrical neurostimulation** are safe interventions that may be associated with potentially clinically meaningful reductions in pain after hip fracture, but further evidence is warranted before any firm conclusions are reached. The obvious drawback of these is the amount of skilled health provider time that must be used to apply and/or teach these modalities correctly. **Physical therapy regimens** may potentially improve pain control in the postoperative period, but there is insufficient evidence to draw firm conclusions.

No evidence could be found that any analgesic intervention attenuated the progression of acute to chronic pain. Furthermore, there was insufficient evidence to show that **multimodal analgesia** (combinations of analgesic interventions) yields improvements over single modalities. Further research in this area might profitably focus on combinations of interventions that are known to be effective in isolation.

**Key Question 3: Adverse effects.** Although most studies reported on adverse effects associated with the specific interventions being evaluated, the included studies were small; thus most studies reported few, if any, adverse effects. Moreover, the horizon for adverse effects was over a short period of time, usually within the acute care setting, and did not examine the development of adverse effects outside of the acute care setting.

**Key Question 4: Effectiveness and safety of pain management in differing subpopulations.** This question was addressed by limited data from two RCTs of nerve blocks—one was restricted participants with heart disease and to participants who were independent prior to the hip fracture. The only significant difference reported was a reduction in acute pain in participants with heart disease who received a nerve block.

## Applicability

The study populations in this body of evidence were relatively homogeneous. Studies included patients with all types of hip fractures due to low energy trauma. All participants were over 50 years of age; the mean age in most studies clustered between 77 and 82 years. Most patients were female. Studies generally included a mixture of hip fracture types and minimal data for specific fracture types were available. A majority of studies excluded patients on the basis of mental status (i.e., patients with dementia or other cognitive disorders). Studies did not generally provide information of the pre-fracture dwelling (i.e., community vs. institution) or social status/support of participants (e.g., married, living with relatives). Interventions were provided across the spectrum of the care pathway from preoperative to postoperative; however, no studies provided data on long-term followup for this patient population.

The other issue regarding applicability for this body of evidence relates to the practitioners administering the interventions (e.g., anesthetists, surgeons, physical therapists, or other health care providers). Outcome effects may differ between the trials and real life practice based on

practitioners' skills and experience, volume of surgery, and variations or rigor surrounding cointerventions or procedural protocols.

## Limitations of Existing Evidence

To our knowledge, no specific evidence-based guidelines for pain management in hip fracture are available; however, this may be indirectly related to the fact that to the best of our knowledge there currently are no committees or task force groups for pain management in hip fracture. Further, there are no recommended standardized outcomes for assessing pain specific to this patient population. This patient population is different from other surgical patients in that they are older and predominantly women with a significant number of coexisting conditions, commonly including altered cognition.

Evaluations of common subpopulations found within the overall hip fracture patient populations were infrequent. A large proportion of the included studies excluded patients with altered cognition due to delirium or dementia, despite the high prevalence of dementia in the hip fracture population. Further, most studies performed limited assessment of either delirium or dementia in their participants using broad cognitive assessment tools (e.g., Mini-Mental State Examination) that were unable to distinguish between onset of dementia or acute delirium. In addition, although multiple comorbidities are common in patients who experience a hip fracture, risk adjustments for illness/health severity were not reported, nor were most of the subpopulations that we intended to investigate (e.g., prefracture functional status). These are all factors that could potentially affect reported pain levels.

Included studies were primarily pharmacologic interventions and represented evaluation by a single discipline (e.g., anesthesiology) despite evidence in other clinical areas that optimal chronic pain management is multidisciplinary.<sup>19,152</sup> In addition studies were primarily conducted in single centers in Europe or Asia with small samples sizes; minimal evidence was available from centers in North America. Study quality was low and thus, clear evidence to support clinical decision making for interventions is limited. Also the choice to limit the search to 1990 might have led to missing some earlier studies on pain management in this population, but its effect is not expected to change the conclusions of this report.

In addition, lack of standardized outcome reporting or use of standardized measures limits the interpretation and applicability of the results. Although pain and function are correlated,<sup>147</sup> most outcomes focused on pain relief and did not evaluate if the intervention had any positive or negative effects on the patients' ability to mobilize postoperatively, a factor that is linked to recovery levels following hip fracture.<sup>153</sup> There was no evidence about managing pain after hospital discharge or examining the long-term effects of early postoperative pain management on subsequent recovery.

Finally, because of the low incidence of complications following surgery, no individual included study had adequate numbers to detect associated adverse effects with the interventions. For example, the rationale for using a nerve block for pain management following a hip fracture is primarily to enable pain to be controlled with lower doses of systemic analgesia. Although the studies demonstrated a reduced requirement for systemic analgesics, this is only clinically useful if it associated with a reduction in the adverse effects of such analgesic use.

## Recommendations for Future Research

**Multicenter research studies.** Adequately powered multi-center research studies are needed to provide a comprehensive assessment of safe, effective, and appropriate pain management

following a hip fracture. Studies need to be large enough to allow subgroup analyses by age, gender, comorbidities, functional groups (e.g., independent vs. dependent in ambulation), or multiple complex interventions (e.g. 3-in-1 vs. femoral block only). In addition, researchers need to consider inclusion of common subpopulations of hip fracture patients. In particular, those with altered cognition who make up a substantial proportion of the overall hip fracture patient population should be included in future studies of pain management following hip fracture.

**Outcomes.** Standardization of outcomes and outcome measures will allow easier and meaningful comparisons across different interventions and among studies. The types of outcomes reported do not reflect the multidimensional nature of pain. Relevant outcomes should include validated pain scores, prescription of opiates and other agents, adverse effects or complications attributable or related to the intervention. There should also be consideration for use of nonverbal pain assessment scales to allow assessment of pain in patients with communication issues such as delirium and/or dementia. Associated outcomes of pain such as function, quality of life, and time to recovery should also be evaluated.

The evaluation of pain should include preoperative assessment, daily assessments while in hospital, as well as regular and longer term followup of pain beyond the acute hospital setting. Researchers should consider pain outcomes up to 6 months post-hip fracture to determine the pattern of pain recovery and whether early effective pain management techniques affects ultimate recovery levels.

**Methods.** Investigators should consider including patients with cognitive impairment in future studies as this group represents a substantial proportion of the hip fracture patient population. Better cognitive screening and assessment tools are needed to determine the presence of delirium and to be able to distinguish between acute delirium and chronic underlying or new onset dementia. Future research should seek to minimize bias by blinding outcome assessors, use of validated and standardized outcome assessment instruments, adequate allocation concealment (where applicable), and appropriate handling and reporting of missing data.

## Conclusions

For the majority of interventions, there are only sparse data available, which precludes firm conclusions for any single approach or for the optimal overall pain management following nonpathological hip fracture due to low energy trauma. The paucity of evidence related to long-term outcomes and the fact that the majority of the data is derived from studies of low methodological quality or from study designs associated with higher risk of bias (i.e., cohort studies). Overall, the evidence shows that most interventions result in improvements in short-term pain scores; however, few differences of long-term clinical importance are evident when comparisons between interventions are available. The rates of complications were generally low and the majority of complications were not significantly different among the interventions. Well-designed and -powered, long-term trials are needed in order to determine the relative effectiveness of pain interventions for hip fracture patients. Until then, pain management in this population will rely heavily on availability of the interventions, staff skills and training and pre-existing patient comorbidities.

**Table 22. Summary of evidence for key outcomes for pain management following hip fracture**

Outcome	Comparison (# studies)	Strength of evidence	Summary
<b><i>Systemic analgesia</i></b>			
Acute pain	Parecoxib IV vs. diclofenac ± meperidine IM (1 RCT)	Insufficient	Significant effect in favor of parecoxib IV (MD = -0.70; 95% CI -1.04, -0.36)
	Intrathecal isotonic clonidine vs. intrathecal hypertonic clonidine (1 RCT)		Significant effect in favor of intrathecal isotonic clonidine (MD = -1.69; 95% CI -2.01, -1.37)
	Lysine clonixinate vs. metamizole (1 RCT)		No significant difference
Acute pain at rest	Lysine clonixinate vs. metamizole (1 RCT)	Insufficient	No significant difference
Chronic pain	None	Insufficient	No data
30-day mortality	None	Insufficient	No data
Delirium	Lysine clonixinate vs. metamizole (1 RCT)	Insufficient	No significant difference
Myocardial infarction	None	Insufficient	No data
Renal failure	None	Insufficient	No data
Stroke	None	Insufficient	No data
<b><i>Anesthesia: spinal vs. general anesthesia</i></b>			
Acute pain	Spinal vs. general anesthesia (1 RCT)	Insufficient	Significant effect in favor of spinal anesthesia (MD = -0.86; 95% CI -1.30, -0.42)
Chronic pain	None	Insufficient	No data
30-day mortality	Spinal vs. general anesthesia (2 RCTs, 2 cohort studies)	Low	No significant difference
Delirium	Spinal vs. general anesthesia (1 RCT)	Insufficient	No significant difference
Myocardial infarction	Spinal vs. general anesthesia (2 RCT)	Insufficient	No significant difference
Renal failure	None	Insufficient	No data
Stroke	None	Insufficient	No data
<b><i>Anesthesia: spinal – continuous vs. single administration</i></b>			
Acute pain	None	Insufficient	No data
Chronic pain	None	Insufficient	No data
30-day mortality	Continuous vs. single administration (3 RCTs, 1 cohort study)	Low	No significant difference
Delirium	Continuous vs. single administration (2 RCTs)	Low	No significant difference
Myocardial infarction	Continuous vs. single administration (1 RCT)	Insufficient	No significant difference
Renal failure	None	Insufficient	No data
Stroke	Continuous vs. single administration (1 RCT)	Insufficient	No significant difference



**Table 22. Summary of evidence for key outcomes for pain management following hip fracture (continued)**

Outcome	Comparison (# studies)	Strength of evidence	Summary
<b><i>Anesthesia: spinal – addition of other medications</i></b>			
Acute pain	Addition of fentanyl vs. standard spinal anesthesia (1 RCT)	Insufficient	No significant difference
	Addition of morphine vs. standard spinal anesthesia (1 RCT)	Insufficient	No significant difference
	Addition of sufentanil vs. standard spinal anesthesia (1 RCT)	Insufficient	No significant difference
Chronic pain	None	Insufficient	No data
30-day mortality	None	Insufficient	No data
Delirium	Addition of morphine vs. standard spinal anesthesia (1 RCT)	Insufficient	No significant difference
Myocardial infarction	None	Insufficient	No data
Renal failure	None	Insufficient	No data
Stroke	None	Insufficient	No data
<b><i>Anesthesia: spinal – different doses</i></b>			
Acute pain	Bupivacaine 2.5mg vs. 5mg (1 cohort study)	Insufficient	No significant difference
Chronic pain	None	Insufficient	No data
30-day mortality	None	Insufficient	No data
Delirium	Bupivacaine 4mg vs. 12mg (1 cohort study)	Insufficient	No significant difference
Myocardial infarction	None	Insufficient	No data
Renal failure	None	Insufficient	No data
Stroke	None	Insufficient	No data
<b><i>Complementary and alternative medicine</i></b>			
Acute pain	Acupressure vs. standard care (1 RCT)	Insufficient	No significant difference
	Relaxation vs. standard care (1 RCT)	Insufficient	No significant difference
Chronic pain	None	Insufficient	No data
30-day mortality	None	Insufficient	No data
Delirium	None	Insufficient	No data
Myocardial infarction	None	Insufficient	No data
Renal failure	None	Insufficient	No data
Stroke	None	Insufficient	No data
<b><i>Multimodal pain management</i></b>			
Acute pain	None	Insufficient	No data
Chronic pain	None	Insufficient	No data
30-day mortality	Multimodal pain management vs. standard care (1 cohort study)	Insufficient	No significant difference
Delirium	Multimodal pain management vs. standard care (1 cohort study)	Insufficient	No significant difference
Myocardial infarction	Multimodal pain management vs. standard care (1 cohort study)	Insufficient	No significant difference
Renal failure	None	Insufficient	No data

**Table 22. Summary of evidence for key outcomes for pain management following hip fracture (continued)**

Outcome	Comparison (# studies)	Strength of evidence	Summary
Stroke	Multimodal pain management vs. standard care (1 cohort study)	Insufficient	No significant difference
<b><i>Nerve blockade</i></b>			
Acute pain	Nerve block vs. no nerve block (11 RCTs)	Moderate	Significant effect in favor of nerve block in subgroup analyses
Pain on movement	Nerve block vs. no nerve block (4 RCTs)	Low	Significant effect in favor of nerve block in subgroup analyses
Pain at rest	Nerve block vs. no nerve block (3 RCTs)	Low	Data inconsistent for conclusions to be made
Day 1 pain	Nerve block vs. no nerve block (1 RCTs)	Insufficient	No significant difference
Chronic pain	None	Insufficient	No data
30-day mortality	Nerve block vs. no nerve block (4 RCTs)	Low	No significant difference
Delirium	Nerve block vs. no nerve block (3 RCTs, 2 cohort studies)	Moderate	Significant effect in favor of nerve block (OR <sub>RCT</sub> = 0.36; 95% CI 0.17, 0.74) (OR <sub>Cohort</sub> = 0.24; 95% CI 0.08, 0.72)
Myocardial infarction	Nerve block vs. no nerve block (2 RCTs, 1 cohort study)	Insufficient	No significant difference
Stroke	Nerve block vs. no nerve block (1 RCT, 1 cohort study)	Insufficient	No significant difference
Renal failure	None	Insufficient	No data
<b><i>Nerve blockade vs. regional anesthesia</i></b>			
Acute pain	Nerve block vs. regional anesthesia (3 RCTs)	Low	No significant difference
Chronic pain	None	Insufficient	No data
30-day mortality	None	Insufficient	No data
Delirium	Nerve block vs. regional anesthesia (1 RCT)	Insufficient	No significant difference
Myocardial infarction	None	Insufficient	No data
Renal failure	None	Insufficient	No data
Stroke	None	Insufficient	No data
<b><i>Nerve Blocks: ropivacaine vs. bupivacaine</i></b>			
Acute pain	None	Insufficient	No data
Chronic pain	None	Insufficient	No data
30-day mortality	None	Insufficient	No data
Delirium	Ropivacaine vs. bupivacaine (1 cohort study)	Insufficient	No significant difference
Myocardial infarction	None	Insufficient	No data
Renal failure	None	Insufficient	No data
Stroke	None	Insufficient	No data
<b><i>Neurostimulation</i></b>			
Acute pain	Neurostimulation vs. standard care (2 RCTs)	Insufficient	Significant effect in favor of neurostimulation (MD = -2.79; 95% CI -4.95, -0.64)
Pain on movement	Neurostimulation vs. standard care (1 RCT)	Insufficient	Significant effect in favor of neurostimulation (MD = -3.90; 95% CI -6.22, -1.58)
Chronic pain	None	Insufficient	No data

**Table 22. Summary of evidence for key outcomes for pain management following hip fracture (continued)**

Outcome	Comparison (# studies)	Strength of evidence	Summary
30-day mortality	None	Insufficient	No data
Delirium	None	Insufficient	No data
Myocardial infarction	None	Insufficient	No data
Renal failure	None	Insufficient	No data
Stroke	None	Insufficient	No data
<b>Rehabilitation</b>			
Acute pain	Physical therapy vs. standard care (1 RCT)	Insufficient	Significant effect in favor of physical therapy (MD = -1.39; 95% CI -2.27, -0.51)
Chronic pain	None	Insufficient	No data
30-day mortality	None	Insufficient	No data
Delirium	None	Insufficient	No data
Myocardial infarction	None	Insufficient	No data
Renal failure	None	Insufficient	No data
Stroke	None	Insufficient	No data
<b>Traction</b>			
Acute pain	Skin traction vs. no traction (7 RCTs)	Low	No significant difference
	Skin traction vs. skeletal traction (1 RCT)	Insufficient	No significant difference
Chronic pain	None	Insufficient	No data
30-day mortality	Skin traction vs. no traction (1 RCT)	Insufficient	No significant difference
	Skeletal traction vs. no traction (1 RCT)	Insufficient	No significant difference
Delirium	None	Insufficient	No data
Myocardial infarction	None	Insufficient	No data
Renal failure	None	Insufficient	No data
Stroke	None	Insufficient	No data

CI = confidence interval; IM = intramuscular; IV = intravenous; MD = mean difference; OR = odds ratio; RCT = randomized controlled trial; SMD = standardized mean difference

## References and Included Studies

1. Brainsky A, Glick H, Lydick E, et al. The economic cost of hip fractures in community-dwelling older adults: a prospective study. *J Am Geriatr Soc* 1997;45(3):281-7.
2. Cooper C, Campion G, Melton LJ. Hip fractures in the elderly: a world-wide projection. *Osteoporos Int* 1992;2(6):285-9.
3. Gullberg B, Johnell O, Kanis JA. World-wide projections for hip fracture. *Osteoporos Int* 1997;7(5):407-13.
4. Maggi S, Kelsey JL, Litvak J, et al. Incidence of hip fractures in the elderly: a cross-national analysis. *Osteoporos Int* 1991;1(4):232-41.
5. Kannegaard PN, van der MS, Eiken P, et al. Excess mortality in men compared with women following a hip fracture: national analysis of comedications, comorbidity and survival. *Age Ageing* 2010;39(2):203-9.
6. Jette AM, Harris BA, Cleary PD, et al. Functional recovery after hip fracture. *Arch Phys Med Rehabil* 1987;68(10):735-40.
7. Magaziner J, Simonsick EM, Kashner TM, et al. Predictors of functional recovery one year following hospital discharge for hip fracture: a prospective study. *J Gerontol* 1990;45(3):M101-M107.
8. Mossey JM, Mutran E, Knott K, et al. Determinants of recovery 12 months after hip fracture: the importance of psychosocial factors. *Am J Public Health* 1989;79(3):279-86.
9. Lyons AR, Karpf DB, Lips P, et al. Clinical outcomes and treatment of hip fractures. *Am J Med* 1997;103(2 A).
10. Ronald LA, McGregor MJ, McGrail KM, et al. Hospitalization rates of nursing home residents and community-dwelling seniors in british columbia. *Can J Aging* 2008;27(1):109-15.
11. Beaupre LA, Cinats JG, Jones CA, et al. Does functional recovery in elderly hip fracture patients differ between patients admitted from long-term care and the community? *J Gerontol A Biol Sci Med Sci* 2007;62(10):1127-33.
12. Donald IP, Bulpitt CJ. The prognosis of falls in elderly people living at home. *Age Ageing* 1999;28(2):121-5.
13. Haentjens P, Autier P, Barette M, et al. The economic cost of hip fractures among elderly women: a one-year, prospective, observational cohort study with matched-pair analysis: Belgian Hip Fracture Study Group. *J Bone Joint Surg Am* 2001;83-A(4):493-500.
14. Wiktorowicz ME, Goeree R, Papaioannou A, et al. Economic implications of hip fracture: health service use, institutional care and cost in Canada. *Osteoporos Int* 2001;12(4):271-8.
15. The management of chronic pain in older persons: AGS panel on chronic pain in older persons: American geriatrics society. *J Am Geriatr Soc* 1998;46(5):635-51.
16. Cleeland CS. Undertreatment of cancer pain in elderly patients. *JAMA* 1998;279(23):1914-5.
17. Ferrell BA. Pain management in elderly people. *J Am Geriatr Soc* 1991;39(1):64-73.
18. Nussenzweig TC. Pain management after total joint replacement and its impact on patient outcomes. *AORN J* 1999;70(6):1060-2.
19. Pergolizzi J, Boger RH, Budd K, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). *Pain Pract* 2008;8(4):287-313.
20. Burke A, Emer S, FitzGerald GA. Analgesic, antipyretic and anti-inflammatory agents; pharmacotherapy of Goat. In: Brunton LL, Lazo JS, Parker KL, eds. *Goodman & Gilman's The Pharmacological Basis of Therapeutics*. 11 ed. The McGraw-Hill Companies; 2006.

21. National Center for Complementary and Alternative Medicine. What is complementary and alternative medicine? Bethesda, MD: National Institutes of Health. Available at: <http://nccam.nih.gov/health/whatiscam/>. Accessed August 9, 2010.
22. Fassoulaki A, Paraskeva A, Kostopanagiotou G, et al. Acupressure on the extra 1 acupoint: the effect on bispectral index, serum melatonin, plasma {beta}-endorphin, and stress. *Anesth Analg* 2007;104(2):312–7.
23. Parker MJ, Griffiths R, Appadu B. Nerve blocks (subcostal, lateral cutaneous, femoral, triple, psoas) for hip fractures. *Cochrane Database Syst Rev* 2002.
24. Congedo E, Sgreccia M, De CG. New drugs for epidural analgesia. *Curr Drug Targets* 2009;10(8):696–706.
25. Parker MJ, Handoll HH. Pre-operative traction for fractures of the proximal femur in adults. *Cochrane Database Syst Rev* 2006;3:CD000168.
26. Resch S, Bjarnetoft B, Thorngren K–G. Preoperative skin traction or pillow nursing in hip fractures: a prospective, randomized study in 123 patients. *Disabil Rehabil* 2005;27(18–19):1191–5.
27. Poitras S, Brosseau L. Evidence-informed management of chronic low back pain with transcutaneous electrical nerve stimulation, interferential current, electrical muscle stimulation, ultrasound, and thermotherapy. *Spine J* 2008;8(1):226–33.
28. Milisen K, Abraham IL, Broos PLO. Postoperative variation in neurocognitive and functional status in elderly hip fracture patients. *J Adv Nurs* 1998;27(1):59–67.
29. Goldstein FC, Strasser DC, Woodard JL, et al. Functional outcome of cognitively impaired hip fracture patients on a geriatric rehabilitation unit. *J Am Geriatr Soc* 1997;45(1):35–42.
30. Francis J. Delirium in older patients. *J Am Geriatr Soc* 1992;40(8):829–38.
31. Williams MA, Campbell EB, Raynor WJ, et al. Reducing acute confusional states in elderly patients with hip fractures. *Res Nurs Health* 1985;8(4):329–37.
32. Wallerstein SL. Scaling clinical pain and pain relief. In: Bromm B, ed. *Pain measurement in man: neurophysiological correlates of pain*. New York: Elsevier; 1984.
33. Todd KH. Clinical versus statistical significance in the assessment of pain relief. *Ann Emerg Med* 1996;27(4):439–41.
34. Kelly AM. The minimum clinically significant difference in visual analogue scale pain score does not differ with severity of pain. *EMERG MED J* 2001;18(3):205–7.
35. Breivik EKP, Bjornsson GAD, Skovlund EP. A comparison of pain rating scales by sampling from clinical trial data. *Clin J Pain* 2000;16(1):22–8.
36. Grilo RM, Treves R, Preux PM, et al. Clinically relevant VAS pain score change in patients with acute rheumatic conditions. *Joint Bone Spine* 2007;74(4):358–61.
37. Stott DJ, Langhorne P, Knight PV. Multidisciplinary care for elderly people in the community. *Lancet* 2008;371(9614):699–700.
38. Berlin JA. Does blinding of readers affect the results of meta-analyses? University of Pennsylvania Meta-analysis Blinding Study Group. *Lancet* 1997;350(9072):185–6.
39. Higgins JPT, Green S, eds. *Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1*. The Cochrane Collaboration; 2008.
40. Wells G, Shea B, O'Connell D, Peterson J, et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Ottawa, Canada: Department of Epidemiology & Community Medicine, University of Ottawa. 2009. Available at: [http://www.ohri.ca/programs/clinical\\_epidemiology/oxford.htm](http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm).
41. Apostolopoulos A. Parecoxib as a post surgical analgesic drug in fractures of the hip joint in comparison with diclofenac–pethidine. *J Bone Joint Surg Br* 2006;88–B(Suppl 1):186.
42. Baker A, Klimscha W, Eisenach JC, et al. Intrathecal clonidine for postoperative analgesia in elderly patients: the influence of baricity on hemodynamic and analgesic effects. *Anesth Analg* 2004;99(1):128–34.

43. Barker R, Kober A, Hoerauf K, et al. Out-of-hospital auricular acupressure in elder patients with hip fracture: a randomized double-blinded trial. *Acad Emerg Med* 2006;13(1):19–23.
44. Vickers AJ. The use of percentage change from baseline as an outcome in a controlled trial is statistically inefficient: a simulation study. *BMC Med Res Methodol* 2001;1:6.
45. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986;7(3):177–88.
46. Bradburn MJ, Deeks JJ, Berlin JA, et al. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. *Stat Med* 2007;26(1):53–77.
47. Lau J, Ioannidis JP, Schmid CH. Summing up evidence: one answer is not always enough. *Lancet* 1998;351(9096):123–7.
48. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002;21(11):1539–58.
49. Hayashino Y, Noguchi Y, Fukui T. Systematic evaluation and comparison of statistical tests for publication bias. *J Epidemiol* 2005;15(6):235–43.
50. Gartlehner G, Hansen RA, Nissman D, Lohr KN, et al. Criteria for Distinguishing Effectiveness From Efficacy Trials in Systematic Reviews: Technical Review 12 (Prepared by the RTI–International–University of North Carolina Evidence-based Practice Center under Contract No. 290–02–0016.). Rockville, MD: Agency for Healthcare Research and Quality. April 2006. AHRQ Publication No. 06-0046.
51. Owens DK, Lohr KN, Atkins D, et al. Grading the strength of a body of evidence when comparing medical interventions–Agency for Healthcare Research and Quality and the Effective Health Care Program. *J Clin Epidemiol* 2009.
52. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ: British Medical Journal* 2008;336(7650):924–6.
53. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009;6(7):e1000097.
54. Martin KR. Relaxation as a postoperative comfort measure in elderly patients with fractured hips [dissertation]. Louisville, KY: Bellarmine College; 1991.
55. Poitevin LA, Pellegrini H, Alvarez CA, et al. Preoperative control in patients with femoral fractures. *Prensa Med Argent* 1999;86(9):913–9. (Spa).
56. Adams HA, Wolf C, Michaelis G, et al. Postoperative course and endocrine stress reaction of geriatric patients with para-articular hip fractures: prospective randomized study comparing spinal anesthesia and halothane intubation narcosis. *Anasth Intensivther Notfallmed* 1990;25(4):263–70. (Ger).
57. Alonso Chico A, Cruz Pardos P, Alvarez Grau J, et al. Comparison of the hemodynamic response in subarachnoid anesthesia with bupivacaine versus bupivacaine with fentanyl in traumatology surgery in elderly patients. *Rev Esp Anesthesiol Reanim* 2003;50(1):17–22. (Spa).
58. Ben-David B, Frankel R, Arzumonov T, et al. Minidose bupivacaine–fentanyl spinal anesthesia for surgical repair of hip fracture in the aged. *Anesthesiology* 2000;92(1):6–10.
59. Bredahl C, Hindsholm KB, Frandsen PC. Changes in body heat during hip fracture surgery: a comparison of spinal analgesia and general anaesthesia. *Acta Anaesthesiol Scand* 1991;35(6):548–52.
60. Casati A, Aldegheri G, Vinciguerra E, et al. Randomized comparison between sevoflurane anaesthesia and unilateral spinal anaesthesia in elderly patients undergoing orthopaedic surgery. *Eur J Anaesthesiol* 2003;20(8):640–6.
61. Danelli G, Baciarello M, Di Cianni S, et al. Effects of baricity of 0.5% or 0.75% levobupivacaine on the onset time of spinal anesthesia: a randomized trial. *Can J Anaesth* 2008;55(8):501–6.

62. Favarel–Garrigues JF, Sztark F, Petitjean ME, et al. Hemodynamic effects of spinal anesthesia in the elderly: single dose versus titration through a catheter. *Anesth Analg* 1996;82(2):312–6.
63. Hooda S, Malhotra N, Kumar L. Evaluation of three doses of intrathecal bupivacaine with fentanyl in geriatric patients undergoing hip surgery. *J Anaesth Clin Pharmacol* 2006;22(3):267–72.
64. Juelsgaard P, Sand NP, Felsby S, et al. Perioperative myocardial ischaemia in patients undergoing surgery for fractured hip randomized to incremental spinal, single–dose spinal or general anaesthesia. *Eur J Anaesthesiol* 1998;15(6):656–63.
65. Klimscha W, Chiari A, Krafft P, et al. Hemodynamic and analgesic effects of clonidine added repetitively to continuous epidural and spinal blocks. *Anesth Analg* 1995;80(2):322–7.
66. Kwan ASK, Lee BB, Brake T. Intrathecal morphine for post–operative analgesia in patients with fractured hips. *Hong Kong Med J* 1997;3(3):250–5.
67. Malek J, Kurzova A. Intrathecal fentanyl and sufentanil added to bupivacaine augments analgesia after surgical repair of hip fracture. *Acute Pain* 2004;6(2):53–6.
68. Martyr JW, Clark MX. Hypotension in elderly patients undergoing spinal anaesthesia for repair of fractured neck of femur: a comparison of two different spinal solutions. *Anaesth Intensive Care* 2001;29(5):501–5.
69. Martyr JW, Stannard KJ, Gillespie G. Spinal–induced hypotension in elderly patients with hip fracture: a comparison of glucose–free bupivacaine with glucose–free bupivacaine and fentanyl. *Anaesth Intensive Care* 2005;33(1):64–8.
70. Maurette P, Bonada G, Djiane V, et al. A comparison between lidocaine alone and lidocaine with meperidine for continuous spinal anesthesia. *Reg Anesth* 1993;18(5):290–5.
71. Minville V, Fourcade O, Grousset D, et al. Spinal anesthesia using single injection small–dose bupivacaine versus continuous catheter injection techniques for surgical repair of hip fracture in elderly patients. *Anesth Analg* 2006;102(5):1559–63.
72. Navas Martínez Á, Ortiz de la Tabla González R, Vazquez Gutierrez T, et al. Continuous subarachnoid blockade versus single shot technique for surgical treatment of the hip fracture [abstract]. *Reg Anesth Pain Med* 2008;33(5 Suppl 1):e30.
73. Olofsson C, Nygard EB, Bjersten AB, et al. Low–dose bupivacaine with sufentanil prevents hypotension after spinal anesthesia for hip repair in elderly patients. *Acta Anaesthesiol Scand* 2004;48(10):1240–4.
74. Qamarul Hoda M. Efficacy and hemodynamic effects of three different dosages of bupivacaine with fentanyl in spinal anaesthesia for surgical repair of hip fracture [abstract]. *Reg Anesth Pain Med* 2003;28(Suppl 1):6.
75. Rais K, Jajje Z, Rami O, et al. Comparative study of two doses of bupivacaine for continuous spinal anesthesia in elderly. *European Society of Anaesthesiology* 2008.
76. Said–Ahmed HAE. Comparison of hypotension after spinal anesthesia in the elderly with either bupivacaine minidose plus fentanyl/sufentanil or bupivacaine conventional dose. *Acta Anaesthesiol Ital* 2006;57(2–3):198–203.
77. Krobot R, Premuzic J, Bacak I. Levobupivacaine–fentanyl spinal anaesthesia for hip fracture repair in the elderly [abstract]. *Reg Anesth Pain Med* 2006;31(5 Suppl 1):33.
78. Koval KJ, Aharonoff GB, Rosenberg AD, et al. Hip fracture in the elderly: the effect of anesthetic technique. *Orthopedics* 1999;22(1):31–4.
79. Labaille T, Benhamou D, Westermann J. Hemodynamic effects of continuous spinal anesthesia: a comparative study between low and high doses of bupivacaine. *Reg Anesth* 1992;17(4):193–6.

80. Malcolmson SE, Freebairn R. Haemodynamic stability and vasopressor use during low-dose spinal anaesthesia in the high risk elderly with fractured neck of femur. *Critical Care and Shock* 2009;12(4):144–56.
81. Miller K, Reichel M, Karlbauer R, et al. The choice of the method of anesthesia as a risk factor in the femoral fracture near the hip joint in elderly patients. *Anaesthesist* 1990;39(2):83–7. (Ger).
82. Minville V, Asehnoune K, Delussy A, et al. Hypotension during surgery for femoral neck fracture in elderly patients: effect of anaesthetic techniques: a retrospective study. *Minerva Anesthesiol* 2008;74(12):691–6.
83. Sen S, Aydin K, Discigil G. Hypotension induced by lateral decubitus or supine spinal anaesthesia in elderly with low ejection fraction undergone hip surgery. *J Clin Monit Comput* 2007;21(2):103–7.
84. Shih YJ, Hsieh CH, Kang TW, et al. General versus spinal anesthesia: which is a risk factor for octogenarian hip fracture repair patients? *Int J Gerontol* 2010;4(1):37–42.
85. Sutcliffe AJ, Parker M. Mortality after spinal and general anaesthesia for surgical fixation of hip fractures. *Anaesthesia* 1994;49(3):237–40.
86. Milisen K, Foreman MD, Abraham IL, et al. A nurse-led interdisciplinary intervention program for delirium in elderly hip-fracture patients. *J Am Geriatr Soc* 2001;49(5):523–32.
87. Ogilvie-Harris DJ, Botsford DJ, Hawker RW. Elderly patients with hip fractures: improved outcome with the use of care maps with high-quality medical and nursing protocols. *J Orthop Trauma* 1993;7(5):428–37.
88. Antonopoulou E, Papaioannou K, Konstantinou G, et al. Continuous femoral block in elderly patients with hip fractures [abstract]. *Reg Anesth Pain Med* 2006;31(5 Suppl 1):92.
89. Chudinov A, Berkenstadt H, Salai M, et al. Continuous psoas compartment block for anesthesia and perioperative analgesia in patients with hip fractures. *Reg Anesth Pain Med* 1999;24(6):563–8.
90. Coad NR. Post-operative analgesia following femoral-neck surgery: a comparison between 3 in 1 femoral nerve block and lateral cutaneous nerve block. *Eur J Anaesthesiol* 1991;8(4):287–90.
91. Cuvillon P, Ripart J, Debureaux S, et al. Analgesia after hip fracture repair in elderly patients: the effect of a continuous femoral nerve block: a prospective and randomised study. *Ann Fr Anesth Reanim* 2007;26(1):2–9. (Fre).
92. De Visme V, Picart F, Le Jouan R., et al. Combined lumbar and sacral plexus block compared with plain bupivacaine spinal anesthesia for hip fractures in the elderly. *Reg Anesth Pain Med* 2000;25(2):158–62.
93. Eyrolle L. Regional anaesthesia for femoral neck fracture surgery: comparison of lumbar plexus block and spinal anaesthesia [abstract]. *Br J Anaesth* 1998;80(Suppl 1):112.
94. Fletcher AK, Rigby AS, Heyes FL. Three-in-one femoral nerve block as analgesia for fractured neck of femur in the emergency department: a randomized, controlled trial. *Ann Emerg Med* 2003;41(2):227–33.
95. Foss NB, Kristensen MT, Kristensen BB, et al. Effect of postoperative epidural analgesia on rehabilitation and pain after hip fracture surgery: a randomized, double-blind, placebo-controlled trial. *Anesthesiology* 2005;102(6):1197–204.
96. Foss NB, Kristensen BB, Bundgaard M, et al. Fascia iliaca compartment blockade for acute pain control in hip fracture patients: a randomized, placebo-controlled trial. *Anesthesiology* 2007;106(4):773–8.
97. Gille J, Gille M, Gahr R, et al. Acute pain management in proximal femoral fractures: femoral nerve block (catheter technique) vs. systemic pain therapy using a clinic internal organisation model. *Anaesthesist* 2006;55(4):414–22. (Ger).
98. Graham CA, Baird K, McGuffie AC. A pilot randomised clinical trial of 3-in-1 femoral nerve block and intravenous morphine as primary analgesia for patients presenting to the emergency department with fractured hip. *Hong Kong J Emerg Med* 2008;15(4):205–11.



99. Haddad FS, Williams RL. Femoral nerve block in extracapsular femoral neck fractures. *J Bone Joint Surg Br* 1995;77(6):922–3.
100. Henderson K, Akhtar S, Sandoval M, et al. Femoral nerve block for pain management of hip fractures in the emergency department: preliminary results of a randomized, controlled trial [abstract]. *Ann Emerg Med* 2008;52(4):S164.
101. Hood G, Edbrooke DL, Gerrish SP. Postoperative analgesia after triple nerve block for fractured neck of femur. *Anaesthesia* 1991;46(2):138–40.
102. Mannion S, Hayes I, Loughnane F, et al. Intravenous but not perineural clonidine prolongs postoperative analgesia after psoas compartment block with 0.5% levobupivacaine for hip fracture surgery. *Anesth Analg* 2005;100(3):873–8.
103. Marhofer P, Schrogendorfer K, Koinig H, et al. Ultrasonographic guidance improves sensory block and onset time of three-in-one blocks. *Anesth Analg* 1997;85(4):854–7.
104. Marhofer P, Schrogendorfer K, Wallner T, et al. Ultrasonographic guidance reduces the amount of local anesthetic for 3-in-1 blocks. *Reg Anesth Pain Med* 1998;23(6):584–8.
105. Marhofer P, Oismüller C, Faryniak B, et al. Three-in-one blocks with ropivacaine: evaluation of sensory onset time and quality of sensory block. *Anesth Analg* 2000;90(1):125–8.
106. Matot I, Oppenheim–Eden A, Ratrot R, et al. Preoperative cardiac events in elderly patients with hip fracture randomized to epidural or conventional analgesia. *Anesthesiology* 2003;98(1):156–63.
107. Monzon DG, Vazquez J, Jauregui JR, et al. Pain treatment in post-traumatic hip fracture in the elderly: regional block vs. systemic non-steroidal analgesics. *Int J Emerg Med* 2010;3(4):321–5.
108. Mouzopoulos G, Vasiliadis G, Lasanianos N, et al. Fascia iliaca block prophylaxis for hip fracture patients at risk for delirium: a randomized placebo-controlled study. *J Orthop Traumatol* 2009;10(3):127–33.
109. Murgue D, Ehret B, Massacrier–Imbert S, et al. Equimolar nitrous oxide/oxygen combined with femoral nerve block for emergency analgesia of femoral neck fractures. *J Eur Urg* 2006;19(1):9–14. (Fre).
110. Scheinin H, Virtanen T, Kentala E, et al. Epidural infusion of bupivacaine and fentanyl reduces perioperative myocardial ischaemia in elderly patients with hip fracture—a randomized controlled trial. *Acta Anaesthesiol Scand* 2000;44(9):1061–70.
111. Segado Jimenez MI, Bayon GM, Arias DJ, et al. [Efficacy of obturator and femoral cutaneous nerve blocks for postoperative analgesia in hip surgery]. *Rev Esp Anestesiol Reanim* 2009;56(10):590–7. (Spa).
112. Segado Jimenez MI, Arias Delgado J, Casas Garca ML, et al. Post-surgical analgesia in hip surgery: a comparison of three techniques. *Rev Soc Esp Dolor* 2010;17(6):259–67.
113. Spansberg NL, Anker–Moller E, Dahl JB, et al. The value of continuous blockade of the lumbar plexus as an adjunct to acetylsalicylic acid for pain relief after surgery for femoral neck fractures. *Eur J Anaesthesiol* 1996;13(4):410–2.
114. Tuncer S, Sert OA, Yosunkaya A, et al. Patient-controlled femoral nerve analgesia versus patient-controlled intravenous analgesia for postoperative analgesia after trochanteric fracture repair. *Acute Pain* 2003;4(3–4):105–8.
115. Turker G, Uckunkaya N, Yavascaoglu B, et al. Comparison of the catheter-technique psoas compartment block and the epidural block for analgesia in partial hip replacement surgery. *Acta Anaesthesiol Scand* 2003;47(1):30–6.
116. Yun MJ. Analgesia before a spinal block for femoral neck fracture: fascia iliaca compartment block. *Acta Anaesthesiol Scand* 2009;2009(10):1282–7.
117. Del Rosario E, Esteve N, Sernandez MJ, et al. Does femoral nerve analgesia impact the development of postoperative delirium in the elderly?: a retrospective investigation. *Acute Pain* 2008;10(2):59–64.

118. Kocum A, Turkoz A, Ulger H, et al. Ropivacaine 0.25% is as effective as bupivacaine 0.25% in providing surgical anaesthesia for lumbar plexus and sciatic nerve block in high-risk patients: preliminary report. *Anaesth Intensive Care* 2007;35(4):510–4.
119. Pedersen SJ, Borgbjerg FM, Schousboe B, et al. A comprehensive hip fracture program reduces complication rates and mortality. *J Am Geriatr Soc* 2008;56(10):1831–8.
120. Gorodetskyi IG, Gorodnichenko AI, Tursin PS, et al. Non-invasive interactive neurostimulation in the post-operative recovery of patients with a trochanteric fracture of the femur: a randomised, controlled trial. *J Bone Joint Surg Br* 2007;89(11):1488–94.
121. Lang T, Barker R, Steinlechner B, et al. TENS relieves acute posttraumatic hip pain during emergency transport. *J Trauma* 2007;62(1):184–8.
122. Di Lorenzo L, Forte A, Formisano R, et al. Low back pain after unstable extracapsular hip fractures: randomized control trial on a specific training. *Eura Medicophys* 2007;43(3):349–57.
123. Finsen V, Borset M, Buvik GE, et al. Preoperative traction in patients with hip fractures. *Injury* 1992;23(4):242–4.
124. Jerre R, Doshe A, Karlsson J. Preoperative skin traction in patients with hip fractures is not useful. *Clin Orthop Relat Res* 2000;(378):169–73.
125. Needoff M, Radford P, Langstaff R. Preoperative traction for hip fractures in the elderly: a clinical trial. *Injury* 1993;24(5):317–8.
126. Resch S, Thorngren KG. Preoperative traction for hip fracture: a randomized comparison between skin and skeletal traction in 78 patients. *Acta Orthop Scand* 1998;69(3):277–9.
127. Rosen JE, Chen FS, Hiebert R, et al. Efficacy of preoperative skin traction in hip fracture patients: a prospective, randomized study. *J Orthop Trauma* 2001;15(2):81–5.
128. Anderson GH, Harper WM, Connolly CD, et al. Preoperative skin traction for fractures of the proximal femur: a randomised prospective trial. *J Bone Joint Surg Br* 1993;75(5):794–6.
129. Ghnaimat M, Aldweri M, Hijazi A, et al. Preoperative skin traction for fractures of the proximal femur. *J Bahrain Med Soc* 2005;17(4):240–2.
130. Saygi B, Ozkan K, Eceviz E, et al. Skin traction and placebo effect in the preoperative pain control of patients with collum and intertrochanteric femur fractures. *Bull NYU Hosp Jt Dis* 2010;68(1):15–7.
131. Yip DK, Chan CF, Chiu PK, et al. Why are we still using pre-operative skin traction for hip fractures? *Int Orthop* 2002;26(6):361–4.
132. Vermeiren J, Brabants K, Van HM. Paralysis of the peroneal nerve following hip fracture treatment. *Acta Orthop Belg* 1995;61(2):122–5.
133. Anderson GH, Harper WM, Badham J, Goodrich N, et al. The effect of pre-operative skin traction on pain and morbidity following fracture of the proximal femur: a randomised prospective trial. *J Bone Joint Surg Br* 1993 p. 42.
134. Barlas P. Ear acupressure appears to be an effective anxiolytic and analgesic modality in elderly people with a broken hip. *Focus Alternative Compl Ther* 2006;11(2):128–9.
135. Barnes P. Preoperative pillow placement under the injured extremity had better analgesic effects than skin traction for hip fracture. *Evid Based Nurs* 2002;5(1):24.
136. Chudinov A, Berkenstadt H, Salai M, Cahana A, et al. Continuous psoas compartment block for anesthesia and perioperative analgesia in patients with hip fractures [abstract]. *Br J Anaesth* 1999 p. 111.
137. Cuvillon P, Debureau S, Boisson C, Viales N, et al. Femoral block does not improve postoperative rehabilitation after hip fracture. 2002 Annual Meeting of the American Society of Anesthesiologists, October 12-16, 2002, Orlando, FL, USA. *Anesthesiology Abstracts of Scientific Papers Annual Meeting* 2002 p. A912.

138. Del Rosario E, Esteve N, Perelló J, et al. Impact of regional analgesia in patients outcomes after hip fracture repair surgery. Meeting of the European Society of Anaesthesiology, 3–5 Jun 2006, Madrid, Spain 2006;121.
139. Finsen V, Borset M, Buvik GE, Hauke I. Preoperative traction in patients with hip fractures. *Acta Orthop Scand Suppl* [243], 21–22. 1991.
140. Jerre R, Doshe A, Karlsson J. Preoperative treatment in patients with hip fractures. *Acta Orthop Scand Suppl* 1999;(284): 40.
141. Koval KJ. Preoperative skin traction was not useful for hip fractures. *J Bone Joint Surg Am* 2001;83–A(2):303.
142. Koval K. 3-in-1 femoral nerve block provided fast pain relief for femoral neck fracture. *J Bone Joint Surg* 2004;86–A(2):441.
143. Marhofer P, Schrogendorfer C, Wallner T, Kapral S, et al. Ultrasonographic guidance reduces the amount of local anaesthetic for 3-in-1 blocks. *Br J Anaesth* 1998 p. 112–3.
144. Needoff M, Radford P, Langstaff R. Preoperative traction for femoral neck fractures. *Injury* 1993;24(4), 280–281.
145. Resch S, Thorngren KG. Preoperative skin vs. skeletal traction in patients with hip fractures: the effect on pain and on patient flow characteristics [abstract]. *Acta Orthop Scand Suppl* 1996;(270):34–5.
146. Hoda MQ, Saeed S, Afshan G, et al. Haemodynamic effects of intrathecal bupivacaine for surgical repair of hip fracture. *J Pak Med Assoc* 2007;57(5):245–8.
147. Morrison RS, Magaziner J, McLaughlin MA, et al. The impact of post-operative pain on outcomes following hip fracture. *Pain* 2003;103(3):303–11.
148. Pasero CL, McCaffery M. Reluctance to order opioids in elders. *Am J Nurs* 1997;97(9):20, 23.
149. Closs SJ. An exploratory analysis of nurses' provision of postoperative analgesic drugs. *J Adv Nurs* 1990;15(1):42–9.
150. Bitsch MS, Foss NB, Kristensen BB, et al. Pathogenesis of and management strategies for postoperative delirium after hip fracture: a review. *Acta Orthop Scand* 2004;75(4):378–89.
151. Roofthoof E, Van d, V. Low-dose spinal anaesthesia for Caesarean section to prevent spinal-induced hypotension. *Curr Opin Anaesthesiol* 2008;21(3):259–62.
152. Malchow RJ, Black IH. The evolution of pain management in the critically ill trauma patient: emerging concepts from the global war on terrorism. *Crit Care Med* 2008;36(7 Suppl):S346–S357.
153. Penrod JD, Boockvar KS, Litke A, et al. Physical therapy and mobility 2 and 6 months after hip fracture. *J Am Geriatr Soc* 2004;52(7):1114–20.

## Acronyms and Abbreviations

AE	adverse effect
AHRQ	Agency for Healthcare Research and Quality
CER	Comparative Effectiveness Review
CAM	complementary and alternative medicine
CI	confidence intervals
COX-2	Cyclooxygenase-2
EPC	Evidence-based Practice Center
GI	gastrointestinal
GRADE	Grading of Recommendation Assessment, Development and Evaluation
HRQOL	health-related quality of life
IM	intramuscular
IQR	interquartile range
IV	intravenous
KQ	Key Question
LOS	length of stay
MD	mean difference
mg	milligrams
MMSE	mini-mental state examination
MI	myocardial infarction
NB	nerve block
NS	neurostimulation
NOS	Newcastle-Ottawa Scale
NSAIDS	nonsteroidal anti-inflammatory drugs
nRCT	nonrandomized controlled trial
NA	not applicable
NE	not estimable
NR	not reported
NRS	numeric rating score
PICOTS	Population, Intervention, Comparison, Outcome, Timing, and Setting
RCT	randomized controlled trial
RoB	risk of bias
SRC	Scientific Resource Center
SD	standard deviation
SMD	standardized mean difference
TENS	transcutaneous electrical neurostimulation
US	ultrasound
UAEPC	University of Alberta Evidence-based Practice Center
VAS	visual analog scale

# Appendix A. Technical Expert Panel and Peer Reviewers

## Technical Expert Panel

In designing the study questions and methodology, the UAEPC consulted several technical and content experts. Broad expertise and perspectives were sought. Divergent and conflicting opinions are common and perceived as healthy scientific discourse that results in a thoughtful, relevant systematic review. Due to these differences in opinion, the study questions, design, and/or methodologic approaches do not necessarily represent the views of individual technical and content experts.

<b>Technical Expert</b>	<b>Affiliations/Location</b>
Paul M. Arnstein, R.N., Ph.D, A.P.R.N.-B.C.	Massachusetts General Hospital Boston, MA
Mohit Bhandari, M.D.	McMaster University Hamilton, ON
Cary A. Brown, Ph.D.	University of Alberta and Glenrose Hospital Edmonton, AB
Jeffrey Fudin, B.S., Pharm.D. D.A.A.P.M., Diplomate, A.A.P.M.	Albany College of Pharmacy & Health Sciences Albany, NY
Jay Magaziner, M.D.	University of Maryland Medical Center Baltimore, MD
Kathleen K. Mangione, P.T., Ph.D.	Arcadia University Glenside, PA
R. Sean Morrison, M.D.	Mount Sinai School of Medicine New York, NY
Richard Rosenquist, M.D.	Anesthesia Pain Clinic Iowa City, IA

## Peer Reviewers

Peer reviewer comments on a preliminary draft of this report were considered by the University of Alberta Evidence-based Practice Center in preparation of the final report. The synthesis presented in this report does not necessarily represent the views of individual reviewers.

<b>Peer Reviewer</b>	<b>Affiliations/Location</b>
Paul M. Arnstein, R.N., Ph.D, A.P.R.N.-B.C.	Massachusetts General Hospital Boston, MA
Jeffrey Fudin, B.S., Pharm.D. D.A.A.P.M., Diplomate, A.A.P.M.	Albany College of Pharmacy & Health Sciences Albany, NY
Jay Magaziner, M.D.	University of Maryland Medical Center Baltimore, MD
Kathleen K Mangione, P.T., Ph.D.	Arcadia University Glenside, PA
John C. Rowlingson, M.D.	University of Virginia Health System Charlottesville, VA
Shelly L. Gray, Pharm.D., M.S.	University of Washington Seattle, WA
Kenneth J. Koval, M.D.	Dartmouth-Hitchcock Medical Center Lebanon, NH
Ian Cameron, M.D.	University of Sydney Sydney, Australia
Roger Chou, M.D.	Oregon Health & Science University Portland, OR
Richard Rosenquist, M.D.	Anesthesia Pain Clinic Iowa City, IA

## **Appendix B. Exact Search Strings**

Table B-1. MEDLINE—Ovid Version

Table B-2. AMED (Allied and Complementary Medicine), Global Health and International Pharmaceutical Abstracts (IPAB)—Ovid Version

Table B-3. BIOSIS Previews—Institute for Scientific Information–Thomson Reuters

Table B-4. CINAHL (Cumulative Index to Nursing & Allied Health Literature), Academic Search Elite and Health Source: Nursing and Academic Edition—Ebsco Version

Table B-5. Cochrane Complementary Medicine Trials Register and CAMPAIN (Complementary and Alternative Medicine and Pain Database) Grant Number R24-AT001293 from the National Center for Complementary and Alternative Medicine (NCCAM)

Table B-6. Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects—Wiley Version

Table B-7. EBM Reviews—Cochrane Central Register of Controlled Trials–Ovid Version

Table B-8. EMBASE—Ovid Version

Table B-9. Global Health Library—World Health Organization

Table B-10. Pascal—Ovid Version

Table B-11. PeDRO—The Physical Therapy Evidence Database

Table B-12. ProQuest Dissertations and Theses–Full Text

Table B-13. Scopus—Elsevier B.V.

Table B-14. Web of Science—Institute for Scientific Information—Thomson Reuters

Table B-15. TOXLINE—ProQuest

### **Conference Proceedings**

Table B-16. Conference Papers Index—ProQuest

Table B-17. OCLC Papers First—OCLC FirstSearch

Table B-18. ScienceDirect Tables of Contents

Table B-19. Conference Proceedings handsearched

## **Trials Registers**

Table B-20. ClinicalStudyResults.org

Table B-21. ClinicalTrials.gov—National Institutes of Health

Table B-22. Current Controlled Trials—Biomed Central

Table B-23. ICTRP Search Portal—World Health Organization

Table B-24. IFPMA Clinical Trials Portal—International Federation of Pharmaceutical Manufacturers & Associations

Table B-25. UMIN-CTR Clinical Trials—University Hospital Medical Information Network



**Table B-1. MEDLINE®—Ovid version**

<p>OvidSP_UI02.01.02.102 1950 to July Week 1 2009</p>	<p>Searched: 09Jul09 Results: 1061</p>
<p>1. exp Pain/ 2. exp "anesthesia and analgesia"/or exp analgesia/ 3. ((an?esthet\$ or an?esthesia) adj4 (regional\$ or local\$ or general or spinal or epidural)).mp. 4. (block or analges*).mp. 5. or/2-4 6. exp Therapeutics/or exp "Outcome Assessment (Health Care)"/or exp "Length of Stay"/or "Quality of Life"/or "functional outcome".ti,ab. 7. ((pain* or discomfort* or ache* or aching or sore* or suffer*) adj3 (assess* or relief or reliev* or reduc* or treat* or manage* or control* or experience* or medicat* or duration or evaluat* or alleviat* or level or score* or subjective or felt or prevent* or duration or outcome* or heal or healing or therap* or recover* or "quality of life")).mp. 8. exp Pain/rt, th, us, rh, dh, su, pc, dt 9. pain postoperative/pc, th 10. Pain Measurement/ 11. or/7-10 12. exp Hip Fractures/rh, nu, th, dt, dh 13. exp Hip Fractures/</p>	<p>14. ((intertrochanter* or petrochanter* or subtrochanter* or extracapsular or petrochant* or trochant* or hip or femoral neck) adj4 (hemiarthroplasty or fracture*)).mp. 15. ("neck of femur" adj4 fractur*).mp. 16. or/13-15 17. 5 and 16 18. 11 and 16 19. 1 and 16 20. 6 and 12 21. or/17-20 22. exp Arthroplasty, Replacement, Hip/ 23. THA.mp. 24. total hip*.mp. 25. or/22-24 26. 21 not 25 27. (pediatric* or child or children* or adolesc* or young or youth* or pregnan*).ti,ab,jw,kw,sh. 28. animals/or exp neoplasms/or case reports/or editorials/or exp Emergency Service, Hospital/ 29. or/27-28 30. 26 not 29 31. limit 30 to yr="1990 - 2009"</p>

**Table B-2. AMED (Allied and Complementary Medicine), Global Health and International Pharmaceutical Abstracts (IPAB)—Ovid version**

OvidSP_UI02.01.02.102		Searched: 10Jul09
<b>Database</b>	<b>Dates Available</b>	<b>Results</b>
AMED	1985 to July 2009	340
Global Health	1910 to June 2009	157
IPAB	1970 to June 2009	95
<p>1. exp Pain/                  2. exp "anesthesia and analgesia"/or exp "Nerve Block"/or exp "anesthesiological techniques"/or exp "analgesic, antiinflammatory, antirheumatic and antigout agents"/or exp "agents interacting with transmitter, hormone or drug receptors"/                  3. (block or analges*).mp.                  4. (Therapy or therapeutics or "disease management" or "quality of life" or treatment or "outcome assessment" or "length of stay" or "functional outcome" or rehabilitation or traction or acupunct* or acupress* or stimulation or "continuous passive motion").ti,cw,cc,bt,id,hw,sh.                  5. exp Pain Assessment/or exp Pain Measurement/                  6. ((pain* or discomfort* or ache* or aching or sore* or suffer*) adj3 (assess* or relief or reliev* or reduc* or treat* or manage* or control* or experience* or medicat* or duration or evaluat* or alleviat* or level or score* or subjective or felt or prevent* or duration or outcome* or heal or healing or therap* or recover* or "quality of life")).mp.                  7. or/1-6</p> <p>8. "fracture, hip"/or hip fracture/or hip fractures/or acetabulum fracture/or femur intertrochanteric fracture/or femur neck fracture/or femur pertrochanteric fracture/or exp femur subtrochanteric fracture/or femur trochanteric fracture/                  9. ((intertrochanter* or petrochanter* or subtrochanter* or intracapsular or extracapsular or petrochant* or trochant* or hip or femoral neck or "neck of femur") adj4 fracture*).mp.                  10. ("neck of femur" adj4 fractur*).mp.                  11. or/8-1012. 7 and 11                  13. (THA or total hip*).mp. or exp "Arthroplasty, Replacement, Hip"/                  14. (neoplasm* or cancer* or carcinoma* or lymphoma or sarcoma* or Emergency).ti,de,cw,cc,bt,id,hw,sh.                  15. case report.ti,de,cw,cc,bt,id,hw,sh.                  16. (pediatric* or child or children* or adolesc* or young or youth* or pregnan*).ti,ab,hw,de,cw,cc,tt,ed,sh.                  17. or/13-16                  18. 12 not 17                  19. limit 18 to yr="1990 -Current"                  20. remove duplicates from 19</p>		

**Table B-3. BIOSIS previews—Institute for Scientific Information—Thomson Reuters**

1926 to 2009	Searched: 14Jul09	Results: 206
<p># 3 #2 AND #1                  Databases=PREVIEWS Timespan=1990-2009                  # 2 TS=(intertrochanter* or petrochanter* or subtrochanter* or intracapsular or extracapsular or petrochant* or trochant* or hip or "femoral neck") SAME TS=(fracture*) AND Taxa Notes=(Humans)                  # 1 TS=(pain* or discomfort* or ache* or aching or sore* or suffer*) SAME TS=(assess* or relief or reliev* or reduc* or treat* or manage* or control* or experience* or medicat* or duration or evaluat* or alleviat* or level or score* or subjective or felt or prevent* or duration or outcome* or heal or healing or therap* or recover* or "quality of life") AND Taxa Notes=(Humans)</p>		

**Table B-4. CINAHL (Cumulative Index to Nursing & Allied Health Literature), Academic Search Complete, Health Source: nursing/academic edition—Ebsco version**

1937 to 2009 (CINAHL) 1985 to 2009 (Academic Search Elite) Searched: 13Jul09	Results: 189
<p>S11 S10 and S3  S10 (S9 or S8 or S7 or S6 or S5 or S4)  S9 ( safe or safety ) or ( adverse w1 effect* or adverse w1 event* or "side effect*" ) or ( harm* or contraindicat* or contra-indicat* )  S8 ( cohort or observation* or control* or prospectiv* or volunteer* or "case-series" or "time-series" or "case-comparison" or "case-referent" or "cross-sectional" or risk* or efficacy )  S7 ( singl* w10 blind* or singl* w10 mask* or doubl* w10 blind* or doubl* w10 mask* or trebl* w10 blind* or trebl* w10 mask* or cross-over or placebo* or control* or random* or factorial or sham* or clin* w10 trial* intervention* w10 trial* or compar* w10 trial* or experiment* w10 trial* or preventive w10 trial* or therapeutic w10 trial* )  S6 ( clin* w25 trial* or random* )  S5 PT clinical trial  S4 ( (MH "Random Assignment") or (MH "Random Sample") or (MH "Crossover Design") or (MH "Clinical Trials+") or (MH "Double-Blind Studies") or (MH "Single-Blind Studies") or (MH "Comparative Studies") or (MH "Control Group") or (MH "Factorial Design") or (MH "Quasi-Experimental Studies") or (MH "Experimental Studies") or (MH "One-Shot Case Study") or (MH "Study Design") or (MH "Placebos") or (MH "Clinical Nursing Research") or (MH "Clinical Research") or (MH "Community Trials") or (MH "Pretest-Postt ...  S3 S2 not S1 Limiters - Exclude MEDLINE records  S2 (MH "Hip Fractures") and ( pain* or "drug therapy" or pharmacological OR "quality of life" OR acupunct* OR accupress* OR traction OR "electrical stimulation" OR "passive motion" or morphine OR acetaminophen or paracetamol or tylenol or anesth* or analges* ) Limiters - Exclude MEDLINE records  S1 TI ( neoplasm* or cancer* or carcinoma* or lymphoma or sarcoma* or "total hip" or "THA" or arthroplasty or replacement ) or TI case report* or TI ( pediatric* or child or children* or adolesc* or young or youth* or pregnan* ) Limiters - Exclude MEDLINE records</p>	

**Table B-5. Cochrane Complementary Medicine Trials Register and CAMPAIN (Complementary and Alternative Medicine and Pain Database) grant number R24-AT001293 from the National Center for Complementary and Alternative Medicine (NCCAM)**

Searched: 23Jul09	Results: 263
<p>ID Search  #1 (SR-SYMPT)  #2 (hip OR "neck of femur" or "femoral neck" or extracapsular or intracapsular or intertrochanter* or petrochanter* or petrochant* or trochant*):ti,ab,kw  #3 (#1 AND #2)  #4 "total hip arthroplasty" OR replacement:ti  #5 (osteoarthr* OR cancer* or knee or carcinoma or sarcoma):ti  #6 MeSH descriptor Arthroplasty, Replacement, Hip explode all trees  #7 (child* or pediatric):ti,ab,kw  #8 (#4 OR #5 OR #6 OR #7)  #9 (#3 AND NOT #8)</p>	

**Table B-6. Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects—Wiley version**

OvidSP_UI02.01.02.102 3rd Quarter 2009	Searched: 27Jul09 Results: 36
<p>#1 (hip OR "neck of femur" or "femoral neck" or extracapsular or intracapsular or intertrochanter* or petrochanter* or petrochant* or trochant*):ti,ab,kw          #2 (osteoarthr* OR cancer* or knee or carcinoma or sarcoma or "total hip arthroplasty" OR replacement):ti          #3 MeSH descriptor Arthroplasty, Replacement, Hip explode all trees          #4 (child* or pediatric):ti,ab,kw          #5 (#2 OR #3 OR #4)          #6 ((an?esthet\$ or an?esthesia) near/4 (regional\$ or local\$ or general or spinal or epidural)) in Cochrane Reviews and Other Reviews          #7 (block or analges*) in Cochrane Reviews and Other Reviews          #8 (pain* or discomfort* or ache* or aching or suffer*) NEAR/3 (assess* or relief or reliev* or reduc* or treat* or manage* or control* or experience* or medicat* or duration or evaluat* or alleviat* or level or score* or subjective or felt or prevent* or duration or outcome* or heal or healing or therap* or recover* or "quality of life") in Cochrane Reviews and Other Reviews          #9 (#6 OR #7 OR #8)          #10 (#1 AND #8)          #11 (#10 AND NOT #5)</p>	

**Table B-7. EBM reviews—Cochrane Central Register of Controlled Trials—Ovid version**

OvidSP_UI02.01.02.102 2nd Quarter 2009	Searched: 09Jul09 Results: 263
<p>1. exp Pain/          2. exp Postoperative pain/          3. exp "anesthesia and analgesia"/or exp "Nerve Block"/or exp "anesthesiological techniques"/or exp "analgesic, antiinflammatory, antirheumatic and antigout agents"/or exp "agents interacting with transmitter, hormone or drug receptors"/          4. (block or analges*).mp.          5. exp Therapy/or exp therapeutics/or disease management/or exp "quality of life"/or exp treatment outcome/or exp "outcome assessment"/or "length of stay"/or "functional outcome".ti,ab.          6. exp Pain Assessment/or exp Pain Measurement/          7. ((pain* or discomfort* or ache* or aching or sore* or suffer*) adj3 (assess* or relief or reliev* or reduc* or treat* or manage* or control* or experience* or medicat* or duration or evaluat* or alleviat* or level or score* or subjective or felt or prevent* or duration or outcome* or heal or healing or therap* or recover* or "quality of life")).mp.          8. or/1-7          9. exp hip fracture/or exp hip fractures/or exp acetabulum fracture/or exp femur intertrochanteric fracture/or exp femur neck fracture/or exp femur pertrochanteric fracture/or exp femur subtrochanteric fracture/or exp femur trochanteric fracture/          10. ((intertrochanter* or petrochanter* or subtrochanter* or intracapsular or extracapsular or petrochant* or trochant* or hip or femoral neck) adj4 fracture*).mp.          11. ("neck of femur" adj4 fractur*).mp.          12. or/9-11          13. 8 and 12          14. (THA or total hip*).mp. or exp "Arthroplasty, Replacement, Hip"/          15. exp neoplasms/or exp Emergency Service, Hospital/          16. (pediatric* or child or children* or adolesc* or young or youth* or pregnan*).ti,ab,hw,jn.          17. or/14-16          18. 13 not 17          19. limit 18 to yr="1990 -Current"</p>	

**Table B-8. EMBASE—Ovid version**

OvidSP_UI02.01.02.102 1980 to 2009 Week 28	Searched: 10Jul09 Results: 1179
<p>1. exp Pain/                  2. exp Postoperative pain/                  3. (pain* or discomfort* or ache* or aching or sore* or suffer*).mp.                  4. or/1-3                  5. exp "Nerve Block"/or exp "anesthesiological techniques"/or exp "analgesic, antiinflammatory, antirheumatic and antigout agents"/or exp "agents interacting with transmitter, hormone or drug receptors"/                  6. (block or analges*).mp.                  7. exp Therapy/or disease management/or exp "quality of life"/or exp treatment outcome/or exp outcome assessment/or "length of stay"/or "functional outcome".ti,ab.                  8. or/5-7                  9. 4 and 8                  10. exp Pain/dt, rh, pc, th, dm, rt, su, dr                  11. exp Pain Assessment/                  12. ((pain* or discomfort* or ache* or aching or sore* or suffer*) adj3 (assess* or relief or relieve* or reduc* or treat* or manage* or control* or experience* or medicat* or duration or evaluat* or alleviat* or level or score* or subjective or felt or prevent* or duration or outcome* or heal or healing or therap* or recover* or "quality of life")),mp.                  13. or/10-12                  14. 9 or 13                  15. exp hip fracture/dm, th, rh, dt                  16. exp femur neck fracture/dm, th, rh, dt                  17. or/15-16</p>	<p>18. exp hip fracture/or exp acetabulum fracture/or exp femur intertrochanteric fracture/or exp femur neck fracture/or exp femur pertrochanteric fracture/or exp femur subtrochanteric fracture/or exp femur trochanteric fracture/                  19. ((intertrochanter* or petrochanter* or subtrochanter* or intracapsular or extracapsular or petrochant* or trochant* or hip or femoral neck) adj4 fracture*).mp.                  20. ("neck of femur" adj4 fractur*).mp.                  21. or/18-20                  22. 14 and 21                  23. (4 or 8) and 17                  24. or/22-23                  25. exp "Total Hip Prosthesis"/                  26. THA.mp.                  27. total hip*.mp.                  28. or/25-27                  29. 24 not 28                  30. limit 29 to (embryo or infant or child or preschool child &lt;1 to 6 years&gt; or school child &lt;7 to 12 years&gt; or adolescent &lt;13 to 17 years&gt;)                  31. (pediatric* or child or children* or adolesc* or young or youth* or pregnan*).ti,ab,hw,jx.                  32. "nonhuman"/or exp neoplasm/or cancer.hw. or case report/or emergency.af.                  33. 29 not (30 or 31 or 32)                  34. limit 33 to yr="1990 - 2009"                  35. limit 34 to (article or conference paper or proceeding or report or "review")</p>

**Table B-9. Global Health Library—World Health Organization**

Searched: 28Jul09	Results: 110
<p>(hip or intertrochanter* or petrochanter* or subtrochanter* or intracapsular or extracapsular or petrochant* or trochant* or hip or "femoral neck") AND fractur* AND (pain* or heal or healing or therap* or recover* or "quality of life" or rehabilitat* or "drug therapy" or pharmacological OR acupunct* OR acupress* OR traction OR "electrical stimulation" OR "passive motion" or morphine OR acetaminophen or paracetamol or tylenol or anesth* or analges*) AND NOT (child* or adolesc* or young or youth or pediatric* or cancer* or replace* or "total hip arthroplasty" or nail or screw or "case reports" or osteoporosis)</p>	

**Table B-10. Pascal—Ovid version**

OvidSP_UI02.01.02.102 1987 to Jan Week 4 2010	Searched: 03Feb10 Results: 169
<p>1. exp Pain/ 2. exp "anesthesia and analgesia"/or exp "Nerve Block"/or exp "anesthesiological techniques"/or exp "analgesic, antiinflammatory, antirheumatic and antigout agents"/or exp "agents interacting with transmitter, hormone or drug receptors"/ 3. (block or analges*).mp. 4. exp Pain Assessment/or exp Pain Measurement/ 5. ((pain* or discomfort* or ache* or aching or sore* or suffer*) adj3 (assess* or relief or reliev* or reduc* or treat* or manage* or control* or experience* or medicat* or duration or evaluat* or alleviat* or level or score* or subjective or felt or prevent* or duration or outcome* or heal or healing or therap* or recover* or "quality of life")).mp. 6. or/1-5 7. "fracture, hip"/or hip fracture/or hip fractures/or acetabulum fracture/or femur intertrochanteric fracture/or femur neck fracture/or femur pertrochanteric fracture/or exp femur subtrochanteric fracture/or femur trochanteric fracture/</p>	<p>8. ((intertrochanter* or petrochanter* or subtrochanter* or intracapsular or extracapsular or petrochant* or trochant* or hip or femoral neck) adj4 fracture*).mp. 9. ("neck of femur" adj4 fractur*).mp. 10. or/7-9 11. 6 and 10 12. (THA or total hip*).mp. or exp "Arthroplasty, Replacement, Hip"/ 13. (neoplasm* or cancer* or carcinoma* or lymphoma or sarcoma* or Emergency).ti,de,cw,cc,bt,id,hw,sh. 14. case report.ti,de,cw,cc,bt,id,hw,sh. 15. (pediatric* or child or children* or adolesc* or young or youth* or pregnan*).ti,ab,hw,de,cw,cc,tt,ed,sh. 16. or/12-15 17. 11 not 16 18. limit 17 to yr="1990 -Current" 19. remove duplicates from 18</p>

**Table B-11. PEDro—The Physiotherapy Evidence Database**

1929 to 2009 Searched: 14Jul09	Results: 256 of which 33 were selected
<p>Problem: pain Body part: thigh or hip Published since 1990</p>	

**Table B-12. ProQuest dissertations and theses—full text**

1637 to 2009 Searched: 24Jul09	Results: 43
<p>(hip or intertrochanter* or petrochanter* or subtrochanter* or intracapsular or extracapsular or petrochant* or trochant* or hip or "femoral neck") AND (fracture*) AND (pain* or "quality of life" or traction or "physical therapy" or acupunct* OR acupress* OR traction OR "electrical stimulation") AND NOT (child* or adolesc* or young or youth or pediatric* or cancer* or replace* or "total hip arthroplasty")</p> <p>Look for terms in: Citation and abstract; Publication type: All publication types</p> <p>(hip or intertrochanter* or petrochanter* or subtrochanter* or intracapsular or extracapsular or petrochant* or trochant* or hip or "femoral neck") AND (fracture*) AND ("passive motion" or morphine OR acetaminophen or paracetamol or tylenol or anesth* or analges*) AND NOT (child* or adolesc* or young or youth or pediatric* or cancer* or replace* or "total hip arthroplasty")</p> <p>Look for terms in: Citation and abstract; Publication type: All publication types</p>	

**Table B-13. Scopus—Elsevier B.V.**

1990 to July 2009	Searched: 13Jul09 Results: 900
<p>(((TITLE(pain*) OR KEY(pain*)) AND SUBJAREA(mult OR agri OR bioc OR immu OR neur OR phar OR mult OR medi OR nurs OR vete OR dent OR heal OR mult OR arts OR busi OR deci OR econ OR psyc OR soci) AND PUBYEAR AFT 1989) AND ((TITLE-ABS-KEY(assess* OR relief OR reliev* OR reduc* OR treat* OR manage* OR control* OR experience* OR medicat* OR duration OR evaluat* OR alleviat* OR level OR score* OR subjective OR felt OR prevent* OR duration OR outcome* OR heal OR healing OR therap* OR recover*) OR TITLE-ABS-KEY("quality of life" OR acupunct* OR accupress* OR traction OR "electrical stimulation" OR "passive motion")) AND SUBJAREA(mult OR agri OR bioc OR immu OR neur OR phar OR mult OR medi OR nurs OR vete OR dent OR heal OR mult OR arts OR busi OR deci OR econ OR psyc OR soci) AND PUBYEAR AFT 1989)) AND NOT ((TITLE-ABS-KEY("total hip replacement" OR "total hip arthroplasty" OR "THA") OR TITLE-ABS-KEY(cancer* OR carcinoma* OR neoplasm* OR pediatric* OR children* OR adolesc* OR "case report")) AND SUBJAREA(mult OR agri OR bioc OR immu OR neur OR phar OR mult OR medi OR nurs OR vete OR dent OR heal OR mult OR arts OR busi OR deci OR econ OR psyc OR soci) AND PUBYEAR AFT 1989)) AND (TITLE-ABS-KEY((hip* OR femur* OR femoral* OR trochant* OR petrochant* OR intertrochant* OR subtrochant* OR intracapsular* OR extracapsular*) AND fractur*) AND SUBJAREA(mult OR agri OR bioc OR immu OR neur OR phar OR mult OR medi OR nurs OR vete OR dent OR heal OR mult OR arts OR busi OR deci OR econ OR psyc OR soci) AND PUBYEAR AFT 1989)) AND NOT (TITLE(diagnos* OR predictive OR accurac* OR specificity OR probability OR likelihood OR screen* OR test* OR "risk factors")) AND (EXCLUDE(DOCTYPE, "no") OR EXCLUDE(DOCTYPE, "sh") OR EXCLUDE(DOCTYPE, "ed")) AND (EXCLUDE(SUBJAREA, "BIOC") OR EXCLUDE(SUBJAREA, "VETE") OR EXCLUDE(SUBJAREA, "ENGI") OR EXCLUDE(SUBJAREA, "DENT") OR EXCLUDE(SUBJAREA, "CENG") OR EXCLUDE(SUBJAREA, "ENVI") OR EXCLUDE(SUBJAREA, "ECON") OR EXCLUDE(SUBJAREA, "COMP") OR EXCLUDE(SUBJAREA,</p>	

**Table B-14. Web of Science—Institute for Scientific Information—Thomson Reuters**

1900 to 2009 Searched: 14Jul09	Results: 596
<p># 4 #2 AND #1 Refined by: [excluding] Subject Areas=( PEDIATRICS OR VETERINARY SCIENCES ) Databases=SCI-EXPANDED, SSCI Timespan=1990-2009 # 3 #2 AND #1 # 2 TS=(intertrochanter* or petrochanter* or subtrochanter* or intracapsular or extracapsular or petrochant* or trochant* or hip or "femoral neck") SAME TS=(fracture*) # 1 TS=(pain* or discomfort* or ache* or aching or sore* or suffer*) SAME TS=(assess* or relief or reliev* or reduc* or treat* or manage* or control* or experience* or medicat* or duration or evaluat* or alleviat* or level or score* or subjective or felt or prevent* or duration or outcome* or heal or healing or therap* or recover* or "quality of life")</p>	

**Table B-15. TOXLINE—ProQuest**

1998 to 2009 Searched: 29Jul09	Results: 74
<p>(TI=(hip or intertrochanter* or petrochanter* or subtrochanter* or intracapsular or extracapsular or petrochant* or trochant* or "femoral neck") or DE=(hip or intertrochanter* or petrochanter* or subtrochanter* or intracapsular or extracapsular or petrochant* or trochant* or "femoral neck") or AB=(hip or intertrochanter* or petrochanter* or subtrochanter* or intracapsular or extracapsular or petrochant* or trochant* or "femoral neck")) and DE=fractur* and (DE=(pain* or heal or healing or therap* or recover* or "quality of life" or rehabilitat* or "drug therapy" or pharmacological OR acupunct* OR acupress* OR traction OR "electrical stimulation" OR "passive motion" or morphine OR acetaminophen or paracetamol or tylenol or anesth* or analges*) or AB=(pain* or heal or healing or therap* or recover* or "quality of life" or rehabilitat* or "drug therapy" or pharmacological OR acupunct* OR acupress* OR traction OR "electrical stimulation" OR "passive motion" or morphine OR acetaminophen or paracetamol or tylenol or anesth* or analges*) or TI=(pain* or heal or healing or therap* or recover* or "quality of life" or rehabilitat* or "drug therapy" or pharmacological OR acupunct* OR acupress* OR traction OR "electrical stimulation" OR "passive motion" or morphine OR acetaminophen or paracetamol or tylenol or anesth* or analges*)) not (DE=(child* or adolesc* or young or youth or pediatric* or cancer* or neoplasm* or carcinoma or anemia or alendronate or replace* or osteoporosis or "total hip arthroplasty" or "hip fractures: prevention control" or "hip fractures: epidemiology" OR "Hip Fractures: chemically induced"))</p>	



## Conference Proceedings

**Table B-16. Conference papers index—ProQuest**

1982 to 2009 Searched: 24Jul09	Results: 97
<p>TI=(hip or intertrochanter* or petrochanter* or subtrochanter* or intracapsular or extracapsular or petrochant* or trochant* or hip or "femoral neck") and DE=(pain* or heal or healing or therap* or recover* or "quality of life" or rehabilitat* or "drug therapy" or pharmacological OR acupunct* OR acupress* OR traction OR "electrical stimulation" OR "passive motion" or morphine OR acetaminophen or paracetamol or tylenol or anesth* or analges* ) not TI=(child* or adolesc* or young or youth or pediatric* or cancer* or replace* or "total hip arthroplasty") Limits: 1990-2009</p>	

**Table B-17. OCLC papers first—OCLC FirstSearch**

Searched: 24Jul09	Results: 12
<p>(((((ti: hip or ti: intertrochanter* or ti: petrochanter* or ti: subtrochanter* or ti: intracapsular or ti: extracapsular or ti: petrochant* or ti: trochant* or ti: hip or ti: femoral w neck)) and kw: pain*) and (kw: heal or kw: healing or kw: therap* or kw: recover* or kw: quality w1 life or kw: rehabilitat* or kw: drug w therapy or kw: pharmacological OR kw: acupunct* OR kw: acupress* OR kw: traction OR kw: electrical w stimulation OR kw: passive w motion or kw: morphine OR kw: acetaminophen or kw: paracetamol or kw: tylenol or kw: anesth* or kw: analges*) and yr: 1990-2009) not (ti: replacement or ti: total w hip) and yr: 1990-2009</p>	

**Table B-18. ScienceDirect tables of contents**

Searched: 28Jul09	Results: 24
<p>Regional Anesthesia and Pain Medicine Pain Management Nursing Acute Pain European Journal of Pain Journal of Pain and Symptom Management Techniques in Regional Anesthesia and Pain Management Anesthesiology Clinics Pain</p> <p>Searched tables of contents using the strategy below for the journals listed above: pub-date &gt; 1989 and TITLE-ABSTR-KEY((intertrochanter* or petrochanter* or subtrochanter* or intracapsular or extracapsular or petrochant* or trochant* or hip or "femoral neck") AND fractur*) and SRCTITLEPLUS(pain)</p>	

**Table B-19. Conference proceedings hand searched**

Searched: 28Jul09	
American Geriatric Society (AGS)	2005-2009
American Physical Therapy Association (APTA)	2005-2009
American Society of Regional Anesthesia and Pain Medicine (ASRA)	2007-2009
European Society of Regional Anesthesia (ESRA)	2005-2009
European Society of Anesthesiology (ESA)	2008-2009
International Anesthesia Research Society (IARS)	2005-2009

## Trials Registers

**Table B-20. ClinicalStudyResults.org**

Searched: 03Sep09	Results: 0
Searched by Indication Word hip fracture	Searched by Study Indication/Disease: Hip Fracture Recovery; Pain, Postoperative; Pain, Postsurgical

**Table B-21. ClinicalTrials.Gov—National Institutes of Health**

Searched: 27Jul09	Results: 33
Pain* AND ( hip OR intertrochanter* OR petrochanter* OR subtrochanter* OR intracapsular OR extracapsular OR petrochant* OR trochant* OR femoral neck ) AND fracture*	

**Table B-22. Current controlled trials—Biomed Central**

*Excluding Leukaemia Research Fund and ClinicalTrials.gov*

Searched: 03Sep09	Results: 17
Pain* AND (hip OR intertrochanter* OR petrochanter* OR subtrochanter* OR intracapsular OR extracapsular OR petrochant* OR trochant* OR femoral neck) AND fracture*	

**Table B-23. ICTRP search portal – World Health Organization**

Searched: 03Sep09	Results: 199
(hip OR intertrochanter* OR petrochanter* OR subtrochanter* OR intracapsular OR extracapsular OR petrochant* OR trochant* OR femoral neck) AND fracture*	
ALL studies (not restricted to Recruiting)	

**Table B-24. IFPMA clinical trials portal—International Federation of Pharmaceutical Manufacturers & Associations**

Searched: 04Sep09	Results: 37
(hip OR intertrochanter* OR petrochanter* OR subtrochanter* OR intracapsular OR extracapsular OR petrochant* OR trochant* OR femoral neck) AND fracture*	

**Table B-25. UMIN-CTR Clinical Trials—University Hospital Medical Information Network**

Searched: 04Sep09	Results: 7
"hip fracture" "femoral neck"	

# **Appendix C. Sample Data Extraction and Quality Assessment Form**

# *Comparative Effectiveness of Pain Management Interventions for Hip Fracture*

Refid:

Study Name:

Reviewer's name:

**Study Demographics:**

<i>Publication type</i>		<i>Study design</i>	
<i>Type of hospital</i>		<i>Country</i>	
<i>Number of centers (n)</i>		<i>Study period (month and year)</i>	
<i>Main inclusion criteria</i>		<i>Main exclusion criteria</i>	
<i>Financial support</i>		<i>Reported outcomes of interest to this review</i>	<p><b>Primary outcomes:</b></p> <p><input type="checkbox"/> Acute pain</p> <p><input type="checkbox"/> Chronic pain</p> <p><b>Secondary outcomes:</b></p> <p><input type="checkbox"/> Mortality</p> <p><input type="checkbox"/> Functional status</p> <p><input type="checkbox"/> Pain medication use; change in type and quantity</p> <p><b>Adverse events:</b></p> <p><input type="checkbox"/> AE related to the pain management interventions</p> <p><input type="checkbox"/> Mental status</p> <p><input type="checkbox"/> Health-related QoL</p> <p><input type="checkbox"/> Quality of sleep in hospital</p> <p><input type="checkbox"/> Ability to participate in rehabilitation</p> <p><input type="checkbox"/> Return to prefracture place of residence</p> <p><input type="checkbox"/> Length of stay for acute hospitalization, skilled nursing facility, subacute care facility</p> <p><input type="checkbox"/> Health service utilization</p>

**Reviewer's Comments:**

**Patient Baseline Demographics:**

	<b>Intervention 1</b>	<b>Intervention 2</b>	<b>Intervention 3</b>	<b>Intervention 4</b>
<b>Classification</b>				
<b>Type of intervention</b>				
<b>Dosage</b>				
<b>Dosage Intervals</b>				
<b>Age (yr)</b>				
<i>Mean ± SD</i>				
<i>Range</i>				
<b>Body weight (Kg)</b>				
<i>Mean ± SD</i>				
<i>Range</i>				
<b>Height (cm)</b>				
<i>Mean ± SD</i>				
<i>Range</i>				
<b>BMI (Kg/ m<sup>2</sup>)</b>				
<i>Mean ± SD</i>				
<i>Range</i>				
<b>Gender</b>				
<i>Females: n (%)</i>				
<i>Males: n (%)</i>				
<b>Pre-fracture residence</b>				
<i>Community: n (%)</i>				
<i>Institutional: n (%)</i>				
<b>Type of fractures</b>				
<i>Femoral neck: n (%)</i>				
<i>Intertrochanteric: n (%)</i>				
<i>Proximal femur: n (%)</i>				
<b>Side of fracture</b>				
<i>Right: n (%)</i>				
<i>Left: n (%)</i>				
<b>ASA Class</b>				
<i>ASA I (%)</i>				
<i>ASA II (%)</i>				
<i>ASA III (%)</i>				
<i>ASA IV (%)</i>				
<b>Timing of intervention</b>				

<i>Time from fall to ER arrival (hr)</i>				
<i>Mean ± SD</i>				
<i>Range</i>				
<i>Time from ER arrival to surgery (hr)</i>				
<i>Mean ± SD</i>				
<i>Range</i>				
<i>Time from fall to surgery (hr)</i>				
<i>Mean ± SD</i>				
<i>Range</i>				
<i>Type of surgery</i>				
<i>Type of anesthesia</i>				
<i>Epidural</i>				
<i>Spinal</i>				
<i>General</i>				
<i>Duration of surgery (hr)</i>				
<i>Mean ± SD</i>				
<i>Range</i>				
<i>Baseline pain score</i>	<i>Scale name []</i>			
<i>Mean ± SD</i>				
<i>Range</i>				

**Reviewer's Comments:**

**Data available on subpopulations:**

	<i>Describe</i>	<i>Outcomes available</i>
<i>Sex</i>		
<i>Age</i>		
<i>Race</i>		
<i>Marital status</i>		
<i>Co-morbidities</i>		
<i>Body mass index</i>		
<i>Pre-fracture functional status</i>		
<i>Family distress</i>		

**Reviewer's Comments:**

**NEWCASTLE - OTTAWA QUALITY ASSESSMENT SCALE**  
**CASE CONTROL STUDIES**

Note: A study can be awarded a maximum of one star for each numbered item within the Selection and Exposure categories. A maximum of two stars can be given for Comparability.

**Selection**

1) Is the case definition adequate?

- a) yes, with independent validation \*
- b) yes, eg record linkage or based on self reports
- c) no description

2) Representativeness of the cases

- a) consecutive or obviously representative series of cases \*
- b) potential for selection biases or not stated

3) Selection of Controls

- a) community controls \*
- b) hospital controls
- c) no description

4) Definition of Controls

- a) no history of disease (endpoint) \*
- b) no description of source

**Comparability**

1) Comparability of cases and controls on the basis of the design or analysis \*

- a) study controls for \_\_\_\_\_ \* (Select the most important factor.)
- b) study controls for any additional factor (This criteria could be modified to indicate specific control for a second important factor.)

**Exposure**

1) Ascertainment of exposure

- a) secure record (eg surgical records) \*
- b) structured interview where blind to case/control status \*
- c) interview not blinded to case/control status
- d) written self report or medical record only
- e) no description

2) Same method of ascertainment for cases and controls

- a) yes \*
- b) no

3) Non-Response rate

- a) same rate for both groups \*
- b) non respondents described
- c) rate different and no designation

## **NEWCASTLE - OTTAWA QUALITY ASSESSMENT SCALE COHORT STUDIES**

Note: A study can be awarded a maximum of one star for each numbered item within the Selection and Outcome categories. A maximum of two stars can be given for Comparability

### **Selection**

#### 1) Representativeness of the exposed cohort

- a) truly representative of the average \_\_\_\_\_ (describe) in the community \*
- b) somewhat representative of the average \_\_\_\_\_ in the community \*
- c) selected group of users eg nurses, volunteers d) no description of the derivation of the cohort

#### 2) Selection of the non exposed cohort

- a) drawn from the same community as the exposed cohort \*
- b) drawn from a different source
- c) no description of the derivation of the non exposed cohort

#### 3) Ascertainment of exposure

- a) secure record (eg surgical records) \*
- b) structured interview \*
- c) written self report
- d) no description

#### 4) Demonstration that outcome of interest was not present at start of study

- a) yes \*
- b) no

### **Comparability**

#### 1) Comparability of cohorts on the basis of the design or analysis

- a) study controls for \_\_\_\_\_ (select the most important factor) \*
- b) study controls for any additional factor \* (This criteria could be modified to indicate specific control for a second important factor.)

### **Outcome**

#### 1) Assessment of outcome

- a) independent blind assessment \*
- b) record linkage \*
- c) self report
- d) no description

#### 2) Was follow-up long enough for outcomes to occur

- a) yes (select an adequate follow up period for outcome of interest) \*
- b) no

#### 3) Adequacy of follow up of cohorts

- a) complete follow up -all subjects accounted for \*
- b) subjects lost to follow up unlikely to introduce bias -small number lost -> \_\_\_\_ % (select an adequate %) follow up, or description provided of those lost) \*
- c) follow up rate < \_\_\_\_% (select an adequate %) and no description of those lost
- d) no statement



**RISK OF BIAS (ROB)  
RANDOMIZED CONTROLLED TRIALS**

<i>Item</i>	<i>Judgment</i>	<i>Description</i>
<i>Adequate sequence generation?</i>		
<i>Allocation concealment?</i>		
<i>Blinding?</i>		
<i>Incomplete outcome data addressed?</i>		
<i>Free of selective reporting?</i>		
<i>Free of other bias?</i>		

**Primary outcome measures:**

	<i>Intervention (1)</i>	<i>Intervention (2)</i>	<i>Intervention (3)</i>	<i>Intervention (4)</i>
<b>Acute pain (% change from baseline)</b>	<i>Scale name</i>			
<i>Maximal pain relief</i> <i>Mean ± SD</i> <i>Range</i>				
<i>Time to max pain relief</i> <i>Mean ± SD</i> <i>Range</i>				
<i>Pain at rest</i> <i>Mean ± SD</i> <i>Range</i>				
<i>Pain on movement</i> <i>Mean ± SD</i> <i>Range</i>				
<b>Acute pain (post-treatment means)</b>	<i>Scale name</i>			
<i>Maximal pain relief</i> <i>Mean ± SD</i> <i>Range</i>				
<i>Time to max pain relief</i> <i>Mean ± SD</i> <i>Range</i>				
<i>Pain at rest</i> <i>Mean ± SD</i> <i>Range</i>				
<i>Pain on movement</i> <i>Mean ± SD</i> <i>Range</i>				

<p><b>Is there acute pain?</b></p> <p><i>Day 1</i></p> <p><i>Day 2</i></p> <p><i>Day <math>\geq 7</math> - 30</i></p> <p><i>Pain at rest</i></p> <p><i>Pain on movement</i></p>				
<p><b>Chronic pain (% change from baseline)</b></p> <p><i>Maximal pain relief</i></p> <p><i>Mean <math>\pm</math> SD</i></p> <p><i>Range</i></p> <p><i>Time to max pain relief</i></p> <p><i>Mean <math>\pm</math> SD</i></p> <p><i>Range</i></p> <p><i>Pain at rest</i></p> <p><i>Mean <math>\pm</math> SD</i></p> <p><i>Range</i></p> <p><i>Pain on movement</i></p> <p><i>Mean <math>\pm</math> SD</i></p> <p><i>Range</i></p>	<i>Scale name</i>			
<p><b>Chronic pain (post-treatment means)</b></p> <p><i>Maximal pain relief</i></p> <p><i>Mean <math>\pm</math> SD</i></p> <p><i>Range</i></p> <p><i>Time to max pain relief</i></p> <p><i>Mean <math>\pm</math> SD</i></p> <p><i>Range</i></p> <p><i>Pain at rest</i></p> <p><i>Mean <math>\pm</math> SD</i></p>	<i>Scale name</i>			

<i>Range</i> <i>Pain on movement</i> <i>Mean ± SD</i> <i>Range</i>				
<i>Is there chronic pain?</i> <i>Pain is present</i> <i>Pain at rest</i> <i>Pain on movement</i>				

Reviewer's Comments:

Secondary outcome measures:

	<i>Intervention (1)</i>	<i>Intervention (2)</i>	<i>Intervention (3)</i>	<i>Intervention (4)</i>
<i>Mortality (30 days)</i>				
<i>Mortality (1-year)</i>				
<i>Functional status (describe)</i>				
<i>Additional pain medication</i> <i>Another medication used</i> <i>Time interval before use</i> <i>Mean ± SD</i> <i>Range</i> <i>Type and Quantity of additional pain medication</i> <i>Change in type (explain)</i>				

Reviewer's Comments:

Adverse events related to the pain management intervention:

	<i>Intervention (1)</i>	<i>Intervention (2)</i>	<i>Intervention (3)</i>	<i>Intervention (4)</i>
<i>Any adverse event</i>				
<i>Incidence of pressure sores</i>				
<i>Peroneal palsy</i>				

	<i>Intervention (1)</i>	<i>Intervention (2)</i>	<i>Intervention (3)</i>	<i>Intervention (4)</i>
<i>Allergic reactions</i>				
<i>Respiratory distress</i>				
<i>Damage to surrounding structures</i>				
<i>GI symptoms</i>				
<i>Bleeding</i>				
<i>Infection at site of injection</i>				
<i>Headache</i>				
<i>Delirium</i>				
<i>Other mental health issues (describe:)</i>				
<i>Health-related QoL</i>	<i>Scale name</i>			
<i>Quality of sleep in hospital</i>	<i>Scale name</i>			
<i>Ability to participate in rehabilitation</i>				

	<i>Intervention (1)</i>	<i>Intervention (2)</i>	<i>Intervention (3)</i>	<i>Intervention (4)</i>
<i>Return to pre-fracture place of residence</i>				
<i>Overall</i>				
<i>Community</i>				
<i>Institutional</i>				
<i>Length of stay for acute hospitalization</i>				
<i>Length of stay at skilled nursing facility</i>				
<i>Length of stay at sub-acute care facility</i>				
<i>Other health service utilization (describe)</i>				

**Reviewer's Comments:**

**Reviewer's Overall Comments:**

## Appendix D. Excluded Studies

### Publication Type/Study Design

1. Ahmed T, Ullah H. Paramedian technique of spinal anaesthesia in elderly patients for hip fracture surgery. *J Coll Physicians Surg Pak* 2007;17(3):184.
2. Ahsan-ul-Haq M, Amin S, Javaid S. Paramedian technique of spinal anesthesia in elderly patients for hip fracture surgery. *J Coll Physicians Surg Pak* 2005;15(3):160-1.
3. Al-Ani AN, Flodin L, Soderqvist A, et al. Does rehabilitation matter in patients with femoral neck fracture and cognitive impairment? A prospective study of 246 patients. *Archives of Physical Medicine & Rehabilitation* 2010;91(1):51-7.
4. Ambulkar R, Shankar R. Analgesia after total hip replacement. *Anaesthesia* 2006;61(5):507.
5. Bard H, Vuillemin-Bodaghi V. Sorting out trochanteric pain. *J Traumatol Sport* 2006;23(3):157-63. French.
6. Barre J, Lefort P, Payen M. Locoregional anesthesia for injuries of the lower limbs. *Cah Anesthesiol* 1996;44(3):197-201. (Fre).
7. Beaudoin FL, Nagdev A, Merchant RC, et al. Ultrasound-guided femoral nerve blocks in elderly patients with hip fractures. *AM J EMERG MED* 2010;28(1):76-81.
8. Biboulet P, Vacher E, Deschodt J, et al. Continuous spinal anesthesia: does low-dose plain or hyperbaric bupivacaine allow the performance of hip surgery in the elderly? *Reg Anesth* 1993;18(3):170-5.
9. Boenigk K, Vloka JD, Hadžic A. Lower extremity nerve blocks: an update. *Progr Anesthesiol* 2001;15(13):231-44.
10. Bone and Joint in brief. *Lippincott's Bone & Joint Newsletter* 2009;15(11):132.
11. Bozdogan N, Caliskan E, Turkoz R. Combination of regional anesthetic blocks for femoropopliteal bypass surgery. *J Cardiothorac Vasc Anesth* 2009;23(3):442.
12. Brombacher J, Hodzovic I, Ridgway S, et al. An observational study of cardiac output changes during regional anaesthesia in patients with fractured neck of femur. *Internet Journal of Anesthesiology* 2009;21(1):-8p.
13. Brooks JM, Titler MG, Ardery G, et al. Effect of evidence-based acute pain management practices on inpatient costs. *Health Serv Res* 2009;44(1):245-63.
14. Bruyere O, Brandi ML, Burlet N, et al. Post-fracture management of patients with hip fracture: A prospective vision. [Italian]. *Clinical Cases in Mineral and Bone Metabolism* 6(3)(pp 270-279), 2009 Date of Publication: September-December 2009 2009;(3):270-9.
15. Bryson GL. Waiting for hip fracture repair: do outcomes and patients suffer? *Can J Anaesth* 2008;55(3):135-9.
16. Butler M, Forte M, Kane RL, et al. Treatment of common hip fractures (Structured abstract). *Agency for Healthcare Research and Quality* 2009;1.

17. Byrd J, Chern KY. Hip pain: non-operative treatment of ACL injury. *Med Sci Sports Exerc* 1995;27(5 Suppl):S198.
18. Cai XZ, Chen XZ, Yan SG. Cemented hemiarthroplasty confers less pain and better mobility than uncemented hemiarthroplasty. *Clin Orthop Relat Res* 2009;467(2):582-4.
19. Cameron ID, Handoll HH, Finnegan TP, et al. WITHDRAWN: Co-ordinated multidisciplinary approaches for inpatient rehabilitation of older patients with proximal femoral fractures. [Review] [34 refs][Update of Cochrane Database Syst Rev. 2001;(3):CD000106; PMID: 11686951]. *COCHRANE DATABASE SYST REV* 2009;(4):CD000106.
20. Candal-Couto JJ, McVie JL, Haslam N, et al. Pre-operative analgesia for patients with femoral neck fractures using a modified fascia iliaca block technique. *Injury* 2005;36(4):505-10.
21. Capdevila X, Pirat P, Bringuier S, et al. Continuous peripheral nerve blocks in hospital wards after orthopedic surgery: a multicenter prospective analysis of the quality of postoperative analgesia and complications in 1,416 patients. *Anesthesiology* 2005;103(5):1035-45.
22. Chakladar A, White SM. Cost estimates of spinal versus general anaesthesia for fractured neck of femur surgery. *Anaesthesia* 2010;65(8):810-4.
23. Chevaleraud E, Bouyer L. Unilateral spinal anaesthesia. *Prat Anest Reanim* 2008;12(3):182-6.
24. Christmas C. Medical care of the hip fracture patient. *CLIN GERIATR* 2006;14(4):40-5.
25. Coe AJ, Revanas B. Is crystalloid preloading useful in spinal anaesthesia in the elderly? *Anaesthesia* 1990;45(3):241-3.
26. Cook JL, Cook J. The lateral femoral cutaneous nerve block. *Dermatol Surg* 2000;26(1):81-3.
27. Crosby G, Culley DJ, Marcantonio ER. Delirium: a cognitive cost of the comfort of procedural sedation in elderly patients? *Mayo Clin Proc* 2010;85(1):12-4.
28. Crotty M, Unroe K, Cameron ID, et al. Rehabilitation interventions for improving physical and psychosocial functioning after hip fracture in older people. *COCHRANE DATABASE SYST REV* 2009;(2).
29. Currie CT. Rehabilitation in the elderly with fractured neck of femur. *Semin Orthod* 1990;5(2):61-7.
30. Cuvillon P, Ripart J, Lalourcey L, et al. The continuous femoral nerve block catheter for postoperative analgesia: bacterial colonization, infectious rate and adverse effects. *Anesth Analg* 2001;93(4):1045-9.
31. Daban JL, De Saint Maurice GP, Batjom E, et al. Postoperative myocardial damages are a key issue in patients' outcome after hip fracture. *AGE AGEING* 2009;38(4):488-9.
32. Davies AJ. Dosage volume or concentration? *Anaesthesia* 1990;45(5):414.
33. Davis FM, Frampton C, Wells JE. Anaesthesia and outcome of surgery for fractured neck of femur. *Br J Anaesth* 1990;64(3):403-4.



34. De Visme V, Buggy D. Peripheral blocks of the lower limb for repair of fractured neck of femur. *Br J Anaesth* 1998;81(3):483-4.
35. Denny NM, Selander DE. Continuous spinal anaesthesia. *Br J Anaesth* 1998;81(4):590-7.
36. Di Lorenzo L. Cervical and trochanteric hip fractures: different stories and different outcomes? *Eur J Phys Rehabil Med* 2008;44(3):367-8.
37. Di Roio C, Vedrinne JM, Hoen JP. Prophylactic intramuscular ephedrine reduces the incidence of hypotension after subarachnoid block in the elderly. *Ann Fr Anesth Reanim* 1997;16(5):483-7. (Fre).
38. Diallo T, Dufeu N, Marret E, et al. Walking in PACU after unilateral spinal anesthesia a criteria for hospital discharge: a 100 out patients survey. *Acta Anaesthesiol Belg* 2009;60(1):3-6.
39. Domskey M, Tarantino D. Patient-controlled spinal analgesia for postoperative pain control. *Anesth Analg* 1992;75(3):453-5.
40. Donatelli F, Tran D, Mistraletti G, et al. Epidural analgesia in the post-anaesthesia care unit. *Current Drug Targets* 2005;6(7):795-806.
41. Eftimova B. Intrathecal morphine and postoperative delirium in elderly orthopedic patients. *European Journal of Pain* 2009;Conference(var.pagings):S183-S184.
42. Eger EI. General versus regional anaesthesia for hip fracture surgery. *Br J Anaesth* 2000;85(3):492.
43. Egol KA, Koval KJ, Zuckerman JD. Functional recovery following hip fracture in the elderly. *J Orthop Trauma* 1997;11(8):594-9.
44. Errando CL. Propofol to facilitate mobilization of patients with a hip fracture. *Can J Anaesth* 2007;54(9):771-2. (Fre).
45. Farny J, Girard M, Drolet P. Posterior approach to the lumbar plexus combined with a sciatic nerve block using lidocaine. *Can J Anaesth* 1994;41(6):486-91.
46. Foss NB, Kristensen MT, Kristensen BB, et al. Physiotherapy in fast track rehabilitation with epidural analgesia in hip fracture patients. *Reg Anesth Pain Med* 2003;28(Suppl 1):14.
47. Fujimoto T, Meguro K, Hase K, et al. Anesthetic management of the elderly patients with femoral neck fracture by sevoflurane and femoral nerve block. *Masui* 2000;49(6):633. (Jap).
48. Gaillat F, Thibault S, Scemama F, et al. Lumbar and sciatic posterior blocks for hip fracture surgery in elderly patients: clinical experience. *Cah Anesthesiol* 2002;50(2):99-104.
49. Gielen MJ. Continuous spinal anesthesia (CSA): does it have a role in surgery and postoperative analgesia? *Acta Anaesthesiol Belg* 1999;50(4):217-20.
50. Gilligan P, Taylor A, Khan A, et al. SOCRATES 6: Synopsis of Cochrane Reviews applicable to emergency services. *EMERG MED J* 2005;22(4):277-8.
51. Gligorijevic S. Continuous spinal technique for fracture of the femoral neck-PRO. 16th Annual congress 1997 Sep, London; 1997.
52. Greengrass RA. Posterior lumbar plexus block. *Tech Reg Anesth Pain Manag* 2003;7(1):3-7.

53. Griffiths R, Rasmussen LS. Delirium in hip fracture patients. *Acta Anaesthesiol Scand* 2010;54(6):661-2.
54. Handoll HH, Cameron ID, Mak JC, et al. Multidisciplinary rehabilitation for older people with hip fractures. *Cochrane database of systematic reviews (Online)* (4)() (pp CD007125), 2009 Date of Publication: 2009 2009;(Online):CD007125.
55. Hempelmann G, Heesen M. Timely anesthesiologic management of hip prosthesis patients. *Anesthesiol Intensivmed Notfallmed Schmerzther* 1994;29(7):383-4. German.
56. Holdgate A, Shepherd SA, Huckson S. Patterns of analgesia for fractured neck of femur in Australian emergency departments. *Emerg Med Australas* 2010;22(1):3-8.
57. Holt G, Todd B. Postsurgical care: time for change. *Br J Hosp Med* 1990;44(6):384.
58. Horlocker TT. Will lower extremity blocks make neuraxial anesthesia and analgesia obsolete? *Tech Reg Anesth Pain Manag* 1999;3(1):1-2.
59. Hossain M. Subcapital fracture of the femoral neck in medically unwell patients: technique for fixation using direct infiltration local anaesthetic rather than regional blockade. *Injury* 2008;39(7):820.
60. Hurley K. Do femoral nerve blocks improve acute pain control in adults with isolated hip fractures? *CJEM* 2004;6(6):441-3.
61. Hutchison GL. Crystalloid preloading in spinal anaesthesia. *Anaesthesia* 1990;45(9):785-6.
62. Ilfeld BM. Preoperative epidural placement in elderly patients with hip fractures: a request for essential information. *Anesthesiology* 2003;99(2):514.
63. Iserson K. Single fascia iliaca compartment block for post-hip fracture pain relief. Annual Meeting of the Society for Academic Emergency Medicine, 2005 May 22-25, New York City, New York (USA) 2005.
64. Jayasekera N, Sharif K, Diggory P, et al. Fascia iliaca block in the pre-operative pain management of elderly patients with hip fracture. 53rd Congress of the Nordic Orthopaedic Federation, Radisson SAS Scandinavia Hotel, 2006 May 31-Jun 2, Oslo, Norway 2006.
65. Jones AG. Three in one block for fractured neck of femur. *Anaesthesia* 1991;46(6):517.
66. Kamibayashi T, Harasawa K, Maze M. Alpha-2 adrenergic agonists. *Can J Anaesth* 1997;44(5 II).
67. Kamibayashi T, Maze M. Perioperative use of alpha-2 adrenergic agonists. *Curr Opin Anaesthesiol* 1996;9(4):323-7.
68. Kannan S, Ben-David B. Ten milligrams intrathecal bupivacaine is too high for spinal anesthesia for hip surgery in the geriatric population. *Anesthesiology* 2000;93(5):1365.
69. Karaca S. Is lumbar plexus block sufficient for hip fracture surgery? *Pain Pract* 2008;8(2):147-8.
70. Kavuri S, Robalino J, Janardhan Y, et al. Low-dose intrathecal-meperidine for lower limb orthopaedic surgery. *Can J Anaesth* 1990;37(8):947-8. Erratum in: *Can J Anaesth* 1991, 38(2):263.

71. Khatouf M, LOUGHNANE FJ, Boini S, et al. Unilateral spinal anaesthesia in elderly patient for hip trauma: a pilot study. *Ann Fr Anesth Reanim* 2005;24(3):249-54.
72. Knight R. A response to 'A study of the initial fluid resuscitation and pain management of patients with fractured neck of femur', Levy N, *Anaesthesia* 2002; 57: 1148. *Anaesthesia* 2003;58(4):403-4.
73. Kondo A, Zierler BK, Isokawa Y, et al. Comparison of outcomes and costs after hip fracture surgery in three hospitals that have different care systems in Japan. *Health Policy* 91(2)(pp 204-210), 2009 Date of Publication: July 2009 2009;(2):204-10.
74. Kontinen N, Rosenberg PH. Outcome after anaesthesia and emergency surgery in patients over 100 years old. *Acta Anaesthesiol Scand* 2006;50(3):283-9.
75. Koursoumi E, Ioakimidou A, Biri E, et al. Acute pain management with femoral nerve block in patients with femoral neck fractures [abstract]. *Reg Anesth Pain Med* 2005;30(5 Suppl 1):51.
76. Koval KJ. Preoperative skin traction was not useful for hip fractures. *J Bone Joint Surg Am* 2001;83-A(2):303.
77. Kunisawa T, Ota M, Suzuki A, et al. Combination of high-dose dexmedetomidine sedation and fascia iliaca compartment block for hip fracture surgery. *J Clin Anesth* 2010;22(3):196-200.
78. Lareau C, Sawyer G. Hip fracture surgical treatment and rehabilitation. *Med Health R I* 2010;93(4):108-11.
79. Lau TW, Leung F, Siu D, et al. Geriatric hip fracture clinical pathway: The Hong Kong experience. *OSTEOPOROSIS INT* 2010;21(SUPPL. 4):S627-S636.
80. Leng K, Barnett SR. Anesthesia and the elderly patient. *Progr Anesthesiol* 2004;18(15):235-48.
81. Lien CA. Regional versus general anesthesia for hip surgery in older patients: does the choice affect patient outcome? *J Am Geriatr Soc* 2002;50(1):191-4.
82. Lindenhovius ALC, Helmerhorst GTT. Erratum: Differences in prescription of narcotic pain medication after operative treatment of hip and ankle fractures in the United States and the Netherlands (*Journal of Trauma* 67:1 (160-167)). *J Trauma Inj Infect Crit Care* 2010;68(3):744.
83. Liu SS, Salinas FV. Continuous plexus and peripheral nerve blocks for postoperative analgesia. *Anesth Analg* 2003;96(1):263-72.
84. Luger TJ, Kammerlander C, Gosch M, et al. Neuroaxial versus general anaesthesia in geriatric patients for hip fracture surgery: does it matter? *OSTEOPOROSIS INT* 2010;21(Suppl:4):4-72.
85. Mackensen GB. Cognitive dysfunction after anesthesia. *J Anesth Intensivbehandlung* 2004;11(2):79-80.
86. Mackenzie J, Pullinger R. The groin cannula: effective pain relief for fractured neck of femur [Letter]. *J Accid Emerg Med* 1997;14(4):269.
87. MacLennan B. News and reviews. *Age & Ageing* 2010;39(2):154-5.

88. MacLeod D, Grant S, Breslin D, et al. Lower limb blocks following general anaesthesia. *Anaesthesia* 2003;58(6):612-3.
89. Mak J, Baguley JJ. Relationship between hip fracture subtypes and analgesia use. *J Am Geriatr Soc* 2007;55(4):626-7.
90. Mak JC, Cameron ID, March LM. Evidence-based guidelines for the management of hip fractures in older persons: an update. *Med J Aust* 2010;192(1):37-41.
91. Mak JC, Lattouf I, O'Rourke F, et al. Relationship between hip fracture subtypes, surgical procedure, and analgesia use. *J Am Geriatr Soc* 2009;57(12):2378-80.
92. Mannion S. Psoas compartment block. *Cont Educ Anaesth Crit Care Pain* 2007;7(5):162-6.
93. Marchant W, Goldsack C. Fractured neck of the femur in the elderly patient. *Br J Hosp Med (Lond)* 2001;62(1):59.
94. Marhofer P, Schrogendorfer K, Wallner T, et al. Ultrasonographic guidance reduces the amount of local anesthetic for 3-in-1 blocks. *Reg Anesth Pain Med* 1998;23(6):584-8.
95. Matot I, Oppenheim-Eden A, Ratrot R, et al. Preoperative cardiac events in elderly patients with hip fracture randomized to epidural or conventional analgesia. *Anesthesiology* 2003;98(1):156-63.
96. Mauffrey C. Re: Intertrochanteric fracture below Birmingham Hip Resurfacing: successful non-operative management in two cases. *Injury* 40(3)(pp 338; author reply 338-339), 2009 Date of Publication: Mar 2009 2009;(3):338-9.
97. McConnell EA. Applying an abduction pillow correctly. *Nursing* 1992;22(6):22.
98. McQuillan P. Regional anesthesia. *Curr Opin Anaesthesiol* 2000;13(5):529-30.
99. Mehmood S, Coleman M, Egan M, et al. Study of the anatomical position of the femoral nerve by magnetic resonance imaging in patients with fractured neck of femur: relevance to femoral nerve block. *J Clin Anesth* 2010;22(2):122-5.
100. Meier G. Peripheral nerve blockades of the lower extremities. *Anaesthesist* 2001;50(7):536-59.
101. Mnif H, Koubaa M, Zrig M, et al. Elderly patient's mortality and morbidity following trochanteric fracture. A 100-cases prospective study. *Rev Chir Orthop Traumatol* 2009;95(7):609-15.
102. Moffa-Trotter ME, Anemaet WK. Home care for hip fracture survivors and fallers: the 'Be HIP!' Program. *TOP GERIATR REHABIL* 1996;12(1):46-58.
103. Monzon DG, Iserson KV, Vazquez JA. Single fascia iliaca compartment block for post-hip fracture pain relief. *J Emerg Med* 2007;32(3):257-62.
104. Morley JE. Hip Fractures. *Journal of the American Medical Directors Association* 11(2)(pp 81-83), 2010 Date of Publication: February 2010 2010;(2):81-3.
105. Morrison RS, Magaziner J, McLaughlin MA, et al. The impact of post-operative pain on outcomes following hip fracture [abstract]. *J Am Geriatr Soc* 2002;50(4 Suppl):S178.
106. Morscher E. Femoral neck fractures. *Schweiz Rundsch Med Prax* 1990;79(40):1159-60. German.

107. Mulroy MF. Extending indications for spinal anesthesia. *Reg Anesth Pain Med* 1998;23(4):380-3.
108. Najran PS, Matharu GS, Porter KM. Non-operative treatment following hip fracture. *Injury* 2010;41(7):1062-3.
109. Nunez Lezama L, Molina Campaña J, de la Matta Martín M., et al. Intrathecal neurolysis using phenol in a patient with a hip fracture. *Rev Esp Anesthesiol Reanim* 2003;50(6):310-2. (Spa).
110. Obideyi A, Srikantharajah I, Grigg L, et al. Nurse administered fascia iliaca compartment block for pre-operative pain relief in adult fractured neck of femur. *Acute Pain* 2008;10(3-4):145-9.
111. Oliveira Filho GR, Garcia JHS, Goldschmidt R, et al. Predictors of early hypotension during spinal anesthesia. *Rev Bras Anesthesiol* 2001;51(4):298-304.
112. Olsson LE, Hansson E, Ekman I, et al. A cost-effectiveness study of a patient-centred integrated care pathway. *J Adv Nurs* 2009;65(8):1626-35.
113. Parker MJ, Griffiths R, Appadu B. Nerve blocks (subcostal, lateral cutaneous, femoral, triple, psoas) for hip fractures. John Wiley & Sons, Ltd; 2002.
114. Parker MJ. Managing an elderly patient with a fractured femur. *Br Med J* 2000;320(7227):102-3.
115. Randall A, Grigg L, Obideyi A, et al. Fascia iliaca compartment block: a nurse-led initiative for preoperative pain management in patients with a fractured neck of femur. *J ORTHOP NURS* 2008;12(2):69-74.
116. Reilly CS. Regional analgesia and myocardial ischaemia. *Br J Anaesth* 1993;71(4):467-8.
117. Reuben SS, Buvanendran A. Preventing the development of chronic pain after orthopaedic surgery with preventive multimodal analgesic techniques. *J Bone Joint Surg Am* 2007;89(6):1343-58.
118. Richez AS, Fuzier R. Indications for continuous or sequential spinal anesthesia in 2008. *Prat Anesth Reanim* 2008;12(1):23-6.
119. Rodgers A, Walker N, Schug S, et al. Reduction of postoperative mortality and morbidity with epidural or spinal anaesthesia: results from overview of randomised trials. *Br Med J* 2000;321(7275):1493-7.
120. Rodgers A. The appropriate roles of audit and randomisation in determining the efficacy of anaesthetic interventions. *Anaesthesia* 1995;50(1):89-90.
121. Rogers BA, Rang S. Femoral nerve block for diaphyseal and distal femoral fractures in the emergency department. *J Bone Joint Surg Am* 2008;90(8):1787-8.
122. Rojas-Rivera W, Abed-R M. Bloqueo femoral tres en uno para cirugía de fractura transtoncantérica de cadera: seguridad y analgesia. *Acta Med Costarric* 2002;44(2):62-7. Spanish.
123. Rozzini R, Trabucchi M. Comanagement of elderly patients admitted to a hospital for hip fracture. *ARCH INTERN MED* 2009;170(4):392-3.

124. Ryan JM, Singh S, Bryant G, et al. Fast tracking patients with a proximal femoral fracture: more than a broken bone. *J Accid Emerg Med* 2000;17(1):76.
125. Sahota O. Reducing the risk of fractures with calcium and vitamin D. *BMJ* 340(7738)(pp 109), 2010 Date of Publication: 16 Jan 2010 2010;(7738):109.
126. Sandby-Thomas M. A national survey: peri-operative anaesthetic management of patients with femoral neck fractures in the UK [abstract]. Annual Meeting of the European Society of Anaesthesiology on Euroanaesthesia (Euroanaesthesia 2007), 2007 Jun 9-12, Munich, Germany 2007.
127. Schemitsch E, Bhandari M. Femoral neck fractures: Controversies and evidence. *Journal of Orthopaedic Trauma* 23(6)(pp 385), 2009 Date of Publication: July 2009 2009;(6):385.
128. Schug SA, Raajkumar A. 11 Local anesthetics. *Side Effects of Drugs Annual* 2008;30:152-63.
129. Schwemmer U, Markus CK, Brederlau J, et al. Regional anesthesia: ultrasound-guided peripheral nerve blockades. *Anesthesiol Intensivmed Notfallmed Schmerzther* 2006;41(7-8):481-90.
130. Scott J. Educate and depate: operate to relieve the pain. *Br Med J* 1994;308(6927):517-9.
131. Scott MA, Stigleman S. What is the best hypnotic for use in the elderly? *J Fam Pract* 2003;52(12):976-8.
132. Sharrock NE. Fractured femur in the elderly: intensive perioperative care is warranted. *Br J Anaesth* 2000;84(2):139-40.
133. Sikorski JM, Senior J. The domiciliary rehabilitation and support program: rationale, organisation and outcome. *Med J Aust* 1993;159(1):23-5.
134. Sindel D, Diracoglu D. Postoperative rehabilitation in patients with hip fracture. [Turkish]. *Turkiye Fiziksel Tip ve Rehabilitasyon Dergisi* 55(SUPPL 1)(pp 8-14), 2009 Date of Publication: 2009 2009;(SUPPL.1):8-14.
135. Singelyn FJ, Gouverneur JM. Continuous 3-in-1 block as postoperative pain treatment after hip, femoral shaft, or knee surgery: a large-scale study of efficacy and side effects [abstract]. *Anesthesiology* 1994;81(3A):A1054.
136. Singelyn FJ. Continuous peripheral nerve blocks and postoperative pain management. *Acta Anaesthesiol Belg* 2006;57(2):109-12.
137. Sites BD, Spence BC, Gallagher J, et al. Regional anesthesia meets ultrasound: a specialty in transition. *Acta Anaesthesiol Scand* 2008;52(4):456-66.
138. Stiltner J. Pain management in the elderly with traumatic hip fracture [dissertation] Mountain State University, Beckley WV; 2008.
139. Stott DJ, Langhorne P, Knight PV. Multidisciplinary care for elderly people in the community. *Lancet* 2008;371(9614):699-700.
140. Swenson JD, Bay N, Loose E, et al. Outpatient management of continuous peripheral nerve catheters placed using ultrasound guidance: an experience in 620 patients. *Anesth Analg* 2006;103(6):1436-43.

141. Syed KA, Bogoch ER. Integrated care pathways in hip fracture management: demonstrated benefits are few. *J Rheumatol* 2000;27(9):2071.
142. Tam CW, Rainer TH. Femoral nerve block for pain management of femoral fractures in the emergency department: evidence based topic review. *Hong Kong J Emerg Med* 2005;12(3):178-81.
143. Tan TT, Coleman MM, Fletcher AK, et al. Femoral blockade for fractured neck of femur in the emergency department. *Ann Emerg Med* 2003;42(4):596-7.
144. Thannikary LJ, Enneking FK. Non-opioid additives to local anesthetics. *Tech Reg Anesth Pain Manag* 2004;8(3):129-40.
145. Touray ST, De Leeuw MA, Zuurmond WWA, et al. Psoas compartment block for lower extremity surgery. *Br J Anaesth* 2009;102(5):721-2.
146. Triner W, Levine J, Lai SY, et al. Femoral nerve block for femur fractures. *Ann Emerg Med* 2005;45(6):679.
147. Tully J. Increasing hip pain after a fall. *JAAPA* 2003;16(4):67-8.
148. Vassiliadis J, Hitos K, Hill CT. Factors influencing prehospital and emergency department analgesia administration to patients with femoral neck fractures. *Emerg Med (Fremantle)* 2002;14(3):261-6.
149. Wahbi S, Lahhlou A. Les fractures pures de la paroi posterieure: a propos de 88 cas. *Pan Arab J Orthop Trauma* 1997;1:19-21. French.
150. Watters M. Hypotension during subarachnoid anaesthesia. *Br J Anaesth* 1996;77(6):808-9.
151. Webster J. Reducing delirium after hip fracture. *J Am Geriatr Soc* 2002;50(3):589.
152. West R. Fractured neck of femur patients. *J Public Health Med* 1995;17(1):116-7.
153. White PF, Kehlet H, Neal JM, et al. The role of the anesthesiologist in fast-track surgery: from multimodal analgesia to perioperative medical care. *Anesth Analg* 2007;104(6):1380-96.
154. White PF. Use of alternative medical therapies in the perioperative period: is it time to get on board? *Anesth Analg* 2007;104(2):251-4.
155. Wilhelm S, Standl T. Anaesthesia in orthopedics and traumasurgery. *Anesthesiol Intensivmed Notfallmed Schmerzther* 2004;39(5):297-327.
156. Wilmore DW, Kehlet H. Management of patients in fast track surgery. *Br Med J* 2001;322(7284):473-6.
157. Wong TC, Chiu Y, Tsang WL, et al. A double-blind, prospective, randomised, controlled clinical trial of minimally invasive dynamic hip screw fixation of intertrochanteric fractures. *Injury* 2009;40(4):422-7.
158. Zaugg M, Schulz C, Wacker J, et al. Sympatho-modulatory therapies in perioperative medicine. *Br J Anaesth* 2004;93(1):53-62.
159. Zink W, Graf BM. Benefit-risk assessment of ropivacaine in the management of postoperative pain. *Drug Saf* 2004;27(14):1093-114.

160. Zuckerman JD. Hip fracture. *N Engl J Med* 1996;334(23):1519-25.

## Population Characteristics

1. Abdul-Hadi O, Parvizi J, Austin MS, et al. Nonsteroidal anti-inflammatory drugs in orthopaedics. *J Bone JT Surg Ser A* 2009;91(8):2020-7.
2. Abrahamsen B, Brixen K. Mapping the prescriptiome to fractures in men--a national analysis of prescription history and fracture risk. *OSTEOPOROSIS INT* 2009;20(4):585-97.
3. Acalovschi I, Bodolea C, Manoiu C. Spinal anesthesia with meperidine: effects of added adrenergic agonists: epinephrine versus clonidine. *Anesth Analg* 1997;84(6):1333-9.
4. Adunsky A, Lusky A, Arad M, et al. A comparative study of rehabilitation outcomes of elderly hip fracture patients: the advantage of a comprehensive orthogeriatric approach. *J Gerontol A Biol Sci Med Sci* 2003;58(6):542-7.
5. Akça O, Melischek M, Scheck T, et al. Postoperative pain and subcutaneous oxygen tension. *Lancet* 1999;354(9172):41-2.
6. Akhtar S, Demuth-Anderson L, Stoller M, et al. Pain assessment and management of hip fractures in the emergency department. *Ann Emerg Med* 2006;48(4 Suppl 1):S60-S61.
7. Aparicio Álvarez F, Cruz Guerrero B, Hernández Morgado JM. Uso de Fármacos en el anciano con fractura de cadera [Use of drugs in the elderly with hip fracture]. *Mediciego* 2003;9(Suppl 2):8-14. (Spa).
8. Ausset S, Minville V, Marquis C, et al. Postoperative myocardial damages after hip fracture repair are frequent and associated with a poor cardiac outcome: a three-hospital study. *AGE AGEING* 2009;38(4):473-6.
9. Azkan S, Gakben M, Acar HV, et al. Spinal anesthesia with low dose bupivacaine-fentanyl in hip prosthesis operations. *Gulhane Med J* 2002;44(2):137-41.
10. Baath C, Wilde-Larsson B, Idvall E, et al. Registered nurses and enrolled nurses assessments of postoperative pain and risk for malnutrition and pressure ulcers in patients with hip fracture. *Int J Trauma Nurs* 2010;14(1):30-9.
11. Balverde M, Castroman P, Noya B, et al. Raquianestesia en fracturas de cadera: dosis bajas de ketamina mejoran el dolor y el posicionamiento [Rachianesthesia in hip fractures: low doses of ketamine reduce pain and improve positioning]. *Rev Argent Anestesiol* 2004;62(1):9-14. (Spa).
12. Bannister J, McClure JH, Wildsmith JAW. Effect of glucose concentration on the intrathecal spread of 0.5% bupivacaine. *Br J Anaesth* 1990;64(2):232-4.
13. Barber M, Braid V, Mitchell SL, et al. Electrical stimulation of quadriceps during rehabilitation following proximal femoral fracture. *Int J Rehabil Res* 2002;25(1):61-3.
14. Bastow MD, Rawlings J, Allison SP. Benefits of supplementary tube feeding after fractured neck of femur: a randomised controlled trial. *Br Med J* 1995;287:1589-92.
15. Abdul-Hadi O, Parvizi J, Austin MS, et al. Nonsteroidal anti-inflammatory drugs in orthopaedics. *J Bone JT Surg Ser A* 2009;91(8):2020-7.



16. Beattie WS, Warriner CB, Etches R, et al. The addition of continuous intravenous infusion of ketorolac to a patient-controlled analgetic morphine regime reduced postoperative myocardial ischemia in patients undergoing elective total hip or knee arthroplasty. *Anesth Analg* 1997;84(4):715-22.
17. Beaupre LA. Effectiveness of a caremap for treatment of elderly patients with hip fracture [dissertation] University of Alberta (Canada); 2004.
18. Becchi C, Al Malyan M, Coppini R, et al. Opioid-free analgesia by continuous psoas compartment block after total hip arthroplasty: a randomized study. *Eur J Anaesthesiol* 2008;25(5):418-23.
19. Bentur N, Eldar R, Davies MA. Process and outcome of care: comparison of two inpatient geriatric rehabilitation settings. *Clin Rehabil* 1994;8(4):307-13.
20. Bernard JM, Kick O, Bonnet F. Comparison of intravenous and epidural clonidine for postoperative patient-controlled analgesia. *Anesth Analg* 1995;81(4):706-12.
21. Bertini L, Tagariello V, Mancini S, et al. 0.75% and 0.5% Ropivacaine for axillary brachial plexus block: a clinical comparison with 0.5% Bupivacaine. *Reg Anesth Pain Med* 1999;24(6):514-8.
22. Biboulet P, Capdevila X, Aubas P, et al. Causes and prediction of maldistribution during continuous spinal anesthesia with isobaric or hyperbaric bupivacaine. *Anesthesiology* 1998;88(6):1487-94.
23. Biboulet P, Morau D, Aubas P, et al. Postoperative analgesia after total-hip arthroplasty: comparison of intravenous patient-controlled analgesia with morphine and single injection of femoral nerve or psoas compartment block: a prospective, randomized, double-blind study. *Reg Anesth Pain Med* 2004;29(2):102-9.
24. Bigat Z, Boztug N, Hadimioglu N, et al. Comparison of low dose bupivacaine and bupivacaine-fentanyl combination for spinal anaesthesia during outpatient arthroscopic surgery. *Turk Anesteziyol Reanim Dernegi Derg* 2004;32(4):289-95.
25. Bischoff-Ferrari HA, Wason-Hughes B, Platz A, et al. Effect of high-dosage cholecalciferol and extended physiotherapy on complications after hip fracture: a randomized controlled trial. *Arch Intern Med* 2010;170(9):813-20.
26. BjOrkelund KB, Hommel A, Thorngren KG, et al. Reducing delirium in elderly patients with hip fracture: a multi-factorial intervention study. *Acta Anaesthesiol Scand* 2010;54(6):678-88.
27. Bohannon RW, Kloter KS, Cooper JA. Outcome of patients with hip fracture treated by physical therapy in an acute care hospital. *TOP GERIATR REHABIL* 1990;6(2):51-8.
28. Bonnet F, Marcandoro J, Minoz O, et al. Conventional vs. continuous spinal anaesthesia with bupivacaine. *Ann Fr Anesth Reanim* 1990;9(3):280-4.
29. Boon J. The effectiveness of massage therapy for managing symptoms of OA of the hip: a pilot study. Fourth Annual Research Symposium of the Canadian Interdisciplinary Network for Complementary and Alternative Medicine Research, Four Seasons Hotel, Vancouver, British Columbia (Canada), 2-3 Nov 2007 2007.

30. Bovy P, Rodrigue V. Rehabilitation after fracture of the femur in elderly patients. *Rev Med Liege* 1997;52(9):577-81. French.
31. Braz JRC, Koguti ES, Braz LG, et al. Effects of clonidine associated to hyperbaric bupivacaine during high-level spinal anesthesia. *Rev Bras Anesthesiol* 2003;53(5):561-72.
32. Brichant JF, Blom-Peters L, Buffels R, et al. Central neural blockade failed to decrease deep venous thrombosis in patients undergoing hip surgery and receiving low molecular weight heparin [abstract]. *Br J Anaesth* 1995;74(Suppl 1):75.
33. Brink AC, Boonstra O, Van Der Wal BCH, et al. Is preoperative traction for proximal femoral fractures beneficial to the patient or a comfort to the doctor? *Eur J Trauma* 2005;31(1):39-43.
34. Brooker RF, Butterworth IV JF, Kitzman DW, et al. Treatment of hypotension after hyperbaric tetracaine spinal anesthesia: a randomized, double-blind, cross-over comparison of phenylephrine and epinephrine. *Anesthesiology* 1997;86(4):797-805.
35. Brown C, Moodie J, Bisley E, et al. Intranasal ketorolac for postoperative pain: a phase 3, double-blind, randomized study. *Pain Med (USA)* 2009;10:1106-14.
36. Buggy D, Higgins P, Moran C, et al. Prevention of spinal anesthesia-induced hypotension in the elderly: comparison between preanesthetic administration of crystalloids, colloids, and no prehydration. *Anesth Analg* 1997;84(1):106-10.
37. Buggy DJ, Power CK, Meeke R, et al. Prevention of spinal anaesthesia-induced hypotension in the elderly: I.M. methoxamine or combined hetastarch and crystalloid. *Br J Anaesth* 1998;80(2):199-203.
38. Burke D, Kennedy S, Bannister J. Spinal anesthesia with 0.5% S(-)-bupivacaine for elective lower limb surgery. *Reg Anesth Pain Med* 1999;24(6):519-23.
39. Burns A. Proximal femoral fractures in the female patient, a controlled trial: the role of the occupational therapist and the physiotherapist. *Br J Occup Ther* 1992;55(10):397-400.
40. Cander B, Girisgin S, Koylu R, et al. The effectiveness of analgesics in traumatic injuries of the extremities. *Adv Ther* 2005;22(5):462-6.
41. Capdevila X, Macaire P, Dadure C, et al. Continuous psoas compartment block for postoperative analgesia after total hip arthroplasty: New landmarks, technical guidelines, and clinical evaluation. *Anesth Analg* 2002;94(6):1606-13.
42. Caplan GA, Coconis J, Board N, et al. Does home treatment affect delirium?: a randomised controlled trial of rehabilitation of elderly and care at home or usual treatment: the REACH-OUT trial. *AGE AGEING* 2006;35(1):53-60.
43. Carmeli E, Sheklow SL, Coleman R. A comparative study of organized class-based exercise programs versus individual home-based exercise programs for elderly patients following hip surgery. *Disabil Rehabil* 2006;28(16):997-1005.
44. Casati A, Fanelli G, Aldegheri G, et al. Frequency of hypotension during conventional or asymmetric hyperbaric spinal block. *Reg Anesth Pain Med* 1999;24(3):214-9.
45. Casati A, Fanelli G, Cappelleri G, et al. Low dose hyperbaric bupivacaine for unilateral spinal anaesthesia. *Can J Anaesth* 1998;45(9):850-4.

46. Chang AK, Bijur PE, Baccellieri A, et al. Efficacy and safety profile of a single dose of hydromorphone compared with morphine in older adults with acute, severe pain: a prospective, randomized, double-blind clinical trial. *Am J Geriatr Pharmacother* 2009;7(1):1-10.
47. Chelly JE, Casati A, Al-Samsam T, et al. Continuous lumbar plexus block for acute postoperative pain management after open reduction and internal fixation of acetabular fractures. *J Orthop Trauma* 2003;17(5):362-7.
48. Chen X, Zhao M, White PF, et al. The recovery of cognitive function after general anesthesia in elderly patients: a comparison of desflurane and sevoflurane. *Anesth Analg* 2001;93(6):1489-94.
49. Choong PF, Langford AK, Dowsey MM, et al. Clinical pathway for fractured neck of femur: a prospective, controlled study. *Med J Aust* 2000;172(9):423-6.
50. Chuang CH, Pinkowsky GJ, Hollenbeak CS, et al. Medicine versus orthopaedic service for hospital management of hip fractures. *Clin Orthop Relat Res* 2010;468(8):2218-23.
51. Cinar SO, Oba S, Eksioğlu B, et al. Comparison of the anaesthetic and analgesic effects of epidural clonidine and fentanyl. *Turk Anesteziyol Reanim* 2001;29(6):271-6.
52. Clarke JV, Campbell C, Murray HM, et al. Validation of local anaesthetic hip arthrograms in the management of hip pain. 7th Domestic Meeting of the European Hip Society (EHS 2006), Sungate Port Royal Hotel, Antalya (Turkey), 21-24 Jun 2006 2006.
53. Cogan L, Martin AJ, Kelly LA, et al. An audit of hip fracture services in the Mater Hospital Dublin 2001 compared with 2006. *Irish Journal of Medical Science* 179(1)(pp 51-55), 2010 Date of Publication: March 2010 2010;(1):51-5.
54. Cohen SP, Strassels SA, Foster L, et al. Comparison of fluoroscopically guided and blind corticosteroid injections for greater trochanteric pain syndrome: multicentre randomised controlled trial. *BMJ: British Medical Journal* 2009;338:b1088.
55. Colak A, Alagöl A, Pamukçu Z, et al. Comparison of patient controlled versus continuous sufentanil addition under continuous spinal or epidural bupivacaine anesthesia in patients undergoing lower extremity fracture operations. *Turk Anesteziyol Reanim Dernegi Derg* 2008;36(5):283-92.
56. Contreras-Dominguez VA, Carbonell-Bellolio PE, Ojeda-Greciet A, et al. Extended three-in-one block versus intravenous analgesia for postoperative pain management after reconstruction of anterior cruciate ligament of the knee. *Rev Bras Anesthesiol* 2007;57(3):280-8.
57. Couture DJ, Cuniff HM, Burkard JF, et al. The addition of clonidine to bupivacaine in combined femoral-sciatic nerve block for anterior cruciate ligament reconstruction. *AANA j* 2004;72(4):273-8.
58. Cree M, Carriere KC, Soskolne CL, et al. Functional dependence after hip fracture. *Am J Phys Med Rehabil* 2001;80(10):736-43.
59. Critchley LA, Conway F. Hypotension during subarachnoid anaesthesia: haemodynamic effects of colloid and metaraminol. *Br J Anaesth* 1996;76(5):734-6.

60. Critchley LA, Stuart JC, Conway F, et al. Hypotension during subarachnoid anaesthesia: haemodynamic effects of ephedrine. *Br J Anaesth* 1995;74(4):373-8.
61. Critchley LA, Stuart JC, Short TG, et al. Haemodynamic effects of subarachnoid block in elderly patients. *Br J Anaesth* 1994;73(4):464-70.
62. Critchley LA, Yu SC. A comparative study of three different methods of administering metaraminol during spinal anaesthesia in the elderly. *Anaesth Intensive Care* 2001;29(2):141-8.
63. Cuellar E, Cruz AE, Hinojosa A, et al. Intravenous patient-controlled analgesia during the postoperative period after traumatologic and orthopedic surgery. *Rev Soc Esp Dolor* 2001;8(2):93-101.
64. Dai Y-T, Huang G-S, Yang R-S, et al. Effectiveness of a multidisciplinary rehabilitation program in elderly patients with hip fractures. *J Formos Med Assoc* 2001;100(2):120-6.
65. Dai YT, Huang GS, Yang RS, et al. Functional recovery after hip fracture: six months' follow-up of patients in a multidisciplinary rehabilitation program. *J Formos Med Assoc* 2002;101(12):846-53.
66. Danelli G, Ghisi D, Fanelli A, et al. The effects of ultrasound guidance and neurostimulation on the minimum effective anesthetic volume of mepivacaine 1.5% required to block the sciatic nerve using the subgluteal approach. *Anesthesia and Analgesia* 2009;109:1674-8.
67. Di Monaco M, Vallero F, Di Monaco R, et al. Hip-fracture type does not affect the functional outcome after acute in-patient rehabilitation: a study of 684 elderly women. *Eura Medicophys* 2007;43(4):439-44.
68. Dobrydnjov I, Axelsson K, Gupta A, et al. Improved analgesia with clonidine when added to local anesthetic during combined spinal-epidural anesthesia for hip arthroplasty: a double-blind, randomized and placebo-controlled study. *Acta Anaesthesiol Scand* 2005;49(4):538-45.
69. Dobrydnjov I, Axelsson K, Samarutel J, et al. Postoperative pain relief following intrathecal bupivacaine combined with intrathecal or oral clonidine. *Acta Anaesthesiol Scand* 2002;46(7):806-14.
70. Dobrydnjov I, Samarutel J. Enhancement of intrathecal lidocaine by addition of local and systemic clonidine. *Acta Anaesthesiol Scand* 1999;43(5):556-62.
71. Dohnert MC, Azevedo LA, Raffone AM, et al. Comparative study between one or two physiotherapeutic treatment daily in patients with close articulation thighbone fracture. *Fisioter Mov* 1992;5(1):32-44. (Por).
72. Drakeford MK, Pettine KA, Brookshire L, et al. Spinal narcotics for postoperative analgesia in total joint arthroplasty: a prospective study. *J Bone Joint Surg Am* 1991;73(3):424-8.
73. Draper P, Scott F. An investigation into the application and maintenance of Hamilton Russell traction on three orthopaedic wards. *J Adv Nurs* 1996;23(3):536-41.
74. Ducloy-Bouthors AS, Davette M, Le Fahler G, et al. Hip-flexed postures do not affect local anaesthetic spread following induction of epidural analgesia for labour. *Int J Obstet Anesth* 2004;13(2):75-81.

75. Effect of Massage on Chronic Low Back Pain. 2010.
76. Efficacy of Acupuncture for Chronic Low Back Pain. 2010.
77. El Hefnawy AG. Effects of anaesthesia on interleukin (I) and migration inhibition factor in orthopaedic patients with fracture femur. *Egypt J Med Lab Sci* 1997;23-34.
78. Elmas C, Elmas Y, Gautschi P, et al. Combined sciatic 3-in-1-block for orthopaedic operations on the lower limb. *Anaesthesist* 1992;41(10):639-43.
79. El-Zahaar MS, Al-Kawally HM, Said AS. A double-blind randomized study of the effects of tourniquet use and type of anesthetic techniques on the incidence of deep vein thrombosis (DVT) in orthopedic surgery. *J Neurol Orthop Med Surg* 1995;16(2):70-4.
80. Erdil F, Bulut S, Demirbilek S, et al. The effects of intrathecal levobupivacaine and bupivacaine in the elderly. *Anaesthesia* 2009;64(9):942-6.
81. Erlacher W, Schuschnig C, Koinig H, et al. Clonidine as adjuvant for mepivacaine, ropivacaine and bupivacaine in axillary, perivascular brachial plexus block. *Can J Anaesth* 2001;48(6):522-5.
82. Erskine R, Janicki PK, Neil G, et al. Spinal anaesthesia but not general anaesthesia enhances neutrophil biocidal activity in hip arthroplasty patients. *Can J Anaesth* 1994;41(7):632-8.
83. Ethans K, Powell C. Rehabilitation of patients with hip fracture. *REV CLIN GERONTOL* 1996;6(4):371-88.
84. Evaluating Yoga for Chronic Low Back Pain. 2010.
85. Fanelli G, Danelli G, Zasa M, et al. Intrathecal ropivacaine 5 mg/ml for outpatient knee arthroscopy: a comparison with lidocaine 10 mg/ml. *Acta Anaesthesiol Scand* 2009;53(1):109-15.
86. Faraj AA. Non-operative treatment of elderly patients with femoral neck fracture. *Acta Orthop Belg* 2008;74(5):627-9.
87. Fattorini F, Ricci Z, Rocco A, et al. Levobupivacaine versus racemic bupivacaine for spinal anaesthesia in orthopaedic major surgery. *Minerva Anesthesiol* 2006;72(7-8):637-44.
88. Faust A, Fournier R, Van Gessel E, et al. Isobaric versus hypobaric spinal bupivacaine for total hip arthroplasty in the lateral position. *Anesth Analg* 2003;97(2):589-94.
89. Feldt K, Bjorklund D, McClurg S. Improving pain treatment in cognitively impaired hip fracture patients. *Gerontologist* 2003;43(Sp. Iss. 1):118.
90. Fernandez-Galinski D, Pulido C, Real J, et al. Comparison of two protocols using low doses of bupivacaine for spinal anaesthesia during joint replacement in elderly patients. *Pain Clinic* 2005;17(1):15-24.
91. Fernandez-Castillo A, Vilchez-Lara MaJ, Caballero J. Post-surgical acute pain complementary assessment in an analgesic power contrast. *Rev Soc Esp Dolor* 2006;13(3):151-8. (Spa).
92. Fernandez-Galinski D, Rué M, Moral V, et al. Spinal anesthesia with bupivacaine and fentanyl in geriatric patients. *Anesth Analg* 1996;83(3):537-41.

93. Fletcher D, Zetlaoui P, Monin S, et al. Influence of timing on the analgesic effect of intravenous ketorolac after orthopedic surgery. *Pain* 1995;61(2):291-7.
94. Fournier R, Van Gessel E, Gaggero G, et al. Postoperative analgesia with '3-in-1' femoral nerve block after prosthetic hip surgery. *Can J Anaesth* 1998;45(1):34-8.
95. Fournier R, Van Gessel E, Weber A, et al. A comparison of intrathecal analgesia with fentanyl or sufentanil after total hip replacement. *Anesth Analg* 2000;90(4):918-22.
96. Franczuk B, Szwarczyk W, Wilk M. The impact of Continuous Passive Motion (CPM) on progress made in rehabilitation by patients with trochanteric hip fractures treated surgically with a Y-type intramedullary nail. *Fizjot Pol* 2005;5(3):297-304. (Pol).
97. Frassanito L, RodolÀ F, Concina G, et al. The efficacy of the psoas compartment block versus the intrathecal combination of morphine, fentanyl and bupivacaine for postoperative analgesia after primary hip arthroplasty: a randomized single-blinded study. *Eur Rev Med Pharmacol Sci* 2008;12(2):117-22.
98. Fredman B, Zohar E, Golan E, et al. Diclofenac does not decrease renal blood flow or glomerular filtration in elderly patients undergoing orthopedic surgery. *Anesth Analg* 1999;88(1):149-54.
99. Fredman B, Zohar E, Tarabykin A, et al. Continuous intravenous diclofenac does not induce opioid-sparing or improve analgesia in geriatric patients undergoing major orthopedic surgery. *J Clin Anesth* 2000;12(7):531-6.
100. Freeman C, Todd C, Camilleri-Ferrante C, et al. Quality improvement for patients with hip fracture: experience from a multi-site audit. *Qual Saf Health Care* 2002;11(3):239-45.
101. Frohlich WH, Fogelman L. Short-term rehab maximizes patient potential. *J Long Term Care Adm* 1994;22(3):4-8.
102. Gabopoulou Z, Mavromati P, Karkala E, et al. The importance of pain management in postoperative cognitive dysfunction after major orthopedic surgery in the elderly. *Pain Pract* 2009;Conference(var.pagings):136-7.
103. Gaggero G, Van Gessel E, Forster A, et al. Comparison of 5 mg tetracaine diluted in 1 ml, 2 ml and 4 ml of 10% glucose for spinal anesthesia. *Acta Anaesthesiol Scand* 1993;37(7):697-701.
104. Galvard H, Samuelsson SM. Orthopedic or geriatric rehabilitation of hip fracture patients: a prospective, randomized, clinically controlled study in Malmo, Sweden. *Aging Clin Exp Res* 1995;7(1):11-6.
105. Ganesh S, Deutsch A. Pain and functional recovery in elderly medicare patients with a hip fracture treated in inpatient rehabilitation facilities [Abstract]. *J Am Geriatr Soc* 2009;57(Suppl1):S205.
106. Garcia-Harel P, Casielles JL, Heredia MP, et al. Parecoxib versus ketorolac for the management of moderate postoperative acute pain. *Rev Soc Esp Dolor* 2005;12(6):326-32. (Spa).
107. Geier KO. Peripheral nerve stimulator for femoral nerve block: is it really necessary? *Rev Bras Anesthesiol* 2003;53(3):338-45.

108. Gentili M, Senlis H, Houssel P, et al. Single-shot spinal anesthesia with small doses of bupivacaine. *Reg Anesth* 1997;22(6):511-4.
109. Gholve PA, Kosygan KP, Sturdee SW, et al. Multidisciplinary integrated care pathway for fractured neck of femur: a prospective trial with improved outcome. *Injury* 2005;36(1):93-8.
110. Giusti A, Barone A, Oliveri M, et al. Home rehabilitation after hip fracture in the elderly. *AGS Annual Meeting 2005*;S216.
111. Gjertsen JE, Vinje T, Engesaeter LB, et al. Internal screw fixation compared with bipolar hemiarthroplasty for treatment of displaced femoral neck fractures in elderly patients. *J BONE JT SURG SER A* 2010;92(3):619-28.
112. Goldsmith ME. Supracondylar femoral fractures. *Trauma* 1997;39(3):3-20.
113. Goldstein FC, Strasser DC, Woodard JL, et al. Functional outcome of cognitively impaired hip fracture patients on a geriatric rehabilitation unit. *J Am Geriatr Soc* 1997;45(1):35-42.
114. Gonzalez-Montalvo JI, Alarcon T, Mauleon JL, et al. The orthogeriatric unit for acute patients: a new model of care that improves efficiency in the management of patients with hip fracture. *Hip Int* 2010;20(2):229-35.
115. Gonzalez-Montalvo JI, Alarcon T, Saez P, et al. Geriatric management of the frail elderly with hip fracture may improve their clinical outcome. *Med Clin (Barc)* 2001;116(1):1-5. (Spa).
116. Gregory JJ, Kostakopoulou K, Cool WP, et al. One-year outcome for elderly patients with displaced intracapsular fractures of the femoral neck managed non-operatively. *Injury* 2010;41(12):1273-6.
117. Griffith JP, Whiteley S, Gough MJ. Prospective randomized study of a new method of providing postoperative pain relief following femoropopliteal bypass. *Br J Surg* 1996;83(12):1735-8.
118. Gulati A. Anaesthesia for hip fracture surgery, a comparison between GA and spinal anaesthesia. *Annual Meeting of the European Society of Anaesthesiology on Euroanaesthesia, 2007 Jun 9-12, Munich, Germany 2007.*
119. Guryay D, Karaege GT, Katircioglu K, et al. The effects of an epidural infusion of ropivacaine versus saline on sensory block after spinal anesthesia. *Reg Anesth Pain Med* 2008;33(3):217-21.
120. Gustafson Y, Brannstrom B, Berggren D, et al. A geriatric-anesthesiologic program to reduce acute confusional states in elderly patients treated for femoral neck fractures. *J Am Geriatr Soc* 1991;39(7):655-62.
121. Hadi MA, Shamsul Kamaruljan H, Saedah A, et al. A comparative study of intravenous patient-controlled analgesia morphine and tramadol in patients undergoing major operation. *Med J Malaysia* 2006;61(5):570-6.
122. Hagsten B, Svensson O, Gardulf A. Early individualized postoperative occupational therapy training in 100 patients improves ADL after hip fracture: a randomized trial. *Acta Orthop Scand* 2004;75(2):177-83.

123. Hallberg I, Bachrach-Lindström M, Hammerby S, et al. Health-related quality of life after vertebral or hip fracture: A seven-year follow-up study. *BMC Musculoskeletal Disord* 2009;10(1).
124. Hannon VF. The relationship between type of anesthesia and incidence of postoperative confusion in elderly female hip fracture patients [dissertation] Western Connecticut State University; 1995.
125. Hay D, Parker MJ. Hip fracture in the immobile patient. *J Bone Joint Surg Br* 2003;85(7):1037-9.
126. Helayel PE, Da Conceição DB, Knaesel JA, et al. Effective anesthetic volumes in sciatic nerve block: comparison between the parasacral and infragluteal-parabiceps approaches with 0.5% bupivacaine with adrenaline and 0.5% ropivacaine. *Rev Bras Anesthesiol* 2009;59(5):521-30.
127. Hempsall VJ, Robertson DR, Campbell MJ, et al. Orthopaedic geriatric care-is it effective?: a prospective population-based comparison of outcome in fractured neck of femur. *J R Coll Physicians Lond* 1990;24(1):47-50.
128. Herrick C, Steger-May K, Sinacore DR, et al. Persistent pain in frail older adults after hip fracture repair. *J Am Geriatr Soc* 2004;52(12):2062-8.
129. Heybeli H, Kaya M, Ozalp G, et al. Psoas compartment block for total hip arthroplasty: a comparison of continuous infusion and patients controlled analgesia. *Anestezi Derg* 2007;15(2):129-33. (Tur).
130. Hofman A, Geelkerken RH, Wille J, et al. Pressure sores and pressure-decreasing mattresses: controlled clinical trial. *Lancet* 1994;343(8897):568-71.
131. Hommel A, Ulander K, Thorngren KG. Improvements in pain relief, handling time and pressure ulcers through internal audits of hip fracture patients. *Scand J Caring Sci* 2003;17(1):78-83.
132. Hunter KF, Cyr D. The effect of delirium education on use of target PRN medications in older orthopaedic patients. *AGE AGEING* 2007;36(1):98-101.
133. Huusko TM, Karppi P, Kautiainen H, et al. Randomized, double-blind, clinically controlled trial of intranasal calcitonin treatment in patients with hip fracture. *Calcif Tissue Int* 2002;71(6):478-84.
134. Hwang U, Richardson LD, Sonuyi TO, et al. Emergency department pain management of older adults with hip fractures [abstract]. *J Gen Intern Med* 2005;20(Suppl 1):45.
135. Iamaroon A, Raksakietisak M, Halilamien P, et al. Femoral nerve block versus fentanyl: analgesia for positioning patients with fractured femur. *Local and Regional Anesthesia* 2010;3(1):21-6.
136. Imani F, Mohammadtaheri F, Entezary S. Evaluation of adding oral gabapentine on patient-controlled IV analgesia (PCIA) on post-operative pain after lower extremity fracture operations [abstract]. *Reg Anesth Pain Med* 2009;33(5 Suppl 1):157.



137. Imbelloni LE, Gouveia MA, Cordeiro JA. Continuous spinal anesthesia versus combined spinal epidural block for major orthopedic surgery: prospective randomized study. *Sao Paulo Med J* 2009;127(1):7-11.
138. Imbelloni LE, Gouveia MA. Postoperative analgesia with paravascular lumbar plexus block: comparison between femoral nerve stimulation and catheter techniques. *Rev Bras Anesthesiol* 2001;51(1):28-36.
139. Indig R, Ronen R, Eldar R, et al. Pressure sores: impact on rehabilitation following surgically treated hip fractures. *Int J Rehabil Res* 1995;18(1):54-5.
140. Iskandar H, Guillaume E, Dixmérias F, et al. The enhancement of sensory blockade by Clonidine selectively added to mepivacaine after midhumeral block. *Anesth Analg* 2001;93(3):771-5.
141. Jacobsen S, Engfred KF, Nielsen PR, et al. Treatment of hip fractures in a department of general surgery and a department of orthopedic surgery: a comparison. *Ugeskr Laeger* 1993;155(10):701-3. (Dan).
142. JAGS abstracts. *Annals of Long Term Care* 2009;17(5):40-2.
143. JAGS Abstracts. *Annals of Long Term Care* 2009;17(7):38-41.
144. JANZING HMJ. The Gotfried percutaneous compression plate versus the dynamic hip screw in the treatment of pertrochanteric hip fractures: minimal invasive treatment reduces operative time and postoperative pain. *J Trauma* 2002;2002(2):293-8.
145. Jellish WS, Abodeely A, Fluder EM, et al. The effect of spinal bupivacaine in combination with either epidural clonidine and/or 0.5% Bupivacaine administered at the incision site on postoperative outcome in patients undergoing lumbar laminectomy. *Anesth Analg* 2003;96(3):874-80.
146. Kalisvaart KJ, De Jonghe JFM, Bogaards MJ, et al. Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study. *J Am Geriatr Soc* 2005;53(10):1658-66.
147. Kalkan E, Torun F, Tavlan A, et al. The effect of meperidine-impregnated autogenous free fat grafts on postoperative pain management in lumbar disc surgery. *J Spinal Disord Tech* 2008;21(2):92-5.
148. Kallio H, Snäll E-VT, Suvanto SJ, et al. Spinal hyperbaric ropivacaine-fentanyl for day-surgery. *Reg Anesth Pain Med* 2005;30(1):48-54.
149. Kamel HK, Iqbal MA, Mogallapu R, et al. Pain management in elderly patients with hip fractures: the practice at a University Teaching Hospital. *J Am Geriatr Soc* 2002;50(4):199 S77.
150. Kandler D, Lisander B. Analgesic action of metoclopramide in prosthetic hip surgery. *Acta Anaesthesiol Scand* 1993;37(1):49-53.
151. Karaaslan P, Pirat A, Tandogan R, et al. Comparison of continuous spinal, continuous epidural and isoflurane-remifentanyl anesthesia in geriatric patients undergoing total hip arthroplasty. *Anestezi Derg* 2006;14(3):186-91.

152. Karn NK, Singh GK, Kumar P, et al. Management of trochanteric fractures of the femur with external fixation in high-risk patients. *Int Orthop* 2009;33(3):785-8.
153. Kaya M, Özalp G, Tuncel G, et al. Patient-controlled regional analgesia after total hip arthroplasty: psoas compartment block versus three-in one femoral nerve block. *Anestezi Derg* 2006;14(1):43-7.
154. Kelly AM. A process approach to improving pain management in the emergency department: development and evaluation. *J Accid Emerg Med* 2000;17(3):185-7.
155. Kjaersgaard-Andersen P. Evaluating codeine plus paracetamol for pain. *Nurs Times* 1991;87(16):52.
156. Klimscha W, Weinstabl C, Ilias W, et al. Continuous spinal anesthesia with a microcatheter and low-dose bupivacaine decreases the hemodynamic effects of centroneuraxis blocks in elderly patients. *Anesth Analg* 1993;77(2):275-80.
157. Kober A, Scheck T, Greher M, et al. Prehospital analgesia with acupressure in victims of minor trauma: a prospective, randomized, double-blinded trial. *Anesth Analg* 2002;95(3):723-7.
158. Koch T, Fichtner A, Schwemmer U, et al. Levobupivacaine for epidural anaesthesia and postoperative analgesia in hip surgery: a multi-center efficacy and safety equivalence study with bupivacaine and ropivacaine. *Anaesthesist* 2008;57(5):475-82.
159. Koot VCM, Peeters PHM, De Jong JR, et al. Functional results after treatment of hip fracture: a multicentre, prospective study in 215 patients. *Eur J Surg* 2000;166(6):480-5.
160. Koval KJ, Aharonoff GB, Rosenberg AD, et al. Functional outcome after hip fracture: effect of general versus regional anesthesia. *Clin Orthop Relat Res* 1998;(348):37-41.
161. Koval KJ, Aharonoff GB, Rosenberg AD, et al. Hip fracture in the elderly: the effect of anesthetic technique. *Orthopedics* 1999;22(1):31-4.
162. Kraus J, Volf V, Burget F, et al. [PCCP versus standard proximal femoral nail in the treatment of pertrochanteric femoral fractures]. [Czech]. *Rozhledy V Chirurgii* 2009;88(8):469-74.
163. Kumar M, Batra YK, Panda NB, et al. Tramadol added to bupivacaine does not prolong analgesia of continuous psoas compartment block. *Pain Pract* 2009;9(1):43-50.
164. Laberge A, Joubert P, Brodeur JM. Le risque de perte d'autonomie fonctionnelle associe a l'utilisation des ressources institutionnelles, pour la readaptation des personnes agees hospitalisees a la suite d'une fracture de la hanche. *Can J Rehabil* 1997;10(3):205-14. (Fre).
165. Lahav M. Functional recovery and pain in hip fractures post DHS and PCCP [abstract]. *J Am Acad Orthop Surg* 2007;2007 February 14-18, San Diego CA.
166. Lamb SE, Oldham JA, Morse RE, et al. Neuromuscular stimulation of the quadriceps muscle after hip fracture: a randomized controlled trial. *Arch Phys Med Rehabil* 2002;83(8):1087-92.
167. Larsen K, Hansen TB, Soballe K. Hip arthroplasty patients benefit from accelerated perioperative care and rehabilitation: a quasi-experimental study of 98 patients. *Acta Orthop* 2008;79(5):624-30.

168. Lauridsen UB, de la Cour BB, Gottschalck L, et al. Intensive physical therapy after trochanteric femoral fracture: a randomized clinical trial. *Ugeskr Laeger* 2002;164(8):1040-4. (Dan).
169. Lee LA, Domino KB. Complications associated with peripheral nerve blocks: lessons from the ASA closed claims project. *Int Anesthesiol Clin* 2005;43(3):111-8.
170. Licciardone JC, Stoll ST, Cardarelli KM, et al. A randomized controlled trial of osteopathic manipulative treatment following knee or hip arthroplasty. *J Am Osteopath Assoc* 2004;104(5):193-202.
171. Lin PC, Wang CH, Chen CS, et al. To evaluate the effectiveness of a discharge-planning programme for hip fracture patients. *J Clin Nurs* 2009;18(11):1632-9.
172. Lindsay R, Silverman SL, Watts NB, et al. Bisphosphonate therapy and hip fractures within the risedronate and alendronate (ReAl) cohort study: subgroup with prior fracture. 14th Annual Meeting of the International Society for Clinical Densitometry, 2008 May 12-15, San Francisco, CA 2008.
173. Lipson MJ, Minassian P. Differences in outcome: hospital rehabilitation vs skilled nursing facility rehabilitation. *Arch Intern Med* 1990;150(7):1550-1.
174. Liu N, Bonnet F, Delaunay L, et al. Partial reversal of the effects of extradural clonidine by oral yohimbine in postoperative patients. *Br J Anaesth* 1993;70(5):515-8.
175. Lopez S, Gros T, Bernard N, et al. Fascia iliaca compartment block for femoral bone fractures in prehospital care. *Reg Anesth Pain Med* 2003;28(3):203-7.
176. Love DR, Owen H, Ilsley AH, et al. A comparison of variable-dose patient-controlled analgesia with fixed-dose patient-controlled analgesia. *Anesth Analg* 1996;83(5):1060-4.
177. Lu G, Chen P-B, Lu F-M. Features of intramedullary nail INTERTAN for intertrochanteric fractures: Retrospective analysis of 19 cases. [Chinese]. *Journal of Clinical Rehabilitative Tissue Engineering Research* 13(26)(pp 5162-5166), 2009 Date of Publication: 25 Jun 2009 2009;(26):5162-6.
178. Lundstrom M, Olofsson B, Stenvall M, et al. Postoperative delirium in old patients with femoral neck fracture: a randomized intervention study. *Aging Clin Exp Res* 2007;19(3):178-86.
179. MacDonald V, Hilton BA. Postoperative pain management in frail older adults. *ORTHOP NURS* 2001;20(3):63-76.
180. MacDonald V, Hilton BA. Postoperative pain management in frail older adults. *Perianesthes Ambul Surg Nurs Update* 2001;9(5):70.
181. Malawer MM, Buch R, Khurana JS, et al. Postoperative infusional continuous regional analgesia: a technique for relief of postoperative pain following major extremity surgery. *Clin Orthop Relat Res* 1991;(266):227-37.
182. Manabe Y, Iwamoto S, Tsuru Y, et al. The effect of oral clonidine premedication on inferior alveolar nerve block. *J Jpn Dent Soc Anesthesiol* 2007;35(2):151-7.

183. Mangione KK, Craik RL, Palombaro KM, et al. Home-based leg-strengthening exercise improves function 1 year after hip fracture: a randomized controlled study. *J Am Geriatr Soc* 2010;58(10):1911-7.
184. Mannion S, O'Callaghan S, Murphy DB, et al. Tramadol as adjunct to psoas compartment block with levobupivacaine 0.5%: a randomized double-blinded study. *Br J Anaesth* 2005;94(3):352-6.
185. Mannion S, O'Callaghan S, Walsh M, et al. In with the new, out with the old?: comparison of two approaches for psoas compartment block. *Anesth Analg* 2005;101(1):259-64.
186. Markel DC, Urquhart B, Derkowska I, et al. Effect of epidural analgesia on venous blood flow after hip arthroplasty. *Clin Orthop Relat Res* 1997;(334):168-74.
187. Marottoli RA, Berkman LF, Leo-Summers L, et al. Predictors of mortality and institutionalization after hip fracture: the New Haven EPESE cohort: Established Populations for Epidemiologic Studies of the Elderly. *Am J Public Health* 1994;84(11):1807-12.
188. Martins Fonseca N, Araújo Ruzi R, Xavier Ferreira F, et al. Postoperative analgesia following orthopedic surgery: a study comparing perivascular lumbar plexus inguinal block with ropivacaine (3 in 1) and spinal anesthesia with morphine. *Rev Bras Anesthesiol* 2003;53(2):188-97.
189. Massage, Meditation, and Tai Chi for Chronic Lower Back Pain. 2010.
190. Matsui H, Terahata N, Makiyama N, et al. Significance of patient-controlled analgesia combined with continuous epidural block for patients with limb trauma. *Int Orthop* 1997;21(5):298-302.
191. Mauker K, Bonvini JM, EkatoDRAMIS G, et al. Continuous spinal anesthesia/analgesia vs. single-shot spinal anesthesia with patient-controlled analgesia for elective hip arthroplasty. *Acta Anaesthesiol Scand* 2003;47(7):878-83.
192. McGilton KS, Mahomed N, Davis AM, et al. Outcomes for older adults in an inpatient rehabilitation facility following hip fracture (HF) surgery. *Arch Gerontol Geriatr* 2009;49(1):e23-e31.
193. McNamee DA, Convery PN, Milligan KR. Total knee replacement: a comparison of ropivacaine and bupivacaine in combined femoral and sciatic block. *Acta Anaesthesiol Scand* 2001;45(4):477-81.
194. Meeds B, Pryor GA. Early home rehabilitation for the elderly patient with hip fracture: the Peterborough hip fracture scheme. *Physiotherapy* 1990;76(2):75-7.
195. Mendelsohn ME, Overend TJ, Connelly DM, et al. Improvement in aerobic fitness during rehabilitation following hip fracture. 55th Annual Meeting on American College of Sports Medicine, 2008 May 28-21, Indianapolis, Indiana (USA) 2008.
196. Merle V, Moret L, Pidhorz L, et al. Does comparison of performance lead to better care? A pilot observational study in patients admitted for hip fracture in three French public hospitals. *International Journal for Quality in Health Care* 2009;21(5):321-9.

197. Michaloudis D, Petrou A, Bakos P, et al. Continuous spinal anaesthesia/analgesia for the perioperative management of high-risk patients. *Eur J Anaesthesiol* 2000;17(4):239-47.
198. Milisen K, Abraham IL, Broos PLO. Postoperative variation in neurocognitive and functional status in elderly hip fracture patients. *J Adv Nurs* 1998;27(1):59-67.
199. Møiniche S, Hjortsø NC, Hansen BL, et al. The effect of balanced analgesia on early convalescence after major orthopaedic surgery. *Acta Anaesthesiol Scand* 1994;38(4):328-35.
200. Moran AP, Stock K, Jenkins C, et al. Co-induction of anaesthesia with 0.75 mg kg propofol followed by sevoflurane: a randomized trial in the elderly with cardiovascular risk factors. *Eur J Anaesthesiol* 2008;25(3):183-7.
201. Morrison RS, Flanagan S, Fischberg D, et al. A novel interdisciplinary analgesic program reduces pain and improves function in older adults after orthopedic surgery. *J Am Geriatr Soc* 2009;57(1):1-10.
202. Morrison RS, Magaziner J, McLaughlin MA, et al. The impact of post-operative pain on outcomes following hip fracture. *Pain* 2003;103(3):303-11.
203. Morrison RS, Siu AL. Inadequate treatment of pain in hip fracture patients [abstract]. *J Am Geriatr Soc* 1998;46(9 Suppl):S14.
204. Moseley AM, SC, Lord SR, et al. Mobility training after hip fracture: a randomised controlled trial. *AGE AGEING* 2009;38(1):74-80.
205. Munuera L, Garcia-Cimbreló E. International meeting on total hip arthroplasty: Hospital La Paz - Madrid, April 6-8, 2000. *HIP International* 2000;10(3):178-90.
206. Murphy PM, Stack D, Kinirons B, et al. Optimizing the dose of intrathecal morphine in older patients undergoing hip arthroplasty. *Anesth Analg* 2003;97(6):1709-15.
207. Mutty CE, Jensen EJ, Manka J, et al. Femoral nerve block for diaphyseal and distal femoral fractures in the emergency department. *J Bone Joint Surg Am* 2007;89 A(12):2599-603.
208. Mutty CE, Jensen EJ, Manka MAJ, et al. Femoral nerve block for diaphyseal and distal femoral fractures in the emergency department: surgical technique. *J Bone Joint Surg Am* 2008;90(Suppl 2 Pt 2):218-26.
209. Naglie G, Tansey C, Kirkland JL, et al. Interdisciplinary inpatient care for elderly people with hip fracture: a randomized controlled trial. *CMAJ* 2002;167(1):25-32.
210. Nelson L, Taylor F, Adams M, et al. Improving pain management for hip fractured elderly. *ORTHOP NURS* 1990;9(3):79-83.
211. Niemi L, Pitkänen M, Tuominen M, et al. Technical problems and side effects associated with continuous intrathecal or epidural post-operative analgesia in patients undergoing hip arthroplasty. *Eur J Anaesthesiol* 1994;11(6):469-74
212. Nishikawa K, Yamakage M, Omote K, et al. Prophylactic IM small-dose phenylephrine blunts spinal anesthesia-induced hypotensive response during surgical repair of hip fracture in the elderly. *Anesth Analg* 2002;95(3):751-6.
213. O'Hara DA, Duff A, Berlin JA, et al. The effect of anesthetic technique on postoperative outcomes in hip fracture repair. *Anesthesiology* 2000;92(4):947-57.

214. Ohsawa S, Miura A, Yagyu M, et al. Assertive rehabilitation for intracapsular fracture of the proximal femur. *Clin Rehabil* 2007;21(1):36-40.
215. Olofsson C, Ahl T, Johansson T, et al. A multicenter clinical study of the safety and activity of maleimide-polyethylene glycol-modified hemoglobin (Hemospan) in patients undergoing major orthopedic surgery. *Anesthesiology* 2006;105(6):1153-63.
216. Olsson LE, Karlsson J, Ekman I. Effects of nursing interventions within an integrated care pathway for patients with hip fracture. *J Adv Nurs* 2007;58(2):116-25.
217. ONG BC. Unipolar versus bipolar hemiarthroplasty: functional Outcome after femoral neck fracture at a minimum of thirty-six months of follow-up. *J Orthop Trauma* 2002;2002(5):317-22.
218. Orebaugh SL, Williams BA, Vallejo M, et al. Adverse outcomes associated with stimulator-based peripheral nerve blocks with versus without ultrasound visualization. *Reg Anesth Pain Med* 2009;34(3):251-5.
219. Palacios Rios D, Colunga Mata JM, Lopez Sala P, et al. Femoral nerve blockade: previous application to spinal or epidural anesthesia in patients with fracture of the diaphysis of the femur. *Anest Mex* 1998;10(3):107-9. (Spa).
220. Pardillos C. Pre-operative '3 in 1' block for hip fracture surgery. *Rev Esp Anesthesiol Reanim* 1997;44(Suppl 1):212.
221. Passot S, Servin F, Pascal J, et al. A comparison of target- and manually controlled infusion propofol and etomidate/desflurane anesthesia in elderly patients undergoing hip fracture surgery. *Anesth Analg* 2005;100(5):1338-42.
222. Pennington P, Caminiti S, Schein JR, et al. Patients' assessment of the convenience of fentanyl HCl iontophoretic transdermal system (ITS) versus morphine intravenous patient-controlled analgesia (IV PCA) in the management of postoperative pain after major surgery. *Pain management nursing: official journal of the American Society of Pain Management Nurses* 2009;10:124-33.
223. Pennington P, Caminiti S, Schein JR, et al. Patients' assessment of the convenience of fentanyl HCl iontophoretic transdermal system (ITS) versus morphine intravenous patient-controlled analgesia (IV PCA) in the management of postoperative pain after major surgery. *Pain management nursing : official journal of the American Society of Pain Management Nurses* 2009;10:124-33.
224. Petrella RJ, Overend T, Chesworth B. FIM™ after hip fracture: is telephone administration valid and sensitive to change? [abstract]. *Am J Phys Med Rehabil* 2002;81(9):639-44.
225. Peyser A, Weil YA, Brocke L, et al. A prospective, randomised study comparing the percutaneous compression plate and the compression hip screw for the treatment of intertrochanteric fractures of the hip. *J Bone Jt Surg Ser B* 2007;89(9):1210-7.
226. Physical CAM Therapies for Chronic Low Back Pain. 2010.
227. Pilot Study to Test the Effectiveness of Combining Conventional and Complementary Medicine to Treat Low Back Pain. 2010.

228. Pitkänen M, Rosenberg P, Silvanto M, et al. Haemodynamic changes during spinal anaesthesia with slow continuous infusion or single dose of plain bupivacaine. *Acta Anaesthesiol Scand* 1992;36(6):526-9.
229. Ponhold H, Kulier AH, Rehak PH. 30 degree trunk elevation and quality of lumbar epidural anaesthesia for lower extremity operations. *Anaesthesist* 1993;42(11):788-92. German.
230. Pretto M, Spirig R, Milisen K, et al. Effects of an interdisciplinary nurse-led Delirium Prevention and Management Program (DPMP) on nursing workload: a pilot study. *Int J Nurs Stud* 2009;46(6):804-12.
231. Puolakka R, Haasio J, Pitkäänen MT, et al. Technical aspects and postoperative sequelae of spinal and epidural anesthesia: a prospective study of 3,230 orthopedic patients. *Reg Anesth Pain Med* 2000;25(5):488-97.
232. Qi X, Liu J-G, Gong Y-B, et al. Treatment of posterior wall fractures of acetabulum. *Chin J Traumatol* 2009;12(2):113-7.
233. Quinlan MR, Quinlan JF, Lenehan B, et al. The need for multi-disciplinary management of combined orthopaedic and genito-urinary injuries. *Eur J Orthop Surg Traumatol* 2009;19(4):249-54.
234. Raaymakers EL, Marti RK. Non-operative treatment of impacted femoral neck fractures. *J Bone Joint Surg Br* 1991;73B(6):950-4.
235. Rabinowitz A, Bourdet B, Minville V, et al. The paramedian technique: a superior initial approach to continuous spinal anesthesia in the elderly. *Anesth Analg* 2007;105(6):1855-7.
236. Rhee KY, Kang K, Kim J, et al. Intravenous clonidine prolongs bupivacaine spinal anesthesia. *Acta Anaesthesiol Scand* 2003;47(8):1001-5.
237. Rivera Ordonez A., Rivera Flores J. Postoperative epidural analgesia: ketamine plus bupivacaine vs. bupivacaine alone in hip and femur surgery. *Rev Mex Anestesiol* 2005;28(1):14-9. Spanish.
238. Roberts HC, Pickering RM, Onslow E, et al. The effectiveness of implementing a care pathway for femoral neck fracture in older people: a prospective controlled before and after study. *AGE AGEING* 2004;33(2):178-84.
239. Ruecker AH. The Treatment of Intertrochanteric Fractures : Results Using an Intramedullary Nail With Integrated Cephalocervical Screws and Linear Compression. *J Orthop Trauma* 2009;2009(1):22-30.
240. Ryan T, Enderby P, Rigby AS. A randomized controlled trial to evaluate intensity of community-based rehabilitation provision following stroke or hip fracture in old age. *Clinical Rehabilitation* 2006;20(2):123-31.
241. Samkaoui MA, Bouaggad A, Al Harrar R, et al. The addition of clonidine to lidocaine 0.5% for intravenous regional anaesthesia. *Ann Fr Anesth Reanim* 2001;20(3):255-9.
242. SaSauter AR, Dodgson MS, Stubhaug A, et al. Electrical nerve stimulation or ultrasound guidance for lateral sagittal infraclavicular blocks: a randomized, controlled, observer-blinded, comparative study. *Anesth Analg* 2008;106(6):1910-5.

243. Schiferer A, Gore C, Gorove L, et al. A randomized controlled trial of femoral nerve blockade administered preclinically for pain relief in femoral trauma. *Anesth Analg* 2007;105(6):1852-4.
244. Schnider TW, Mueller-Duysing S, Jöhr M, et al. Incremental dosing versus single-dose spinal anesthesia and hemodynamic stability. *Anesth Analg* 1993;77(6):1174-8.
245. Seeberger MD, Urwyler A. Paravascular lumbar plexus block: block extension after femoral nerve stimulation and injection of 20 vs. 40 ml mepivacaine 10 mg/ml. *Acta Anaesthesiol Scand* 1995;39(6):769-73.
246. Sell A, Olkkola KT, Jalonen J, et al. Isobaric bupivacaine via spinal catheter for hip replacement surgery: ED50 and ED95 dose determination. *Acta Anaesthesiol Scand* 2006;50(2):217-21.
247. Senthilnathan S, Muralidharan V, Vijayaraj R, et al. Effect of anaesthesia on duration of hip surgery [abstract]. 7th Domestic Meeting of the European Hip Society (EHS 2006), 2006 Jun 21-24, Antalya, Turkey 2006.
248. Shiri-Sharvit O, Arad M, Mizrahi EH, et al. The association between psychotropic medication use and functional outcome of elderly hip-fracture patients undergoing rehabilitation. *Arch Phys Med Rehabil* 2005;86(7):1389-93.
249. Shyu Y-I, Liang J, Wu C-C, et al. A pilot investigation of the short-term effects of an interdisciplinary intervention program on elderly patients with hip fracture in Taiwan. *J Am Geriatr Soc* 2005;53(5):811-8.
250. Shyu YI, Liang J, Wu CC, et al. Interdisciplinary intervention for hip fracture in older Taiwanese: benefits last for 1 year. *J Gerontol A Biol Sci Med Sci* 2008;63(1):92-7.
251. Siddiqui ZI, Cepeda MS, Denman W, et al. Continuous lumbar plexus block provides improved analgesia with fewer side effects compared with systemic opioids after hip arthroplasty: a randomized controlled trial. *Reg Anesth Pain Med* 2007;32(5):393-8.
252. Sieber FE, Zakriya KJ, Gottschalk A, et al. Sedation depth during spinal anesthesia and the development of postoperative delirium in elderly patients undergoing hip fracture repair. *Mayo Clin Proc* 2010;85(1):18-26.
253. Singelyn FJ, Ferrant T, Malisse MF, et al. Effects of intravenous patient-controlled analgesia with morphine, continuous epidural analgesia, and continuous femoral nerve sheath block on rehabilitation after unilateral total-hip arthroplasty. *Reg Anesth Pain Med* 2005;30(5):452-7.
254. Singelyn FJ, Gouverneur JMA. Postoperative analgesia after total hip arthroplasty: IV PCA with morphine, patient-controlled epidural analgesia, or continuous '3-in-1' block?: a prospective evaluation by our acute pain service in more than 1,300 patients. *J Clin Anesth* 1999;11(7):550-4.
255. Singelyn FJ, Vanderelst PE, Gouverneur JMA. Extended femoral nerve sheath block after total hip arthroplasty: continuous versus patient-controlled techniques. *Anesth Analg* 2001;92(2):455-9.



256. Sites BD, Beach M, Biggs R, et al. Intrathecal clonidine added to a bupivacaine-morphine spinal anesthetic improves postoperative analgesia for total knee arthroplasty. *Anesth Analg* 2003;96(4):1083-8.
257. Solares Ahedo R, Torres Valtierra E, Bojórquez Hernández F. Tratamiento de las fracturas del fémur en el anciano a nivel de la cadera: osteosíntesis con fijación externa: estudio preliminar. *Rev Mex Ortop Traumatol* 1997;11(6):400-4. (Spa).
258. Souron V, Delaunay L, Schiffrine P. Intrathecal morphine provides better postoperative analgesia than psoas compartment block after primary hip arthroplasty. *Can J Anaesth* 2003;50(6):574-9.
259. Standl TG, Horn EP, Luckmann M, et al. Subarachnoid sufentanil for early postoperative pain management in orthopedic patients: a placebo-controlled, double-blind study using spinal microcatheters. *Anesthesiology* 2001;94(2):230-8.
260. Stenvall M, Olofsson B, Nyberg L, et al. Improved performance in activities of daily living and mobility after a multidisciplinary postoperative rehabilitation in older people with femoral neck fracture: a randomized controlled trial with 1-year follow-up. *Journal of Rehabilitation Medicine* 2007;39(3):232-8.
261. Sternlo JE, Rettrup A, Sandin R. Prophylactic i.m. ephedrine in bupivacaine spinal anaesthesia. *Br J Anaesth* 1995;74(5):517-20.
262. Stevens RD, Van Gessel E, Flory N, et al. Lumbar plexus block reduces pain and blood loss associated with total hip arthroplasty. *Anesthesiology* 2000;93(1):115-21.
263. Strömberg L, Öhlén G, Nordin C, et al. Postoperative mental impairment in hip fracture patients: a randomized study of reorientation measures in 223 patients. *Acta Orthop Scand* 1999;70(3):250-5.
264. Suetta C, Magnusson SP, Rosted A, et al. Resistance training in the early postoperative phase reduces hospitalization and leads to muscle hypertrophy in elderly hip surgery patients: a controlled, randomized study. *J Am Geriatr Soc* 2004;52(12):2016-22.
265. Sundarathiti P, Sirinan C, Seangrung R, et al. Selective spinal anesthesia versus intravenous propofol in transrectal ultrasound-guided prostate biopsy. *J Med Assoc Thai* 2009;92(7):920-4.
266. Swanson CE, Day GA, Yelland CE, et al. The management of elderly patients with femoral fractures: a randomised controlled trial of early intervention versus standard care. *Med J Aust* 1998;169(10):515-8.
267. Taylor AL. Risedronate: a new bisphosphonate on the block. *Med Today* 2001;2(6):109-10.
268. Tha HS, Armstrong D, Broad J, et al. Hip fracture in Auckland: contrasting models of care in two major hospitals. *Intern Med J* 2009;39(2):89-94.
269. Titler MG, Herr K, Brooks JM, et al. Translating research into practice intervention improves management of acute pain in older hip fracture patients. *Health Serv Res* 2009;44(1):264-87.

270. Tjardes T, Paffrath T, Baethis H, et al. Computer assisted percutaneous placement of augmented iliosacral screws: a reasonable alternative to sacroplasty. *Spine* 2008;33(13):1497-500.
271. Topcu I, Luleci N, Tekin S, et al. Effectiveness of clonidine and fentanyl addition to bupivacaine in postoperative patient controlled epidural analgesia. *Anesthesiol Intensivmed Notfallmed Schmerzther* 2005;40(9):521-5.
272. Tuncer S, Bariskaner H, Reisli R, et al. Effect of gabapentin on postoperative pain: a randomized, placebo-controlled clinical study. *Pain Clinic* 2005;17(1):95-9.
273. Tuominen M, Pitkanen M, Rosenberg PH. Effect of speed of injection of 0.5% plain bupivacaine on the spread of spinal anaesthesia. *Br J Anaesth* 1992;69(2):148-9.
274. Ungemach JW, Andres FJ, Eggert E, et al. The role of anaesthesia in geriatric patients with hip fractures: a prospective study. *Eur J Anaesthesiol* 1993;10(5):380.
275. Urbanek B, Duma A, Kimberger O, et al. Onset time, quality of blockade, and duration of three-in-one blocks with levobupivacaine and bupivacaine. *Anesth Analg* 2003;97(3):888-92.
276. Use of the pain reliever propoxyphene is associated with a higher risk of hip fracture among the elderly. *AHRQ Res Act* 2007;(319):16-7.
277. Usual Care Vs Choice of Alternative Rx: Low Back Pain. 2010.
278. Utebey G, Akkaya T, Alptekin A, et al. The effects of lumbar plexus block and epidural block on total blood loss and postoperative analgesia in total hip arthroplasty. *Agri* 2009;21(2):62-8.
279. Uy C, Kurrle SE, Cameron ID. Inpatient multidisciplinary rehabilitation after hip fracture for residents of nursing homes: a randomised trial. *Australas J Ageing* 2008;27(1):43-4.
280. Van Geffen GJ, Van Den Broek E, Braak GJJ, et al. A prospective randomised controlled trial of ultrasound guided versus nerve stimulation guided distal sciatic nerve block at the popliteal fossa. *Anaesth Intensive Care* 2009;37(1):32-7.
281. Van Gessel EF, Forster A, Schweizer A, et al. Comparison of hypobaric, hyperbaric, and isobaric solutions of bupivacaine during continuous spinal anaesthesia. *Anesth Analg* 1991;72(6):779-84.
282. Van Leeuwen FL, Bronselaer K, Gilles M, et al. The 'three in one' block as locoregional analgesia in an emergency department. *Eur J Emerg Med* 2000;7(1):35-8.
283. Van-Gessel EF, Miege B, Forster A, et al. Comparison of hyperbaric solutions of bupivacaine and tetracaine during continuous spinal anaesthesia. *Can J Anaesth* 1992;39(4):323-9.
284. Vidan M, Serra JA, Moreno C, et al. Efficacy of a comprehensive geriatric intervention in older patients hospitalized for hip fracture: a randomized, controlled trial. *J Am Geriatr Soc* 2005;53(9):1476-82.
285. Wahlen BM, Kilian M, Schuster F, et al. Patient-controlled versus continuous anesthesiologist-controlled sedation using propofol during regional anesthesia in orthopedic procedures: a pilot study. *Expert Opin Pharmacother* 2008;9(16):2733-9.

286. Watson MW, Mitra D, McLintock TC, et al. Continuous versus single-injection lumbar plexus blocks: comparison of the effects on morphine use and early recovery after total knee arthroplasty. *Reg Anesth Pain Med* 2005;30(6):541-7.
287. Weatherall M. Does a delay in transfer to a rehabilitation unit for older people affect outcome after fracture of the proximal femur? *N Z Med J* 2001;114(1145):547-9.
288. Wiens CA, Jones A, Feeny DH, et al. A prospective study of pharmaceutical management of pain in patients with hip fracture. *J Am Geriatr Soc* 2003;51(4):573.
289. Wilhelm S, Standl T, Burmeister M, et al. Comparison of continuous spinal with combined spinal-epidural anesthesia using plain bupivacaine 0.5% in trauma patients. *Anesth Analg* 1997;85(1):69-74.
290. Wong YY. Assessment of acute pain in older adults with hip fracture: Current nursing practice. *Int J Orthop Trauma Nurs* 2010;14(4):228-9.
291. Yap JC, Critchley LA, Yu SC, et al. A comparison of three fluid-vasopressor regimens used to prevent hypotension during subarachnoid anaesthesia in the elderly. *Anaesth Intensive Care* 1998;26(5):497-502.
292. Yu-Yahiro JA, Resnick B, Orwig D, et al. Design and implementation of a home-based exercise program post-hip fracture: the Baltimore hip studies experience. *Pm & R* 2009;1(4):308-18.
293. Zevedo Alves TC, Cerqueira Braz JR. Clinical evaluation of clonidine associated to ropivacaine for epidural anesthesia. *Rev Bras Anesthesiol* 2002;52(4):410-9.

## **No Extractable Data Related to Outcomes of Interest**

1. Cao QQ, Xu XZ, Lu YY, et al. Comparison of lumbar plexus block and epidural block for elderly patients undergoing intertrochanteric femoral fracture surgery. *Zhonghua Yi Xue Za Zhi* 2008;88(37):2614-7. (Chi).
2. Cappannoli A, Covotta M, Perrella SM, et al. Local anesthesia in medial femoral compound fractures in critically ill patients. *Reg Anesth Pain Med* 2010;Conference(var.pagings):E73-October.
3. Darling JR, Murray JM, Hainsworth AM, et al. The effect of isoflurane or spinal anesthesia on indocyanine green disappearance rate in the elderly. *Anesth Analg* 1994;78(4):706-9.
4. Draper P, Scott F. An evaluation of Hamilton-Russell traction in the pre-operative management of patients with hip fracture. *Clin Eff Nurs* 1997;1(4):179-88.
5. Draper P, Scott F. Using traction. *Nurs Times* 1998;94(12):31-2.
6. Draper P. A clinical trial of Hamilton-Russell traction on a) incidence of pressure sores, and b) pre-operative pain, in patients with fractured neck of femur. The National Research Register. 2000. [Accessed: 2009 Nov 5]; Available from: URL: [https://portal.nihr.ac.uk/Profiles/NRR.aspx?Publication\\_ID=D0100101](https://portal.nihr.ac.uk/Profiles/NRR.aspx?Publication_ID=D0100101).
7. Ginz HF, Henche HR, Gottschall V. Obturator nerve blockade during hip surgery. *Anesthesiol Intensivmed* 2000;41(2):83-7.

8. Gioka M, Manoudis A, Panagiotou E, et al. Sedation with propofol and remifentanyl in exterior osteosynthesis of femoral neck fractures in elderly patients. *Reg Anesth Pain Med* 2004;29(Suppl 2):8.
9. Hemmingsen C, Nielsen JE. Intravenous ketamine for prevention of severe hypotension during spinal anaesthesia. *Acta Anaesthesiol Scand* 1991;35(8):755-7.
10. Heyburn G. The efficacy of analgesia in the elderly hip fracture patient [abstract]. *Age Ageing* 2001;29(Suppl 1):26.
11. Kristensen BB, Rasmussen S, Foldager S, et al. Fast track rehabilitation with continuous epidural analgesia for hip fracture: fase I [abstract]. *Reg Anesth Pain Med* 2003;28(Suppl 1):19.
12. Lafuente A, Moncada R, Hernandez M, et al. Hip fracture in ICU-ambulance: pain relief with remifentanil, 3To1 blockade & morphine [abstract]. 19th Annual Congress of the European Society of Intensive Care Medicine (ESICM 2006), 2006 Sep 24-27, CCIB Convention Centre, Barcelona (Spain) 2006.
13. Magistris L, Greco M, Bertoli E, et al. Postoperative analgesia with fascia iliaca block in elderly patients with hip fracture [abstract]. Meeting of the European Society of Anaesthesiology (ESA 2006), 2006 Jun 2-5, Madrid, Spain 2006.
14. Messaoudi K, Azaiez W, Ammous A, Raddaoui K, et al. Combined lumbar and sciatic plexus block compared with unilateral bupivacaine spinal anesthesia for hip fractures in the elderly: preliminary results. 2009.
15. Mortensen NHM, Kuurl E, Schantz K, et al. Post-operative analgesic treatment in hip fracture patients: a controlled comparison of nicomorphine and morphine. *Acta Orthop Scand Suppl* 1991;62(246):42-3.
16. Mosaffa F, Esmaelijah A, Khoshnevis H. Analgesia before performing a spinal block in the lateral decubitus position in patients with femoral neck fracture: a comparison between fascia iliaca block and IV fentanyl [Abstract]. *Reg Anesth Pain Med* 2005;30(5 Suppl):61.
17. Mosaffa F, Razavi S. A comparison between fascia iliaca block and IV fentanyl for analgesia before spinal block in the lateral decubitus position in femoral neck fracture. *Pain Pract* 2009;148.
18. Mosaffa F. A comparison between fascia iliaca block and IV fentanyl for analgesia before performing a spinal block in the sitting position in patients with femoral neck fracture [Abstract]. 14th World Congress of Anaesiologists (WCA 2008), 2008 Mar 2-7, Cape Town International Convention Center, Cape Town (South Africa) 2008.
19. Peiro CM, Errando CL, Soriano JL, et al. Single shot spinal anaesthesia with low dose hyperbaric bupivacaine (3.75 mg), for hip fracture repair surgery in the elderly. XXVI Annual Congress of the European Society of Regional Anaesthesia and Pain Therapy (ESRA 2007), 2007 Sep 12-15, Valencia, Spain 2007.
20. Rebelo H, Garcia T, Oliveira R, et al. Postoperative epidural analgesia in femoral neck fracture. *Reg Anesth Pain Med* 2010;Conference(var.pagings):E161-October.
21. Scott F, Butler M. Easing the pressure for hip fracture patients. *Nurs Times* 91[29], 30-31. 1995.

22. Shaaban Ali M, Abd El Hakeem E, Askar OA, et al. Pre-incisional versus postoperative 3-in-1 femoral nerve block in patients undergoing surgery for fracture neck of femur [abstract]. *Reg Anesth Pain Med* 2007;32(5 Suppl 1):129.
23. Szucs S, Iohom G. Functional recovery following operative fixation of fractured neck of femur in the elderly. *Reg Anesth Pain Med* 2010;E181.
24. Triki Z. Comparison between hypobaric unilateral spinal anaesthesia and conventional spinal anesthesia in elderly patients for hip trauma. Annual Meeting of the European Society of Anaesthesiology on Euroanaesthesia (Euroanaesthesia 2007), 2007 June 9-12, Munich, Germany 2007.
25. Twiston-Davies CW, Goodwin MI, Baxter PJ. Rectal indomethacin for postoperative pain in orthopaedic surgery: a double-blind study. *J Bone Joint Surg Br* 1990;72(3):510-1.
26. Vaca JM, Aldecoa C, Fernandez A, et al. Block 3 in 1 versus morphine intravenous P.C.A. in postoperative orthopaedic hip surgery pain. *Rev Soc Esp Dolor* 1995;2(1):11-4. (Spa).
27. Van Haevre V, Biboulet P, Jourdan A, et al. Comparison of the hemodynamic effects in the aged patient with hip fracture during continuous spinal anesthesia, propofol targeted controlled infusion and sevoflurane anesthesia. *Acta Anaesthesiol Belg* 2009;60(2):143.
28. Yao CZ, Zhang Z, Diao YC, et al. Surgical repair of the fracture of neck of femur using spinal anesthesia with hypobaric bupivacaine. *Chin J Anesthesiol* 1997;17(5):305-7. (Chi).

## Ongoing, Unpublished Trial

1. A new clinical pathway for patients with fractured neck of femur. *Clinicaltrials gov.* 2009. [Accessed: 2009 Nov 3]; Available from: URL: <http://ClinicalTrials.gov/show/NCT00667914>.
2. Cameron J. Ultrasound guided three-in-one nerve block for the relief of acute pain from fractured neck of femur: a double-blind, randomised, controlled trial. *ACTRN.* 2009. [Accessed: 2009 Nov 3]; Available from: URL: <http://www.anzctr.org.au/ACTRN12608000067370.aspx>.
3. Continuous spinal anesthesia versus combined spinal epidural block. *Clinicaltrials gov.* 2009. [Accessed: 2009 Nov 3]; Available from: URL: <http://ClinicalTrials.gov/show/NCT00616044>.
4. Fascia iliaca compartment blockade as analgesia for hip fractures in the acute phase. *Clinicaltrials gov.* 2009. [Accessed: 2009 Nov 3]; Available from: URL: <http://ClinicalTrials.gov/show/NCT00162630>.
5. Gustafson Y. Home rehabilitation for older people with hip fracture: a randomised controlled trial. *ISRCTN.* 2009. [Accessed: 2009 Nov 5]; Available from: URL: <http://www.controlled-trials.com/ISRCTN15738119/>.
6. Improving pain and function in hip fracture. *Clinicaltrials gov.* 2009. [Accessed: 2009 Nov 3]; Available from: URL: <http://ClinicalTrials.gov/show/NCT00749489>.
7. Intrathecal Magnesium and Postoperative Analgesia. *Clinicaltrials gov.* 2009. [Accessed: 2009 Nov 3]; Available from: URL: <http://ClinicalTrials.gov/show/NCT00560092>.

8. Levens FA. Intra-and post-operative analgesia for patients undergoing surgery for hip fracture: role of fascia iliaca compartment block. *ISRCTN*. 2009. [Accessed: 2009 Nov 10]; Available from: URL: <http://www.controlled-trials.com/ISRCTN75659782/ISRCTN75659782>.
9. Morrison RS. Improving pain and function in hip fracture. *CRISP*. 2009.
10. Norspan versus oxycontin as postoperative painkiller to proximal extracapsular fractures of the femur. *Clinicaltrials gov*. 2009. [Accessed: 2009 Nov 3]; Available from: URL: <http://ClinicalTrials.gov/show/NCT00964808>.
11. Park E. Ultrasound-guided femoral nerve block as a mode of analgesia in patients presenting with a hip fracture to the emergency department. *ANZCTR*. 2009. [Accessed: 2009 Nov 10]; Available from: URL: <http://www.anzctr.ora.au/ACIRN12609000526279.aspx>.
12. Postoperative analgesia with local infiltration after hip fracture. *Clinicaltrials gov*. 2009. Available from: URL: <http://ClinicalTrials.gov/show/NCT00529425>.
13. Resnick B. Testing the exercise plus program following hip fracture. *CRISP*. 2009.
14. TRAUMEEL for pain after fracture of neck of femur. *Clinicaltrials gov*. 2009. [Accessed: 2009 Nov 3]; Available from: URL: <http://ClinicalTrials.gov/show/NCT00307905>.
15. Winso O. Femoral nerve blockade in hip fracture patients: a randomised controlled trial. *ISRCTN*. 2009. [Accessed: 209 Nov 12]; Available from: URL: <http://www.controlled-trials.com/ISRCTN46653818/ISRCTN46653818>.

### **Foreign Language With No Translation Available for Review**

1. Asao Y, Kasai SY, Higuchi T, et al. Which anesthetic technique is more suitable for hip fracture surgery in patients above the age of 85, spinal or epidural? *Masui* 2005;54(6):638-42. (Jap).
2. Bendtsen TF, Koscielniak-Nielsen ZJ. Ultralydvejledt perifer nervebloade. *Ugeskr Laeger* 2007;169(12):1096. (Nor).
3. Biffoli F, Piacentino V, Meconcelli G, et al. The effect of anesthesiologic technique on the mental state of elderly patients submitted for orthopedic surgery of the lower limbs. *Minerva Anesthesiol* 1998;64(1-2):13-9. (Ita).
4. Gregersen M, Jensen NC, Morch MM, et al. [The effect of geriatric intervention on rehabilitation of elderly patients with hip fracture]. *Ugeskr Laeg* 2009;171(46):3336-40. (Dan).
5. Idland G, Bjercke KA, Ljunggren AE. Pilot project in Ulleval: early rehabilitation of elderly patients with femoral neck fractures. *Sykepleien Fag* 1993;81(6):48-51. (Nor).
6. Kamitani K, Higuchi A, Asahi T, et al. Postoperative delirium after general anesthesia vs. spinal anesthesia in geriatric patients. *Masui* 2003;52(9):972-5. (Jap).
7. Kullenberg B, Ysberg B, Heilman M, et al. Femoral nerve block as pain relief in hip fracture: a good alternative in perioperative treatment proved by a prospective study. *Lakartidningen* 2004;101(24):2104-7. (Swe).

8. Nagara M, Uchimura K, Nagara H, et al. Epidural anesthesia for the repair of the femoral neck fracture in elderly patients. *Masui* 1995;44(3):419-22. (Jap).
9. Palm H, Foss NB, Kristensen MT. [Reconvalescence after surgery for proximal femoral fractures]. *Ugeskr Laeg* 2009;171(40):2896-9. (Dan).
10. Rasmussen S, Kristensen BB, Foldager S, et al. Accelerated recovery programme after hip fracture. *Ugeskr Laeger* 2003;165(1):29-33. (Dan).
11. Wajima Z, Kurosawa H, Inoue T, et al. Changes in dementia rating scale scores of elderly patients with femoral neck fracture during perioperative period. *Masui* 1995;44(11):1489-97. (Jap).

## Unavailable for Review Through Library Services

1. Ali AM, Tahoun HM, Ahmed AA, et al. Comparative study between the analgesic efficacies of nerve stimulator-guided 3-in-1 block, ultrasonographic-guided 3-in-1 block and posterior approach lumbar plexus block following total hip arthroplasty. *Egypt J Anaesth* 2003;19(1):39-44.
2. Berlin JE. Physical activity during rehabilitation and functional outcomes after rehabilitation in patients with hip fractures. Combined Sections Meeting of the Specialty Sections of the American Physical Therapy Association (CSM 2006), San Diego Convention Center, San Diego, California (USA), 1-5 Feb 2006 2006.
3. Bonilla CÃ, Nieto E. Fracturas pertrocant3ricas del extremo proximal del f3mur en pacientes mayores de 60 a3os: evaluaci3n de dos m3todos terap3uticos a3os 1998-2003. *Rev venez cir ortop traumatol* 2008;40(1):5-11. (Spa).
4. Chen FS, Rosen JE, Hiebert R, Koval KJ, et al. The efficacy of preoperative skin traction after hip fractures: a prospective randomized study. 2009.
5. Derossi D, Bo A, Bergonzi R, et al. Six-week administration of a mixture of ergogenic and osteotrophic ingredients (Restorfast) improves the clinical course of elderly patients after hip fracture surgery. [Italian]. *Trends in Medicine* 2009;9(4):235-42.
6. Draper P, Scott F. Report of a project to evaluate the use of Hamilton Russell traction in the pre-operative management of patients with hip fracture [abstract]. *J Orthop Nurs* 2[1], 56-57. 1997.
7. Farkas G. Utilization of inpatient care rehabilitation in patients with hip fracture. 7th European Trauma Congress, Cankarjev dom, Cultural and Congress Centre, 2006 14-17 May, Ljubljana, Slovenia 2006.
8. Frondini C, Lunardelli ML. Comprehensive care of elderly patients with hip fracture: the orthogeriatric model. *Ital J Med* 2010;4(2):105-10.
9. Hadzic A. Lower extremity peripheral nerve blocks: an update. *Lijec Vjesn* 2005;127(SUPPL. 2):52-60.
10. Johansen A. Optimising hip fracture aftercare. *Care Elderly* 1995;7(3):8.
11. Othman MM, Hasheesh MA, Attia AA. Optimal sedation of propofol versus midazolam in geriatrics during regional anaesthesia for hip orthopedic surgery. *Benha Med J* 2000;171-88.

12. Scivoletto G, Bo A, Derossi D, et al. Ten week administration of a polynutritional supplement with muscle tone action (Riablylex) improves the functional recovery in elderly hip fracture patients during home rehabilitation. [Italian]. Trends in Medicine 2010;10(2):113-20.
13. Thiagarajah S, Samad S, Maguire P, et al. Anaesthetic vs. operative time in patients undergoing femoral neck fracture fixation. First Joint Congress of the European Association for Trauma and Emergency Surgery and the European Trauma Society, 2007 May 23-26, Graz, Austria 2007.
14. Xu ZH, Tang S, Luo AL, et al. [Application of lumbar plexus blockade for hip fracture repair in elderly patients]. [Chinese]. Chung-Kuo i Hsueh Ko Hsueh Yuan Hsueh Pao Acta Academiae Medicinae Sinicae 2010;32(3):328-31.



## Appendix E. Description of Included Studies

**Table E-1. Systemic analgesia**

Study	Study characteristics	Interventions	Inclusion/Exclusion criteria
Apostolopoulos 2006 <sup>41</sup>	Study design: RCT Study period: Jan-03 to Jul-04 Type of hospital: General hospital Country: Switzerland Financial support: NR	Intervention #1: Classification: IV analgesia Intervention: Parecoxib IV Dosage: 40mg Intervals: Every 12hrs  Intervention #2: Classification: IM analgesia Intervention: Diclofenac IM; Pethidine IM Dosage: 75mg; NR Intervals: Every 12hrs; on demand	Main inclusion criteria: Pts operated for fracture of hip joint  Main exclusion criteria: NR
Baker 2004 <sup>42</sup>	Study design: RCT Study period: NR Type of hospital: University hospital Country: Austria Financial support: Financial support provided by institutional and/or departmental sources	Intervention #1: Classification: Intrathecal analgesia Intervention: Clonidine (Isotonic) Dosage: 150ug Intervals: Single administration  Intervention #2: Classification: Intrathecal analgesia Intervention: Clonidine (Hypertonic) Dosage: 150ug Intervals: Single administration	Main inclusion criteria: Elderly pts undergoing surgery after traumatic hip fractures under general anesthesia  Main exclusion criteria: Contraindications to spinal anesthesia, unable to understand study protocol, severe deformities of spine, history of untreated hypertensive disease, or receiving treatment with $\beta$ -adrenergic blockers
Poitevin 1999 <sup>55</sup>	Study design: Randomized controlled trials Study period: NR to NR Type of hospital: University hospital Country: Argentina Financial support: NR	Intervention #1: Classification: Analgesia Intervention: Lysine clonixinate Dosage: 125mg Intervals: every 8 hr  Intervention #2: Classification: Analgesia Intervention: Metamizole Dosage: 400mg Intervals: every 8 hr	Main inclusion criteria: Patients aged 50-85 years old; <3 days since trauma leading to hip fracture; undergoing surgery  Main exclusion criteria: Patients with allergies to investigational drug; GI problems; psychiatric disorders; any other use of anti-inflammatory analgesic drugs

IM = intramuscular; IV = intravenous; NR = NR; RCT = randomized controlled trial

**Table E-2. Anesthesia**

<b>Study</b>	<b>Study characteristics</b>	<b>Interventions</b>	<b>Inclusion/Exclusion criteria</b>
Adams 1990 <sup>56</sup>	Study design: Randomized controlled trials Study period: NR to NR Type of hospital: University hospital Country: Germany Financial support:	Intervention #1: Classification: Spinal anesthesia Intervention: Bupivacaine 0.5%/Mepivacaine 4% Dosage: NR Intervals: NR  Intervention #2: Classification: General anesthesia Intervention: NR Dosage: NR Intervals: NR	Main inclusion criteria: age 60+, proximal hip fracture  Main exclusion criteria: Patients who insisted on a specific type of anesthesia or who were not eligible for the anesthesia types used in the study
Alonso Chico 2003 <sup>57</sup>	Study design: Randomized controlled trials Study period: NR to NR Type of hospital: University hospital Country: Spain Financial support: NR	Intervention #1: Classification: Spinal anesthesia Intervention: Bupivacaine 0.5%/ Fenantyl Dosage: 5mg/15ug Intervals: Single administration  Intervention #2: Classification: Spinal anesthesia Intervention: Bupivacaine 0.5% Dosage: 7.5mg Intervals: Single administration	Main inclusion criteria: Patients aged >75 years; ASA II-III; pro-trochanteric fracture  Main exclusion criteria: Patients with contraindications to subarachnoid anesthesia or uncontrolled cardiac; respiratory; or neurologic disease
Ben-David 2000 <sup>58</sup>	Study design: RCT Study period: NR Type of hospital: General hospital Country: Israel Financial support: Financial support provided by institutional and/or departmental sources	Intervention #1: Classification: Spinal anesthesia (single) Intervention: Bupivacaine/Fentanyl Dosage: 4mg/20ug Intervals: Single administration  Intervention #2: Classification: Spinal anesthesia (single) Intervention: Bupivacaine Dosage: 10mg Intervals: Single administration	Main inclusion criteria: Pts >70yr presenting for open surgical repair of hip fracture  Main exclusion criteria: NR

**Table E-2. Anesthesia (continued)**

<b>Study</b>	<b>Study characteristics</b>	<b>Interventions</b>	<b>Inclusion/Exclusion criteria</b>
Bredahl 1991 <sup>59</sup>	Study design: Randomized Controlled Trial Study period: NR Type of hospital: University Hospital Country: Denmark Financial support: NR	Intervention #1: Classification: Spinal Anaesthesia Intervention: Bupivacaine 0.5% Dosage: 2.5-3 ml Intervals: NR  Intervention #2: Classification: General Anaesthesia Intervention: Thiopentone Dosage: 2-4 mg/kg Intervals: once	Main inclusion criteria: female patients, more than 60 years old, with hip fracture, otherwise healthy (ASA class I or II)  Main exclusion criteria: NR
Casati 2003 <sup>60</sup>	Study design: RCT Study period: NR Type of hospital: University hospital Country: Italy Financial support: NR	Intervention #1: Classification: Spinal anesthesia (single) Intervention: Bupivacaine 0.5% Dosage: 7.5mg Intervals: Single administration  Intervention #2: Classification: General anesthesia Intervention: None Dosage: NA Intervals: NA	Main inclusion criteria: Pts ASA II-III undergoing hemiarthroplasty for repair of fractured femur  Main exclusion criteria: Contraindications to spinal anesthesia or laryngeal mask placement, severe cardiovascular or pulmonary disease, or psychiatric pathology
Danelli 2008 <sup>61</sup>	Study design: RCT Study period: May-06 to Jul-06 Type of hospital: University hospital Country: Italy Financial support: NR	Intervention #1: Classification: Spinal anesthesia (single) Intervention: Levobupivacaine 0.5% Dosage: 15mg Intervals: Single administration  Intervention #2: Classification: Spinal anesthesia (single) Intervention: Levobupivacaine 0.75% Dosage: 15mg Intervals: Single administration	Main inclusion criteria: ASA I-III; >18 yrs  Main exclusion criteria: Unable to understand, cooperate, or communicate with investigators, any contraindication to spinal anesthesia, or had a known history of hypersensitivity to local anesthetics

**Table E-2. Anesthesia (continued)**

Study	Study characteristics	Interventions	Inclusion/Exclusion criteria
Favarel-Garrigues 1996 <sup>62</sup>	Study design: RCT Study period: Sep-92 to Apr-94 Type of hospital: University hospital Country: France Financial support: NR	<p>Intervention #1: Classification: Spinal anesthesia (continuous) Intervention: Bupivacaine 0.5% Dosage: Bolus: Bupivacaine 5mg (1ml); Maintenance: Bupivacaine 2.5mg (0.5ml) Intervals: Single administration; Continuous administration on demand</p> <p>Intervention #2: Classification: Spinal anesthesia (single) Intervention: Bupivacaine 0.5% Dosage: Based on age and ht (15mg between 70 and 79 yr and/or &gt;170 cm height, 12.5mg between 80 and 90 yr and/or between 150 and 170 cm, 10mg &gt;90 yr and/or &lt;150 cm) Intervals: Single administration</p>	<p>Main inclusion criteria: Pts ≥ 70 yrs, ASA I-III, undergoing hip fracture surgery</p> <p>Main exclusion criteria: Pts did not accept regional anesthesia, or had contraindications for spinal anesthesia, or severely altered mental status</p>
Hooda 2006 <sup>63</sup>	Study design: RCT Study period: NR Type of hospital: University hospital Country: India Financial support: NR	<p>Intervention #1: Classification: Spinal anesthesia (single) Intervention: Bupivacaine 0.5%/Fentanyl Dosage: 4mg (0.8ml)/20mg (0.4ml) Intervals: Single administration</p> <p>Intervention #2: Classification: Spinal anesthesia (single) Intervention: Bupivacaine 0.5%/Fentanyl Dosage: 5mg (1.0ml)/20mg (0.4ml) Intervals: Single administration</p> <p>Intervention #3: Classification: Spinal anesthesia (single) Intervention: Bupivacaine 0.5%/Fentanyl Dosage: 6mg (1.2ml)/20mg (0.4ml) Intervals: Single administration</p>	<p>Main inclusion criteria: Pts of either sex, ≥60 yrs, scheduled to undergo open surgical repair of hip fractures</p> <p>Main exclusion criteria: &lt;60 yrs, ASA III or more, contraindications to spinal anesthesia (e.g., peripheral neuropathy, coagulopathy, spinal deformity, infection at the injection site), or known hypersensitivity to amide local anesthetics or fentanyl</p>

**Table E-2. Anesthesia (continued)**

<b>Study</b>	<b>Study characteristics</b>	<b>Interventions</b>	<b>Inclusion/Exclusion criteria</b>
Juelsgaard 1998 <sup>64</sup>	Study design: RCT Study period: NR Type of hospital: University hospital Country: Denmark Financial support: NR	Intervention #1: Classification: Spinal anesthesia (incremental) Intervention: Bupivacaine 0.5% Dosage: 1.6ml Intervals: Incremental dosage  Intervention #2: Classification: Spinal anesthesia (single) Intervention: Bupivacaine 0.5% Dosage: 2.5ml Intervals: Single administration  Intervention #3: Classification: General anesthesia Intervention: Fentanyl Dosage: Bolus: 1-2ug per kg/Maintenance: 25-50ug Intervals: Single administration/Continuous administration (on demand)	Main inclusion criteria: Pts with known CAD scheduled for osteosynthesis of a femoral neck fracture  Main exclusion criteria: Uncooperative pts, recent myocardial infarction, unstable angina pectoris, significant aortic stenosis, or contraindication to spinal anesthesia, or had factors that adversely affect the quality of the Holter analysis or had failure of monitoring for 36hrs

**Table E-2. Anesthesia (continued)**

<b>Study</b>	<b>Study characteristics</b>	<b>Interventions</b>	<b>Inclusion/Exclusion criteria</b>
Klimscha 1995 <sup>65</sup>	Study design: RCT Study period: NR Type of hospital: University hospital Country: Austria Financial support: NR	Intervention #1: Classification: Spinal anesthesia (continuous) Intervention: Bupivacaine 0.5% plus clonidine Dosage: 1ml bupivacaine/1ml Clonidine Intervals: Continuous administration (3 repetitive doses)  Intervention #2: Classification: Spinal anesthesia (continuous) Intervention: Bupivacaine 0.5% Dosage: 10ml bupivacaine Intervals: Continuous administration (3 repetitive doses)  Intervention #3: Classification: Epidural anesthesia (continuous) Intervention: Bupivacaine 0.5%/clonidine Dosage: 10ml bupivacaine/1ml Clonidine Intervals: Continuous administration (3 repetitive doses)  Intervention #4: Classification: Epidural anesthesia (continuous) Intervention: Bupivacaine 0.5% Dosage: 10ml bupivacaine Intervals: Continuous administration (3 repetitive doses)	Main inclusion criteria: Elderly pts undergoing hip surgery after traumatic fractures  Main exclusion criteria: Pts with usual contraindications to spinal or epidural anesthesia, had senile dementia and those with severe deformities of the spinal column

**Table E-2. Anesthesia (continued)**

<b>Study</b>	<b>Study characteristics</b>	<b>Interventions</b>	<b>Inclusion/Exclusion criteria</b>
Koval 1999 <sup>78</sup>	Study design: Prospective Cohort Study Study period: July 1987 to June 1995 Type of hospital: University Hospital Country: USA Financial support: NR	Intervention #1: Classification: Spinal Anaesthesia Intervention: NR Dosage: NR Intervals: NR  Intervention #2: Classification: General Anaesthesia Intervention: NR Dosage: NR Intervals: NR	Main inclusion criteria: age ≥ 65, previously ambulatory and home dwelling, and had femoral neck or intertrochanteric hip fracture of non-pathologic origin  Main exclusion criteria: moderate to severe dementia
Krobot 2006 <sup>77</sup>	Study design: nRCT Study period: NR Type of hospital: General hospital Country: Croatia Financial support: NR	Intervention #1: Classification: Spinal anesthesia (single) Intervention: Levobupivacaine/Fentanyl Dosage: 7.5mg/0.01mg Intervals: Single administration  Intervention #2: Classification: Spinal anesthesia (single) Intervention: Levobupivacaine Dosage: 10mg Intervals: Single administration	Main inclusion criteria: Elderly pts undergoing hip fracture repair  Main exclusion criteria: NR
Kwan 1997 <sup>66</sup>	Study design: RCT Study period: Jul-95 to Dec-95 Type of hospital: General hospital Country: Hong Kong Financial support: NR	Intervention #1: Classification: Spinal anesthesia (single) Intervention: Bupivacaine 0.5%/Morphine Dosage: 2.2ml/0.2mg Intervals: Single administration  Intervention #2: Classification: Spinal anesthesia (single) Intervention: Bupivacaine 0.5% Dosage: 2.2ml Intervals: Single administration	Main inclusion criteria: Pts, ASA I-IV, scheduled for emergency surgery for a fractured hip  Main exclusion criteria: Pts who had contraindications to regional anesthesia, or an allergy to the study drugs (bupivacaine, morphine)

**Table E-2. Anesthesia (continued)**

Study	Study characteristics	Interventions	Inclusion/Exclusion criteria
Labaille 1992 <sup>79</sup>	Study design: Prospective cohort study Study period: NR Type of hospital: General hospital Country: France Financial support: NR	Intervention #1: Classification: Spinal anesthesia (continuous) Intervention: Bupivacaine 0.125%/Bupivacaine 0.125% Dosage: Bolus: 3ml/Maintenance: 1ml Intervals: Single administration/Continuous administration (on demand)  Intervention #2: Classification: Spinal anesthesia (continuous) Intervention: Bupivacaine 0.5%/Bupivacaine 0.5% Dosage: Bolus: 3ml/Maintenance: 1ml Intervals: Single administration/Continuous administration (on demand)	Main inclusion criteria: Pts, ASA I-II, aged 70-97 yrs old without any known CVD who were scheduled for repair of femoral neck or trochanteric fracture under spinal anesthesia  Main exclusion criteria: NR
Malek 2004 <sup>67</sup>	Study design: RCT Study period: NR Type of hospital: University hospital Country: Czech Republic Financial support: Financial support provided by institutional and/or departmental sources	Intervention #1: Classification: Spinal anesthesia (single) Intervention: Bupivacaine 0.5%/Fentanyl Dosage: 3ml/50ug Intervals: Single administration  Intervention #2: Classification: Spinal anesthesia (single) Intervention: Bupivacaine 0.5%/Sufentanil Dosage: 3ml/5ug Intervals: Single administration  Intervention #3: Classification: Spinal anesthesia (single) Intervention: Bupivacaine 0.5% Dosage: 3ml Intervals: Single administration	Main inclusion criteria: Pts scheduled to be operated on for hip fracture  Main exclusion criteria: Pts with suspected allergy to opiates, common contraindications of spinal anesthesia and inability to perform dural puncture in L3—L4 or L2—L3 vertebral interspaces



**Table E-2. Anesthesia (continued)**

Study	Study characteristics	Interventions	Inclusion/Exclusion criteria
Martyr 2001 <sup>68</sup>	Study design: RCT Study period: NR Type of hospital: General hospital Country: Australia Financial support: Financial support provided by institutional and/or departmental sources	Intervention #1: Classification: Spinal anesthesia (single) Intervention: Bupivacaine/Fentanyl Dosage: 7.5mg/20ug Intervals: Single administration  Intervention #2: Classification: Spinal anesthesia (single) Intervention: Bupivacaine Dosage: 12.5mg Intervals: Single administration	Main inclusion criteria: Pts with a fractured neck of femur requiring internal fixation with a Richards pin and plate  Main exclusion criteria: NR
Martyr 2005 <sup>69</sup>	Study design: RCT Study period: NR Type of hospital: General hospital Country: Australia Financial support: Financial support provided by institutional and/or departmental sources	Intervention #1: Classification: Spinal anesthesia (single) Intervention: Bupivacaine/Fentanyl Dosage: 9.0mg/20ug Intervals: Single administration  Intervention #2: Classification: Spinal anesthesia (single) Intervention: Bupivacaine Dosage: 11.0mg Intervals: Single administration	Main inclusion criteria: >70 yrs with fractured neck of femur requiring internal fixation with a DHS or hemiarthroplasty and < 70 kg estimated body weight  Main exclusion criteria: NR
Maurette 1993 <sup>70</sup>	Study design: RCT Study period: NR Type of hospital: University hospital Country: France Financial support: NR	Intervention #1: Classification: Spinal anesthesia (continuous) Intervention: Bolus: lidocaine 1.6%/meperidine 1%; Maintenance: lidocaine 1.6% Dosage: NA/4ml (200mg); NA Intervals: Continuous administration  Intervention #2: Classification: Spinal anesthesia (continuous) Intervention: Bolus: lidocaine 1.6%; Maintenance: lidocaine 1.6% Dosage: NA Intervals: Continuous administration	Main inclusion criteria: Pts undergoing elective surgery for fracture of the neck of the femur and able to describe their pain with accuracy  Main exclusion criteria: Bedridden pts or suffering from severe dehydration or senile dementia

**Table E-2. Anesthesia (continued)**

<b>Study</b>	<b>Study characteristics</b>	<b>Interventions</b>	<b>Inclusion/Exclusion criteria</b>
Miller 1990 <sup>81</sup>	Study design: Retrospective cohort study Study period: 30317 to 32478 Type of hospital: General hospital Country: Germany Financial support:	Intervention #1: Classification: Spinal anesthesia Intervention: Mepivacaine 4 % Dosage: 2ml (80 mg) Intervals: NR  Intervention #2: Classification: General anesthesia Intervention: Fentanyl Dosage: 3-5mg per kg Intervals: NR	Main inclusion criteria: Proximal hip fracture  Main exclusion criteria: NR
Minville 2006 <sup>71</sup>	Study design: RCT Study period: Nov-03 to Nov-04 Type of hospital: University hospital Country: France Financial support: NR	Intervention #1: Classification: Spinal anesthesia (continuous) Intervention: Bupivacaine Dosage: 2.5mg Intervals: Continuous administration  Intervention #2: Classification: Spinal anesthesia (single) Intervention: Bupivacaine Dosage: 7.5mg Intervals: Single administration	Main inclusion criteria: 75 yrs who underwent surgery for open surgical repair of hip fracture  Main exclusion criteria: Contraindication to spinal anesthesia or continuous spinal anesthesia including patient refusal, intracranial hypertension, major hemostasis anomalies or local infection, dementia, allergic reaction to local anesthetics, anemia (hemoglobin <10 g/dL), as well as being treated with aspirin

**Table E-2. Anesthesia (continued)**

<b>Study</b>	<b>Study characteristics</b>	<b>Interventions</b>	<b>Inclusion/Exclusion criteria</b>
Minville 2008 <sup>82</sup>	<p>Study design: Retrospective cohort study</p> <p>Study period: Jan-01 to Dec-04</p> <p>Type of hospital: University hospital</p> <p>Country: France</p> <p>Financial support: No external funding</p>	<p>Intervention #1: Classification: Spinal anesthesia (continuous) Intervention: Bupivacaine 0.5% Dosage: 2.5mg Intervals: Continuous administration</p> <p>Intervention #2: Classification: Spinal anesthesia (continuous) Intervention: Bupivacaine 0.5% Dosage: 5mg Intervals: Continuous administration</p> <p>Intervention #3: Classification: Spinal anesthesia (single) Intervention: Bupivacaine 0.5% Dosage: NR Intervals: Single administration</p> <p>Intervention #4: Classification: General anesthesia Intervention: Sulfentanil Dosage: NR Intervals: NR</p>	<p>Main inclusion criteria: Pts over 75 yrs old who underwent surgical repair of femoral neck fractures</p> <p>Main exclusion criteria: NR</p>
Navas 2008 <sup>72</sup>	<p>Study design: RCT</p> <p>Study period: NR</p> <p>Type of hospital: University hospital</p> <p>Country: Spain</p> <p>Financial support: NR</p>	<p>Intervention #1: Classification: Spinal anesthesia (continuous) Intervention: Bupivacaine 0.15-0.25% Dosage: NR Intervals: Continuous administration</p> <p>Intervention #2: Classification: Spinal anesthesia (single) Intervention: Bupivacaine 0.5% Dosage: NR Intervals: Single administration</p>	<p>Main inclusion criteria: Pts undergoing surgery for hip fracture</p> <p>Main exclusion criteria: NR</p>

**Table E-2. Anesthesia (continued)**

Study	Study characteristics	Interventions	Inclusion/Exclusion criteria
Olofsson 2004 <sup>73</sup>	Study design: RCT Study period: NR Type of hospital: General hospital Country: Sweden Financial support: Financial support provided by institutional and/or departmental sources	<p>Intervention #1: Classification: Spinal anesthesia (single) Intervention: Bupivacaine/sufentanil Dosage: 7.5mg/5mg Intervals: Single administration</p> <p>Intervention #2: Classification: Spinal anesthesia (single) Intervention: Bupivacaine Dosage: 15mg Intervals: Single administration</p>	<p>Main inclusion criteria: Pts, ASA II, scheduled for surgery after hip fracture, who could understand oral information</p> <p>Main exclusion criteria: Uncooperative pts, unstable angina, significant aortic stenosis, recent myocardial infarction, coagulation disorders, contraindications to spinal anesthesia</p>
Qamarul Hoda 2007 <sup>146</sup>	Study design: RCT Study period: NR Type of hospital: University hospital Country: Pakistan Financial support: NR	<p>Intervention #1: Classification: Spinal anesthesia (single) Intervention: Bupivacaine/Fentanyl Dosage: 6mg/20ug Intervals: Single administration</p> <p>Intervention #2: Classification: Spinal anesthesia (single) Intervention: Bupivacaine/Fentanyl Dosage: 8mg/20ug Intervals: Single administration</p> <p>Intervention #3: Classification: Spinal anesthesia (single) Intervention: Bupivacaine Dosage: 10mg Intervals: Single administration</p>	<p>Main inclusion criteria: Elderly pts, ASA I-III, 65 yrs and scheduled for surgical repair of hip fracture.</p> <p>Main exclusion criteria: Pts with any contraindication for spinal anesthesia</p>

**Table E-2. Anesthesia (continued)**

<b>Study</b>	<b>Study characteristics</b>	<b>Interventions</b>	<b>Inclusion/Exclusion criteria</b>
Rais 2008 <sup>75</sup>	Study design: RCT Study period: NR Type of hospital: Orthopedic hospital Country: Tunisia Financial support: NR	Intervention #1: Classification: Spinal anesthesia (continuous) Intervention: Bupivacaine 0.5% Dosage: 2.5mg Intervals: Single administration  Intervention #2: Classification: Spinal anesthesia (continuous) Intervention: Bupivacaine 0.5% Dosage: 5mg Intervals: Single administration	Main inclusion criteria: Pts with no contraindication to continuous spinal anesthesia  Main exclusion criteria: NR
Said-Ahmed 2006 <sup>76</sup>	Study design: RCT Study period: NR Type of hospital: University hospital Country: Egypt Financial support: NR	Intervention #1: Classification: Spinal anesthesia (single) Intervention: Bupivacaine 0.5%/Fentanyl Dosage: 5mg/20mcg Intervals: Single administration  Intervention #2: Classification: Spinal anesthesia (single) Intervention: Bupivacaine 0.5%/Sufentanil Dosage: 5mg/5mcg Intervals: Single administration  Intervention #3: Classification: Spinal anesthesia (single) Intervention: Bupivacaine 0.5% Dosage: 10mg Intervals: Single administration	Main inclusion criteria: Pts, ASA I-II, aged 70 yrs or older, undergoing either insertion of Austin-Moore prosthesis or DHS for fixation of femur neck fractures  Main exclusion criteria: NR

**Table E-2. Anesthesia (continued)**

<b>Study</b>	<b>Study characteristics</b>	<b>Interventions</b>	<b>Inclusion/Exclusion criteria</b>
Sen 2007 <sup>83</sup>	Study design: Retrospective cohort study Study period: Aug-00 to Oct-01 Type of hospital: University hospital Country: Turkey Financial support: NR	Intervention #1: Classification: Spinal anesthesia (single - lateral) Intervention: Bupivacaine 0.5% Dosage: 10mg Intervals: Single administration  Intervention #2: Classification: Spinal anesthesia (single - supine) Intervention: Bupivacaine 0.5% Dosage: 10mg Intervals: Single administration	Main inclusion criteria: Elderly pts, ASA I-II, who had undergone spinal anesthesia for hip surgery and who had ejection fraction < 50%  Main exclusion criteria: NR
Shih 2010 <sup>84</sup>	Study design: Retrospective Cohort Study Study period: 2002 to 2006 Type of hospital: University Hospital Country: Taiwan Financial support: NR	Intervention #1: Classification Spinal Anaesthesia Intervention: Bupivacaine Dosage: 8-15 mg Intervals: once  Intervention #2: Classification: General Anaesthesia Intervention: Thiopental Dosage: NR Intervals: NR	Main inclusion criteria: NR  Main exclusion criteria: Patients with multiple fractures, with pathologic fractures, with other acute diseases when admitted, or with patient-controlled analgesia, or received both spinal and general anesthesia
Sutcliffe 1994 <sup>85</sup>	Study design: Prospective Cohort Study Study period: NR Type of hospital: University Hospital Country: England Financial support: NR	Intervention #1: Classification: Spinal Anaesthesia Intervention: Bupivacaine Dosage: NR Intervals: NR Intervention #2: Classification: General Anaesthesia Intervention: NR Dosage: NR Intervals: NR	Main inclusion criteria: NR  Main exclusion criteria: NR

ASA = American Society of Anesthesiology; IM = intramuscular; IV = intravenous; NR = NR; nRCT = nonrandomized controlled trial; RCT = randomized controlled trial

**Table E-3. Complementary and alternative medicine (CAM)**

<b>Study</b>	<b>Study characteristics</b>	<b>Interventions</b>	<b>Inclusion/Exclusion criteria</b>
Barker 2006 <sup>43</sup>	Study design: RCT Study period: NR Type of hospital: University hospital Country: Austria Financial support: NR	Intervention #1: Classification: Auricular acupressure Intervention: 1-mm plastic acupressure beads Dosage: 3 true auricular acupressure points Intervals: Single administration  Intervention #2: Classification: Sham Control Intervention: 1-mm acupressure plastic beads Dosage: 3 sham auricular acupressure points Intervals: Single administration	Main inclusion criteria: Pts aged 80–95 yrs, ASA II–III, who sustained an isolated hip fracture without any additional trauma  Main exclusion criteria: Not fluent in German, with ear deformity, severe neurologic or psychiatric disorders, long-term use of sedatives or analgesics
Martin 1991 <sup>54</sup>	Study design: RCT Study period: 1988 to 1989 Type of hospital: General hospital Country: US Financial support: NR	Intervention #1: Classification: Relaxation Intervention: Jacobson relaxation technique/ Meperidine/ Morphine Dosage: NA Intervals: Instruction given prior to surgery  Intervention #2: Classification: Analgesia Intervention: Meperidine/Morphine Dosage: NR Intervals: NR	Main inclusion criteria: Pts, 60 yrs old and older with a fractured hip to be surgically repaired by internal fixation  Main exclusion criteria: Pts with known psychiatric illness or mental retardation, pathologic fractures as a result of metastasis to bone, inability to cooperate or follow instructions, and multiple trauma

ASA = American Society of Anesthesiology; IM = intramuscular; IV = intravenous; NR = NR; RCT = randomized controlled trial

**Table E-4. Multimodal pain management**

Study	Study characteristics	Interventions	Inclusion/Exclusion criteria
Milisen 2001 <sup>86</sup>	Study design: Prospective cohort study Study period: Sep-96 to Mar-97 Type of hospital: University hospital Country: Belgium Financial support: NR	Intervention #1: Classification: Multimodal pain management Intervention: Bolus: Tramadol IV; Maintainence (48hrs): Tramadol IV + propacetamol IV; Maintainence (Day 3-5): oral tramadol + oral paracetamol Dosage: 3mg/ kg; 6mg/k/ 24hrs; 120mg per kg per 24hours/NA Intervals: Continuous administration  Intervention #2: Classification: Standard care Intervention: NR Dosage: NR Intervals: NR	Main inclusion criteria: Dutch-speaking and verbally testable pts admitted with a traumatic fracture of proximal femur within 24 hrs of surgery  Main exclusion criteria: Pts with multiple trauma, concussion, pathological fractures, surgery occurring > 72 hrs after admission, aphasia, blindness, deafness, and < 9 yrs formal education
Ogilvie-Harris 1993 <sup>87</sup>	Study design: Prospective cohort study Study period: NR Type of hospital: University hospital Country: Canada Financial support: NR	Intervention #1: Classification: Mutlimodal pain management Intervention: Skin Traction/Morphine/Acetaminophen Dosage: NA/2.5-5mg/1000mg Intervals: Rewrap every 8hrs/every 4hrs/every 4hrs  Intervention #2: Classification: Standard care Intervention: NR Dosage: NR Intervals: NR	Main inclusion criteria: Geriatric pts with hip fractures  Main exclusion criteria: NR

ASA = American Society of Anesthesiology; IM = intramuscular; IV = intravenous; NR = NR; RCT = randomized controlled trial



**Table E-5. Nerve blocks**

<b>Study</b>	<b>Study characteristics</b>	<b>Interventions</b>	<b>Inclusion/Exclusion criteria</b>
Antonopoulou 2006 <sup>88</sup>	Study design: RCT Study period: NR Type of hospital: General hospital Country: Greece Financial support: NR	Intervention #1: Classification: Femoral nerve block Intervention: Bolus: Levobupivacaine 0.25%; Maintenance: Levobupivacaine 0.12% Dosage: 18ml Intervals: Single administration; Continuous administration  Intervention #2: Classification: Analgesia Intervention: Paracetamol; Pethidine Dosage: 500mg; NR Intervals: Every 8hrs; on demand	Main inclusion criteria: Pts with hip fracture  Main exclusion criteria: NR
Chudinov 1999 <sup>89</sup>	Study design: RCT Study period: NR Type of hospital: General hospital Country: Israel Financial support: NR	Intervention #1: Classification: Psoas Compartment Block (continuous) Intervention: Bupivacaine 0.25% Dosage: Bolus: 2mg per kg; Maintenance: 2mg per kg Intervals: Single administration/Maintenance: every 12hrs  Intervention #2: Classification: IM analgesia Intervention: Meperidine IM Dosage: 1mg per kg Intervals: On demand (max every 5hrs)	Main inclusion criteria: Pts with unilateral fractures of the neck of the femur  Main exclusion criteria: Severe cardiac, pulmonary, renal, or liver dysfunction, systemic infection, decubitus ulcers, dementia, aspirin or anticoagulant treatment, or known hypersensitivity to local anesthetic agents

**Table E-5. Nerve blocks (continued)**

<b>Study</b>	<b>Study characteristics</b>	<b>Interventions</b>	<b>Inclusion/Exclusion criteria</b>
Coad 1991 <sup>90</sup>	<p>Study design: RCT                      Study period: NR                      Type of hospital: General hospital                      Country: UK                      Financial support: NR</p>	<p>Intervention #1:                      Classification: 3-in-1 nerve block                      Intervention: Bupivacaine 0.5%                      Dosage: 15ml                      Intervals: Single administration</p> <p>Intervention #2:                      Classification: Lateral cutaneous Nerve Block                      Intervention: Bupivacaine 0.5%                      Dosage: 15ml                      Intervals: Single administration</p> <p>Intervention #3:                      Classification: Standard care                      Intervention: NR                      Dosage: NR                      Intervals: NR</p>	<p>Main inclusion criteria: Pts undergoing either pin-and-plate or compression-screw fixation of the femoral neck</p> <p>Main exclusion criteria: Pts who were receiving analgesic drugs, were suffering from dementia, or if regional anesthesia was thought to be indicated</p>
Cuvillon 2007 <sup>91</sup>	<p>Study design: Randomized controlled trials                      Study period: 36404 to 37408                      Type of hospital: University hospital                      Country: France                      Financial support: Fondation de l'avenir (Paris)</p>	<p>Intervention #1:                      Classification: 3-in-1 nerve block (NS)                      Intervention: Ropivacaine                      Dosage: Catheter attached to pump allowing continuous ropivacaine 0.2% at 10 mL/hr x 48 hr                      Intervals: Continuous</p> <p>Intervention #2:                      Classification: Analgesia                      Intervention: Paracetamol                      Dosage: 1st dose 2g then 2g                      Intervals: every 6 hours</p> <p>Intervention #3:                      Classification: Analgesia                      Intervention: Morphine                      Dosage: 2 mg q5min in post-op until VAS &lt;30 then 0.1 mg/kg q4 hr; if VAS &gt;30 dosage increased by 50%                      Intervals: NA</p>	<p>Main inclusion criteria: Pts ≥70 yrs; operation for traumatic fracture sup. femur under spinal anesthetic</p> <p>Main exclusion criteria: Patient refusal to participate; &gt; 72 hr delay between fall and surgery; Pts &lt; 70 yrs; weight &lt; 40 kg; ASA score &gt; 4; contraindications to locoregional analgesia; neuropathy; severe renal or hepatic insufficiency; noncooperative patients; mini mental score less than 15/30</p>

**Table E-5. Nerve blocks (continued)**

Study	Study characteristics	Interventions	Inclusion/Exclusion criteria
de Visme 2000 <sup>92</sup>	Study design: RCT Study period: NR Type of hospital: University hospital Country: France Financial support: Financial support provided by institutional and/or departmental sources	Intervention #1: Classification: Combined lumbar/sacral plexus block (NS) Intervention: Lidocaine 1.33% Dosage: 45mL Intervals: Single administration  Intervention #2: Classification: Spinal anesthesia (single) Intervention: Bupivacaine 0.5% Dosage: 3mL Intervals: Single administration	Main inclusion criteria: Pts > 65 yrs with proximal femoral fracture  Main exclusion criteria: Pts with evidence of cognitive deficit (MMSE <5), contraindication to spinal anesthesia, or peripheral nerve block
Del Rosario 2008 <sup>117</sup>	Study design: Retrospective cohort study Study period: Oct-04 to Oct-05 Type of hospital: General hospital Country: Spain Financial support: NR	Intervention #1: Classification: Femoral nerve block (NS)/IV analgesia Intervention: Bolus: Bupivacaine 0.25%; Maintenance: bupivacaine 0.1%; PCA: Paracetamol IV/metamizol IV Dosage: 30ml/5ml/1g/2g Intervals: Single administration; Maintenance: every hr; Patient controlled bolus: every 6hrs/every 8hrs  Intervention #2: Classification: IV analgesia Intervention: Paracetamol IV; metamizol IV Dosage: 1g; 2g Intervals: Every 6hrs; every 8hrs	Main inclusion criteria: Pts > 50 yrs who underwent hip fracture surgery with intradural anesthesia  Main exclusion criteria: Pts who received general or epidural analgesia, presented failure of femoral analgesia, or had localized infection or coagulopathy

**Table E-5. Nerve blocks (continued)**

Study	Study characteristics	Interventions	Inclusion/Exclusion criteria
Eyrolle 1998 <sup>93</sup>	Study design: RCT Study period: NR Type of hospital: University hospital Country: France Financial support: NR	Intervention #1: Classification: Posterior lumbar plexus block Intervention: Lidocaine 2%/Bupivacaine 0.5% Dosage: NR Intervals: NR  Intervention #2: Classification: Spinal anesthesia (single) Intervention: Bupivacaine 0.5% Dosage: NR Intervals: Single administration	Main inclusion criteria: Pts undergoing femoral neck osteosynthesis  Main exclusion criteria: NR
Fletcher 2003 <sup>94</sup>	Study design: RCT Study period: Feb to Aug Type of hospital: General hospital Country: UK Financial support: NR	Intervention #1: Classification: 3-in-1 nerve block (NS) Intervention: Bupivacaine 0.5% Dosage: 20mL Intervals: Single administration  Intervention #2: Classification: IV analgesia Intervention: Morphine IV Dosage: 5-10mg Intervals: On demand	Main inclusion criteria: Pts with all types of fractured neck of femur  Main exclusion criteria: Confused, with a bleeding diathesis, taking warfarin, local or systemic infection, or previous hypersensitivity to local anesthetics

**Table E-5. Nerve blocks (continued)**

Study	Study characteristics	Interventions	Inclusion/Exclusion criteria
Foss 2005 <sup>95</sup>	<p>Study design: RCT            Study period: Jan-03 to Apr-04            Type of hospital: University hospital            Country: Denmark            Financial support: Financial support provided by governmental sources</p>	<p>Intervention #1:            Classification: Epidural analgesia (continuous)            Intervention: Bupivacaine 0.125%/morphine            Dosage: 4ml of 50ug per ml per hr            Intervals: Continuous infusion (four days)</p> <p>Intervention #2:            Classification: Placebo            Intervention: Saline            Dosage: NA            Intervals: Continuous infusion (four days)</p>	<p>Main inclusion criteria: ≥65 yrs living in own home, intact cognitive status, able to provide written informed consent, New Mobility Score of ≥3 (indicating independent indoor ambulation)</p> <p>Main exclusion criteria: Refused to participate, prefracture hospitalization, contraindications to epidural analgesia, regular prefracture opioid or glucocorticoid therapy, alcohol or substance abuse, morphine intolerance, and postoperative restrictions for ambulation</p>
Foss 2007 <sup>96</sup>	<p>Study design: Randomized controlled trials            Study period: May-03 to Jan-06            Type of hospital: University hospital            Country: Denmark            Financial support: Imk Almene Fond</p>	<p>Intervention #1:            Classification: Fascia iliaca compartment nerve block (CT)            Intervention: 1.0% mepivacaine            Dosage: 40 mL 1.0% mepivacaine with 1:200 000 epinephrine; 0.02 mL/kg placebo IM injection of 0.9% saline            Intervals: Single dose</p> <p>Intervention #2:            Classification: Analgesia            Intervention: Morphine            Dosage: 40 mL placebo FICB with 0.9% saline; 0.02 mL/kg 5.0 mg/mL morphine            Intervals: Single dose</p>	<p>Main inclusion criteria: Clinical signs of hip fracture as assessed by the ED staff; intact cognitive status on admission; and the ability to provide written informed consent.</p> <p>Main exclusion criteria: Refusal to participate in the study; previous surgery in the affected hip; regular prefracture opioid or glucocorticoid therapy; alcohol or substance abuse; infection at the injection site; morphine intolerance; or any previous opioid administration for the acute pain and nonconfirmation of the hip fracture suspicion on x-ray</p>

**Table E-5. Nerve blocks (continued)**

<b>Study</b>	<b>Study characteristics</b>	<b>Interventions</b>	<b>Inclusion/Exclusion criteria</b>
Gille 2006 <sup>97</sup>	<p>Study design: Randomized controlled trials</p> <p>Study period: NR to NR</p> <p>Type of hospital: University hospital</p> <p>Country: Germany</p> <p>Financial support: No industry funding</p>	<p>Intervention #1:</p> <p>Classification: Femoral nerve block</p> <p>Intervention: Prilocaine 1%/ Ropivacaine 0.2%</p> <p>Dosage: 40ml/ 30ml</p> <p>Intervals: Single administration/ Continuous (every 6hrs)</p> <p>Intervention #2:</p> <p>Classification: Analgesia</p> <p>Intervention: Metamizol/ Tilidine; Ibuprofen</p> <p>Dosage: 1g / 100mg; 400mg</p> <p>Intervals: Single administration/ single administration; every 8hrs</p>	<p>Main inclusion criteria: Isolated hip fracture</p> <p>Main exclusion criteria: Open fracture or fracture associated with neurological injury; age&lt;18 years; inability to swallow pills; contraindication for regional anesthesia or medications in trial; ongoing opioid analgesic therapy; multiple injuries; repeat intervention</p>
Graham 2008 <sup>98</sup>	<p>Study design: RCT</p> <p>Study period: Apr-00 to Oct-01</p> <p>Type of hospital: General hospital</p> <p>Country: UK</p> <p>Financial support: NR</p>	<p>Intervention #1:</p> <p>Classification: 3-in-1 nerve block (NS)</p> <p>Intervention: Bupivacaine 0.5%</p> <p>Dosage: 30ml</p> <p>Intervals: Single administration</p> <p>Intervention #2:</p> <p>Classification: IV analgesia</p> <p>Intervention: Morphine IV</p> <p>Dosage: 0.1mg per kg</p> <p>Intervals: Single administration</p>	<p>Main inclusion criteria: Pts &gt; 16 yrs presenting with clinical or radiological evidence of fractured hip</p> <p>Main exclusion criteria: Pts with suspected allergy or contraindication to either morphine or bupivacaine, or if they had an abbreviated mental test score &lt;9</p>
Haddad 1995 <sup>99</sup>	<p>Study design: RCT</p> <p>Study period: NR</p> <p>Type of hospital: General hospital</p> <p>Country: UK</p> <p>Financial support: No external funding</p>	<p>Intervention #1:</p> <p>Classification: Femoral nerve block (CT)</p> <p>Intervention: Bupivacaine 0.25%</p> <p>Dosage: 0.3ml per kg</p> <p>Intervals: Single administration</p> <p>Intervention #2:</p> <p>Classification: Standard care</p> <p>Intervention: NR</p> <p>Dosage: NR</p> <p>Intervals: NR</p>	<p>Main inclusion criteria: Pts with extracapsular fractures of the femoral neck</p> <p>Main exclusion criteria: Pts who were unable to score their pain due to dementia</p>

**Table E-5. Nerve blocks (continued)**

<b>Study</b>	<b>Study characteristics</b>	<b>Interventions</b>	<b>Inclusion/Exclusion criteria</b>
Henderson 2008 <sup>100</sup>	Study design: RCT Study period: NR Type of hospital: General hospital Country: US Financial support: NR	Intervention #1: Classification: Femoral nerve block/Opioids Intervention: Bupivacaine 0.5% Dosage: NR/NR Intervals: Continuous/On demand  Intervention #2: Classification: Standard care Intervention: Opioids Dosage: NR Intervals: Intermittent	Main inclusion criteria: ≥55 yrs presenting to the ED with acute hip fractures  Main exclusion criteria: NR
Hood 1991 <sup>101</sup>	Study design: RCT Study period: NR Type of hospital: General hospital Country: UK Financial support: NR	Intervention #1: Classification: 3-in-1 nerve block Intervention: Prilocaine 0.75% Dosage: 43ml Intervals: Single administration  Intervention #2: Classification: Standard care Intervention: NR Dosage: NR Intervals: NR	Main inclusion criteria: > 60 yrs with intertrochanteric fractures of neck of femur requiring surgical correction with compression screw or pin and plate devices  Main exclusion criteria: Contraindication to a regional technique, allergy to local anesthetic agents, or systemic disease that indicated an alternative method of anesthesia
Kocum 2007 <sup>118</sup>	Study design: Retrospective cohort study Study period: Sep-04 to Aug-05 Type of hospital: University hospital Country: Turkey Financial support: NR	Intervention #1: Classification: Lumbar plexus plus sciatic block (NS) Intervention: Ropivacaine 0.25% Dosage: 60ml Intervals: Single administration  Intervention #2: Classification: Lumbar plexus plus sciatic block (NS) Intervention: Bupivacaine 0.25% Dosage: 60ml Intervals: Single administration	Main inclusion criteria: Pts, ASA III-IV, who underwent unilateral femur or hip surgery with lumbar plexus and sciatic nerve blockade  Main exclusion criteria: Pts ASA I-II and those who received additional anesthesia modalities or who had other fractures

**Table E-5. Nerve blocks (continued)**

Study	Study characteristics	Interventions	Inclusion/Exclusion criteria
Mannion 2005 <sup>102</sup>	Study design: RCT Study period: NR Type of hospital: University hospital Country: Ireland Financial support: NR	<p>Intervention #1: Classification: Psoas compartment block (NS) Intervention: Levobupivacaine 0.5%/Clonidine IV Dosage: 0.4mL per kg/1ug per kg Intervals: Single administration</p> <p>Intervention #2: Classification: Psoas compartment block (NS) Intervention: Levobupivacaine 0.5%/Clonidine (peripheral) Dosage: 0.4mL per kg/1ug per kg Intervals: Single administration</p> <p>Intervention #3: Classification: Psoas compartment block (NS) Intervention: Levobupivacaine 0.5% Dosage: 0.4mL per kg Intervals: Single administration</p>	<p>Main inclusion criteria: Pts scheduled for surgical repair of traumatic hip fractures</p> <p>Main exclusion criteria: Concurrent medication with adrenoceptor agonists, antagonists, or contraindications to regional anesthesia</p>
Marhofer 1997 <sup>103</sup>	Study design: RCT Study period: NR Type of hospital: University hospital Country: Austria Financial support: NR	<p>Intervention #1: Classification: 3-in-1 nerve block (US) Intervention: Bupivacaine 0.5% Dosage: 20ml Intervals: Single administration</p> <p>Intervention #2: Classification: 3-in-1 nerve block (NS) Intervention: Bupivacaine 0.5% Dosage: 20ml Intervals: Single administration</p>	<p>Main inclusion criteria: Pts undergoing hip surgery after trauma</p> <p>Main exclusion criteria: Pts who refused to participate or had contraindication to local anesthetics or puncture in the inguinal area, or unable to understand the study protocol</p>



**Table E-5. Nerve blocks (continued)**

Study	Study characteristics	Interventions	Inclusion/Exclusion criteria
Marhofer 1998 <sup>104</sup>	Study design: RCT Study period: NR Type of hospital: University hospital Country: Austria Financial support: NR	<p>Intervention #1: Classification: 3-in-1 nerve block (US) Intervention: Bupivacaine 0.5% Dosage: 20ml Intervals: Single administration</p> <p>Intervention #2: Classification: 3-in-1 nerve block (NS) Intervention: Bupivacaine 0.5% Dosage: 20ml Intervals: Single administration</p> <p>Intervention #3: Classification: 3-in-1 nerve block (NS) Intervention: Bupivacaine 0.5% Dosage: 30ml Intervals: Single administration</p>	<p>Main inclusion criteria: Pts, ASA II-III, scheduled for surgery of nondislocated hip fractures following trauma</p> <p>Main exclusion criteria: Refusal by the patient, allergies to local anesthetics, or general contraindications against puncture in the inguinal area, or unable to understand the study protocol because of language or other difficulty</p>
Marhofer 2000 <sup>105</sup>	Study design: RCT Study period: NR Type of hospital: University hospital Country: Austria Financial support: NR	<p>Intervention #1: Classification: 3-in-1 nerve block (NS) Intervention: Ropivacaine 0.5% Dosage: 20ml Intervals: Single administration</p> <p>Intervention #2: Classification: 3-in-1 nerve block (NS) Intervention: Bupivacaine 0.5% Dosage: 20ml Intervals: Single administration</p>	<p>Main inclusion criteria: ASA I-III, scheduled for hip surgery after trauma</p> <p>Main exclusion criteria: Refusal by the patient, inability to understand study protocol, allergies to local anesthetics, and contraindications against puncture in the inguinal area</p>

**Table E-5. Nerve blocks (continued)**

<b>Study</b>	<b>Study characteristics</b>	<b>Interventions</b>	<b>Inclusion/Exclusion criteria</b>
Matot 2003 <sup>106</sup>	<p>Study design: RCT            Study period: Oct-98 to Sep-98            Type of hospital: University hospital            Country: Israel            Financial support: Financial support provided by institutional and/or departmental sources</p>	<p>Intervention #1:            Classification: Epidural analgesia (continuous)            Intervention: Bolus: Bupivacaine 0.25%/Methadone; Maintenance: Bupivacaine 0.5%/Methadone            Dosage: 7-10mL/4mg; 45mg/16mg            Intervals: Continuous (24hrs)</p> <p>Intervention #2:            Classification: IM analgesia            Intervention: Meperidine IM            Dosage: 1mg per kg            Intervals: Every 6hrs</p>	<p>Main inclusion criteria: ≥60 yrs with traumatic hip fracture, able to sign informed consent, known CAD or at high risk for CAD</p> <p>Main exclusion criteria: Contraindications to epidural analgesia, suspected allergy to study drugs, acute coronary insufficiency, ECG evidence of left bundle branch block, or ≥ 10 hrs from the time of injury</p>
Monzon 2010 <sup>107</sup>	<p>Study design: Randomized Controlled Trial            Study period: June 2006 to Jan 2008            Type of hospital: University Hospital            Country: Argentina            Financial support: No conflicts of interest</p>	<p>Intervention #1:            Classification: Fasciialia compartment block            Intervention: 0.25% bupivacaine            Dosage: 0.3 ml/kg            Intervals: NR</p> <p>Intervention #2:            Classification: General Anaesthesia            Intervention: IV NSAID analgesics            Dosage: NR            Intervals: NR</p>	<p>Main inclusion criteria: adult patients more than 65 years old who presented to the ED because of a previously undiagnosed and untreated hip fracture</p> <p>Main exclusion criteria: anatomical abnormalities in the inguinal area different from fracture, known coagulation disorders, a history of allergy to any of the active ingredients used during the study and refusal to participate</p>
Mouzopoulos 2009 <sup>108</sup>	<p>Study design: RCT            Study period: Jul-04 to Mar-08            Type of hospital: General hospital            Country: Greece            Financial support: NR</p>	<p>Intervention #1:            Classification: Fascia iliaca compartment nerve block (CT)            Intervention: Bupivacaine            Dosage: 0.25mg dose of 0.3mL per kg            Intervals: every 24h before and after surgery</p> <p>Intervention #2:            Classification: Placebo            Intervention: Saline            Dosage: NA            Intervals: Every 24h before and after surgery</p>	<p>Main inclusion criteria: ≥ 70 yrs, admitted for hip fracture</p> <p>Main exclusion criteria: Delirium at admission, metastatic hip cancer, hx bupivacaine allergy, use of cholinesterase inhibitors, severe coagulopathy, Parkinsonism, epilepsy, levodopa treatment, delay of surgery &gt; 72 hrs after admission, inability to participate in interviews (e.g. dementia, respiratory isolation, intubation, aphasia, coma or terminal illness)</p>

**Table E-5. Nerve blocks (continued)**

Study	Study characteristics	Interventions	Inclusion/Exclusion criteria
Murgue 2006 <sup>109</sup>	Study design: Randomized controlled trials Study period: 37622 to 37987 Type of hospital: General hospital Country: France Financial support: NR	<p>Intervention #1: Classification: Femoral nerve block Intervention: Mepivacaine Dosage: 20 cc Intervals: NA</p> <p>Intervention #2: Classification: Analgesia Intervention: IV morphine Dosage: 2 mg Intervals: 1 mg q5 min until p&lt;=4</p> <p>Intervention #3: Classification: Analgesia Intervention: IV paracetamol + ketoprofen Dosage: 1 g P + 100 mg K Intervals: NA</p>	<p>Main inclusion criteria: Patients with suspected fractured neck of femur admitted to ED; cognitive functioning to assess pain &gt;27 high SES &gt;24 low SES</p> <p>Main exclusion criteria: Contraindications to equimolar mix of nitrous oxide/O<sub>2</sub>; contraindications to femoral block; allergy to morphine and/or paracetamol/ketoprofene; known renal insufficiency; already receiving morphine Rx</p>
Pedersen 2008 <sup>119</sup>	Study design: Retrospective cohort study Study period: Jan-03 to Mar-04 Type of hospital: University hospital Country: Denmark Financial support: No external funding	<p>Intervention #1: Classification: 3-in-1 nerve block Intervention: Bupivacaine Dosage: Bolus: 100mg; Maintenance: 50mg Intervals: Single administration; continuous (every 8hrs)</p> <p>Intervention #2: Classification: Analgesia Intervention: Preoperative: Morphine SC or tablets; Postoperative: Morphine SR tablets/acetaminophen or ibuprofen Dosage: 2.5-5mg/10-20mg; 1g/or 400mg Intervals: Every 12hrs; every 8hr/or every 12hrs</p>	<p>Main inclusion criteria: Pts undergoing surgery for a nonpathological, low-energy hip fracture</p> <p>Main exclusion criteria: Pts who did not receive a femoral nerve catheter or were not admitted to hip fracture unit</p>

**Table E-5. Nerve blocks (continued)**

Study	Study characteristics	Interventions	Inclusion/Exclusion criteria
Scheinin 2000 <sup>110</sup>	Study design: RCT Study period: Jan-95 to Jan-97 Type of hospital: University hospital Country: Finland Financial support: Financial support provided by institutional, departmental and/or governmental sources	Intervention #1: Classification: Epidural analgesia (continuous) Intervention: Bupivacaine/Fentanyl Dosage: 1mg per ml + 10ug per ml Intervals: Continuous administration  Intervention #2: Classification: IM analgesia Intervention: Oxycodone IM Dosage: 0.1-0.15mg per kg Intervals: On demand (max every 6hrs)	Main inclusion criteria: Elderly pts admitted for surgical repair of a traumatic hip fracture  Main exclusion criteria: Known coagulation abnormalities, progressive neurologic diseases, sepsis and skin infections in lumbar region, restless or uncooperative (e.g., dementia), or significant conduction abnormalities or no sinus rhythm
Segado Jiménez 2009 <sup>111</sup>	Study design: RCT Study period: May 2008 to Dec 2008 Type of hospital: University hospital Country: Spain Financial support: NR	Intervention #1: Classification: Obturator/ Femoral cutaneous nerve block Intervention: NR Dosage: NR Intervals: NR  Intervention #2: Classification: Obturator nerve block Intervention: NR Dosage: NR Intervals: NR  Intervention #3: Classification: IV analgesia Intervention: NR Dosage: NR Intervals: NR	Main inclusion criteria: Patients undergoing hip surgery with subarachnoid blockage  Main exclusion criteria: General anesthesia, IV analgesic drugs during surgery, untreated chronic pain, arrhythmias/MI, or neurological disorders

**Table E-5. Nerve blocks (continued)**

Study	Study characteristics	Interventions	Inclusion/Exclusion criteria
Segado Jimenez 2010 <sup>112</sup>	Study design: Randomized Controlled Trial Study period: 2009 to 2010 Type of hospital: University Hospital Country: Spain Financial support: No funding	Intervention #1: Classification: Fascia iliaca compartment block Intervention: Bupivacaine 0.5% Dosage: 30 ml Intervals: NR  Intervention #2: Classification: Obturator /femoralcutaneous nerves block Intervention: Bupivacaine 0.5% Dosage: 15ml / 5 ml Intervals: NR  Intervention #3: Classification: General Anaesthesia Intervention: NR Dosage: NR Intervals: NR	Main inclusion criteria: patients with hip surgery, total or partial arthroplasty, and osteosynthesis of femor  Main exclusion criteria: patients with previous treatment for chronic pain, ischemic cardiopathic, or arrhythmia, psychiatric and neurodegenerative diseases, poor collaboration and comprehension, allergy to local anaesthetics, and contraindication to local/regional anaesthetics
Spansberg 1996 <sup>113</sup>	Study design: RCT Study period: NR Type of hospital: University hospital Country: Denmark Financial support: NR	Intervention #1: Classification: Lumbar plexus block (NS) Intervention: Bolus: Bupivacaine 0.5%; Maintenance: Bupivacaine 0.25% Dosage: 0.4mL per kg; 0.14mL per kg per hr Intervals: Single administration; Continuous administration  Intervention #2: Classification: Placebo Intervention: Bolus: Saline; Maintenance: Saline Dosage: 0.4mL per Kg; 0.14mL per kg per hr Intervals: Continuous administration	Main inclusion criteria: Pts with femoral neck fractures  Main exclusion criteria: NR

**Table E-5. Nerve blocks (continued)**

<b>Study</b>	<b>Study characteristics</b>	<b>Interventions</b>	<b>Inclusion/Exclusion criteria</b>
Tuncer 2003 <sup>114</sup>	<p>Study design: RCT            Study period: NR            Type of hospital: University hospital            Country: Turkey            Financial support: NR</p>	<p>Intervention #1:            Classification: 3-in-1 nerve block (NS)            Intervention: Bolus: Lidocaine 2%/Maintainence: Bupivacaine 0.125%; PCA bolus: Bupivacaine 0.125%            Dosage: 30ml; 4ml per hr; 3ml            Intervals: Single administration;            Continuous administration; Patient cotrolled bolus on demand</p> <p>Intervention #2:            Classification: IV analgesia            Intervention: Morphine IV            Dosage: 1mg            Intervals: On demand</p>	<p>Main inclusion criteria: Pts, ASA I–II, scheduled for trochanteric fracture repair</p> <p>Main exclusion criteria: Pts with coagulation abnormalities, &lt;18 or &gt;80 yrs, wt &lt;50 or &gt;100 kg, suspected allergy to bupivacaine or opioids, previous analgesic treatment with opioids, inability to understand pain scales or use a patient controlled analgesia device</p>
Turker 2003 <sup>115</sup>	<p>Study design: RCT            Study period: NR            Type of hospital: University hospital            Country: Turkey            Financial support: NR</p>	<p>Intervention #1:            Classification: Psoas compartment block (NS)            Intervention: Bupivacaine 0.5%            Dosage: 30ml            Intervals: Single administration</p> <p>Intervention #2:            Classification: Epidural anesthesia (single)            Intervention: Bupivacaine 0.5%            Dosage: 15ml            Intervals: Single administration</p>	<p>Main inclusion criteria: Pts, ASA I–III, scheduled for unilateral hip surgery</p> <p>Main exclusion criteria: Contraindications to regional anesthesia, suspected allergy to any local anesthetic, dementia preventing proper comprehension, and refusal of the procedure</p>

**Table E-5. Nerve blocks (continued)**

Study	Study characteristics	Interventions	Inclusion/Exclusion criteria
Yun 2009 <sup>116</sup>	Study design: Randomized controlled trials Study period: 39264 to 39417 Type of hospital: University hospital Country: Korea Financial support: NR	Intervention #1: Classification: Fascia iliaca compartment nerve block (CT) Intervention: Ropivacaine Dosage: 30 mL 3.75 mg/mL 2-3 min Intervals: Single dose  Intervention #2: Classification: Analgesia Intervention: Alfentanil Dosage: 10 ug/kg bolus; 0.25 ug/kg/min 2 min Intervals: Single dose	Main inclusion criteria: Patients with an isolated femoral neck fracture scheduled to undergo either compression hip screw or hip replacement surgery.  Main exclusion criteria: A suspected allergy to amide local anaesthetics; haemorrhagic diathesis; periperal neuropathy or mental disorders.

ASA = American Society of Anesthesiology; CT = clinical touch; IM = intramuscular; IV = intravenous; NR = NR; NS = nerve stimulation; RCT = randomized controlled trial; US = ultrasound

**Table E-6. Neurostimulation**

Study	Study characteristics	Interventions	Inclusion/Exclusion criteria
Gorodetskyi 2007 <sup>120</sup>	Study design: RCT Study period: Feb-05 to Nov-05 Type of hospital: University hospital Country: Russia Financial support: Financial support provided by a commercial party	Intervention #1: Classification: Neurostimulation Intervention: InterX 5000 device Dosage: high peak amplitude averaging 17 volts on skin with low current of 6 mA, and damped biphasic electrical impulses Intervals: Every 24hrs  Intervention #2: Classification: Sham Control Intervention: NA Intervals: Every 24hrs	Main inclusion criteria: Between 60 and 75 yrs, undergone stabilization of A2 femoral trochanteric fracture  Main exclusion criteria: Limitations that interfere with electrical stimulation (e.g., insulin pumps, pacemakers, neurostimulation implants), hx epilepsy or seizure, bilateral fractures, fractures of pathological origin, excluding osteoporosis
Lang 2007 <sup>121</sup>	Study design: RCT Study period: NR Type of hospital: University hospital Country: Austria Financial support: NR	Intervention #1: Classification: Neurostimulation Intervention: Transcutaneous electrical nerve stimulation Dosage: 70 mA, frequency range: 0.5 to 120 Hz, pulse width: 60 to 300 us, Intervals: Single administration  Intervention #2: Classification: Sham Control Intervention: NA Intervals: Single administration	Main inclusion criteria: >19 yrs, acute pain (>60 mm VAS) in region of hip  Main exclusion criteria: Analgesics in previous 48 hr, neurologic impairment of legs, cognitive impairment or inability to communicate, potentially dangerous internal diseases (ASA score >3), or hip pain from causes other than fracture

ASA = American Society of Anesthesiology; IM = intramuscular; IV = intravenous; NR = not reported; RCT = randomized controlled trial



**Table E-7. Rehabilitation**

<b>Study</b>	<b>Study characteristics</b>	<b>Interventions</b>	<b>Inclusion/Exclusion criteria</b>
Di Lorenzo 2007 <sup>122</sup>	Study design: RCT Study period: Jan-02 to Oct-06 Type of hospital: General hospital Country: Italy Financial support: NR	Intervention #1: Classification: Rehabilitation Intervention: Stretching/strengthening of spinal and psoas muscles Dosage: 1 hr of training Intervals: Every 12 hrs for 4 wk  Intervention #2: Classification: Standard care Intervention: NR Dosage: NR Intervals: NR	Main inclusion criteria: Pts with extracapsular unstable hip fracture who underwent surgery and have back pain on ipsilateral side of fracture despite standard rehabilitation  Main exclusion criteria: Previous chronic back pain, back surgery, spinal stenosis, spondylolisthesis or anxiety and depression

NR = Not reported; RCT = randomized controlled trial

**Table E-8. Traction**

<b>Study</b>	<b>Study characteristics</b>	<b>Interventions</b>	<b>Inclusion/Exclusion criteria</b>
Anderson 1993 <sup>128</sup>	Study design: nRCT Study period: Nov-91 to Jul-93 Type of hospital: General hospital Country: UK Financial support: No external funding	Intervention #1: Classification: Skin traction Intervention: Hamilton-Russell skin traction Dosage: 5lb (2.3kg)  Intervention #2: Classification: Standard care Intervention: NR Dosage: NR	Main inclusion criteria: Pts with fractures of the proximal femur  Main exclusion criteria: Refused informed consent or consent could not be obtained (e.g., dementia), contraindications for use of skin traction (e.g., poor skin, ulceration of lower limb, peripheral arterial disease, severe edema and lower limb deformities)
Finsen 1992 <sup>123</sup>	Study design: RCT Study period: NR Type of hospital: General hospital Country: Norway Financial support: NR	Intervention #1: Classification: Skin traction Intervention: Elastic bandages Dosage: 3kg  Intervention #2: Classification: Skeletal traction Intervention: Steinman pin Dosage: 10% of the patient's body weight  Intervention #3: Classification: Pillow Intervention: Standard pillow	Main inclusion criteria: > 50 yrs admitted with recent cervical, trochanteric or subtrochanteric hip fractures  Main exclusion criteria: NR
Ghnamat 2005 <sup>129</sup>	Study design: nRCT Study period: Feb-02 to Oct-04 Type of hospital: General hospital Country: Jordan Financial support: NR	Intervention #1: Classification: Skin traction Intervention: Skin traction Dosage: 6lb Intervals: NA  Intervention #2: Classification: Standard care Intervention: NR Dosage: NR Intervals: NR	Main inclusion criteria: Pts admitted with fractures of the proximal femur  Main exclusion criteria: Allergy to adhesive bandages, ulceration in lower limbs, peripheral arterial disease, severe edema or lower limb deformities, or refused to be part of the study

**Table E-8. Traction (continued)**

<b>Study</b>	<b>Study characteristics</b>	<b>Interventions</b>	<b>Inclusion/Exclusion criteria</b>
Jerre 2000 <sup>124</sup>	<p>Study design: RCT                      Study period: NR                      Type of hospital: University hospital                      Country: Sweden                      Financial support: NR</p>	<p>Intervention #1:                      Classification: Skin traction                      Intervention: Foam rubber boot with straps around the lower leg                      Dosage: 3Kg                      Intervals: NA</p> <p>Intervention #2:                      Classification: Standard care                      Intervention: NR                      Dosage: NR                      Intervals: NR</p> <p>Intervention #3:                      Classification: Skin traction                      Intervention: Foam rubber boot with straps around the lower leg                      Dosage: 3Kg                      Intervals: NA</p> <p>Intervention #4:                      Classification: Standard care                      Intervention: NR                      Dosage: NR                      Intervals: NR</p>	<p>Main inclusion criteria: Pts with cervical or trochanteric hip fractures</p> <p>Main exclusion criteria: Pts unwilling or unable to provide consent for enrollment</p>
Needoff 1993 <sup>125</sup>	<p>Study design: RCT                      Study period: NR                      Type of hospital: General hospital                      Country: UK                      Financial support: NR</p>	<p>Intervention #1:                      Classification: Skin traction                      Intervention: Ventilated foam strap secured by means of a crepe bandage                      Dosage: 2.5kg                      Intervals: NA</p> <p>Intervention #2:                      Classification: Pillow                      Intervention: Standard pillow                      Dosage: NA                      Intervals: NA</p>	<p>Main inclusion criteria: &gt; 60 yrs with cervical or pertrochanteric femoral fractures undergoing surgical hip fracture repair</p> <p>Main exclusion criteria: Cognitively impaired pts on the Mini-Mental State Examination</p>

**Table E-8. Traction (continued)**

<b>Study</b>	<b>Study characteristics</b>	<b>Interventions</b>	<b>Inclusion/Exclusion criteria</b>
Resch 1998 <sup>126</sup>	Study design: RCT Study period: NR Type of hospital: University hospital Country: Sweden Financial support: Financial support provided by governmental sources	Intervention #1: Classification: Skin traction Intervention: Foam boot Dosage: 3kg Intervals: NA  Intervention #2: Classification: Skeletal traction Intervention: K-wire Dosage: 3-5kg (5-10% body weight) Intervals: NA	Main inclusion criteria: Displaced hip fractures  Main exclusion criteria: Pts who could not give consent, declined participation or had local skin problems (e.g., leg ulcers)
Resch 2005 <sup>26</sup>	Study design: RCT Study period: NR Type of hospital: University hospital Country: Sweden Financial support: Financial support provided by institutional and/or departmental sources	Intervention #1: Classification: Skin traction Intervention: Foam rubber boot Dosage: 3kg Intervals: NA  Intervention #2: Classification: Pillow Intervention: Lasse Pillow Dosage: NA Intervals: NA  Intervention #3: Classification: Pillow Intervention: Standard pillow Dosage: NA Intervals: NA	Main inclusion criteria: Pts who had a dislocated cervical or trochanteric hip fracture, ability to give informed consent, and no local problems which would prohibit the use of skin traction, such as ulcers, eczema, or peripheral vascular disease  Main exclusion criteria: NR
Rosen 2001 <sup>127</sup>	Study design: RCT Study period: Jun-95 to Feb-97 Type of hospital: University hospital Country: US Financial support: No external funding	Intervention #1: Classification: Skin traction Intervention: Foam traction boot Dosage: 5lb Intervals: NA  Intervention #2: Classification: Pillow Intervention: Standard pillow Dosage: NA Intervals: NA	Main inclusion criteria: Pts with an isolated femoral neck or intertrochanteric hip fracture  Main exclusion criteria: < 50 yrs, underlying dementia, other concomitant injury, delayed hospital presentation (e.g., >24 hrs after the initial injury)

**Table E-8. Traction (continued)**

<b>Study</b>	<b>Study characteristics</b>	<b>Interventions</b>	<b>Inclusion/Exclusion criteria</b>
Saygi 2010 <sup>130</sup>	<p>Study design: Retrospective cohort study            Study period: NR            Type of hospital: General hospital            Country: Turkey            Financial support: No external funding</p>	<p>Intervention #1:            Classification: Skin traction            Intervention: Traction bandages            Dosage: 2kg            Intervals: NA</p> <p>Intervention #2:            Classification: Sham traction            Intervention: Traction bandages            Dosage: 0kg            Intervals: NA</p> <p>Intervention #3:            Classification: Pillow            Intervention: Standard pillow            Dosage: NA            Intervals: NA</p>	<p>Main inclusion criteria: Pts with hip fracture</p> <p>Main exclusion criteria: Refusal to participate in the study or a cognitive inadequacy detected in their simple mental scores</p>
Vermeiren 1995 <sup>132</sup>	<p>Study design: Prospective cohort study            Study period: Jul-87 to Jun-89            Type of hospital: General hospital            Country: Belgium            Financial support: NR</p>	<p>Intervention #1:            Classification: Skeletal traction            Intervention: Skeletal traction with pillows for foot elevation            Dosage: 1 kg traction weight/10 kg body weight            Intervals: NA</p> <p>Intervention #2:            Classification: Skeletal traction            Intervention: Skeletal traction with metal splint            Dosage: 1 kg traction weight/10 kg body weight            Intervals: NA</p>	<p>Main inclusion criteria: Pts admitted with an intertrochanteric or subtrochanteric hip fracture</p> <p>Main exclusion criteria: NR</p>

**Table E-8. Traction (continued)**

<b>Study</b>	<b>Study characteristics</b>	<b>Interventions</b>	<b>Inclusion/Exclusion criteria</b>
Yip 2002 <sup>131</sup>	Study design: nRCT Study period: Aug-95 to Dec-97 Type of hospital: University hospital Country: Hong Kong Financial support: Financial support provided by institutional and/or departmental sources	Intervention #1: Classification: Skin traction Intervention: Foam boot Dosage: 2kg Intervals: NA  Intervention #2: Classification: Pillow Intervention: Standard pillow Dosage: NA Intervals: NA	Main inclusion criteria: Pts with proximal femur fracture and consenting to enrollment  Main exclusion criteria: Pts that were senile or had been taking regular analgesia prior to admission

NA = not applicable; NR = n; nRCT = nonrandomized controlled trial; RCT = randomized controlled trial

## Appendix F. Characteristics of Interventions

**Table F-1. Systemic analgesia**

		Intervention 1	Intervention 2	Intervention 3	Intervention 4
Apostolopoulos 2006 <sup>41</sup>	Classification	IV analgesia	IM analgesia	NA	NA
	Type of intervention	Parecoxib IV	Diclofenac IM; Pethidine IM		
	Dosage	40mg	75mg; NR		
	Dosage Intervals	Every 12hrs	Every 12hrs; on demand		
	Timing of intervention	Postoperative	Postoperative		
	Type of intervention	Clonidine (Isotonic)	Clonidine (Hypertonic)		
	Dosage	150 ug	150 ug		
	Dosage Intervals	Single administration	Single administration		
	Timing of intervention	Postoperative	Postoperative		
	Baseline pain score (VAS) Mean ± SD (n)	6.51 ± 0.63 (15)	7.18 ± 0.37 (15)		
Poitevin 1999 <sup>55</sup>	Classification	Analgesia	Analgesia	NA	NA
	Type of intervention	Lysine clonixinate	Metamizole		
	Dosage	125mg	400mg		
	Dosage Intervals	every 8 hr	every 8 hr		
	Age (yr) Mean ± SD	76.91 ± 6.00	77.60 ± 6.10		
	Gender				
	Females: n (%)	35/48 (72.92%)	35/46 (76.09%)		
	Males: n (%)	13/48 (27.08%)	9/46 (19.57%)		

IM = intramuscular; IV = intravenous; NA = not applicable; NR = not reported; VAS = visual analogue scale

**Table F-2. Anesthesia**

	<b>Intervention 1</b>	<b>Intervention 2</b>	<b>Intervention 3</b>	<b>Intervention 4</b>
Adams 1990 <sup>56</sup>				
Classification	Spinal anesthesia	General anesthesia	NA	NA
Type of intervention	Bupivacaine 0.5%/ Mepivacaine 4%	NR		
Dosage	NR	NR		
Dosage Intervals	NR	NR		
Age (yr)				
Mean	81	79		
Range	(70 – 88)	(63 – 96)		
Body weight (Kg)				
Mean	63	58		
Range	(45 – 100)	(40 – 80)		
Height (cm)				
Mean ± SD	161.00 ± 178	161.00 ± 178		
Range	(150 – 182)	(150 – 178)		
BMI (Kg/ m <sup>2</sup> )				
Mean	24.3	22.4		
Gender				
Females: n (%)	18/ 24 (75.00%)	28/ 32 (87.50%)		
Males: n (%)	6/ 24 (25.00%)	4/ 32 (12.50%)		
Type of fractures				
Femoral neck: n (%)	24/ 24 (100.00%)	32/ 32 (100.00%)		
Intertrochanteric: n (%)	0/ 24 (0.00%)	0/ 32 (0.00%)		
Proximal femur: n (%)	0/ 24 (0.00%)	0/ 32 (0.00%)		



**Table F-2. Anesthesia (continued)**

	<b>Intervention 1</b>	<b>Intervention 2</b>	<b>Intervention 3</b>	<b>Intervention 4</b>		
Ben-David 2000 <sup>58</sup>	Classification	Spinal anesthesia (single)	Spinal anesthesia (single)	NA	NA	
	Type of intervention	Bupivacaine/Fentanyl	Bupivacaine			
	Dosage	4mg/20ug	10mg			
	Dosage Intervals	Single administration	Single administration			
	Timing of intervention	Intra-operative	Intra-operative			
	Type of surgery	Richard's platescrew internal fixation of femoral neck fx in 8/10 ; Austin–Moore hemiarthroplasty for subcapital fx of femoral neck in 2/10	Richard's platescrew internal fixation of femoral neck fx and Austin–Moore hemiarthroplasty for subcapital fx of femoral neck in all			
	Type of anesthesia					
	Epidural	0/10 (0%)	0/10 (0%)			
	Spinal	10/10 (100%)	10/10 (100%)			
	General	0/10 (0%)	0/10 (0%)			
	Bredahl 1991 <sup>59</sup>	Classification	Spinal anaesthesia	General anaesthesia	NA	NA
		Type of intervention	Bupivacaine 0.5%	Thiopentone		
		Dosage	2.5-3 ml	2-4 mg/kg		
		Dosage Intervals	NR	Once		
Timing of intervention		Intra-operative	Intra-operative			
Type of surgery		internal fixation/hemiarthroplasty	internal fixation/hemiarthroplasty			
Type of anesthesia						
Epidural		0/15 (0%)	0/15 (0%)			
Spinal		15/15 (100%)	0/15(0%)			
General		0/15(0%)	13/13(100%)			
Duration of surgery (hr)						
Mean ± SD		1.00 ± 0.40	1.10 ± 0.40			
(Range)		(0.50 –2.00)	(0.60 –1.75)			
Age (yr)						
Mean ± SD	80.00± 5.81	79.00 ± 7.93				
(Range)	(72 – 93)	(60 – 90)				
Body weight (Kg)						
Mean ± SD	56.00 ± 6.97	56.00 ± 7.93				
Range	(40 – 65)	(45 – 70)				

**Table F-2. Anesthesia (continued)**

	Intervention 1	Intervention 2	Intervention 3	Intervention 4
Gender				
Females: n (%)	15/15 (100%)	13/13 (100%)		
Males: n (%)	0/15 (0%)	0/13 (0%)		
Type of fractures				
Femoral neck: n (%)	12/15 (80%)	8/13 (61.50%)		
Intertrochanteric: n (%)	3/15 (20%)	5/13 (38.50%)		
Proximal femur: n (%)	0/15 (0%)	0/13 (0%)		
Casati 2003 <sup>60</sup>				
Classification	Spinal anesthesia (single)	General anesthesia	NA	NA
Type of intervention	Bupivacaine 0.5%	None		
Dosage	7.5mg	NA		
Dosage Intervals	Single administration	NA		
Timing of intervention	Intra-operative	Intra-operative		
Type of anesthesia				
Epidural	0/15 (0%)	0/15 (0%)		
Spinal	15/15 (100%)	0/15 (0%)		
General	0/15 (0%)	15/15 (100%)		
Duration of surgery (hr)				
Range	(0.75 –1.83)	(0.83 –1.67)		
Baseline pain score	Scale name [NRS (1-5)]			
Mean ± SD (n)	1.67 ± 0.49 (15)	2.13 ± 0.74 (15)		
(Range)	(1.00 – 2.00)	(1.00 – 3.00)		
Danelli 2008 <sup>61</sup>				
Classification	Spinal anesthesia (single)	Spinal anesthesia (single)	NA	NA
Type of intervention	Levobupivacaine 0.5%	Levobupivacaine 0.75%		
Dosage	15mg	15mg		
Dosage Intervals	Single administration	Single administration		
Timing of intervention	Intra-operative	Intra-operative		
Type of surgery	Gamma-nail fixation or hip hemiarthroplasty in all	Gamma-nail fixation or hip hemiarthroplasty in all		
Type of anesthesia				
Epidural	0/29 (0%)	0/31 (0%)		
Spinal	29/29 (100%)	31/31 (100%)		
General	0/29 (0%)	0/31 (0%)		

**Table F-2. Anesthesia (continued)**

		<b>Intervention 1</b>	<b>Intervention 2</b>	<b>Intervention 3</b>	<b>Intervention 4</b>
Favarel-Garrigues 1996 <sup>62</sup>	Classification	Spinal anesthesia (continuous)	Spinal anesthesia (single)	NA	NA
	Type of intervention	Bupivacaine 0.5%	Bupivacaine 0.5%		
	Dosage	Bolus: Bupivacaine 5mg (1ml); Maintenance: Bupivacaine 2.5mg (0.5ml)	Based on age and ht: 15mg 70-79 yr or >170 cm; 12.5mg 80-90 yr or 150-170 cm; 10mg >90 yr or <150 cm		
	Dosage Intervals	Single administration; Continuous administration on demand	Single administration		
	Timing of intervention	Intra-operative	Intra-operative		
	Type of anesthesia				
	Epidural	0/30 (0%)	0/30 (0%)		
	Spinal	30/30 (100%)	30/30 (100%)		
	General	0/30 (0%)	0/30 (0%)		
	Duration of surgery (hr) Mean ± SD	1.42 ± 0.71	1.38 ± 0.55		
Hooda 2006 <sup>63</sup>	Classification	Spinal anesthesia (single)	Spinal anesthesia (single)	Spinal anesthesia (single)	
	Type of intervention	Bupivacaine 0.5%/Fentanyl	Bupivacaine 0.5%/Fentanyl	Bupivacaine 0.5%/Fentanyl	
	Dosage	4mg (0.8ml)/20mg (0.4ml)	5mg (1.0ml)/20mg (0.4ml)	6mg (1.2ml)/20mg (0.4ml)	
	Dosage Intervals	Single administration	Single administration	Single administration	
	Timing of intervention	Intra-operative	Intra-operative	Intra-operative	
	Type of anesthesia				
	Epidural	0/30 (0%)	0/30 (0%)	0/30 (0%)	
	Spinal	30/30 (100%)	30/30 (100%)	30/30 (100%)	
	General	0/30 (0%)	0/30 (0%)	0/30 (0%)	
	Duration of surgery (hr) Mean ± SD (Range)	0.98 ± 0.27 (0.42 –1.42)	1.00 ± 0.41 (0.50 –2.67)	1.03 ± 0.21 (0.67 –1.50)	
Juelsgaard 1998 <sup>64</sup>	Classification	Spinal anesthesia (incremental)	Spinal anesthesia (single)	General anesthesia	
	Type of intervention	Bupivacaine 0.5%	Bupivacaine 0.5%	Fentanyl	
	Dosage	1.6ml	2.5ml	Bolus: 1-2ug/kg/ Maintenance: 25-50ug	

**Table F-2. Anesthesia (continued)**

	<b>Intervention 1</b>	<b>Intervention 2</b>	<b>Intervention 3</b>	<b>Intervention 4</b>
Dosage Intervals	Incremental dosage	Single administration	Single administration/ Continuous administration (on demand)	
Timing of intervention	Intra-operative	Intra-operative	Intra-operative	
Type of surgery	Internal fixation in 4/14; hemiarthroplasty in 10/14	Internal fixation in 5/15; hemiarthroplasty in 10/15	Internal fixation in 3/14; hemiarthroplasty in 11/14	
Type of anesthesia				
Epidural	0/14 (0%)	0/15 (0%)	0/14 (0%)	
Spinal	14/14 (100%)	15/15 (100%)	0/14 (0%)	
General	0/14 (0%)	0/15 (0%)	14/14 (100%)	
Duration of surgery (hr)				
Mean	1.09	1.17	1.13	
(Range)	(0.45 –2.00)	(0.45 –2.40)	(0.45 –1.20)	
Klimscha 1995 <sup>65</sup>				
Classification	Spinal anesthesia (continuous)	Spinal anesthesia (continuous)	Epidural anesthesia (continuous)	Epidural anesthesia (continuous)
Type of intervention	Bupivacaine 0.5% plus clonidine	Bupivacaine 0.5%	Bupivacaine 0.5%/clonidine	Bupivacaine 0.5%
Dosage	1ml bupivacaine/1ml Clonidine	10ml bupivacaine	10ml bupivacaine/ 1ml Clonidine	10ml bupivacaine
Dosage Intervals	Continuous administration (3 repetitive doses)	Continuous administration (3 repetitive doses)	Continuous administration (3 repetitive doses)	Continuous administration (3 repetitive doses)
Timing of intervention	Intra-operative	Intra-operative	Intra-operative	Intra-operative
Type of anesthesia				
Epidural	0/10 (0%)	0/10 (0%)	10/10 (100%)	10/10 (100%)
Spinal	10/10 (100%)	10/10 (100%)	0/10 (0%)	0/10 (0%)
General	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)
Koval 1999 <sup>8</sup>				
Classification	Spinal anaesthesia	General anaesthesia	NA	NA
Type of intervention	NR	NR		
Dosage	NR	NR		
Dosage Intervals	NR	NR		
Timing of intervention	Intra-operative	Intra-operative		
Type of surgery	Internal fixation, Prosthetic replacement	Internal fixation, Prosthetic replacement		

**Table F-2. Anesthesia (continued)**

	Intervention 1	Intervention 2	Intervention 3	Intervention 4
Type of anesthesia				
Epidural	0/280 (0%)	0/362 (0%)		
Spinal	143/280 (51.07%)	196/362 (54.14%)		
General	137/280 (48.93%)	166/362 (48.86%)		
Age (yr)				
Mean ± SD	81.00	78.50		
(Range)	(65 – 105)	(65 – 104)		
Gender				
Females: n (%)	213/280 (76.07%)	62/362 (17.13%)		
Males: n (%)	67/280 (23.93%)	300/362 (82.87%)		
Type of fractures				
Femoral neck: n (%)	143/280(51.07%)	196/362(54.14%)		
Intertrochanteric: n (%)	137/280(48.93%)	166/362(45.86%)		
Proximal femur: n (%)	0/280(0%)	0/362(0%)		
Krobot 2006 <sup>77</sup>				
Classification	Spinal anesthesia (single)	Spinal anesthesia (single)	NA	NA
Type of intervention	Levobupivacaine/Fentanyl	Levobupivacaine		
Dosage	7.5mg/0.01mg	10mg		
Dosage Intervals	Single administration	Single administration		
Timing of intervention	Intra-operative	Intra-operative		
Kwan 1997 <sup>66</sup>				
Classification	Spinal anesthesia (single)	Spinal anesthesia (single)	NA	NA
Type of intervention	Bupivacaine 0.5%/Morphine	Bupivacaine 0.5%		
Dosage	2.2ml/0.2mg	2.2ml		
Dosage Intervals	Single administration	Single administration		
Timing of intervention	Intra-operative	Intra-operative		
Type of surgery	Austin Moore arthroplasty or compression hip screw	Austin Moore arthroplasty or compression hip screw		
Baseline pain score	Scale name [VAS]			
Mean ± SD (n)	4.68 ± 2.14 (20)	5.40 ± 2.76 (20)		
Labaille 1992 <sup>79</sup>				
Classification	Spinal anesthesia (continuous)	Spinal anesthesia (continuous)	NA	NA
Type of intervention	Bupivacaine 0.125%/Bupivacaine 0.125%	Bupivacaine 0.5%/Bupivacaine 0.5%		

**Table F-2. Anesthesia (continued)**

	<b>Intervention 1</b>	<b>Intervention 2</b>	<b>Intervention 3</b>	<b>Intervention 4</b>
Dosage	Bolus: 3ml/Maintaninence: 1ml	Bolus: 3ml/Maintaninence: 1ml		
Dosage Intervals	Single administration/ Continuous administration (on demand)	Single administration/ Continuous administration (on demand)		
Timing of intervention	Intra-operative	Intra-operative		
Malek 2004 <sup>67</sup>				
Classification	Spinal anesthesia (single)	Spinal anesthesia (single)	Spinal anesthesia (single)	NA
Type of intervention	Bupivacaine 0.5%/Fentanyl	Bupivacaine 0.5%/Sufentanil	Bupivacaine 0.5%	
Dosage	3ml/50ug	3ml/5ug	3ml	
Dosage Intervals	Single administration	Single administration	Single administration	
Timing of intervention	Intra-operative	Intra-operative	Intra-operative	
Type of anesthesia				
Epidural	0/21 (0%)	0/21 (0%)	0/21 (0%)	
Spinal	21/21 (100%)	21/21 (100%)	21/21 (100%)	
General	0/21 (0%)	0/21 (0%)	0/21 (0%)	
Duration of surgery (hr)				
Mean ± SD	1.57 ± 0.43	1.75 ± 0.33	1.60 ± 0.50	
Martyr 2001 <sup>68</sup>				
Classification	Spinal anesthesia (single)	Spinal anesthesia (single)	NA	NA
Type of intervention	Bupivacaine/Fentanyl	Bupivacaine		
Dosage	7.5mg/20ug	12.5mg		
Dosage Intervals	Single administration	Single administration		
Timing of intervention	Intra-operative	Intra-operative		
Type of surgery	Richards pin and plate in all	Richards pin and plate in all		
Type of anesthesia				
Epidural	0/20 (0%)	0/22 (0%)		
Spinal	20/20 (100%)	22/22 (100%)		
General	0/20 (0%)	0/22 (0%)		
Duration of surgery (hr)				
Mean ± SD	1.27 ± 0.50	1.10 ± 0.24		
Martyr 2005 <sup>69</sup>				
Classification	Spinal anesthesia (single)	Spinal anesthesia (single)	NA	NA
Type of intervention	Bupivacaine/Fentanyl	Bupivacaine		
Dosage	9.0mg/20ug	11.0mg		
Dosage Intervals	Single administration	Single administration		
Timing of intervention	Intra-operative	Intra-operative		

**Table F-2. Anesthesia (continued)**

	<b>Intervention 1</b>	<b>Intervention 2</b>	<b>Intervention 3</b>	<b>Intervention 4</b>
Type of surgery	DHS in 13/20 pts; hemianthroplasty in 7/20 pts	DHS in 11/20 pts; hemianthroplasty in 9/20 pts		
Type of anesthesia				
Epidural	0/20 (0%)	0/20 (0%)		
Spinal	20/20 (100%)	20/20 (100%)		
General	0/20 (0%)	0/20 (0%)		
Duration of surgery (hr)				
Mean ± SD	0.85 ± 0.40	0.78 ± 0.33		
Maurette 1993 <sup>70</sup>				
Classification	Spinal anesthesia (continuous)	Spinal anesthesia (continuous)	NA	NA
Type of intervention	Bolus: lidocaine 1.6%/ meperidine 1%; Maintainence: lidocaine 1.6%	Bolus: lidocaine 1.6%; Maintainence: lidocaine 1.6%		
Dosage	NA/4ml (200mg); NA	NA		
Dosage Intervals	Continuous administration	Continuous administration		
Timing of intervention	Intra-operative	Intra-operative		
Type of anesthesia				
Epidural	0/19 (0%)	0/15 (0%)		
Spinal	19/19 (100%)	15/15 (100%)		
General	0/19 (0%)	0/15 (0%)		
Duration of surgery (hr)				
Mean ± SD	1.33 ± 0.60	1.35 ± 0.40		
Miller 1990 <sup>81</sup>				
Classification	Spinal anesthesia	General anesthesia		
Type of intervention	Mepivacaine 4 %	Fentanyl		
Dosage	2ml (80 mg)	3-5mg per kg		
Dosage Intervals	NR	NR		
Age (yr)				
Mean	79.8	80.5		
Type of fractures				
Femoral neck: n (%)	0/ 180 (0.00%)	0/ 137 (0.00%)		
Intertrochanteric: n (%)	0/ 180 (0.00%)	0/ 137 (0.00%)		
Proximal femur: n (%)	180/ 180 (100.00%)	137/ 137 (100.00%)		
Minville 2006 <sup>71</sup>				
Classification	Spinal anesthesia (continuous)	Spinal anesthesia (single)	NA	NA
Type of intervention	Bupivacaine	Bupivacaine		
Dosage	2.5mg	7.5mg		
Dosage Intervals	Continuous administration	Single administration		

**Table F-2. Anesthesia (continued)**

	<b>Intervention 1</b>	<b>Intervention 2</b>	<b>Intervention 3</b>	<b>Intervention 4</b>
Timing of intervention	Intra-operative	Intra-operative		
Type of surgery	DHS in 12/36 pts; Austin-Moore arthroplasty in 18/36; hip hemiarthroplasty in 6/36	DHS in 10/37 pts; Austin-Moore arthroplasty in 22/37; hip hemiarthroplasty in 5/37		
Type of anesthesia				
Epidural	0/36 (0%)	0/37 (0%)		
Spinal	36/36 (100%)	37/37 (100%)		
General	0/36 (0%)	0/37 (0%)		
Duration of surgery (hr)				
Mean ± SD	0.87 ± 0.30	0.85 ± 0.28		
Classification	Spinal anesthesia (continuous)	Spinal anesthesia (continuous)	Spinal anesthesia (single)	General anesthesia
Type of intervention	Bupivacaine 0.5%	Bupivacaine 0.5%	Bupivacaine 0.5%	Sulfentanil
Dosage	2.5mg	5mg	NR	NR
Dosage Intervals	Continuous administration	Continuous administration	Single administration	NR
Timing of intervention	Intra-operative	Intra-operative	Intra-operative	Intra-operative
Time from ED arrival to surgery (hr)				
Mean ± SD	24.00 ± 10.00	17.00 ± 12.00	18.00 ± 10.00	23.00 ± 7.00
Type of surgery	Osteosynthesis in 76/121; intermediate prosthesis in 33/12; total hip replacement in 12/121	osteosynthesis 34/61; intermediate prosthesis 19/61; total hip replacement 8/61	osteosynthesis 52/109; intermediate prosthesis 41/109; total hip replacement 16/109	osteosynthesis 20/42; intermediate prosthesis 8/42; total hip replacement 14/42
Type of anesthesia				
Epidural	0/121 (0%)	0/61 (0%)	0/109 (0%)	0/42 (0%)
Spinal	121/121 (100%)	61/61 (100%)	109/109 (100%)	0/42 (0%)
General	0/121 (0%)	0/61 (0%)	0/109 (0%)	42/42 (100%)
Duration of surgery (hr)				
Mean ± SD	1.00 ± 0.33	1.03 ± 0.32	1.10 ± 0.48	1.30 ± 0.48
Classification	Spinal anesthesia (continuous)	Spinal anesthesia (single)	NA	NA
Type of intervention	Bupivacaine 0.15-0.25%	Bupivacaine 0.5%		
Dosage	NR	NR		
Dosage Intervals	Continuous administration	Single administration		
Timing of intervention	Intra-operative	Intra-operative		
Classification	Spinal anesthesia (single)	Spinal anesthesia (single)	NA	NA



**Table F-2. Anesthesia (continued)**

	<b>Intervention 1</b>	<b>Intervention 2</b>	<b>Intervention 3</b>	<b>Intervention 4</b>
Type of intervention	Bupivacaine/sufentanil	Bupivacaine		
Dosage	7.5mg/5mg	15mg		
Dosage Intervals	Single administration	Single administration		
Timing of intervention	Intra-operative	Intra-operative		
Type of surgery	internal fixation of femoral neck fractures with two parallel screws or DHS for subcapital fractures of the femoral neck in all pts	internal fixation of femoral neck fractures with two parallel screws or DHS for subcapital fractures of the femoral neck in all		
Type of anesthesia				
Epidural	0/25 (0%)	0/25 (0%)		
Spinal	25/25 (100%)	25/25 (100%)		
General	0/25 (0%)	0/25 (0%)		
Duration of surgery (hr)				
Mean ± SD	0.82 ± 0.13	0.65 ± 0.08		
Qamarul Hoda 2007 <sup>14b</sup>				
Classification	Spinal anesthesia (single)	Spinal anesthesia (single)	Spinal anesthesia (single)	NA
Type of intervention	Bupivacaine/Fentanyl	Bupivacaine/Fentanyl	Bupivacaine	
Dosage	6mg/20ug	8mg/20ug	10mg	
Dosage Intervals	Single administration	Single administration	Single administration	
Timing of intervention	Intra-operative	Intra-operative	Intra-operative	
Rais 2008 <sup>5</sup>				
Classification	Spinal anesthesia (continuous)	Spinal anesthesia (continuous)	NA	NA
Type of intervention	Bupivacaine 0.5%	Bupivacaine 0.5%		
Dosage	2.5mg	5mg		
Dosage Intervals	Single administration	Single administration		
Timing of intervention	Intra-operative	Intra-operative		
Said-Ahmed 2006 <sup>7b</sup>				
Classification	Spinal anesthesia (single)	Spinal anesthesia (single)	Spinal anesthesia (single)	NA
Type of intervention	Bupivacaine 0.5%/Fentanyl	Bupivacaine 0.5%/Sufentanil	Bupivacaine 0.5%	
Dosage	5mg/20mcg	5mg/5mcg	10mg	
Dosage Intervals	Single administration	Single administration	Single administration	
Timing of intervention	Intra-operative	Intra-operative	Intra-operative	
Type of surgery	Austin-Moore prosthesis in 14/20 pts; DHS in 6/20 pts	Austin-Moore prosthesis in 14/20; DHS in 6/20	Austin-Moore prosthesis 14/20; DHS 6/20	
Type of anesthesia				
Epidural	0/20 (0%)	0/20 (0%)		

**Table F-2. Anesthesia (continued)**

	<b>Intervention 1</b>	<b>Intervention 2</b>	<b>Intervention 3</b>	<b>Intervention 4</b>	
Sen 2007 <sup>83</sup>	Spinal	20/20 (100%)	20/20 (100%)		
	General	0/20 (0%)	0/20 (0%)		
	Classification	Spinal anesthesia (single - lateral)	Spinal anesthesia (single - supine)	NA	NA
	Type of intervention	Bupivacaine 0.5%	Bupivacaine 0.5%		
	Dosage	10mg	10mg		
	Dosage Intervals	Single administration	Single administration		
	Timing of intervention	Intra-operative	Intra-operative		
	Type of anesthesia				
	Epidural	0/23 (0%)	0/18 (0%)		
	Spinal	23/23 (100%)	18/18 (100%)		
Shih 2010 <sup>84</sup>	General	0/23 (0%)	0/18 (0%)		
	Classification	Spinal anaesthesia	General anaesthesia	NA	NA
	Type of intervention	Bupivacaine	Thiopental		
	Dosage	8-15 mg	NR		
	Dosage Intervals	NR	NR		
	Timing of intervention	Intra-operative	Intra-operative		
	Type of surgery	NR	NR		
	Type of anesthesia				
	Epidural	0/168 (0%)	0/167 (0%)		
	Spinal	168/168 (100%)	0/167 (0%)		
	General	0/168 (0%)	167/167(100%)		
	Duration of surgery (hr)				
	Mean ± SD	NR	NR		
	Range	(1.33 –4.92)	(1.42 –8.53)		
Age (yr)					
Mean ± SD	84.93 ± 4.04	83.96 ± 3.71			
(Range)	(80 – 99)	(80 – 99)			
Gender					
Females: n (%)	74/168 (44.05%)	72/167 (43.11%)			
Males: n (%)	94/168 (55.95%)	95/167 (56.89%)			

**Table F-2. Anesthesia (continued)**

	Intervention 1	Intervention 2	Intervention 3	Intervention 4
ASA Class				
ASA I (%)	0/168 (0%)	0/167 (0%)		
ASA II (%)	45/168 (26.79%)	47/167 (28.14%)		
ASA III (%)	120/168 (71.43%)	115/167 (68.86%)		
ASA IV (%)	2/168 (1.19%)	1/167 (0.60%)		
Sutcliffe 1994 <sup>85</sup>				
Classification	Spinal anaesthesia	General anaesthesia	NA	NA
Type of intervention	Bupivacaine	NR		
Dosage	NR	NR		
Dosage Intervals	NR	NR		
Timing of intervention	Intra-operative	Intra-operative		
Time from fall to surgery (hr)				
Mean ± SD	57.00 ± NR	56.00 ± NR		
Type of surgery	internal fixation, hemiarthroplasty, dynamic hip screw or nail plate fixation, other fixation devices	internal fixation, hemiarthroplasty, dynamic hip screw or nail plate fixation, other fixation devices		
Type of anesthesia				
Epidural	0/383 (0%)	0/950 (0%)		
Spinal	383/383 (100%)	0/950 (100%)		
General	0/383 (0%)	950/950 (0%)		
Age (yr)				
Mean ± SD	80.00 ± NR	79.00 ± NR		
Gender				
Females: n (%)	303/383 (79.11%)	788/950 (82.95%)		
Males: n (%)	80/ 383 (20.89%)	162/ 950 (17.05%)		
Pre-fracture residence				
Community: n (%)	92/383 (24.00)	266/950 (28.00)		
Institutional: n (%)	291/383 (76.00)	684/950 (72.00)		

NA = not applicable; NR = not reported; NRS = numeric rating scale; VAS = visual analogue scale

**Table F-3. Complementary and alternative medicine (CAM)**

		<b>Intervention 1</b>	<b>Intervention 2</b>	<b>Intervention 3</b>	<b>Intervention 4</b>
Barker 2006 <sup>43</sup>	Classification	Auricular acupressure	Sham Control	NA	NA
	Type of intervention	1-mm plastic acupressure beads	1-mm acupressure plastic beads		
	Dosage	3 true auricular acupressure points	3 sham auricular acupressure points		
	Dosage Intervals	Single administration	Single administration		
	Timing of intervention	Pre-operative	Pre-operative		
	Time from fall to ED arrival (hr)				
	Mean ± SD	0.48 ± 0.20	0.53 ± 0.25		
	Baseline pain score	Scale name [VAS]			
	Mean ± SD (n)	6.39 ± NR (18)	6.56 ± NR (20)		
Martin 1991 <sup>54</sup>	Classification	Relaxation	Analgesia	NA	NA
	Type of intervention	Jacobson relaxation technique/Meperidine/Morphine	Meperidine/Morphine		
	Dosage	NA	NR		
	Dosage Intervals	Instruction given prior to surgery	NR		
	Timing of intervention	Pre-operative	Pre-operative		

NA = not applicable; NR = not reported; VAS = Visual analogue scale

**Table F-4. Multimodal pain management**

		<b>Intervention 1</b>	<b>Intervention 2</b>	<b>Intervention 3</b>	<b>Intervention 4</b>
Milisen 2001 <sup>86</sup>	Classification	Multimodal pain management	Standard care	NA	NA
	Type of intervention	Bolus: Tramadol IV; Maintainence (48hrs): Tramdol IV + propacetamol IV; Maintainence (Day 3-5): oral tramadol + oral paracetamol	NR		
	Dosage	3mg/ kg; 6mg/ kg/ 24hrs; 120mg/ kg/ 24hours/NA	NR		
	Dosage Intervals	Continuous administration	NR		
	Timing of intervention	Postoperative	Postoperative		
Ogilvie-Harris 1993 <sup>87</sup>	Classification	Multimodal pain management	Standard care	NA	NA
	Type of intervention	Skin Traction/ Morphine/Acetaminophen	NR		
	Dosage	NA/2.5-5mg/1000mg	NR		
	Dosage Intervals	Rewrap every 8hrs/every 4hrs/every 4hrs	NR		
	Timing of intervention	Preoperative	Preoperative		

IV = intravenous; NA = not applicable; NR = not reported

**Table F-5. Nerve blocks**

		<b>Intervention 1</b>	<b>Intervention 2</b>	<b>Intervention 3</b>	<b>Intervention 4</b>
Antonopoulou 2006 <sup>88</sup>	Classification	Femoral nerve block	Analgesia	NA	NA
	Type of intervention	Bolus: Levobupivacaine 0.25%; Maintenance: Levobupivacaine 0.12%	Paracetamol; Pethidine		
	Dosage	18ml	500mg; NR		
	Dosage Intervals	Single administration; Continuous administration	Every 8hrs; on demand		
	Timing of intervention	Postoperative	Postoperative		
	Type of anesthesia				
	Epidural	0/49 (0%)	0/35 (0%)		
	Spinal	49/49 (100%)	35/35 (100%)		
General	0/49 (0%)	0/35 (0%)			
Chudinov 1999 <sup>89</sup>	Classification	Psoas Compartment Block (continuous)	IM analgesia	NA	NA
	Type of intervention	Bupivacaine 0.25%	Meperidine IM		
	Dosage	Bolus: 2mg/kg; Maintenance: 2mg/kg	1mg/kg		
	Dosage Intervals	Single administration/ Maintenance: every 12hrs	On demand (max every 5hrs)		
	Timing of intervention	Preoperative	Preoperative		
	Type of anesthesia				
	Epidural	0/20 (0%)	0/20 (0%)		
	Spinal	11/20 (55%)	19/20 (95%)		
General	1/20 (5%)	1/20 (5%)			
Baseline pain score	Scale name [VAS]				
Mean ± SD (n)	4.30 ± 0.60 (20)	4.30 ± 0.70 (20)			

**Table F-5. Nerve blocks (continued)**

		<b>Intervention 1</b>	<b>Intervention 2</b>	<b>Intervention 3</b>	<b>Intervention 4</b>
Coad 1991 <sup>90</sup>	Classification	3-in-1 nerve block	Lateral cutaneous nerve block	Standard care	NA
	Type of intervention	Bupivacaine 0.5%	Bupivacaine 0.5%	NR	
	Dosage	15ml	15ml	NR	
	Dosage Intervals	Single administration	Single administration	NR	
	Timing of intervention	Postoperative	Postoperative	Postoperative	
	Type of surgery	Compression screw 12/17 pts; pin and plate 5/17	Compression screw 13/17 pts; pin and plate 4/17	Compression screw 11/17; pin and plate 5/17	
	Type of anesthesia				
	Epidural	0/17 (0%)	0/17 (0%)	0/16 (0%)	
	Spinal	0/17 (0%)	0/17 (0%)	0/16 (0%)	
General	17/17 (100%)	17/17 (100%)	16/16 (100%)		
Cuvillon 2007 <sup>91</sup>	Classification	3-in-1 nerve block (NS)	Analgesia	Analgesia	
	Type of intervention	Ropivacaine	Paracetamol	Morphine	
	Dosage	Catheter attached to pump allowing continuous ropivacaine 0.2% at 10 mL/hr x 48 hr	1st dose 2g then 2g	2 mg q5min in post-op until VAS <30 then 0.1 mg/kg q4 hr; if VAS >30 dosage increased by 50%	
	Dosage Intervals	Continuous	Every 6 hours		
	Age (yr)				
	Mean ± SD	83 ± 5.00	83 ± 7.00	81.00 ± 8.00	
	Body weight (Kg)				
	Mean ± SD	60.00 ± 11.00	57.00 ± 10.00	59.00 ± 13.00	
	Height (cm)				
	Mean ± SD	159.00 ± 10.00	158.00 ± 10.00	159.00 ± 10.00	
Gender					
Females: n (%)	18/ 21 (85.71%)	19/ 21 (90.48%)	16/ 20 (80.00%)		
Males: n (%)	3/ 21 (14.29%)	2/ 21 (9.52%)	4/ 20 (20.00%)		
de Visme 2000 <sup>92</sup>	Classification	Combined lumbar/sacral plexus block (NS)	Spinal anesthesia (single)	NA	NA
	Type of intervention	Lidocaine 1.33%	Bupivacaine 0.5%		
	Dosage	45mL	3mL		
	Dosage Intervals	Single administration	Single administration		

**Table F-5. Nerve blocks (continued)**

	<b>Intervention 1</b>	<b>Intervention 2</b>	<b>Intervention 3</b>	<b>Intervention 4</b>
Timing of intervention	Intra-operative	Intra-operative		
Type of surgery	Gamma nail osteosynthesis 9/15; Moore prosthesis 2/15; intermediary prosthesis 0/15; pinnings 4/15	Gamma nail osteosynthesis 11/14; Moore prosthesis 1/14; intermediary prosthesis 2/14; pinnings 0/14		
Type of anesthesia				
Epidural	0/15 (0%)	0/14 (0%)		
Spinal	0/15 (0%)	14/14 (100%)		
General	0/15 (0%)	0/14 (0%)		
Duration of surgery (hr) Mean ± SD (Range)	0.73 ± NR (0.32 –1.30)	1.02 ± NR (0.53 –2.67)		
Del Rosario 2008 <sup>117</sup>				
Classification	Femoral nerve block (NS)/IV analgesia	IV analgesia	NA	NA
Type of intervention	Bolus: Bupivacaine 0.25%; Maintainence: bupivaine 0.1%; PCA: Paracetamol IV/metamizol IV	Paracetamol IV; metamizol IV		
Dosage	30ml/5ml/1g/2g	1g; 2g		
Dosage Intervals	Single administration; Maintainence: every hour; Patient controlled bolus: every 6hrs/every 8hrs	Every 6hrs; every 8hrs		
Timing of intervention	Postoperative	Postoperative		
Type of anesthesia				
Epidural	0/49 (0%)	0/50 (0%)		
Spinal	49/49 (100%)	50/50 (100%)		
General	0/49 (0%)	0/50 (0%)		
Eyrolle 1998 <sup>93</sup>				
Classification	Posterior lumbar plexus block	Spinal anesthesia (single)	NA	NA
Type of intervention	Lidocaine 2%/Bupivacaine 0.5%	Bupivacaine 0.5%		
Dosage	NR	NR		
Dosage Intervals	NR	Single administration		
Timing of intervention	Intra-operative	Intra-operative		



**Table F-5. Nerve blocks (continued)**

	Intervention 1	Intervention 2	Intervention 3	Intervention 4
	Type of anesthesia			
	Epidural	0/25 (0%)	0/25 (0%)	
	Spinal	0/25 (0%)	25/25 (100%)	
	General	0/25 (0%)	0/25 (0%)	
Fletcher 2003 <sup>94</sup>	Classification	3-in-1 nerve block (NS)	IV analgesia	NA
	Type of intervention	Bupivacaine 0.5%	Morphine IV	
	Dosage	20mL	5-10mg	
	Dosage Intervals	Single administration	On demand	
	Timing of intervention	Preoperative	Preoperative	
	Time from fall to ED arrival (hr) Mean $\pm$ SD	29.30 $\pm$ 20.80	27.40 $\pm$ 16.50	
	Baseline pain score	Scale name [NRS (0-3)]		
	Mean $\pm$ SD (n)	2.80 $\pm$ 0.40 (24)	2.70 $\pm$ 0.60 (26)	
Foss 2005 <sup>95</sup>	Classification	Epidural analgesia (continuous)	Placebo	NA
	Type of intervention	Bupivacaine 0.125%/morphine	Saline	
	Dosage	4ml of 50ug per ml per hr	NA	
	Dosage Intervals	Continuous infusion (four days)	Continuous infusion (four days)	
	Timing of intervention	Postoperative	Postoperative	
	Type of surgery	Arthroplasty 10/28; intramedullar nailing 0/28; partial screws 6/28; sliding screws 12/28	Arthroplasty 8/2; intramedullar nailing 4/27; partial screws 4/27; sliding screws 11/27	
	Type of anesthesia			
	Epidural	28/28 (100%)	27/27 (100%)	
	Spinal	0/28 (0%)	0/27 (0%)	
	General	0/28 (0%)	0/27 (0%)	
Foss 2007 <sup>96</sup>	Classification	Fascia iliaca compartment nerve block (CT)	Analgesia	NA
	Type of intervention	1.0% mepivacaine	Morphine	

**Table F-5. Nerve blocks (continued)**

	<b>Intervention 1</b>	<b>Intervention 2</b>	<b>Intervention 3</b>	<b>Intervention 4</b>
Dosage	40 mL 1.0% mepivacaine with 1:200 000 epinephrine; 0.02 mL/kg placebo IM injection of 0.9% saline	40 mL placebo FICB with 0.9% saline; 0.02 mL/kg 5.0 mg/mL morphine		
Dosage Intervals	Single dose	Single dose		
Age (yr)				
Mean	83	77		
Range	(75 – 88)	(69 – 88)		
Body weight (Kg)				
Mean	60.00	60.00		
Range	(50 – 80)	(50 – 65)		
BMI (Kg/ m <sup>2</sup> )				
Mean	22.80	21.30		
Range	(20 – 28)	(19 – 21)		
Gender				
Females: n (%)	14/ 24 (58.33%)	21/ 24 (87.50%)		
Males: n (%)	10/ 24 (41.67%)	3/ 24 (12.50%)		
ASA Class				
ASA I (%)	0/24 (0.00%)	3/ 24 (12.50%)		
ASA II (%)	13/24 (54.17%)	15/ 24 (62.50%)		
ASA III (%)	11/24 (45.83%)	6/ 24(25.00%)		
ASA IV (%)	0/24 (0.00%)	0/24 (0.00%)		
Gille 2006 <sup>97</sup>				
Classification	Femoral nerve block	Analgesia	NA	NA
Type of intervention	Prilocaine 1%/ Ropivacaine 0.2%	Metamizol/Tilidine; Ibuprofen		
Dosage	40ml/ 30ml	1g / 100mg; 400mg		
Dosage Intervals	Single administration/ Continuous (every 6hrs)	Single administration/single administration; every 8hrs		
Age (yr)				
Mean ± SD	82 ± 8.85	78 ± 13.16		
Range	(61 – 103)	(35 – 93)		
Body weight (Kg)				
Mean ± SD	64.00 ± 13.41	67.00 ± 14.54		
Height (cm)				
Mean	163.00	165.00		

**Table F-5. Nerve blocks (continued)**

	Intervention 1	Intervention 2	Intervention 3	Intervention 4
BMI (Kg/ m <sup>2</sup> )				
Mean	24.10	24.60		
Gender				
Females: n (%)	39/ 50 (78.00%)	38/ 50 (76.00%)		
Males: n (%)	11/ 50 (22.00%)	12/ 50 (24.00%)		
Type of fractures				
Femoral neck: n (%)	0/ 50 (0.00%)	0/ 50 (0.00%)		
Intertrochanteric: n (%)	0/ 50 (0.00%)	0 /50 (0.00%)		
Proximal femur: n (%)	50/ 50 (100.00%)	50/ 50 (100.00%)		
Graham 2008 <sup>98</sup>				
Classification	3-in-1 nerve block (NS)	IV analgesia	NA	NA
Type of intervention	Bupivacaine 0.5%	Morphine IV		
Dosage	30ml	0.1mg per kg		
Dosage Intervals	Single administration	Single administration		
Timing of intervention	Preoperative	Preoperative		
Haddad 1995 <sup>99</sup>				
Classification	Femoral nerve block CT)	Standard care	NA	NA
Type of intervention	Bupivacaine 0.25%	NR		
Dosage	0.3ml per kg	NR		
Dosage Intervals	Single administration	NR		
Timing of intervention	Preoperative	Preoperative		
Type of surgery	Internal fixation with DHS in all pts	Internal fixation with DHS in all pts		
Baseline pain score	Scale name [VAS]			
Mean (n)	7.40 (25)	7.10 (25)		
(Range)	(2.00 – 10.00)	(3.00 – 10.00)		
Henderson 2008 <sup>100</sup>				
Classification	Femoral nerve block/ Opioids	Standard care	NA	NA
Type of intervention	Bupivacaine 0.5%	Opioids		
Dosage	NR/NR	NR		
Dosage Intervals	Continuous/On demand	Intermittent		
Timing of intervention	Preoperative	Preoperative		
Hood 1991 <sup>101</sup>				
Classification	3-in-1 nerve block	Standard care	NA	NA
Type of intervention	Prilocaine 0.75%	NR		
Dosage	43ml	NR		

**Table F-5. Nerve blocks (continued)**

	<b>Intervention 1</b>	<b>Intervention 2</b>	<b>Intervention 3</b>	<b>Intervention 4</b>
	Dosage Intervals	Single administration	NR	
	Timing of intervention	Intra-operative	Intra-operative	
	Type of surgery	Compression screw or pin and plate device	Compression screw or pin and plate device	
	Type of anesthesia General	25/25 (100%)	25/25 (100%)	
Kocum 2007 <sup>118</sup>	Classification	Lumbar plexus plus sciatic block (NS)	Lumbar plexus plus sciatic block (NS)	NA
	Type of intervention	Ropivacaine 0.25%	Bupivacaine 0.25%	
	Dosage	60ml	60ml	
	Dosage Intervals	Single administration	Single administration	
	Timing of intervention	Intra-operative	Intra-operative	
	Duration of surgery (hr) Mean ± SD	1.05 ± 0.39	1.03 ± 0.29	
Mannion 2005 <sup>102</sup>	Classification	Psoas compartment block (NS)	Psoas compartment block (NS)	Psoas compartment block (NS)
	Type of intervention	Levobupivacaine 0.5%/Clonidine IV	Levobupivacaine 0.5%/Clonidine (peripheral)	Levobupivacaine 0.5%
	Dosage	0.4mL per kg/1ug per kg	0.4mL per kg/1ug/kg	0.4mL/ kg
	Dosage Intervals	Single administration	Single administration	Single administration
	Timing of intervention	Intra-operative	Intra-operative	Intra-operative
	Type of surgery	Hemiarthroplasty in 6/12 pts; DHS in 6/12 pts	Hemiarthroplasty in 7/12 pts; DHS in 5/12 pts	Hemiarthroplasty in 5/12 pts; DHS in 7/12 pts
	Type of anesthesia General	12/12 (100%)	12/12 (100%)	12/12 (100%)
Marhofer 1997 <sup>103</sup>	Classification	3-in-1 nerve block (US)	3-in-1 nerve block (NS)	NA
	Type of intervention	Bupivacaine 0.5%	Bupivacaine 0.5%	
	Dosage	20ml	20ml	
	Dosage Intervals	Single administration	Single administration	
	Timing of intervention	Preoperative	Preoperative	

**Table F-5. Nerve blocks (continued)**

	Intervention 1	Intervention 2	Intervention 3	Intervention 4
	Type of anesthesia			
	Epidural	0/20 (0%)	0/20 (0%)	
	Spinal	20/20 (100%)	20/20 (100%)	
	General	0/20 (0%)	0/20 (0%)	
Marhofer 1998 <sup>104</sup>	Classification	3-in-1 nerve block (US)	3-in-1 nerve block (NS)	3-in-1 nerve block (NS) NA
	Type of intervention	Bupivacaine 0.5%	Bupivacaine 0.5%	Bupivacaine 0.5%
	Dosage	20ml	20ml	30ml
	Dosage Intervals	Single administration	Single administration	Single administration
	Timing of intervention	Pre-operative	Pre-operative	Pre-operative
Marhofer 2000 <sup>105</sup>	Classification	3-in-1 nerve block (NS)	3-in-1 nerve block (NS)	NA NA
	Type of intervention	Ropivacaine 0.5%	Bupivacaine 0.5%	
	Dosage	20ml	20ml	
	Dosage Intervals	Single administration	Single administration	
	Timing of intervention	Preoperative	Preoperative	
Matot 2003 <sup>106</sup>	Classification	Epidural analgesia (continuous)	IM analgesia	NA NA
	Type of intervention	Bolus: Bupivacaine 0.25%/ Methadone; Maintainence: Bupivacaine 0.5%/ Methadone	Meperidine IM	
	Dosage	7-10mL/4mg; 45mg/16mg	1mg/ kg	
	Dosage Intervals	Continuous (24hrs)	Every 6hrs	
	Timing of intervention	Preoperative	Preoperative	
	Time from fall to ED arrival (hr)			
	Mean ± SD	4.38 ± 2.50	4.18 ± 2.21	
	Time from ED arrival to surgery (hr) Mean ± SD	25.90 ± 16.70	28.60 ± 18.20	
	Type of surgery	DHS and plate fixation 20/34; hemiarthroplasty 12/34; cannulated hip screw 2/34	DHS and plate fixation 17/34; hemiarthroplasty 11/34; cannulated hip screw 2/34	

**Table F-5. Nerve blocks (continued)**

	Intervention 1	Intervention 2	Intervention 3	Intervention 4
Type of anesthesia				
Epidural	30/34 (88.24%)	0/34 (0%)		
Spinal	0/34 (0%)	27/34 (79.41%)		
General	4/34 (11.76%)	3/34 (8.82%)		
Baseline pain score	Scale name [VAS]			
Mean ± SD (n)	5.16 ± 1.74 (34)	4.91 ± 2.03 (34)		
Monzon 2010 <sup>107</sup>	Classification	Fascia iliaca compartment block	General anaesthesia	NA
	Type of intervention	0.25% bupivacaine	IV NSAID analgesics	
	Dosage	0.3 ml/kg	NR	
	Dosage Intervals	NR	NR	
	Timing of intervention	Intra-operative	Intra-operative	
	Type of surgery	NR	NR	
	Type of anesthesia			
	Epidural	0/92 (0%)	0/62 (0%)	
	Spinal	92/92 (100%)	0/62 (0%)	
	General	0/92 (0%)	62/62 (100%)	
	Baseline pain score			
	Scale name [VAS]			
	Mean ± SD (n)	8.50 ± 0.72 (n = 92)	7.60 ± 0.22 (n = 62)	
	Gender			
	Females: n (%)	59/92 (64.13%)	37/62 (59.68%)	
	Males: n (%)	33/92 (35.87%)	25/62 (40.32%)	
Mouzopoulos 2009 <sup>108</sup>	Classification	Fascia iliaca compartment nerve block (CT)	Placebo	NA
	Type of intervention	Bupivacaine	Saline	
	Dosage	0.25mg dose of 0.3mL/ kg	NA	
	Dosage Intervals	every 24h pre-/post surgery	Every 24h pre-/post surgery	
	Timing of intervention	Preoperative	Preoperative	
	Baseline pain score	Scale name [Visual analogue scale]		
	Mean ± SD (n)	6.14 ± NR (102)	6.82 ± NR (105)	

**Table F-5. Nerve blocks (continued)**

		<b>Intervention 1</b>	<b>Intervention 2</b>	<b>Intervention 3</b>	<b>Intervention 4</b>	
Murgue 2006 <sup>109</sup>	Classification	Femoral nerve block	Analgesia	Analgesia	NA	
	Type of intervention	Mepivacaine	IV morphine	IV paracetamol + ketoprofen		
	Dosage	20 cc	2 mg	1 g P + 100 mg K		
	Dosage Intervals		1 mg q5 min until p<=4			
	Age (yr) Mean ± SD Range	85.90 ± 6.60 (70 – 96)	85.90 ± 6.60 (70 – 96)	85.90 ± 6.60 (70 – 96)		
Pedersen 2008 <sup>119</sup>	Classification	3-in-1 nerve block	Analgesia	NA	NA	
	Type of intervention	Bupivacaine	Preoperative: Morphine SC or tablets; Postoperative: Morphine SR tablets/ acetaminophen/ ibuprofen			
	Dosage	Bolus: 100mg; Maintainence: 50mg	2.5-5mg/10-20mg; 1g/or 400mg			
	Dosage Intervals	Single administration; continuous (every 8hrs)	Every 12hrs; every 8hr/or every 12hrs			
	Timing of intervention	Preoperative	Preoperative			
	Time from ED arrival to surgery (hr) Mean ± SD	26.40 ± 19.30	27.60 ± 29.10			
	Type of surgery	Screws 39/178; DHS 50/178; intramedullary hip screw 43/178; Hemialloplasty 44/178; total hip arthroplasty 2/178	Screws 66/357; DHS 109/357; intramedullary hip screw 81/357; hemialloplasty 101/357; total hip arthroplasty 0/357			
	Type of anesthesia					
	Epidural	0/178 (0%)	0/357 (0%)			
	Spinal	42/178 (23.60%)	48/357 (13.45%)			
General	136/178 (76.40%)	309/357 (86.55%)				
Scheinin 2000 <sup>110</sup>	Classification	Epidural analgesia (continuous)	IM analgesia	NA	NA	
	Type of intervention	Bupivacaine/Fentanyl	Oxycodone IM			
	Dosage	1mg per ml + 10ug/ ml	0.1-0.15mg/ kg			

**Table F-5. Nerve blocks (continued)**

	<b>Intervention 1</b>	<b>Intervention 2</b>	<b>Intervention 3</b>	<b>Intervention 4</b>
Dosage Intervals	Continuous administration	On demand (max every 6hrs)		
Timing of intervention	Preoperative	Preoperative		
Type of surgery	Screw, lamina or prothesis in all pts	Screw, lamina or prothesis in all pts		
Type of anesthesia				
Epidural	0/38 (0%)	0/39 (0%)		
Spinal	38/38 (100%)	39/39 (100%)		
General	0/38 (0%)	0/39 (0%)		
Baseline pain score	Scale name [VAS]			
Mean ± SD (n)	3.40 ± 2.40 (38)	4.20 ± 2.90 (39)		
Segado Jiménez 2009 <sup>111</sup>	Classification	Obturator/ Femoral cutaneous nerve block	Obturator nerve block	IV analgesia
	Type of intervention	NR	NR	Opioid analgesia
	Dosage	NR	NR	NR
	Dosage Intervals	NR	NR	NR
	Timing of intervention	Postoperative	Postoperative	Postoperative
Segado Jiménez 2010 <sup>112</sup>	Classification	Fascia iliaca compartment block	Obturator /femoralcutaneous nerves block	General anaesthesia NA
	Type of intervention	Bupivacaine 0.5%	Bupivacaine 0.5%	NR
	Dosage	30 ml	15ml / 5 ml	NR
	Dosage Intervals	NR	NR	NR
	Timing of intervention	Intra-operative	Intra-operative	Intra-operative
	Type of surgery	total/partial arthroplasty, osteosynthesis, Richards osteosynthesis	total/partial arthroplasty, osteosynthesis, Richards osteosynthesis	total/partial arthroplasty, osteosynthesis, Richards osteosynthesis
	Type of anesthesia			
	Epidural	0/30 (0%)	0/30 (0%)	0/30 (0%)
	Spinal	30/30 (100%)	30/30 (100%)	0/30 (0%)
	General	0/30 (0%)	0/30 (0%)	30/30 (100%)



**Table F-5. Nerve blocks (continued)**

	Intervention 1	Intervention 2	Intervention 3	Intervention 4
Baseline pain score				
Scale name [VAS]				
Mean ± SD	0.84 (n = 30)	0.84 (n = 30)	7.47 (n = 30)	
Age (yr)				
Mean ± SD	71.30 ± 12.60	74.60 ± 10.10	71.10 ± 10.20	
Body weight (Kg)				
Mean ± SD	69.70 ± 8.60	68.60 ± 10.20	68.20 ± 9.60	
Height (cm)				
Mean ± SD	157.00 ± 6.00	158.00 ± 7.00	157.00 ± 6.00	
BMI (Kg/ m2)				
Mean ± SD	28.20 ± 4.20	27.30 ± 4.20	27.6 ± 3.80	
Spansberg 1996 <sup>113</sup>	Classification	Lumbar plexus block (NS)	Placebo	NA
	Type of intervention	Bolus: Bupivacaine 0.5%; Maintenance: Bupivacaine 0.25%	Bolus: Saline; Maintenance: Saline	
	Dosage	0.4mL per kg; 0.14mL/kg/hr	0.4mL per Kg; 0.14mL/kg/hr	
	Dosage Intervals	Single administration; Continuous administration	Continuous administration	
	Timing of intervention	Postoperative	Postoperative	
	Type of anesthesia			
	Spinal	10/10 (100%)	10/10 (100%)	
	Duration of surgery (hr)			
	Mean ± SD (Range)	0.96 ± NR (0.50 –1.83)	1.18 ± NR (0.75 –2.08)	
Tuncer 2003 <sup>114</sup>	Classification	3-in-1 nerve block (NS)	IV analgesia	NA
	Type of intervention	Bolus: Lidocaine 2%/Maintenance: Bupivacaine 0.125%; PCA bolus: Bupivacaine 0.125%	Morphine IV	
	Dosage	30ml; 4ml/hr; 3ml	1mg	

**Table F-5. Nerve blocks (continued)**

	<b>Intervention 1</b>	<b>Intervention 2</b>	<b>Intervention 3</b>	<b>Intervention 4</b>
Dosage Intervals	Single administration; Continuous administration; Patient cotrolled bolus on demand	On demand		
Timing of intervention	Postoperative	Postoperative		
Turker 2003 <sup>115</sup>	Classification	Psoas compartment block (NS)	Epidural anesthesia (single)	NA
	Type of intervention	Bupivacaine 0.5%	Bupivacaine 0.5%	
	Dosage	30ml	15ml	
	Dosage Intervals	Single administration	Single administration	
	Timing of intervention	Intra-operative	Intra-operative	
	Type of surgery	Partial hip replacement	Partial hip replacement	
	Type of anesthesia			
	Epidural	0/15 (0%)	15/15 (100%)	
	Spinal	0/15 (0%)	0/15 (0%)	
	General	15/15 (100%)	15/15 (100%)	
	Duration of surgery (hr)			
	Mean ± SD	2.19 ± 0.31	2.15 ± 0.44	
	Baseline pain score	Scale name [VAS]		
	Mean ± SD (n)	1.56 ± 0.97 (15)	1.23 ± 1.05 (15)	
Yun 2009 <sup>116</sup>	Classification	Fascia iliaca compartment nerve block (CT)	Analgesia	
	Type of intervention	Ropivacaine	Alfentanil	
	Dosage	30 mL 3.75 mg/mL 2-3 min	10 ug/kg bolus; 0.25 ug/kg/min 2 min	
	Dosage Intervals	Single dose	Single dose	
	Age (yr)			
	Mean ± SD	75	75.10	
	Range	(69 – 85)	(62 – 88)	
	Body weight (Kg)			
	Mean ± SD	60.60 ± 7.20	60.30 ± 11.30	
	Height (cm)			
	Mean	156.20	160.80	

**Table F-5. Nerve blocks (continued)**

	<b>Intervention 1</b>	<b>Intervention 2</b>	<b>Intervention 3</b>	<b>Intervention 4</b>
Gender				
Females: n (%)	13/ 20 (65.00%)	13/ 20 (65.00%)		
Males: n (%)	5/ 20 (25.00%)	7/ 20 (35.00%)		

CT = clinical touch; FICB = fascia iliaca compartment block; IM = intramuscular; IV = intravenous; NA = not applicable; NR = not reported; NRS = numeric rating scale; NS = nerve stimulation; NSAID = non-steroidal anti-inflammatory drugs; US = ultrasound; VAS = visual analogue scale

**Table F-6. Neurostimulation**

		<b>Intervention 1</b>	<b>Intervention 2</b>	<b>Intervention 3</b>	<b>Intervention 4</b>	
Gorodetskyi 2007 <sup>120</sup>	Classification	Neurostimulation	Sham Control	NA	NA	
	Type of intervention	InterX 5000 device	NA			
	Dosage	High peak amplitude 17 volts , low current 6 mA, damped biphasic electrical impulses	NA			
	Dosage Intervals	Every 24hrs	Every 24hrs			
	Timing of intervention	Postoperative	Postoperative			
	Type of surgery	DHS/dynamic condylar screw for noncomplex fractures 25/30; Gorodnichenko external fixation method for complex fractures 5/30	DHS/dynamic condylar screw for noncomplex fractures 27/30; Gorodnichenko external fixation method for complex fractures 3/30			
	Type of anesthesia General	30/30 (100%)	30/30 (100%)			
	Baseline pain score Mean $\pm$ SD (n) Range	Scale name [VAS] 9.00 $\pm$ NR (30) (7.50 – 10.00)	8.80 $\pm$ NR (30) (7.50 – 10.00)			
	Lang 2007 <sup>121</sup>	Classification	Neurostimulation	Sham Control	NA	NA
		Type of intervention	Transcutaneous electrical nerve stimulation	NA		
Dosage		70 mA, range: 0.5-120 Hz, pulse width: 60 to 300 us	NA			
Dosage Intervals		Single administration	Single administration			
Timing of intervention		Preoperative	Preoperative			
Time from fall to ED arrival (hr) Mean $\pm$ SD		29.80 $\pm$ 8.50	28.20 $\pm$ 12.30			
Baseline pain score Mean $\pm$ SD (n)		Scale name [VAS] 8.90 $\pm$ 0.90 (30)	8.60 $\pm$ 1.20 (33)			

NA = not applicable; VAS = visual analogue scale

**Table F-7. Rehabilitation**

		<b>Intervention 1</b>	<b>Intervention 2</b>	<b>Intervention 3</b>	<b>Intervention 4</b>
Di Lorenzo 2007 <sup>122</sup>	Classification	Rehabilitation	Standard care	NA	NA
	Type of intervention	Stretching-strengthening of spinal and psoas muscles	NR		
	Dosage	1 hr of training	NR		
	Dosage Intervals	Every 12 hrs for four wk	NR		
	Timing of intervention	Postoperative	Postoperative		
	Baseline pain score	Scale name [VAS]			
	Mean $\pm$ SD (n)	7.94 $\pm$ 0.80 (18)	7.94 $\pm$ 0.82 (19)		
	Range	(7.00 – 9.00)	(7.00 – 9.00)		

NA = not applicable; NR = not reported; VAS = visual analogue scale

**Table F-8. Traction**

		<b>Intervention 1</b>	<b>Intervention 2</b>	<b>Intervention 3</b>	<b>Intervention 4</b>	
Anderson 1993 <sup>128</sup>	Classification	Skin traction	Standard care	NA	NA	
	Type of intervention	Hamilton-Russell skin traction	NR			
	Dosage	5lb (2.3kg)	NR			
	Dosage Intervals	NA	NR			
	Timing of intervention	Preoperative	Preoperative			
	Baseline pain score Mean $\pm$ SD (n)	Scale name [VAS] 5.11 $\pm$ NR (101)	5.42 $\pm$ NR (151)			
Finsen 1992 <sup>123</sup>	Classification	Skin traction	Skeletal traction	Pillow	NA	
	Type of intervention	Elastic bandages	Steinman pin	Standard pillow		
	Dosage	3Kg	10% of patient's wt	NA		
	Dosage Intervals	NA	NA	NA		
	Timing of intervention	Preoperative	Preoperative	Preoperative		
	Time from ED arrival to surgery (hr) Mean $\pm$ SD (Range)	24.00 $\pm$ NR (10.00 – 52.00)	23.00 $\pm$ NR (8.00 – 68.00)	26.00 $\pm$ NR (10.00 – 90.00)		
	Type of surgery	Hip compression screws or uncemented endoprosthesis	Hip compression screws or uncemented endoprosthesis	Hip compression screws, uncemented endoprosthesis 24/25; cemented endoprosthesis 1/25		
Ghnaimat 2005 <sup>129</sup>	Classification	Skin traction	Standard care	NA	NA	
	Type of intervention	Skin traction	NR			
	Dosage	6lb	NR			
	Dosage Intervals	NA	NR			
	Timing of intervention	Preoperative	Preoperative			

**Table F-8. Traction (continued)**

		<b>Intervention 1</b>	<b>Intervention 2</b>	<b>Intervention 3</b>	<b>Intervention 4</b>
Jerre 2000 <sup>124</sup>	Classification	Skin traction	Standard care	Skin traction	Standard care
	Type of intervention	Foam rubber boot with straps around lower leg	NR	Foam rubber boot with straps around lower leg	NR
	Dosage	3Kg	NR	3Kg	NR
	Dosage Intervals	NA	NR	NA	NR
	Timing of intervention	Preoperative	Preoperative	Preoperative	Preoperative
	Time from ED arrival to surgery (hr) Mean ± SD	21.50 ± 37.70	18.50 ± 9.40	16.30 ± 8.20	15.20 ± 9.30
	Time from fall to surgery (hr) Mean ± SD	34.50 ± 44.30	27.20 ± 10.00	25.00 ± 9.30	28.60 ± 18.80
	Baseline pain score Mean ± SD (n)	Scale name [VAS] 4.10 ± 2.70 (30)	4.50 ± 2.60 (30)	4.30 ± 2.40 (30)	3.90 ± 2.70 (30)
	Needoff 1993 <sup>125</sup>	Classification	Skin traction	Pillow	NA
Type of intervention		Ventilated foam strap secured by means of a crepe bandage	Standard pillow		
Dosage		2.5kg	NA		
Dosage Intervals		NA	NA		
Timing of intervention		Preoperative	Pre-operative		
Duration of surgery (hr) Mean ± SD		0.69 ± NR	0.77 ± NR		
Baseline pain score Mean ± SD (n)		Scale name [VAS] 6.82 ± NR (30)	6.32 ± NR (34)	NA	NA
Resch 1998 <sup>126</sup>	Classification	Skin traction	Skeletal traction	NA	NA
	Type of intervention	Foam boot	K-wire		
	Dosage	3kg	3-5kg (5-10% body weight)		
	Dosage Intervals	NA	NA		
	Timing of intervention	Preoperative	Preoperative		
	Time from ED arrival to surgery (hr) Mean ± SD (Range)	24.00 ± 13.00 (20.00 – 28.00)	21.00 ± 9.00 (18.00 – 24.00)		

**Table F-8. Traction (continued)**

	<b>Intervention 1</b>	<b>Intervention 2</b>	<b>Intervention 3</b>	<b>Intervention 4</b>
Duration of surgery (hr)				
Mean ± SD (Range)	0.80 ± 0.40 (0.68 – 0.92)	0.97 ± 0.60 (0.78 – 1.15)		
Baseline pain score	Scale name [VAS]			
Mean ± SD (n)	4.80 ± 2.50 (40)	3.80 ± 2.00 (38)		
Range	(4.00 – 5.60)	(3.20 – 4.40)		
Resch 2005 <sup>26</sup>				
Classification	Skin traction	Pillow	Pillow	NA
Type of intervention	Foam rubber boot	Lasse Pillow	Standard pillow	
Dosage	3kg	NA	NA	
Timing of intervention	Preoperative	Preoperative	Preoperative	
Time from ED arrival to surgery (hr) Mean ± SD	22.00 ± 6.70	24.00 ± 6.50	23.00 ± 6.60	
Duration of surgery (hr)				
Mean ± SD	0.88 ± 0.52	1.08 ± 0.95	0.98 ± 0.55	
Baseline pain score	Scale name [VAS]			
Mean ± SD (n)	4.30 ± 2.20 (49)	3.30 ± 2.50 (21)	3.90 ± 1.90 (53)	
Rosen 2001 <sup>127</sup>				
Classification	Skin traction	Pillow	NA	NA
Type of intervention	Foam traction boot	Standard pillow		
Dosage	5lb	NA		
Timing of intervention	Preoperative	Preoperative		
Time from ED arrival to surgery (hr) Mean ± SD	28.80 ± 15.36	31.44 ± 25.44		
Baseline pain score	Scale name [VAS]			
Mean ± SD (n)	5.86 ± 2.73 (50)	6.12 ± 2.08 (50)		
Saygi 2010 <sup>130</sup>				
Classification	Skin traction	Sham traction	Pillow	NA
Type of intervention	Foam traction boot	Standard pillow	Standard pillow	
Dosage	2kg	0kg	NA	
Timing of intervention	Preoperative	Preoperative	Preoperative	
Time from fall to surgery (hr) Mean	52.8	52.6	54.2	
Baseline pain score	Scale name [Visual analogue scale]			
Mean ± SD (n)	6.93 ± 1.14 (36)	7.04 ± 1.08 (36)	6.85 ± 1.29 (36)	



**Table F-8. Traction (continued)**

		<b>Intervention 1</b>	<b>Intervention 2</b>	<b>Intervention 3</b>	<b>Intervention 4</b>
Vermeiren 1995 <sup>132</sup>	Classification	Skeletal traction	Skeletal traction	NA	NA
	Type of intervention	Skeletal traction with pillows for foot elevation	Skeletal traction with metal splint		
	Dosage	1 kg traction weight/10 kg body weight	1 kg traction weight/10 kg body weight		
	Dosage Intervals	NA	NA		
	Timing of intervention	Preoperative	Preoperative		
	Type of surgery	Nail-plates or screw plates 62/64; sliding hip nials 4/64	Nail-plates or screw-plates 46/68; sliding hip nails 16/68; Ender nails 5/68; cancellous screw fixation 1/68		
Yip 2002 <sup>131</sup>	Classification	Skin traction	Pillow	NA	NA
	Type of intervention	Foam boot	Standard pillow		
	Dosage	2kg	NA		
	Dosage Intervals	NA	NA		
	Timing of intervention	Preoperative	Preoperative		
	Time from fall to ED arrival (hr)				
	Mean ± SD (Range)	17.52 ± 14.16 (0.00 – 96.00)	17.52 ± 14.88 (0.00 – 72.00)		
	Time from ED arrival to surgery (hr)				
	Mean ± SD	113.52 ± 51.84	112.56 ± 71.76		
	Type of surgery	Hemiarthroplasty 52/166; DHS 99/166; percutaneous hip screws 10/166; other types of surgeries 4/166	Hemiarthroplasty in 45/145; DHS 78/145; percutaneous hip screws 16/145; other types of surgeries 5/145		
	Baseline pain score	Scale name [VAS]			
Mean ± SD (n)	0.24 ± NR (166)	0.30 ± NR (145)			

NA = not applicable; NR = not reported; VAS = visual analogue scale

# Appendix G. Risk of Bias Assessment for Randomized Controlled Trials and Nonrandomized Controlled Trials

## Guidelines and Decision Rules for Risk of Bias Assessments

### Sequence Generation:

- If computer-generated, random number list, flipping coins, randomly picking envelopes, etc. is specified → YES
- If the description only includes ‘random,’ ‘randomly generated,’ ‘randomized,’ etc., do not assume additional details → UNCLEAR
- If the description is quasi-randomized (e.g. alternate randomization, day of the year, day of the month, birth date, birth month, beginning letter of last name, availability of investigator or specialist, etc.) → NO

### Allocation Concealment:

- If the assignment is conducted by central telephone, pharmacy, etc. → YES
- If dark (or opaque), sealed, sequentially numbered envelopes are used → YES
- If the envelopes are not stated to dark and sealed, or sequentially numbered → UNCLEAR

Note: sequential numbering of the envelopes is only required for adequate allocation concealment if the method of randomization was anything other than randomly picking envelopes (i.e., the envelopes were only used for allocation concealment and not as part of the randomization process).

### Blinding:

- If the study was stated to be blinded (masked) and the blinding is considered to be possible, and not likely to be broken → YES
- If the study is only stated to be blinded, double-blinded, double-dummy, etc. without any further details → UNCLEAR
- If the study states the use of a placebo (dummy) but with no further details → UNCLEAR
- If no mention of blinding → NO

### Incomplete Outcome Data:

- Look for intention-to-treat analysis (all randomized pts. are analyzed) → YES
- If all participants were accounted for (i.e. no drop-outs or censored analysis conducted) → YES
- If the numbers and reasons for withdrawal/dropouts were described and comparable across groups (and ≤ approximately 10 percent) → YES
- If there is between 10 percent and 30 percent dropout and no ITT analysis → UNCLEAR

- If there is greater 30 percent dropout and no ITT analysis → NO

### **Selective Outcome Reporting:**

- If the study protocol is available (referenced in the manuscript), compare the outcomes reported in the publication to those specified in the protocol. If they match → YES
- If the study protocol is available (referenced in the manuscript), compare the outcomes reported in the publication to those specified in the protocol. If they do not match, but there is reference to another publication with this information presented → YES
- If the study protocol is not available, compare the outcomes reported in the Methods and Results sections. If they match → YES

### **Other Sources of Bias:**

- Assess for baseline imbalances that could have biased the results (or were not accounted for).
- Assess for early stopping for benefit.
- Assess for appropriateness of cross-over design (e.g., inadequate washout period).
- Assess for inappropriate influence of funders that could have biased the results:
  - If sponsor is acknowledged and there is a clear statement regarding no involvement of sponsor in trial conduct or data management/analysis, or coauthorship → YES
  - If sponsor is acknowledged with no further information provided or (co)author works for a pharmaceutical company → NO
  - If there is no mention of funding source → UNCLEAR
- Note any “other” sources of bias.

## Risk of Bias (RoB) Assessments

**Table G-1. Pharmacologic Analgesia**

Study	Item	Judgment	Description
Apostolopoulos 2006 <sup>41</sup>	Adequate sequence generation?	UNCLEAR	Reported as a randomized trial without any further details
	Allocation concealment?	UNCLEAR	No description of allocation concealment reported
	Blinding?	UNCLEAR	NR
	Incomplete outcome data addressed?	UNCLEAR	Not enough information provided in the text to make a precise decision
	Free of selective reporting?	UNCLEAR	Not enough information provided in the text to make a precise decision
	Free of other bias?	UNCLEAR	No information on baseline characteristics or any information on financial support.
Baker 2004 <sup>42</sup>	Adequate sequence generation?	UNCLEAR	Reported as a randomized trial without any further details
	Allocation concealment?	UNCLEAR	No description of allocation concealment reported
	Blinding?	YES	Reported as a double-blind trial and that the study solutions were freshly prepared by an anesthesiologist who had no further part in the study. Also reported that the anesthesiologist who injected the study solution and the investigator were blinded to the baricity of the clonidine solution administered
	Incomplete outcome data addressed?	YES	All pts completed the study and were included in the analyses (intention-to-treat)
	Free of selective reporting?	YES	Protocol not available, but the outcomes in the methods match those in the results
	Free of other bias?	YES	Baseline characteristics were balanced and the source of funding was declared to be institutional
Poitevin 1999 <sup>55</sup>	Adequate sequence generation?	UNCLEAR	Reported as a randomized trial without any further details
	Allocation concealment?	UNCLEAR	NR
	Blinding?	YES	Reported as a double-blind study using identical matching placebos
	Incomplete outcome data addressed?	YES	All pts completed the study and were included in the analyses (intention-to-treat)
	Free of selective reporting?	YES	Protocol not available, but the outcomes in the methods match those in the results
	Free of other bias?	UNCLEAR	Baseline characteristics are balanced but there is no source of funding declared

**Table G-2. Anesthesia**

<b>Study</b>	<b>Item</b>	<b>Judgment</b>	<b>Description</b>
Adams 1990 <sup>56</sup>	Adequate sequence generation?	NO	Quasi-randomization based on the date of admission
	Allocation concealment?	NO	Based on even or odd calendar dates of admission
	Blinding?	UNCLEAR	NR
	Incomplete outcome data addressed?	YES	All pts completed the study and were included in the analyses (intention-to-treat)
	Free of selective reporting?	YES	Protocol not available, but the outcomes in the methods match those in the results
	Free of other bias?	UNCLEAR	Baseline characteristics are balanced but there is no source of funding declared
Alonso Chico 2003 <sup>57</sup>	Adequate sequence generation?	UNCLEAR	Reported as a randomized trial without any further details
	Allocation concealment?	UNCLEAR	NR
	Blinding?	UNCLEAR	NR
	Incomplete outcome data addressed?	YES	All pts completed the study and were included in the analyses (intention-to-treat)
	Free of selective reporting?	YES	Protocol not available, but the outcomes in the methods match those in the results
	Free of other bias?	UNCLEAR	Baseline characteristics are balanced but there is no source of funding declared
Ben-David 2000 <sup>58</sup>	Adequate sequence generation?	UNCLEAR	Reported the use of a sealed-envelope technique with no further details
	Allocation concealment?	UNCLEAR	Reported the use of sealed-envelope technique with no further details
	Blinding?	YES	Reported that all pts received the same injectate volume. Additionally the syringes were prepared by one researcher and administered by a second who remained blinded to its contents. Patient assessment and care were conducted and study data were recorded by the second blinded researcher. Finally, the protocol allowed for conversion to general anesthesia as deemed necessary by the blinded anesthesiologist. No mention of patient blinding was reported.
	Incomplete outcome data addressed?	YES	All pts completed the study and were included in the analyses (intention-to-treat)
	Free of selective reporting?	YES	Protocol not available, but the outcomes in the methods match those in the results
	Free of other bias?	YES	Baseline characteristics were balanced and the source of funding was declared to be institutional

**Table G-2. Anesthesia (continued)**

<b>Study</b>	<b>Item</b>	<b>Judgment</b>	<b>Description</b>
Bredahl1991 <sup>59</sup>	Adequate sequence generation?	Unclear	Reported as a randomized trial without any further details
	Allocation concealment?	Unclear	No description of allocation concealment reported
	Blinding?	Unclear	NR
	Incomplete outcome data addressed?	Unclear	No ITT. 13.3% exclusion in general a. group due to the incomplete data and sampling.
	Free of selective reporting?	Yes	Protocol not available, but the outcomes in the methods match those in the results.
	Free of other bias?	Unclear	Baseline characteristics are balanced but there is no source of funding declared.
Casati 2003 <sup>60</sup>	Adequate sequence generation?	UNCLEAR	Reported the use of a sealed-envelope technique with no further details
	Allocation concealment?	UNCLEAR	Reported that Allocation concealment was via a sealed-envelope technique with no further details
	Blinding?	NO	Reported that the orthopedic and rehabilitation staff who assessed the clinical criteria prior to discharge from hospital were blinded to the anesthesia technique used during surgery. There is no mention of clinicians or patients being blinded. Additionally since pts in the spinal group were awake, while the pts in the general anesthesia group were unconscious, pt blinding was not possible. Finally, no mention of any procedure to blind the clinicians performing the surgery or anesthesia.
	Incomplete outcome data addressed?	YES	All pts completed the study and were included in the analyses (intention-to-treat)
	Free of selective reporting?	YES	Protocol not available, but the outcomes in the methods match those in the results
	Free of other bias?	UNCLEAR	Baseline characteristics were balanced but there is no source of funding declared
	Danelli 2008 <sup>61</sup>	Adequate sequence generation?	YES
Allocation concealment?		YES	Reported that allocation concealment was ensured using sequentially numbered, sealed opaque envelopes
Blinding?		YES	Reported as a double-blind study with an independent observer, who was blinded to group allocation, recording the observations.
Incomplete outcome data addressed?		YES	Principle of Intention-to-treat not used in the analyses with 9% of randomized pts were excluded with reasons provided
Free of selective reporting?		YES	Protocol not available, but the outcomes in the methods match those in the results

**Table G-2. Anesthesia (continued)**

<b>Study</b>	<b>Item</b>	<b>Judgment</b>	<b>Description</b>
	Free of other bias?	UNCLEAR	Baseline characteristics were balanced but there is no source of funding declared
Favarel-Garrigues 1996 <sup>62</sup>	Adequate sequence generation?	UNCLEAR	Reported as a randomized trial without any further details
	Allocation concealment?	UNCLEAR	No description of allocation concealment reported
	Blinding?	UNCLEAR	NR
	Incomplete outcome data addressed?	YES	All patient completed the study and followed up for one month post-operatively (intention-to-treat)
	Free of selective reporting?	YES	Protocol not available, but the outcomes in the methods match those in the results
	Free of other bias?	UNCLEAR	Baseline characteristics were balanced but there is no source of funding declared
Hooda 2006 <sup>63</sup>	Adequate sequence generation?	UNCLEAR	Reported as a randomized trial without any further details
	Allocation concealment?	UNCLEAR	No description of allocation concealment reported
	Blinding?	YES	Reported as a double-blind trial and that In order to facilitate blinding; spinal anesthesia was administered by a fellow colleague and observer did not know the amount of drug received by the patient
	Incomplete outcome data addressed?	YES	All pts completed the study and were included in the analyses (intention-to-treat)
	Free of selective reporting?	YES	Protocol not available, but the outcomes in the methods match those in the results
	Free of other bias?	UNCLEAR	Baseline characteristics were balanced but there is no source of funding declared
Juelsgaard 1998 <sup>64</sup>	Adequate sequence generation?	UNCLEAR	Reported as a randomized trial without any further details
	Allocation concealment?	UNCLEAR	No description of allocation concealment reported
	Blinding?	YES	Reported that the investigator was blinded to the randomization
	Incomplete outcome data addressed?	NO	Intention-to-treat principle was not used in the analyses with 11/54 (%) of randomized pts excluded from the analyses with reasons provided
	Free of selective reporting?	YES	Protocol not available, but the outcomes in the methods match those in the results
	Free of other bias?	UNCLEAR	Baseline characteristics were balanced but there is no source of funding declared
Klimscha 1995 <sup>65</sup>	Adequate sequence generation?	YES	Reported that randomization was performed by having an assistant blindly pick from an envelope a piece of paper with the name of the study solution and route of administration written on it

**Table G-2. Anesthesia (continued)**

<b>Study</b>	<b>Item</b>	<b>Judgment</b>	<b>Description</b>
	Allocation concealment?	UNCLEAR	Reported as using envelopes with no further details
	Blinding?	YES	Reported that an assisting anesthesiologist inserted the catheters, prepared the fresh study solution, injected it, and covered the injection port with a cotton towel to blind the other anesthesiologist to the group assignment.
	Incomplete outcome data addressed?	YES	All pts completed the study and were included in the analyses (intention-to-treat)
	Free of selective reporting?	YES	Protocol not available, but the outcomes in the methods match those in the results
	Free of other bias?	UNCLEAR	Baseline characteristics were balanced but there is no source of funding declared. There was mention of 'valuable support' from an employee of a pharmaceutical company with no further explanation
Krobot 2006 <sup>77</sup>	Adequate sequence generation?	NO	NR to be a randomized trial
	Allocation concealment?	UNCLEAR	No description of allocation concealment reported
	Blinding?	UNCLEAR	NR
	Incomplete outcome data addressed?	UNCLEAR	Not enough information provided in the text to make a precise decision
	Free of selective reporting?	YES	Protocol not available, but the outcomes in the methods match those in the results
	Free of other bias?	UNCLEAR	Baseline characteristics not provided nor any disclosure on sources of funding
Kwan 1997 <sup>66</sup>	Adequate sequence generation?	UNCLEAR	Reported as a randomized trial without any further details
	Allocation concealment?	YES	Injections were prepared by another investigator who was not performing the block.
	Blinding?	YES	Reported as double-blind design. Two different investigators prepared the solutions and administered them. An assessment of pain level conducted by investigator who was unaware of the constituents of the allocation
	Incomplete outcome data addressed?	YES	Intention-to-treat analysis was not used with 10% of participants dropped-out of the trial with reasons provided
	Free of selective reporting?	YES	Protocol not available, but the outcomes in the methods match those in the results
	Free of other bias?	UNCLEAR	Baseline characteristics were balanced but there is no source of funding declared
Malek 2004 <sup>67</sup>	Adequate sequence generation?	UNCLEAR	Reported the use of a sealed-envelope technique with no further details
	Allocation concealment?	UNCLEAR	Reported the use of sealed-envelope technique with no further details



**Table G-2. Anesthesia (continued)**

<b>Study</b>	<b>Item</b>	<b>Judgment</b>	<b>Description</b>
	Blinding?	UNCLEAR	Reported that only the anesthesiologist and anesthetic nurse were aware of the allocation, but there is no reporting on how was in charge of monitoring the patients and recording the outcomes
	Incomplete outcome data addressed?	YES	All pts completed the study and were included in the analyses (intention-to-treat)
	Free of selective reporting?	YES	Protocol not available, but the outcomes in the methods match those in the results
	Free of other bias?	YES	Baseline characteristics were balanced and the source of funding was declared to be institutional
Martyr 2001 <sup>68</sup>	Adequate sequence generation?	UNCLEAR	Reported that for each patient a numbered syringe was chosen at random from the supply kept in the Pharmacy Department with no further details
	Allocation concealment?	YES	Reported that the coded syringes were chosen at random
	Blinding?	YES	Reported that the syringes were prepared by Baxter Healthcare and the study solution syringes were the same volume as the standard solution syringes and were all numbered and coded such that the administering anesthetist was blinded to their contents.
	Incomplete outcome data addressed?	NO	Intention-to-treat principle was not used in the analyses with 6/48 (12.50%) of randomized pts excluded from the analyses with reasons provided
	Free of selective reporting?	YES	Protocol not available, but the outcomes in the methods match those in the results
	Free of other bias?	UNCLEAR	Baseline characteristics were balanced but there is no source of funding declared
Martyr 2005 <sup>69</sup>	Adequate sequence generation?	YES	Reported that randomization was performed using a computer-generated randomization
	Allocation concealment?	YES	Reported that randomization was performed by a third-party and syringes were sequentially numbered and administered
	Blinding?	YES	Reported that the syringes were prepared by a third party and stored in the hospital pharmacy, and that the anesthesiologists and nurses that administered and monitored the patients were not aware of the allocation
	Incomplete outcome data addressed?	YES	All pts completed the study and were included in the analyses (intention-to-treat)
	Free of selective reporting?	YES	Protocol not available, but the outcomes in the methods match those in the results

**Table G-2. Anesthesia (continued)**

<b>Study</b>	<b>Item</b>	<b>Judgment</b>	<b>Description</b>
	Free of other bias?	UNCLEAR	Baseline characteristics were balanced, and disclosure of institutional financial support is provided, but the interventions were provided by Baxter Healthcare and it is not clear if they were provided as a type of financial support for the trial or were co
Maurette 1993 <sup>70</sup>	Adequate sequence generation?	UNCLEAR	Reported as a randomized trial without any further details
	Allocation concealment?	UNCLEAR	No description of allocation concealment reported
	Blinding?	YES	Reported as double-blind, and that the investigator that administered the medications was different from the one that prepared them
	Incomplete outcome data addressed?	YES	Intention-to-treat principle was not used with 1/35 (2.86%) of randomized pts were excluded with reasons provided
	Free of selective reporting?	YES	Protocol not available, but the outcomes in the methods match those in the results
	Free of other bias?	UNCLEAR	Baseline characteristics were balanced but there is no source of funding declared
Minville 2006 <sup>71</sup>	Adequate sequence generation?	UNCLEAR	Reported as a randomized trial without any further details
	Allocation concealment?	UNCLEAR	No description of allocation concealment reported
	Blinding?	UNCLEAR	Reported that a blinded observer assessed the dermatome level of sensory blockade, but no details of who assessed the outcome measures
	Incomplete outcome data addressed?	YES	Intention-to-treat principle was not used in the analyses with one pt not completing the investigation and not included in the analyses
	Free of selective reporting?	YES	Protocol not available, but the outcomes in the methods match those in the results
	Free of other bias?	UNCLEAR	Baseline characteristics were balanced but there is no source of funding declared
Navas 2008 <sup>72</sup>	Adequate sequence generation?	UNCLEAR	Reported as a randomized trial without any further details
	Allocation concealment?	UNCLEAR	No description of allocation concealment reported
	Blinding?	UNCLEAR	NR
	Incomplete outcome data addressed?	UNCLEAR	Not enough information provided in the text to make a precise decision
	Free of selective reporting?	YES	Protocol not available, but the outcomes in the methods match those in the results
	Free of other bias?	UNCLEAR	Baseline characteristics were balanced but there is no source of funding declared
Olofsson 2004 <sup>73</sup>	Adequate sequence generation?	UNCLEAR	Reported the use of a sealed-envelope technique with no further details
	Allocation concealment?	UNCLEAR	Reported the use of sealed-envelope technique with no further details

**Table G-2. Anesthesia (continued)**

<b>Study</b>	<b>Item</b>	<b>Judgment</b>	<b>Description</b>
	Blinding?	YES	Reported that the study was double-blind and that all pts received the same injectate volume which was prepared by a nurse not involved in the study
	Incomplete outcome data addressed?	YES	All pts completed the study and were included in the analyses (intention-to-treat)
	Free of selective reporting?	YES	Protocol not available, but the outcomes in the methods match those in the results
	Free of other bias?	YES	Baseline characteristics were balanced and the source of funding was declared to be institutional
Qamarul Hoda 2007 <sup>146</sup>	Adequate sequence generation?	UNCLEAR	Reported that randomization was performed using the sealed envelope technique with no further details
	Allocation concealment?	UNCLEAR	Reported the use of sealed envelopes with no further details
	Blinding?	UNCLEAR	NR
	Incomplete outcome data addressed?	YES	All pts completed the study and were included in the analyses (intention-to-treat)
	Free of selective reporting?	YES	Protocol not available, but the outcomes in the methods match those in the results
	Free of other bias?	UNCLEAR	Baseline characteristics were balanced but there is no source of funding declared
Rais 2008 <sup>75</sup>	Adequate sequence generation?	UNCLEAR	Reported as a randomized trial without any further details
	Allocation concealment?	UNCLEAR	No description of allocation concealment reported
	Blinding?	UNCLEAR	NR
	Incomplete outcome data addressed?	YES	All pts completed the study and were included in the analyses (intention-to-treat)
	Free of selective reporting?	YES	Protocol not available, but the outcomes in the methods match those in the results
	Free of other bias?	UNCLEAR	Baseline characteristics were balanced but there is no source of funding declared
Said-Ahmed 2006 <sup>76</sup>	Adequate sequence generation?	UNCLEAR	Reported the use of randomization using sealed envelopes with no further details
	Allocation concealment?	UNCLEAR	Reported the use of sealed envelopes with no further details
	Blinding?	YES	Reported that the syringes were prepared by a researcher and passed to a second investigator who was blinded to its content. The second investigator was reported to have administered the drug and collected the study data.

**Table G-2. Anesthesia (continued)**

<b>Study</b>	<b>Item</b>	<b>Judgment</b>	<b>Description</b>
	Incomplete outcome data addressed?	YES	All pts completed the study and were included in the analyses (intention-to-treat)
	Free of selective reporting?	YES	Protocol not available, but the outcomes in the methods match those in the results
	Free of other bias?	UNCLEAR	Baseline characteristics were balanced but there is no source of funding declared

**Table G-3. Complementary and alternative medicine (CAM)**

<b>Study</b>	<b>Item</b>	<b>Judgment</b>	<b>Description</b>
Barker 2006 <sup>43</sup>	Adequate sequence generation?	UNCLEAR	Reported as a randomized trial without any further details
	Allocation concealment?	UNCLEAR	Reported using a sealed envelope to determine the patient's group assignment without any further details
	Blinding?	YES	Reported that the trial was double-blind and that following the administration of the intervention, one paramedic covered the ears of all subjects with ear patches to assure blinding of the other paramedic, who was involved in the outcome assessment
	Incomplete outcome data addressed?	YES	All pts completed the study and were included in the analyses (intention-to-treat)
	Free of selective reporting?	YES	Protocol not available, but the outcomes in the methods match those in the results
	Free of other bias?	UNCLEAR	Baseline characteristics were balanced but there is no source of funding declared
Martin 1991 <sup>54</sup>	Adequate sequence generation?	YES	Reported that randomization was performed using a table of random numbers coding system
	Allocation concealment?	UNCLEAR	No description of allocation concealment reported
	Blinding?	NO	Reported that the researcher that was instructing the patients on the use of the intervention was also the one measuring outcomes; including subjective assessments of pain.
	Incomplete outcome data addressed?	UNCLEAR	Pts were randomized before receiving confirmation of inclusion in the study with no mention of the number excluded after randomization
	Free of selective reporting?	NO	Protocol not available, but methods section numerates differing outcomes than were presented in the results
	Free of other bias?	UNCLEAR	Baseline characteristics were balanced but there is no source of funding declared

**Table G-4. Nerve blocks**

<b>Study</b>	<b>Item</b>	<b>Judgment</b>	<b>Description</b>
Antonopoulou 2006 <sup>88</sup>	Adequate sequence generation?	UNCLEAR	Reported as a randomized trial without any further details
	Allocation concealment?	UNCLEAR	No description of allocation concealment reported
	Blinding?	UNCLEAR	NR
	Incomplete outcome data addressed?	UNCLEAR	Not enough information provided in the text to make a precise decision
	Free of selective reporting?	NO	Protocol not available, but methods section numerates differing outcomes than were presented in the results
	Free of other bias?	UNCLEAR	Baseline characteristics were balanced but there is no source of funding declared
Chudinov 1999 <sup>89</sup>	Adequate sequence generation?	UNCLEAR	Reported as a randomized trial without any further details
	Allocation concealment?	UNCLEAR	No description of allocation concealment reported
	Blinding?	UNCLEAR	NR
	Incomplete outcome data addressed?	YES	All pts completed the study and were included in the analyses (intention-to-treat)
	Free of selective reporting?	YES	Protocol not available, but the outcomes in the methods match those in the results
	Free of other bias?	UNCLEAR	Baseline characteristics were balanced but there is no source of funding declared
Coad 1991 <sup>90</sup>	Adequate sequence generation?	UNCLEAR	Reported as a randomized trial without any further details
	Allocation concealment?	UNCLEAR	No description of allocation concealment reported
	Blinding?	YES	Reported that the nurses who prescribed rescue analgesia were unaware of the patients' allocation
	Incomplete outcome data addressed?	YES	All pts completed the study and were included in the analyses (intention-to-treat)
	Free of selective reporting?	NO	Protocol not available, but it was noted that the authors abandoned a pilot study for measuring pain score using VAS due to unsatisfactory results.
	Free of other bias?	UNCLEAR	Baseline characteristics were balanced but there is no source of funding declared

**Table G-4. Nerve blocks (continued)**

<b>Study</b>	<b>Item</b>	<b>Judgment</b>	<b>Description</b>
Cuvillon 2007 <sup>91</sup>	Adequate sequence generation?	UNCLEAR	Reported as a randomized trial without any further details
	Allocation concealment?	UNCLEAR	Reported the use of sealed, numbered envelopes with no further details
	Blinding?	UNCLEAR	NR
	Incomplete outcome data addressed?	YES	All pts completed the study and were included in the analyses (intention-to-treat)
	Free of selective reporting?	YES	Protocol not available, but the outcomes in the methods match those in the results
	Free of other bias?	YES	Baseline characteristics are balanced and the source of funding was declared to be institutional
de Visme 2000 <sup>92</sup>	Adequate sequence generation?	UNCLEAR	Reported as a randomized trial without any further details
	Allocation concealment?	YES	Randomization was performed in the hospital pharmacy (third party)
	Blinding?	NO	NR, but also not possible with the study design
	Incomplete outcome data addressed?	NO	Intention-to-treat principle was not used in the analyses with 11/29 (37.93%) of randomized pts excluded from analysis
	Free of selective reporting?	YES	Protocol not available, but the outcomes in the methods match those in the results
	Free of other bias?	YES	Baseline characteristics were balanced and the source of funding was declared to be institutional
Eyrolle 1998 <sup>93</sup>	Adequate sequence generation?	UNCLEAR	Reported as a randomized trial without any further details
	Allocation concealment?	UNCLEAR	No description of allocation concealment reported
	Blinding?	UNCLEAR	NR
	Incomplete outcome data addressed?	YES	All pts completed the study and were included in the analyses (intention-to-treat)
	Free of selective reporting?	NO	Protocol is not available and the intended outcomes were not clearly described in the methods section
	Free of other bias?	UNCLEAR	Baseline characteristics were balanced but there is no source of funding declared
Fletcher 2003 <sup>94</sup>	Adequate sequence generation?	YES	Reported that randomization was performed using a random number generator
	Allocation concealment?	YES	Reported the use of sealed opaque envelopes
	Blinding?	NO	Reported that data collectors and outcome assessors were blinded but patients were not blinded to group allocation
	Incomplete outcome data addressed?	YES	All pts completed the study and were included in the analyses (intention-to-treat)

**Table G-4. Nerve blocks (continued)**

<b>Study</b>	<b>Item</b>	<b>Judgment</b>	<b>Description</b>
	Free of selective reporting?	NO	Protocol not available, but one of the outcomes in the methods is not presented in the results (i.e., time to discharge)
	Free of other bias?	UNCLEAR	Baseline characteristics were balanced but there is no source of funding declared
Foss 2005 <sup>95</sup>	Adequate sequence generation?	YES	Reported that randomization was performed using a computer-generated randomization list
	Allocation concealment?	YES	Reported that randomization was performed by a third party
	Blinding?	YES	Reported that it was a double-blind trials and that the epidural cassettes were packed by the local pharmacy and blinded and supplied with a randomization number by a person not affiliated with the project
	Incomplete outcome data addressed?	YES	Intention-to-treat principle was not used in the analyses with 5/60 (8.33%) pts excluded from the analyses with reasons given
	Free of selective reporting?	YES	Protocol not available, but the outcomes in the methods match those in the results
	Free of other bias?	YES	Baseline characteristics were balanced and source of funding declared as governmental
Foss 2007 <sup>96</sup>	Adequate sequence generation?	YES	Reported that randomization was performed using computer-generated list
	Allocation concealment?	YES	Reported that the medicine used for each individual patient was prepared by a nurse not otherwise involved with the collection of patient data
	Blinding?	YES	Reported that the study was double blind with placebo injections given along with the intervention studied in each group
	Incomplete outcome data addressed?	YES	All pts completed the study and were included in the analyses (intention-to-treat)
	Free of selective reporting?	YES	The outcomes reported in the publication match those in the protocol (NCT00162630)
	Free of other bias?	YES	Gender is imbalanced between the groups but this is unlikely to introduce bias; Funding provided by IMK Almene Fond, a private research fund
Gille 2006 <sup>97</sup>	Adequate sequence generation?	UNCLEAR	Reported as a randomized trial without any further details
	Allocation concealment?	UNCLEAR	NR
	Blinding?	UNCLEAR	NR
	Incomplete outcome data addressed?	UNCLEAR	Not clear if all pts completed the trial and were included in the analyses
	Free of selective reporting?	YES	Protocol not available, but the outcomes in the methods match those in the results



**Table G-4. Nerve blocks (continued)**

<b>Study</b>	<b>Item</b>	<b>Judgment</b>	<b>Description</b>
	Free of other bias?	YES	Baseline characteristics are balanced and the source of funding was declared to be institutional
Graham 2008 <sup>98</sup>	Adequate sequence generation?	UNCLEAR	Reported the use of numbered, sequential, sealed opaque envelopes with no further details
	Allocation concealment?	YES	Reported that allocation concealment was ensured using numbered, sequential, sealed opaque envelopes
	Blinding?	NO	Reported as an 'open-label' trial
	Incomplete outcome data addressed?	NO	Intention-to-treat principle was not used in the analyses with 7/40 (17.50%) of randomized pts excluded from analyses with reasons provided
	Free of selective reporting?	YES	Protocol not available, but the outcomes in the methods match those in the results
	Free of other bias?	UNCLEAR	Baseline characteristics were balanced but there is no source of funding declared
Haddad 1995 <sup>99</sup>	Adequate sequence generation?	UNCLEAR	Reported as randomized by using sealed envelopes with no further details
	Allocation concealment?	UNCLEAR	Reported the use of sealed-envelope technique with no further details
	Blinding?	YES	Reported that the staff that monitored the patients and provided rescue analgesia were unaware of the patients' allocation
	Incomplete outcome data addressed?	YES	Intention-to-treat principle was not used with 5/50 (10%) of randomized pts were excluded with reasons provided
	Free of selective reporting?	YES	Protocol not available, but the outcomes in the methods match those in the results
	Free of other bias?	UNCLEAR	Baseline characteristics were balanced but there is no source of funding declared
Henderson 2008 <sup>100</sup>	Adequate sequence generation?	UNCLEAR	Reported as a randomized trial without any further details
	Allocation concealment?	UNCLEAR	No description of allocation concealment reported
	Blinding?	UNCLEAR	NR
	Incomplete outcome data addressed?	YES	All pts completed the study and were included in the analyses (intention-to-treat)
	Free of selective reporting?	YES	Protocol not available, but the outcomes in the methods match those in the results
	Free of other bias?	UNCLEAR	No information on baseline characteristics or any information on financial support.
Hood 1991 <sup>101</sup>	Adequate sequence generation?	UNCLEAR	Reported the use of unmarked envelopes with no further details
	Allocation concealment?	UNCLEAR	Reported the use of sealed-envelope technique with no further details

**Table G-4. Nerve blocks (continued)**

<b>Study</b>	<b>Item</b>	<b>Judgment</b>	<b>Description</b>
	Blinding?	YES	Reported that all the patients had their skin prepared and an elastoplast placed over the possible injection site to minimize bias, while staff providing rescue analgesia administration and assessing the quality of analgesia after operation were blinded to the patients' allocation
	Incomplete outcome data addressed?	YES	All pts completed the study and were included in the analyses (intention-to-treat)
	Free of selective reporting?	YES	Protocol not available, but the outcomes in the methods match those in the results
	Free of other bias?	UNCLEAR	Baseline characteristics were balanced but there is no source of funding declared
Mannion 2005 <sup>102</sup>	Adequate sequence generation?	YES	Reported that randomization was performed using a randomization table restricted to blocks of 12 (block randomization)
	Allocation concealment?	UNCLEAR	Reported as using sealed envelopes without any further details
	Blinding?	YES	Reported as a double-blind trial and that the drug solutions to be administered were prepared by an anesthesiologist not involved in block performance, patient care, or data collection.
	Incomplete outcome data addressed?	YES	All pts completed the study and were included in the analyses (intention-to-treat)
	Free of selective reporting?	YES	Protocol not available, but the outcomes in the methods match those in the results
	Free of other bias?	UNCLEAR	Baseline characteristics were balanced but there is no source of funding declared
Marhofer 1997 <sup>103</sup>	Adequate sequence generation?	UNCLEAR	Reported as a randomized trial without any further details
	Allocation concealment?	UNCLEAR	No description of allocation concealment reported
	Blinding?	UNCLEAR	NR
	Incomplete outcome data addressed?	YES	All pts completed the study and were included in the analyses (intention-to-treat)
	Free of selective reporting?	YES	Protocol not available, but the outcomes in the methods match those in the results
	Free of other bias?	UNCLEAR	Baseline characteristics were balanced but there is no source of funding declared
Marhofer 1998 <sup>104</sup>	Adequate sequence generation?	UNCLEAR	Reported as a randomized trial without any further details
	Allocation concealment?	UNCLEAR	No description of allocation concealment reported

**Table G-4. Nerve blocks (continued)**

<b>Study</b>	<b>Item</b>	<b>Judgment</b>	<b>Description</b>
	Blinding?	YES	Reported that all blocks were performed by one anesthesiologist while another anesthesiologist unaware of the group assignment performed the monitoring
	Incomplete outcome data addressed?	YES	All pts completed the study and were included in the analyses (intention-to-treat)
	Free of selective reporting?	YES	Protocol not available, but the outcomes in the methods match those in the results
	Free of other bias?	UNCLEAR	Baseline characteristics were balanced but there is no source of funding declared
Marhofer 2000 <sup>105</sup>	Adequate sequence generation?	UNCLEAR	Reported as a randomized trial without any further details
	Allocation concealment?	UNCLEAR	No description of allocation concealment reported
	Blinding?	UNCLEAR	Reported as a double-blind trial without any further details
	Incomplete outcome data addressed?	YES	All pts completed the study and were included in the analyses (intention-to-treat)
	Free of selective reporting?	YES	Protocol not available, but the outcomes in the methods match those in the results
	Free of other bias?	UNCLEAR	Baseline characteristics were balanced but there is no source of funding declared
Matot 2003 <sup>106</sup>	Adequate sequence generation?	YES	Reported that randomization was performed using random numbers
	Allocation concealment?	UNCLEAR	No description of allocation concealment reported
	Blinding?	NO	NR, but also not possible with the study design
	Incomplete outcome data addressed?	YES	All pts completed the study and were included in the analyses (intention-to-treat)
	Free of selective reporting?	YES	Protocol not available, but the outcomes in the methods match those in the results
	Free of other bias?	YES	Baseline characteristics were balanced and the source of funding was declared to be institutional
Monzon 2010 <sup>107</sup>	Adequate sequence generation?	Yes	Computer-generated
	Allocation concealment?	Yes	The randomization list was kept by one of the authors who did not interact with the patients. He gave instructions to the patient's ED nurse about which treatment should be administered.
	Blinding?	Unclear	NR
	Incomplete outcome data addressed?	Unclear	No ITT, and 13.6 exclusion.

**Table G-4. Nerve blocks (continued)**

<b>Study</b>	<b>Item</b>	<b>Judgment</b>	<b>Description</b>
Mouzopoulos 2009 <sup>108</sup>	Free of selective reporting?	Yes	Protocol not available, but the outcomes in the methods match those in the results.
	Free of other bias?	Yes	Baseline characteristics are balanced; no funding
	Adequate sequence generation?	YES	Reported that randomization was performed using a computer-generated randomization code
	Allocation concealment?	UNCLEAR	No description of allocation concealment reported
	Blinding?	YES	Reported that patients were blinded to the treatment using a placebo with identical appearance and route of administration to the study medication
	Incomplete outcome data addressed?	YES	Intention-to-treat principle was not used in the analyses with 12/219 (5.48%) of randomized pts not included in the analyses
	Free of selective reporting?	YES	Protocol not available, but the outcomes in the methods match those in the results
Murgue 2006 <sup>109</sup>	Free of other bias?	UNCLEAR	Baseline characteristics were balanced but there is no source of funding declared
	Adequate sequence generation?	UNCLEAR	Reported as a randomized trial without any further details
	Allocation concealment?	UNCLEAR	NR
	Blinding?	UNCLEAR	NR
	Incomplete outcome data addressed?	YES	All pts completed the study and were included in the analyses (intention-to-treat)
	Free of selective reporting?	YES	Protocol not available, but the outcomes in the methods match those in the results
Scheinin 2000 <sup>110</sup>	Free of other bias?	UNCLEAR	Baseline characteristics are balanced but there is no source of funding declared
	Adequate sequence generation?	YES	Reported that randomization was performed using permuted blocks with strata
	Allocation concealment?	UNCLEAR	No description of allocation concealment reported
	Blinding?	NO	Reported as an "open-label" trial
	Incomplete outcome data addressed?	NO	Intention-to-treat principle was not used in the analyses with 18/77 (23.38%) of randomized pts excluded from the analyses
	Free of selective reporting?	YES	Protocol not available, but the outcomes in the methods match those in the results
	Free of other bias?	NO	Baseline characteristics were unbalanced with more males allocated to the parenteral analgesia group, but the source of funding is declared to be governmental and institutional.

**Table G-4. Nerve blocks (continued)**

<b>Study</b>	<b>Item</b>	<b>Judgment</b>	<b>Description</b>
Segado Jiménez 2009 <sup>111</sup>	Adequate sequence generation?	UNCLEAR	Reported as a randomized trial without any further details
	Allocation concealment?	UNCLEAR	No description of allocation concealment reported
	Blinding?	UNCLEAR	Reported as double-blind without any further details
	Incomplete outcome data addressed?	UNCLEAR	Not enough information provided in the text to make a precise decision
	Free of selective reporting?	YES	Protocol not available, but the outcomes in the methods match those in the results
	Free of other bias?	UNCLEAR	Baseline characteristics were not presented and there is no source of funding declared
Segado Jimenez 2010 <sup>112</sup>	Adequate sequence generation?	Unclear	Reported as a randomized trial without any further details
	Allocation concealment?	Unclear	NR
	Blinding?	No	Surgeons and evaluators were independants. nothing is reported about patients.
	Incomplete outcome data addressed?	Yes	All patients completed the study and were included in the analyses (intention-to-treat)
	Free of selective reporting?	Yes	Protocol not available, but the outcomes in the methods match those in the results.
	Free of other bias?	Unclear	Baseline characteristics are balanced. No conflict of interest for funding.
Spansberg 1996 <sup>113</sup>	Adequate sequence generation?	YES	Reported that randomization was performed using a computer-generated randomization.
	Allocation concealment?	UNCLEAR	No description of allocation concealment reported
	Blinding?	YES	Reported as a double-blind trial and reported the use of a placebo (saline) to blind patients, recovery staff and observers.
	Incomplete outcome data addressed?	YES	All pts completed the study and were included in the analyses (intention-to-treat)
	Free of selective reporting?	YES	Protocol not available, but the outcomes in the methods match those in the results
	Free of other bias?	UNCLEAR	Baseline characteristics were balanced but there is no source of funding declared
Tuncer 2003 <sup>114</sup>	Adequate sequence generation?	UNCLEAR	Reported as a randomized trial without any further details
	Allocation concealment?	UNCLEAR	No description of allocation concealment reported
	Blinding?	NO	NR, but also not possible with the study design

**Table G-4. Nerve blocks (continued)**

<b>Study</b>	<b>Item</b>	<b>Judgment</b>	<b>Description</b>
	Incomplete outcome data addressed?	YES	All pts completed the study and were included in the analyses (intention-to-treat)
	Free of selective reporting?	YES	Protocol not available, but the outcomes in the methods match those in the results
	Free of other bias?	UNCLEAR	Baseline characteristics were balanced but there is no source of funding declared
Turker 2003 <sup>115</sup>	Adequate sequence generation?	UNCLEAR	Reported as a randomized trial without any further details
	Allocation concealment?	UNCLEAR	No description of allocation concealment reported
	Blinding?	UNCLEAR	Reported that the outcomes assessment was blinded (single-blind)
	Incomplete outcome data addressed?	YES	All pts completed the study and were included in the analyses (intention-to-treat)
	Free of selective reporting?	YES	Protocol not available, but the outcomes in the methods match those in the results
	Free of other bias?	UNCLEAR	Baseline characteristics were balanced but there is no source of funding declared
Yun 2009 <sup>116</sup>	Adequate sequence generation?	YES	'using an allocation sequence (which was generated by Y.H. Kim using a computer)'
	Allocation concealment?	UNCLEAR	'The random allocation sequence was concealed until group was assigned' - no further details.
	Blinding?	NO	Although the anaesthesiologist who performed the spinal block and recorded the UAS scores during patient positioning was unaware of group assignments the clinical effects of i.v. alfentanil were evident in most patients which may have introduced a bias'
	Incomplete outcome data addressed?	YES	All the patients in both groups were included in the statistical analysis'
	Free of selective reporting?	YES	Protocol not available, but the outcomes in the methods match those in the results
	Free of other bias?	UNCLEAR	Baseline characteristics are balanced but source of funding is not declared

**Table G-5. Neurostimulation**

<b>Study</b>	<b>Item</b>	<b>Judgment</b>	<b>Description</b>
Gorodetskyi 2007 <sup>120</sup>	Adequate sequence generation?	UNCLEAR	Reported as randomized using a fixed randomization scheme with sealed envelopes with no further details.
	Allocation concealment?	UNCLEAR	Reported as using sealed envelopes with no further details
	Blinding?	YES	Reported that all the assessing surgeons, patients and research personnel involved in determining and recording outcome measurements were blinded. Additionally reported that the sham device had an identical appearance and application to the active device, but did not produce interactive neurostimulation
	Incomplete outcome data addressed?	YES	All pts completed the study and were included in the analyses (intention-to-treat)
	Free of selective reporting?	YES	Protocol not available, but the outcomes in the methods match those in the results
	Free of other bias?	NO	Baseline characteristics were balanced but there is financial support from a commercial party
	Lang 2007 <sup>121</sup>	Adequate sequence generation?	YES
Allocation concealment?		YES	Reported that they used sealed, sequentially-numbered, opaque envelopes
Blinding?		YES	Reported that the investigator that recorded the data was not aware of the allocation, neither was the patient (use of a sham procedure)
Incomplete outcome data addressed?		NO	Intention-to-treat principle was not used in the analyses with 9/72 (12.50%) of randomized pts excluded from analyses with reasons provided
Free of selective reporting?		YES	Protocol not available, but the outcomes in the methods match those in the results
Free of other bias?		UNCLEAR	Baseline characteristics were balanced but there is no source of funding declared

**Table G-6. Rehabilitation**

<b>Study</b>	<b>Item</b>	<b>Judgment</b>	<b>Description</b>
Di Lorenzo 2007 <sup>122</sup>	Adequate sequence generation?	YES	Reported that randomization was performed using a random numerical table (simple dichotomized admission table)
	Allocation concealment?	UNCLEAR	Reported that the allocation was performed by a 'blinded' nurse but without any further details
	Blinding?	NO	Reported as an 'open' trial.
	Incomplete outcome data addressed?	YES	All pts completed the study and were included in the analyses (intention-to-treat)
	Free of selective reporting?	YES	Protocol not available, but the outcomes in the methods match those in the results
	Free of other bias?	UNCLEAR	Baseline characteristics were balanced but there is no source of funding declared



**Table G-7. Traction**

Study	Item	Judgment	Description
Finsen 1992 <sup>123</sup>	Adequate sequence generation?	YES	Reported that randomization was performed using random numbers
	Allocation concealment?	UNCLEAR	No description of allocation concealment reported
	Blinding?	NO	NR, but also not possible with the study design
	Incomplete outcome data addressed?	NO	Intention-to-treat principle was not used in the analyses with 38/118 (32.20%) of randomized pts excluded with reasons provided
	Free of selective reporting?	YES	Protocol not available, but the outcomes in the methods match those in the results
	Free of other bias?	UNCLEAR	Baseline characteristics were balanced but there is no source of funding declared
Jerre 2000 <sup>124</sup>	Adequate sequence generation?	UNCLEAR	Reported as a randomized trial without any further details
	Allocation concealment?	UNCLEAR	No description of allocation concealment reported
	Blinding?	NO	NR, but also not possible with the study design
	Incomplete outcome data addressed?	YES	All pts completed the study and were included in the analyses (intention-to-treat)
	Free of selective reporting?	YES	Protocol not available, but the outcomes in the methods match those in the results
	Free of other bias?	UNCLEAR	Baseline characteristics were balanced but there is no source of funding declared
Needoff 1993 <sup>125</sup>	Adequate sequence generation?	UNCLEAR	Reported as a randomized trial without any further details
	Allocation concealment?	UNCLEAR	No description of allocation concealment reported
	Blinding?	NO	NR, but also not possible with the study design
	Incomplete outcome data addressed?	YES	All pts completed the study and were included in the analyses (intention-to-treat)
	Free of selective reporting?	YES	Protocol not available, but the outcomes in the methods match those in the results
	Free of other bias?	UNCLEAR	Baseline characteristics were balanced but there is no source of funding declared

**Table G-7. Traction (continued)**

Study	Item	Judgment	Description
Resch 1998 <sup>126</sup>	Adequate sequence generation?	UNCLEAR	Reported as a randomized trial without any further details
	Allocation concealment?	UNCLEAR	No description of allocation concealment reported
	Blinding?	NO	NR, but also not possible with the study design
	Incomplete outcome data addressed?	YES	All pts completed the study and were included in the analyses (intention-to-treat)
	Free of selective reporting?	YES	Protocol not available, but the outcomes in the methods match those in the results
	Free of other bias?	YES	Baseline characteristics were balanced and source of funding declared as governmental
Resch 2005 <sup>26</sup>	Adequate sequence generation?	UNCLEAR	Reported as a randomized trial without any further details
	Allocation concealment?	UNCLEAR	No description of allocation concealment reported
	Blinding?	NO	NR, but also not possible with the study design
	Incomplete outcome data addressed?	YES	All pts completed the study and were included in the analyses (intention-to-treat)
	Free of selective reporting?	YES	Protocol not available, but the outcomes in the methods match those in the results
	Free of other bias?	UNCLEAR	Baseline characteristics were not described for the groups, but the source of funding was declared to be institutional. Additionally, reasons for the 1:2:1 randomization scheme was not provided
Rosen 2001 <sup>127</sup>	Adequate sequence generation?	YES	Reported that randomization was performed using computer-generated randomization
	Allocation concealment?	UNCLEAR	No description of allocation concealment reported
	Blinding?	NO	NR, but also not possible with the study design
	Incomplete outcome data addressed?	YES	All pts completed the study and were included in the analyses (intention-to-treat)
	Free of selective reporting?	YES	Protocol not available, but the outcomes in the methods match those in the results
	Free of other bias?	YES	Baseline characteristics were balanced and declaration made of no external funding

**Table G-7. Traction (continued)**

Saygi 2010 <sup>130</sup>	Adequate sequence generation?	NO	Reported as allocation according to the order of admission to the hospital
	Allocation concealment?	NO	Quasi-randomization
	Blinding?	NO	NR, but also not possible with the study design
	Incomplete outcome data addressed?	YES	All pts completed the study and were included in the analyses (intention-to-treat)
	Free of selective reporting?	YES	Protocol not available, but the outcomes in the methods match those in the results
	Free of other bias?	YES	Baseline characteristics were balanced and declaration made of no external funding
Yip 2002 <sup>131</sup>	Adequate sequence generation?	NO	Patients were randomised into the two study arms depending on whether their hospital admission number was an even or an odd number.
	Allocation concealment?	NO	Patients were randomised into the two study arms depending on whether their hospital admission number was an even or an odd number.
	Blinding?	NO	There was no blinding.
	Incomplete outcome data addressed?	YES	All pts completed the study and were included in the analyses (intention-to-treat)
	Free of selective reporting?	YES	Protocol not available, but the outcomes in the methods match those in the results
	Free of other bias?	YES	Baseline characteristics are balanced and declaration of a noncommercial source of funding is provided

## Appendix H. Summary Risk of Bias Assessments

**Table H-1. Pharmacological analgesia**

Domain	High	Unclear	Low
Adequate sequence generation	0 (0%)	3 (100%)	0 (0%)
Allocation concealment	0 (0%)	3 (100%)	0 (0%)
Blinding	0 (0%)	1 (33.33%)	2 (66.67%)
Incomplete outcome data addressed	0 (0%)	1 (33.33%)	2 (66.67%)
Free of selective reporting	0 (0%)	1 (33.33%)	2 (66.67%)
Free of other bias	0 (0%)	2 (66.67%)	1 (33.33%)

**Table H-2. Anesthesia**

Domain	High	Unclear	Low
Adequate sequence generation	2 (9.09%)	17 (77.27%)	3 (13.64%)
Allocation concealment	1 (4.55%)	17 (77.27%)	4 (18.18%)
Blinding	1 (4.55%)	10 (45.45%)	11 (50.00%)
Incomplete outcome data addressed	2 (9.09%)	3 (13.64%)	17 (77.27%)
Free of selective reporting	0 (0%)	0 (0%)	22 (100%)
Free of other bias	0 (0%)	19 (86.36%)	3 (13.64%)

**Table H-3. Complementary and alternative medicine (CAM)**

Domain	High	Unclear	Low
Adequate sequence generation	0 (0%)	1 (50%)	1 (50%)
Allocation concealment	0 (0%)	2 (100%)	0 (0%)
Blinding	1 (50%)	0 (0%)	1 (50%)
Incomplete outcome data addressed	0 (0%)	0 (0%)	2 (100%)
Free of selective reporting	0 (0%)	0 (0%)	2 (100%)
Free of other bias	0 (0%)	2 (100%)	0 (0%)

**Table H-4. Nerve blocks**

Domain	High	Unclear	Low
Adequate sequence generation	0 (0%)	19 (65.52%)	10 (34.48%)
Allocation concealment	0 (0%)	23 (79.31%)	6 (20.69%)
Blinding	7 (24.14%)	13 (44.83%)	9 (31.03%)
Incomplete outcome data addressed	3 (10.35%)	3 (10.35%)	23 (79.31%)
Free of selective reporting	4 (13.79%)	0 (0%)	25 (86.21%)
Free of other bias	1 (3.45%)	21 (72.41%)	7 (24.14%)

**Table H-5. Neurostimulation**

<b>Domain</b>	<b>High</b>	<b>Unclear</b>	<b>Low</b>
Adequate sequence generation	0 (0%)	1 (50%)	1 (50%)
Allocation concealment	0 (0%)	1 (50%)	1 (50%)
Blinding	0 (0%)	0 (0%)	2 (100%)
Incomplete outcome data addressed	1 (50%)	0 (0%)	1 (50%)
Free of selective reporting	0 (0%)	0 (0%)	2 (100%)
Free of other bias	1 (50%)	1 (50%)	0 (0%)

**Table H-6. Rehabilitation**

<b>Domain</b>	<b>High</b>	<b>Unclear</b>	<b>Low</b>
Adequate sequence generation	0 (0%)	0 (0%)	1 (100%)
Allocation concealment	0 (0%)	1 (100%)	0 (0%)
Blinding	1 (100%)	0 (0%)	0 (0%)
Incomplete outcome data addressed	0 (0%)	0 (0%)	1 (100%)
Free of selective reporting	0 (0%)	0 (0%)	1 (100%)
Free of other bias	0 (0%)	1 (100%)	0 (0%)

**Table H-7. Traction**

<b>Domain</b>	<b>High</b>	<b>Unclear</b>	<b>Low</b>
Adequate sequence generation	4 (40.00%)	4 (40.00%)	2 (20.00%)
Allocation concealment	4 (40.00%)	6 (60.00%)	0 (0%)
Blinding	10 (100%)	0 (0%)	0 (0%)
Incomplete outcome data addressed	1 (10.00%)	0 (0%)	9 (90.00%)
Free of selective reporting	1 (10.00%)	0 (0%)	9 (90.00%)
Free of other bias	0 (0.00%)	5 (50.00%)	5 (50.00%)

# Appendix I. Newcastle-Ottawa Scale Assessment of Cohort Studies

## *NEWCASTLE - OTTAWA QUALITY ASSESSMENT SCALE CASE CONTROL STUDIES*

Note: A study can be awarded a maximum of one star for each numbered item within the Selection and Exposure categories. A maximum of two stars can be given for Comparability.

### **Selection**

#### 1) Is the case definition adequate?

- a) yes, with independent validation \*
- b) yes, e.g., record linkage or based on self reports
- c) no description

#### 2) Representativeness of the cases

- a) consecutive or obviously representative series of cases \*
- b) potential for selection biases or not stated

#### 3) Selection of Controls

- a) community controls \*
- b) hospital controls
- c) no description

#### 4) Definition of Controls

- a) no history of disease (endpoint) \*
- b) no description of source

### **Comparability**

#### 1) Comparability of cases and controls on the basis of the design or analysis \*

- a) study controls for \_\_\_\_\_ \* (Select the most important factor.)
- b) study controls for any additional factor (This criteria could be modified to indicate specific control for a second important factor.)

### **Exposure**

#### 1) Ascertainment of exposure

- a) secure record (eg surgical records) \*
- b) structured interview where blind to case/control status \*
- c) interview not blinded to case/control status
- d) written self report or medical record only
- e) no description

#### 2) Same method of ascertainment for cases and controls

- a) yes \*
- b) no

#### 3) Non-Response rate

- a) same rate for both groups \*
- b) nonrespondents described
- c) rate different and no designation

**NEWCASTLE - OTTAWA QUALITY ASSESSMENT SCALE  
COHORT STUDIES**

Note: A study can be awarded a maximum of one star for each numbered item within the Selection and Outcome categories. A maximum of two stars can be given for Comparability

**Selection**

1) Representativeness of the exposed cohort

- a) truly representative of the average \_\_\_\_\_ (describe) in the community \*
- b) somewhat representative of the average \_\_\_\_\_ in the community \*
- c) selected group of users eg nurses, volunteers d) no description of the derivation of the cohort

2) Selection of the non exposed cohort

- a) drawn from the same community as the exposed cohort \*
- b) drawn from a different source
- c) no description of the derivation of the non exposed cohort

3) Ascertainment of exposure

- a) secure record (eg surgical records) \*
- b) structured interview \*
- c) written self report
- d) no description

4) Demonstration that outcome of interest was not present at start of study

- a) yes \*
- b) no

**Comparability**

1) Comparability of cohorts on the basis of the design or analysis

- a) study controls for \_\_\_\_\_ (select the most important factor) \*
- b) study controls for any additional factor \* (This criteria could be modified to indicate specific control for a second important factor.)

**Outcome**

1) Assessment of outcome

- a) independent blind assessment \*
- b) record linkage \*
- c) self report
- d) no description

2) Was followup long enough for outcomes to occur

- a) yes (select an adequate follow up period for outcome of interest) \*
- b) no

3) Adequacy of follow up of cohorts

- a) complete follow up -all subjects accounted for \*
- b) subjects lost to followup unlikely to introduce bias -small number lost -> \_\_\_\_ % (select an adequate %) followup, or description provided of those lost) \*
- c) followup rate < \_\_\_\_ % (select an adequate %) and no description of those lost
- d) no statement

**Table I-1. Anesthesia**

Author, year	Study design	Selection			Comparability		Outcome		Total stars	
		Representativeness of cohort	Selection of non-exposed cohort	Ascertainment of exposure	Outcome of interest	Comparability of cohorts	Assessment of outcome	Adequate duration of followup		Adequate follow-up of cohort
Koval 1999 <sup>78</sup>	Prospective cohort study	B (1*)	A (1*)	D (0)	A (1*)	B (1*)	D (0)	A (1*)	C (0)	5
Labaille 1992 <sup>79</sup>	Prospective cohort study	B (1*)	A (1*)	B (1*)	A (1*)	A (1*)	B (1*)	A (1*)	A (1*)	8
Miller 1990 <sup>81</sup>	Retrospective cohort study	A (1*)	A (1*)	D (0)	A (1*)	A (1*)	B (1*)	A (1*)	A (1*)	7
Minville 2008 <sup>71</sup>	Retrospective cohort study	B (1*)	A (1*)	A (1*)	A (1*)	B (1*)	B (1*)	A (1*)	A (1*)	8
Sen 2007 <sup>83</sup>	Retrospective cohort study	B (1*)	A (1*)	A (1*)	B (0)	A (1*)	B (1*)	A (1*)	A (1*)	7
Shih 2010 <sup>84</sup>	Retrospective cohort study	B (1*)	A (1*)	A (1*)	A (1*)	B (1*)	B (1*)	A (1*)	A (1*)	8
Sutcliffe 1994 <sup>85</sup>	Prospective cohort study	B (1*)	B (0)	D (0)	A (1*)	B (1*)	D (0)	A (1*)	A (1*)	5

**Table I-2. Multimodal pain management**

Author, year	Study design	Selection			Comparability		Outcome		Total stars	
		Representativeness of cohort	Selection of non-exposed cohort	Ascertainment of exposure	Outcome of interest	Comparability of cohorts	Assessment of outcome	Adequate duration of followup		Adequate follow-up of cohort
Milisen 2001 <sup>86</sup>	Prospective cohort study	B (1*)	A (1*)	A (1*)	A (1*)	A,B (2*)	C (0)	A (1*)	A (1*)	8
Ogilvie-Harris 1993 <sup>87</sup>	Prospective cohort study	D (0)	C (0)	A (1*)	A (1*)	B (1*)	B (1*)	A (1*)	D (0)	5



**Table I-3. Nerve blocks**

Author, year	Study design	Selection			Comparability		Outcome		Total stars	
		Representativeness of cohort	Selection of non-exposed cohort	Ascertainment of exposure	Outcome of interest	Comparability of cohorts	Assessment of outcome	Adequate duration of followup		Adequate follow-up of cohort
Del Rosario 2008 <sup>117</sup>	Retrospective cohort study	B (1*)	A (1*)	A (1*)	B (0)	B (1*)	B (1*)	A (1*)	A (1*)	7
Kocum 2007 <sup>118</sup>	Retrospective cohort study	B (1*)	A (1*)	A (1*)	A (1*)	A (1*)	B (1*)	A (1*)	B (1*)	8
Pedersen 2008 <sup>119</sup>	Retrospective cohort study	A (1*)	A (1*)	A (1*)	A (1*)	A,B (2*)	B (1*)	A (1*)	A (1*)	9

**Table I-4. Traction**

Author, year	Study design	Selection			Comparability		Outcome		Total stars	
		Representativeness of cohort	Selection of non-exposed cohort	Ascertainment of exposure	Outcome of interest	Comparability of cohorts	Assessment of outcome	Adequate duration of followup		Adequate follow-up of cohort
Vermeiren 1995 <sup>132</sup>	Prospective cohort study	A (1*)	A (1*)	A (1*)	A (1*)	(0)	B (1*)	A (1*)	B (1*)	7

## Appendix J. GRADE Tables: Assessing the Strength of Evidence

Each major outcome was provided a summary of the body of evidence (e.g., number of studies, study designs), the quality of the evidence, the results of pooling (if performed), and an overall grade for the quality of evidence for each outcome using the AHRQ GRADE approach. Randomized trials were considered to high quality unless downgraded as a result of concerns of important limitations (e.g., high risk of bias, inconsistent results, etc.). Cohorts were considered to be lower quality unless upgraded as a result of both confidence in the lack of any major limitations and characterized by having special strengths (e.g., large effect size).

**Table J-1. Analgesia for hip fracture**

Quality assessment							Summary of findings				
No of studies	Design	Risk of Bias	Consistency	Directness	Precision	Other considerations	No of patients		Effect	Quality	
							Analgesia	control	Relative (95% CI)		Absolute
<b>Acute pain (post-treatment means) - IM Analgesia (Better indicated by lower values)</b>											
1	RCT	High	Unknown	Direct	Precise	Publication bias: Not investigated	35	55	-	MD 0.7 lower (1.04 to 0.36 lower)	INSUFFICIENT
<b>Acute pain (post-treatment means) - Oral analgesia (Better indicated by lower values)</b>											
1	RCT	High	Unknown	Direct	Imprecise	Publication bias: Not investigated	48	46	-	MD 0.43 lower (1.3 lower to 0.44 higher)	INSUFFICIENT
<b>Acute pain (post-treatment means) - Intrathecal analgesia (Better indicated by lower values)</b>											
1	RCT	High	Unknown	Direct	Precise	Publication bias: Not investigated	15	15	-	MD 1.69 lower (2.01 to 1.37 lower)	INSUFFICIENT
<b>Acute pain (rest) - Oral analgesia (Better indicated by lower values)</b>											
1	RCT	High	Unknown	Direct	Imprecise	Publication bias: Not investigated	48	46	-	MD 0.43 lower (1.3 lower to 0.44 higher)	INSUFFICIENT
<b>Delirium - Oral analgesia</b>											
1	RCT	High	Unknown	Direct	Imprecise	Publication bias: Not investigated	1/48 (2.1%)	1/46 (2.2%)	OR 0.96 (0.06 to 15.77)	1 fewer per 1,000 (from 20 fewer to 238 more)	INSUFFICIENT

RCT = randomized controlled trial; IM = intramuscular; MD = mean difference; OR = odds ratio

**Table J-2. Spinal versus general anesthesia for hip fracture**

Quality assessment							Summary of findings				
No of studies	Design	Risk of Bias	Consistency	Directness	Precision	Other considerations	No of patients		Effect		Quality
							Analgesia	control	Relative (95% CI)	Absolute	
<b>Acute pain (post-treatment means) - Spinal anesthesia (single) (Better indicated by lower values)</b>											
1	RCT	High	Unknown	Direct	Imprecise	Publication bias: Not investigated	15	15	-	MD 0.86 lower (1.3 to 0.42 lower)	INSUFFICIENT
<b>Delirium - Spinal anesthesia (single)</b>											
3	1 RCT; 2 Cohorts	High	Unknown	Direct	Imprecise	Publication bias: Not investigated	8/15 (53.3%)	9/15 (60%)	OR 0.76 (0.18 to 3.24)	67 fewer per 1,000 (from 387 fewer to 229 more)	INSUFFICIENT
<b>Mortality 30 days</b>											
4	2 RCTs; 5 Cohorts	High	Consistent	Direct	Imprecise	Publication bias: Not investigated	10/53 (18.9%)	5/46 (10.9%)	OR 1.73 (0.53 to 5.68)	66 more per 1,000 (from 48 fewer to 301 more)	LOW
<b>Myocardial Infarction</b>											
2	1 RCT; 1 Cohort	High	Unknown	Direct	Imprecise	Publication bias: Not investigated	1/29 (3.4%)	0/14 (0%)	OR 1.55 (0.06 to 42.91)	0 more per 1,000 (from 0 fewer to 0 more)	INSUFFICIENT
<b>Renal failure</b>											
1	Cohort	High	Unkown	Direct	Imprecise	Publication bias: Not investigated	1/168 (0.6%)	2/167 (1.2%)	OR 0.49 (0.04 to 5.5)	6 fewer per 1,000 (from 11 fewer to 51 more)	INSUFFICIENT
<b>Stroke</b>											
2	Cohorts	High	Consistent	Direct	Imprecise	Publication bias: Not investigated	3/448 (0.7%)	4/529 (0.8%)	3/448 (0.7%)	0 fewer per 1,000 (from 6 fewer to 23 more)	INSUFFICIENT

**Table J-3. Spinal anesthesia (continuous vs. single administration) for hip fracture**

Quality assessment							Summary of findings				
No of studies	Design	Risk of Bias	Consistency	Directness	Precision	Other considerations	No of patients		Effect		Quality
							Analgesia	control	Relative (95% CI)	Absolute	
<b>Delirium</b>											
2	RCTs	High	Consistent	Direct	Imprecise	Publication bias: Not investigated	5/67 (7.5%)	4/67 (6%)	OR 1.27 (0.32 to 4.99)	15 more per 1,000 (from 40 fewer to 181 more)	LOW
<b>Mortality 30 days</b>											
4	3 RCTs; 1 Cohort	High	Consistent	Direct	Imprecise	Publication bias: Not investigated	2/81 (2.5%)	4/82 (4.9%)	OR 0.46 (0.07 to 3.02)	26 fewer per 1,000 (from 45 fewer to 85 more)	INSUFFICIENT
<b>Myocardial Infarction</b>											
1	RCT	High	Unknown	Direct	Imprecise	Publication bias: Not investigated	0/14 (0%)	1/15 (6.7%)	OR 0.33 (0.01 to 8.88)	44 fewer per 1,000 (from 66 fewer to 321 more)	INSUFFICIENT
<b>Stroke</b>											
1	RCT	High	Unknown	Direct	Imprecise	Publication bias: Not investigated	0/37 (0%)	0/37 (0%)	not pooled	not pooled	INSUFFICIENT

**Table J-4. Spinal anesthesia (single): addition of fentanyl for hip fracture**

Quality assessment							Summary of findings				
No of studies	Design	Risk of Bias	Consistency	Directness	Precision	Other considerations	No of patients		Effect		Quality
							Analgesia	control	Relative (95% CI)	Absolute	
<b>Acute pain (post-treatment means) (Better indicated by lower values)</b>											
1	RCT	High	Unknown	Direct	Imprecise	Publication bias: Not investigated	20	20	-	not pooled	INSUFFICIENT

**Table J-4. Spinal anesthesia (single): addition of fentanyl for hip fracture (continued)**

Quality assessment							Summary of findings				
No of studies	Design	Risk of Bias	Consistency	Directness	Precision	Other considerations	No of patients		Effect		Quality
							Analgesia	control	Relative (95% CI)	Absolute	
<b>Day 1 pain</b>											
1	RCT	High	Unknown	Direct	Imprecise	Publication bias: Not investigated	6/40 (15%)	5/40 (12.5%)	OR 1.24 (0.34 to 4.48)	not pooled	INSUFFICIENT

**Table J-5. Spinal anesthesia (single): addition of morphine for hip fracture**

Quality assessment							Summary of findings				
No of studies	Design	Risk of Bias	Consistency	Directness	Precision	Other considerations	No of patients		Effect		Quality
							Analgesia	control	Relative (95% CI)	Absolute	
<b>Acute pain (post-treatment means) (Better indicated by lower values)</b>											
1	RCTs	High	Unknown	Direct	Imprecise	Publication bias: Not investigated	20	20	-	MD 0.36 lower (1.11 lower to 0.39 higher)	INSUFFICIENT
<b>Delirium</b>											
1	RCT	High	Unknown	Direct	Imprecise	Publication bias: Not investigated	1/20 (5%)	0/20 (0%)	OR 3.15 (0.12 to 82.16)	0 more per 1,000 (from 0 fewer to 0 more)	INSUFFICIENT

**Table J-6. Spinal anesthesia (single): addition of sufentanil for hip fracture**

Quality assessment							Summary of findings				
No of studies	Design	Risk of Bias	Consistency	Directness	Precision	Other considerations	No of patients		Effect		Quality
							Analgesia	control	Relative (95% CI)	Absolute	
<b>Acute pain (post-treatment means) (Better indicated by lower values)</b>											
1	RCT	High	Unknown	Direct	Imprecise	Publication bias: Not investigated	25	25	-	not pooled	INSUFFICIENT

**Table J-7. Spinal anesthesia: Different doses (Bupivacaine 2.5 mg vs. 5mg) for hip fracture**

Quality assessment							Summary of findings				
No of studies	Design	Risk of Bias	Consistency	Directness	Precision	Other considerations	No of patients		Effect		Quality
							Analgesia	control	Relative (95% CI)	Absolute	
<b>Mortality 30 days</b>											
1	Cohort	Low	Unknown	Direct	Imprecise	Publication bias: Not investigated	4/121 (3.3%)	4/61 (6.6%)	OR 0.49 (0.12 to 2.02)	32 fewer per 1,000 (from 57 fewer to 59 more)	INSUFFICIENT

**Table J-8. Spinal anesthesia: Different doses (Bupivacaine 2.5 mg vs. 5mg) for hip fracture**

Quality assessment							Summary of findings				
No of studies	Design	Risk of Bias	Consistency	Directness	Precision	Other considerations	No of patients		Effect		Quality
							Analgesia	control	Relative (95% CI)	Absolute	
<b>Mortality 30 days</b>											
1	Cohort	Low	Unknown	Direct	Imprecise	Publication bias: Not investigated	2/30 (6.7%)	4/30 (13.3%)	OR 0.46 (0.08 to 2.75)	67 fewer per 1,000 (from 1,000 fewer to 164 more)	INSUFFICIENT

**Table J-9. Comparative alternative medicine for hip fracture**

Quality assessment							Summary of findings				
No of studies	Design	Risk of Bias	Consistency	Directness	Precision	Other considerations	No of patients		Effect		Quality
							Analgesia	control	Relative (95% CI)	Absolute	
<b>Acute pain (post-treatment means) - Acupressure (Better indicated by lower values)</b>											
1	RCT	High	Unknown	Direct	Imprecise	Publication bias: Not investigated	18	20	-	MD 3.01 lower (4.53 to 1.49 lower)	INSUFFICIENT

**Table J-9. Comparative alternative medicine for hip fracture (continued)**

Quality assessment							Summary of findings				
No of studies	Design	Risk of Bias	Consistency	Directness	Precision	Other considerations	No of patients		Effect		Quality
							Analgesia	control	Relative (95% CI)	Absolute	
<b>Acute pain (post-treatment means) - Relaxation (better indicated by lower values)</b>											
1	RCT	High	Unknown	Direct	Precise	Publication bias: Not investigated	30	30	-	MD 1.1 lower (1.43 to 0.77 lower)	INSUFFICIENT

**Table J-10. Multimodal pain management**

Quality assessment							Summary of findings				
No of studies	Design	Risk of Bias	Consistency	Directness	Precision	Other considerations	No of patients		Effect		Quality
							Analgesia	control	Relative (95% CI)	Absolute	
<b>Delirium - Protocol #1</b>											
1	Cohort	Medium	Unknown	Direct	Imprecise	Publication bias: Not investigated	12/60 (20%)	14/60 (23.3%)	OR 0.82 (0.34 to 1.96)	34 fewer per 1,000 (from 140 fewer to 140 more)	INSUFFICIENT
<b>Delirium - Protocol #2</b>											
1	Cohort	Medium	Unknown	Direct	Imprecise	Publication bias: Not investigated	1/55 (1.8%)	2/51 (3.9%)	OR 0.45 (0.04 to 5.16)	21 fewer per 1,000 (from 38 fewer to 135 more)	INSUFFICIENT
<b>Mortality 30 days - Protocol #2</b>											
1	Cohort	Medium	Unknown	Direct	Imprecise	Publication bias: Not investigated	5/55 (9.1%)	8/51 (15.7%)	OR 0.54 (0.16 to 1.77)	66 fewer per 1,000 (from 128 fewer to 91 more)	INSUFFICIENT
<b>Myocardial Infarction - Protocol #2</b>											
1	Cohort	Medium	Unknown	Direct	Imprecise	Publication bias: Not investigated	1/55 (1.8%)	2/51 (3.9%)	OR 0.45 (0.04 to 5.16)	21 fewer per 1,000 (from 38 fewer to 135 more)	INSUFFICIENT

**Table J-10. Multimodal pain management (continued)**

Quality assessment							Summary of findings				
No of studies	Design	Risk of Bias	Consistency	Directness	Precision	Other considerations	No of patients		Effect		Quality
							Analgesia	control	Relative (95% CI)	Absolute	
<b>Stroke - Protocol #2</b>											
1	Cohort	Medium	Unknown	Direct	Imprecise	Publication bias: Not investigated	0/55 (0%)	1/51 (2%)	OR 0.13 (0.00 to 6.32)	17 fewer per 1,000 (from 20 to 93 more)	INSUFFICIENT

**Table J-11. Nerve blocks vs. no block for hip fracture**

Quality assessment							Summary of findings				
No of studies	Design	Risk of Bias	Consistency	Directness	Precision	Other considerations	No of patients		Effect		Quality
							Analgesia	control	Relative (95% CI)	Absolute	
<b>Acute pain (post-treatment means) (better indicated by lower values)</b>											
13	RCTs	High	Consistent	Direct	Precise	Publication bias: Unlikely	508	492	-	Not pooled	MODERATE
<b>Pain on movement (post-treatment) (better indicated by lower values)</b>											
4	RCTs	High	Inconsistent	Direct	Imprecise	Publication bias: Not investigated	128	130	-	Not pooled	LOW
<b>Pain on rest (post-treatment) (better indicated by lower values)</b>											
3	RCTs	High	Inconsistent	Direct	Imprecise	Publication bias: Not investigated	104	104	-	Not pooled	LOW
<b>Day 1 Pain</b>											
1	RCT	High	Unknown	Direct	Precise	Publication bias: Not investigated	7/25 (28%)	20/25 (80%)	OR 0.1 (0.03 to 0.36)	514 fewer per 1,000 (from 210 fewer to 693 fewer)	INSUFFICIENT



**Table J-11. Nerve blocks vs. no block for hip fracture (continued)**

Quality assessment							Summary of findings				
No of studies	Design	Risk of Bias	Consistency	Directness	Precision	Other considerations	No of patients		Effect		Quality
							Analgesia	control	Relative (95% CI)	Absolute	
<b>Delirium</b>											
6	4 RCTs; 2 Cohorts	Medium	Consistent	Direct	Precise	Publication bias: Not investigated	11/242 (4.5%)	33/219 (7.9%)	OR 0.33 (0.16 to 0.66)	95 fewer per 1,000 (from 46 fewer to 123 fewer)	MODERATE
<b>Mortality 30 days</b>											
4	RCTs	HIGH	Consistent	Direct	Imprecise	Publication bias: Not investigated	2/114 (1.8%)	10/114 (8.8%)	OR 0.28 (0.07 to 1.12)	62 fewer per 1,000 (from 81 fewer to 10 more)	LOW
<b>Myocardial Infarction</b>											
3	2 RCTs; 1 Cohort	High	Consistent	Direct	Imprecise	Publication bias: Not investigated	1/72 (1.4%)	1/73 (1.4%)	OR 1 (0.06 to 16.67)	0 fewer per 1,000 (from 13 fewer to 174 more)	INSUFFICIENT
<b>Stroke</b>											
2	1 RCT; 1 Cohort	High	Consistent	Direct	Imprecise	Publication bias: Not investigated	1/25 (4%)	0/25 (0%)	OR 3.12 (0.12 to 80.39)	0 more per 1,000 (from 0 fewer to 0 more)	INSUFFICIENT

**Table J-12. Nerve blocks vs. regional anesthesia for hip fracture**

Quality assessment							Summary of findings				
No of studies	Design	Risk of Bias	Consistency	Directness	Precision	Other considerations	No of patients		Effect		Quality
							Analgesia	control	Relative (95% CI)	Absolute	
<b>Acute pain (post-treatment means) (Better indicated by lower values)</b>											
3	RCTs	High	Consistent	Direct	Imprecise	Publication bias: Not investigated	55	54	-	MD 0.35 lower (1.1 lower to 0.39 higher)	LOW

**Table J-12. Nerve blocks vs. regional anesthesia for hip fracture (continued)**

Quality assessment							Summary of findings				
No of studies	Design	Risk of Bias	Consistency	Directness	Precision	Other considerations	No of patients		Effect		Quality
							Analgesia	control	Relative (95% CI)	Absolute	
<b>Delirium</b>											
1	RCT	High	Unknown	Direct	Imprecise	Publication bias: Not investigated	6/15 (40%)	5/14 (35.7%)	OR 1.2 (0.27 to 5.4)	43 more per 1,000 (from 227 fewer to 393 more)	INSUFFICIENT

**Table J-13. Nerve Blocks: Ropivacaine vs. Bupivacaine for hip fracture**

Quality assessment							Summary of findings				
No of studies	Design	Risk of Bias	Consistency	Directness	Precision	Other considerations	No of patients		Effect		Quality
							Analgesia	control	Relative (95% CI)	Absolute	
<b>Delirium</b>											
1	Cohort	Low	Unknown	Direct	Imprecise	Publication bias: Not investigated	2/32 (6.3%)	1/30 (3.3%)	OR 1.93 (0.17 to 22.5)	29 more per 1,000 (from 28 fewer to 404 more)	INSUFFICIENT

**Table J-14. Neurostimulation for hip fracture**

Quality assessment							Summary of findings				
No of studies	Design	Risk of Bias	Consistency	Directness	Precision	Other considerations	No of patients		Effect		Quality
							Analgesia	control	Relative (95% CI)	Absolute	
<b>Acute pain (post-treatment means) (Better indicated by lower values)</b>											
2	RCTs	High	Consistent	Direct	Imprecise	Publication bias: Not investigated	60	63	-	MD 2.79 lower (4.95 to 0.64 lower)	INSUFFICIENT
<b>Pain on movement (post-treatment) (Better indicated by lower values)</b>											
1	RCT	High	Unknown	Direct	Imprecise	Publication bias: Not investigated	30	30	-	MD 3.9 lower (6.22 to 1.58 lower)	INSUFFICIENT

**Table J-15. Rehabilitation for hip fracture**

Quality assessment							Summary of findings				
No of studies	Design	Risk of Bias	Consistency	Directness	Precision	Other considerations	No of patients		Effect		Quality
							Analgesia	control	Relative (95% CI)	Absolute	
<b>Acute pain (post-treatment means) (Better indicated by lower values)</b>											
1	RCTs	High	Unknown	Direct	Imprecise	Publication bias: Not investigated	18	19	-	MD 1.39 lower (2.27 to 0.51 lower)	INSUFFICIENT

**Table J-16. Traction for hip fracture**

Quality assessment							Summary of findings				
No of studies	Design	Risk of Bias	Consistency	Directness	Precision	Other considerations	No of patients		Effect		Quality
							Analgesia	control	Relative (95% CI)	Absolute	
<b>Acute pain (post-treatment means) - Skin traction versus no traction (Better indicated by lower values)</b>											
8	RCTs	High	Consistent	Direct	Imprecise	Publication bias: Not investigated	498	594	-	MD 0.20 higher (0.24 lower to 0.65 higher)	MODERATE
<b>Mortality 30 days (traction vs. no traction)</b>											
2	RCTs	High	Unknown	Direct	Imprecise	Publication bias: Not investigated	0/55 (0%)	2/25 (8%)	OR 0.14 (0.01 to 1.44)	65 fewer per 1,000 (from 78 fewer to 35 more)	INSUFFICIENT
<b>Mortality 30 days (skin vs. skeletal) - Skin traction versus skeletal traction</b>											
1	RCTs	High	Unknown	Direct	Imprecise	Publication bias: Not investigated	0/26 (0%)	0/29 (0%)	not pooled	not pooled	INSUFFICIENT